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Abstract 
Despite recent advances in the clinic to integrate novel targeted therapeutic agents into 
standard therapy, colorectal cancer (CRC) remains a significant cause of mortality. The high 
attrition rate of novel compounds at phase III clinical trials for CRC, has been attributed to 
limited information from pre-clinical strategies, in particular, the use of inadequate xenograft 
models. In response, this thesis aimed to utilise robust and relevant genetically engineered 
mouse models of CRC to evaluate a number of novel therapeutic strategies.  
Whilst mutations in the tumour suppressor APC are crucial for initiation of CRC, mutations 
which lead to activation of the PI3K and MAPK signalling pathways, such as through loss of the 
tumour suppressor protein PTEN and activation of oncogenic KRAS, have been implicated in 
promoting progression of CRC. As such, combinations of these genetic alterations within the 
murine intestine, using the Cre-LoxP system, lead to differing mouse models of invasive 
intestinal adenocarcinoma. This thesis reports therapeutic targeting of the PI3K and MAPK 
signalling pathways using the dual PI3K and mTOR inhibitor NVP-BEZ235, and the MEK 
inhibitor MEK162, respectively. For this, compounds were initially evaluated for 
pharmacodynamic and anti-tumour effects through short term exposure experiments. These 
analyses yielded a range of effects, some of which appeared predictive of long term efficacy, 
others which were contradictory and some which revealed novel feedback mechanisms. 
Furthermore, these agents were assessed in a long term therapeutic setting to evaluate the 
effect of continuous treatment on longevity and tumour burden of tumour models. Here, 
whilst dual PI3K/mTOR inhibition significantly increased longevity of all mouse models, MEK 
inhibition was only effective in the Apc and Apc Kras mutant settings, identifying Pten loss as a 
marker of non-response to MEK inhibition, independently and also in the Kras mutant setting. 
Furthermore, analysis of the combination therapy in short term settings identified scheduling 
of these agents to be key to achieve concomitant pathway inhibition, particularly in the Apc 
Pten deficient tumour setting. Ultimately, when evaluated in a long term setting, although the 
combination therapy displayed no further benefit in the Pten deficient setting, this had 
additive benefits in the Kras mutant setting and synergistic benefits in the Pten Kras mutant 
setting. 
Nevertheless despite the promise of targeted therapy, standard chemotherapeutic agents 
such as 5-flurouracil (5-FU) remain the backbone of therapy for CRC, regardless of only 
moderate benefits of 10-15% in advanced tumour settings. Furthermore, resistance to 5-FU 
predominantly through upregulation of the enzyme thymidylate synthase (TS) frequently 
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occurs in human tumours. Investigations reported here aimed to target tumours with 
upregulated TS using novel analogues of the anti-viral agent Brivudin (BVDU), metabolites of 
which are converted to anti-cancer metabolites by TS. 
Initially, In vitro characterisation of a small library of compounds reported here identified a 
number of potent compounds. Following further in vitro characterisation and short term 
evaluation in the Apc Pten tumour model of invasive adenocarcinoma, two lead compounds: 
CPF472 and CPF3172 were taken forward for long term experiments. Subsequently, this study 
evaluated and identified compounds which showed increased efficacy in the TS upregulated 
setting. 
Taken together, the investigations presented in this thesis highlight the utility of appropriate 
mouse models in evaluating novel therapeutic strategies and generating clinically relevant 
hypotheses.
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1 General Introduction 
 
1.1 Colorectal cancer 
1.1.1 Colorectal cancer statistics and causes 
Although significant advances have recently been made to improve outcomes of patients with 
early and advanced colorectal cancer (CRC), it remains the third most common cancer 
worldwide after breast and lung cancer (Cancer Research UK, 2013). With more than 16,000 
deaths annually in the UK, CRC accounts for approximately 10% of female and 11% of male 
cancer deaths. Bowel cancer mortality rates are strongly related to age with 80% of all deaths 
occurring in people aged 65 and over. This relationship is largely a consequence of mild early 
symptoms (for example bloating and diarrhoea) of the disease and hence late detection i.e. 
often when the disease has metastasised (Cancer Research UK, 2013).  
CRC is traditionally split into hereditary and sporadic. Hereditary conditions contribute 
between 20-25% of bowel cancers namely through Familial Adenomatous Polyposis (FAP) and 
Hereditary non-polyposis colorectal cancer (HNPCC or Lynch Syndrome)(de la Chapelle, 2004). 
FAP results in hundreds to thousands of adenomas throughout the bowel and if left untreated 
this will lead to near 100% penetrance of CRC. HNPCC is associated with germ line mutations 
of mismatch repair genes with a penetrance of 80% for colorectal cancer (de la Chapelle, 2004, 
Fearnhead et al., 2002).  
The high incidence of sporadic bowel cancer is largely attributed to environmental factors 
including poor diet, obesity, increased alcohol consumption and smoking (Cancer research UK, 
2013). High intake of red meat and processed meat has been consistently linked to increased 
risk of bowel cancer with a recent study estimating that 18% of all cases in 2010 were linked to 
high consumption of red meat and processed meat (Parkin, 2011). Epidemiology data has also 
suggested that obesity remains an increasing risk factor for developing CRC in the western 
world (Moghaddam et al., 2007). Importantly, many studies have shown an inverse correlation 
linking colorectal cancer risk with intake of vegetables, physical exercise as well as non-
steroidal anti-inflammatory drugs and hormone replacement therapy (Watson and Collins, 
2011).  
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1.1.2 TNM classification of colorectal cancer 
The gold standard for CRC prognostication remains pathological staging through the Tumour-
Node-Metastasis (TNM) system, modified from the Duke’s system initially proposed by 
Cuthbert Dukes in 1932 (Walther et al., 2009). This system assesses the size and invasion of 
the primary tumour (T), pathological review of tumour cells in surrounding lymph nodes (N) 
and local or distant spread of tumour i.e. metastasis (M) (Wolpin and Mayer, 2008) 
(summarised in table 1.1). Additional clinical and pathological features are often used to 
further assess prognosis and risk of recurrence including poorly differentiated histology, 
lymphovascular invasion and high pre-operative carcinoembryonic antigen levels (Steinberg et 
al., 1986, Wanebo et al., 1978). 
UICC/TNM Duke's 
Stage 0 Carcinoma in situ 
A 
Stage I 
No nodal involvement, no distant metastasis 
Tumour invades submucosa (T1, N0, M0) 
Tumour invades muscularis propria (T2, N0, M0) 
Stage II 
No nodal involvement, no distant metastasis 
B Tumour invades subserosa (T3, N0, M0) 
Tumour invades into other organs (T4, N0, M0) 
Stage III 
No nodal involvement, no distant metastasis 
C 1-3 regional lymph nodes involved (any T, N1, M0) 
4 or more regional lymph nodes involved (any T1, N2, M0) 
Stage IV Distant metastasis (any T or N, M1) D 
Table 1-1 Outline of system used to stage colorectal cancers, adapted from Cancer Research 
UK, Stats 2013 
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1.1.3 Current therapeutic strategies for patients with CRC 
Clinical options for CRC patients primarily involve tumour and metastasis resection in 
conjunction with radiotherapy or chemotherapy. These are either used in the neoadjuvant 
setting to shrink the tumour prior to surgery or alternatively, in the adjuvant setting (after 
surgery) to prevent recurrence.  
In terms of chemotherapy, 5-fluorouracil (5-FU) remains the cornerstone of systemic 
treatment for CRC patients. Developed by Charles Heidelberger in 1957, 5-FU is a fluorinated 
pyrimidine that functions by inhibiting Thymidylate synthase (TS), the rate-limiting enzyme in 
pyrimidine nucleotide synthesis (Sobrero et al., 2000). Despite 5-FU being the most widely 
used anti-cancer therapy to treat the disease, its’ efficacy as a monotherapy remains modest, 
with 10-15% response rates and an overall medium survival of around 8 months (Johnston and 
Kaye, 2001). 5-FU is now most commonly administered with leucovorin, a reduced folate, 
thought to stabilize interactions between 5-FU and TS (Zhang et al., 1992). A meta-analysis of 
19 randomized trials found that 20% of metastatic CRC patients receiving 5-FU with 
leucovorin, had a 50% reduction in tumour size and median survival had increased from 6 to 
12 months (Thirion et al., 2004) compared to 5-FU alone.  
Over the past 15 years, significant advances have been made in the treatment of metastatic 
colorectal cancer, with the approval of 3 new cytotoxic agents. This includes the 
topoisomerase I inhibitor irinotecan (Pfizer), the platinum compound oxaliplatin (Sanofi-
Aventis) and the oral prodrug of fluorouracil capecitabine (Roche). Randomized clinical trials 
have shown improvements in progression-free and overall survival when irinotecan was added 
to 5-FU and leucovorin (Douillard and Group, 2000). Similarly, the addition of oxaliplatin to 5-
FU and leucovorin increased tumour response rates and disease-free survival rates (Giacchetti 
et al., 2000). Importantly, patients receiving all three cytotoxics-fluorouracil, irinotecan and 
oxaliplatin had an increased median survival of approximately 20 months (Grothey and 
Goldberg, 2004).  
Despite the improvements described above, anti-cancer therapy is largely limited by the 
damage it inflicts on normal tissues. Therefore, the search for agents which specifically target 
tumour cells whilst sparing normal cells is often described as one of the ‘holy grails’ of cancer 
research (Keefe and Bateman, 2012). In light of this, the addition of targeted agents for the 
treatment of metastatic CRC has been implemented to further improve clinical outcomes. 
Bevacizumab (Genentech), a human monoclonal antibody against the vascular endothelial 
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growth factor (VEGF), is currently being evaluated in addition with standard chemotherapeutic 
schedules, to target the key signalling pathway which mediates angiogenesis, an essential 
process in tumour development. Initial studies have shown the addition of bevacizumab to 
fluoruracil and leucovorin prolonged median overall survival after failure of an irinotecan 
containing regime. Despite this, toxicity issues similar to those observed with chemotherapy 
alone, remain with bevacizumab treatment. (Kabbinavar et al., 2005, Glusker et al., 2006, 
Guijarro-Muñoz et al., 2013). Additionally to targeting VEGF, antibodies against the Epidermal 
growth factor receptor (EGFR) have been integrated into current therapeutic strategies for 
CRC, given that EGFR is overexpressed in 70% of CRCs (Resnick et al., 2004). Cetuximab 
(ImClone) and panitumumab (Amgen) are monoclonal antibodies against EGFR, a 
transmembrane glycoprotein involved in stimulating cellular growth, proliferation and 
inhibiting programmed cell death (Scaltriti and Baselga, 2006). Both molecules bind to the 
extracellular domain of EGFR whereby leading to inhibition of downstream signalling. 
Promisingly, cetuximab has shown efficacy in patients with irinotecan-refractory metastatic 
CRC as well as improvements in progression-free survival and overall survival as a weekly 
treatment for patients that progressed on 5-FU, irinotecan and oxaliplatin (Jonker et al., 2007). 
Despite this, extensive retrospective analysis of clinical trials has identified that mutations 
downstream EGFR signalling mediate non-response to cetuximab and panitumumab (further 
discussed in section 1.5.2 and 1.5.3), limiting the population of patients which benefit from 
this treatment.  
Therefore, whilst substantial advances have been made over the last decade to integrate 
targeted biological agents into the treatment of CRC, they have had little impact on the crucial 
5-year survival rates (Jonker et al., 2007). Hence, efforts are continuing to develop a variety of 
agents targeting processes involved in colorectal tumour development, in the hope to vastly 
improve patient outcomes. 
 
1.2 Intestinal biology and maintenance of homeostasis 
1.2.1 Basic anatomy and function of the intestines 
The intestines are part of the digestive system where they play a key role in the digestion and 
absorption of nutrients, water and form a part of the body’s defence to ingested pathogens. 
The intestinal structure consists of a tube extending from the stomach to the anus. The small 
intestine has three segments, the duodenum (receives chyme-partly digested material, from 
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the stomach and digestive secretions from the pancreas and liver), the jejunum (responsible 
for the chemical digestion and nutrient absorption) and the ileum (controls flow of material to 
the large intestine via the caecum). The surface of the small intestine is covered in a single 
layer of epithelial cells that form invaginations called crypts of Lieberkühn (commonly called 
crypts) deep in the lamina propria. From these, finger-like projections called villi are formed 
and these function to increase the surface area for nutrient absorption (Figure 1.1). The lamina 
propria forms a support of mesenchymal (stromal) fibroblasts around the crypts and also 
extends up to the top of the villus. This contains an extensive network of capillaries which 
carry absorbed nutrients and a lacteal which transports material too large to be absorbed, 
including lipids packaged as lipoproteins. The small intestine wall is made up of a layer of 
smooth muscle which is responsible for peristalsis, an important muscle movement which 
increases absorption of nutrients and movement of material through the intestine (Figure 1.1) 
(L et al., 1989, H, 2006, Williams et al., 1989, Martini, 2006).  
The large intestine is made up of the caecum, colon, rectum and the anal canal. The caecum 
collects and stores material from the ileum and is also the region of the large intestine where 
the appendix is located. The reabsorption of water is the main function of the colon and it is 
also where faecal material is stored prior to ejection from the body through the rectum and 
the anal canal. The large intestine is made up of a single layer of columnar epithelial cells like 
the small intestine, however unlike the small intestine, the cells form a flat surface of 
epithelium and don’t have raised villi (Figure 1.1) (Williams et al. 1989, Martini 2006).  
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The small intestine is a single epithelial layer made up finger-like projections called villi and 
invaginations called crypts, supported by stromal fibroblasts and surrounded by a layer of 
smooth muscle. The large intestine is also a single epithelial layer but is only made up of crypts 
which consist of enteroendocrine and goblet cells.  
 
 
 
Figure 1.1 Structure of the small and large intestine 
9 
 
1.2.2 Small intestine and large intestine histology 
The epithelial layer of the small intestine undergoes rapid renewal every 5-6 days in humans 
and every 2-3 days in the mouse, a process which is driven by the proliferative compartment 
found in crypts (Creamer, 1967, Wright and Alison, 1984). The intestinal stem cells are located 
at the bottom of the crypt and give rise to their progeny, transit-amplifying cells. These cells 
divide 4-5 times before terminally differentiating as they migrate up the villus where they are 
subsequently shed into the lumen (Hall et al., 1994, Grossmann et al., 2002), with the 
exception of paneth cells which migrate downwards and occupy the base of the crypt (Figure 
1.2). The main differentiated cell types found in the small intestine include absorptive 
enterocytes, secretory goblet, enteroendocrine cells and Paneth cells, and to a lesser extent, 
M cells (membranous or microfold cells), cup cells and tuft cells. Enterocytes are the most 
abundant cell type in the small and large intestine. They are tightly packed specialised cells 
which function to maintain cell polarity and to provide a barrier to microbes. Also, their apical 
surfaces are covered in microvilli to maximise surface area for absorption of nutrients. Goblet 
cells are secretory cells located near the crypt-villus junction and all along the villus. They 
primarily function to lubricate and protect the epithelium from the mechanical stress of 
material movement by secreting mucin but also by secreting trefoil proteins to aid repair of 
damaged tissue. Enteroendocrine cells are also secretory cells found along the villus and 
secrete hormones to maintain vital gut function. Paneth cells are long-lived secretory cells 
which escape migration and reside at the bottom of the crypt intercalated between the crypt 
base columnar cells. Here, they are responsible for innate immunity and function by secreting 
defensins and anti-microbials such as lysozyme (Williams et al. 1989, Martini 2006).  
The often over-looked M cells, cup cells and tuft cells are also found in the intestinal 
epithelium. M cells are microbial trafficking cells, primarily found overlying Peyer’s patches. 
These cells possess an unusual membrane structure which allows presentation of microbes to 
the underlying lymphocytes, macrophages and dendritic cells, and therefore provide a layer of 
interphase between immune cells and the luminal content (Owen and Jones, 1974). Also 
found in the intestine are elusive wine glass-shaped cup cells. These have a shorter brush 
border than other columnar cells and express Vimentin, much like M cells (filament protein 
which is a mesenchymal cell marker) however, their function remains largely unidentified 
(Ramirez and Gebert, 2003). Finally, tuft cells (also known as brush cells) are on rare occasions 
found in both crypts and villi of the small intestinal epithelium. The role of these cells was 
largely unknown until recent studies by Gerbe et al revealed them to be of a secretory lineage, 
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a source of prostanoids, prostaglandins, the largest source of opiods and β-endorphins in the 
intestine. It is hypothesised that tuft cells contribute to essential maintenance of homeostasis 
in the intestine as well as vasoconstriction, peristalsis and pain detection (Gerbe et al., 2009, 
Gerbe et al., 2011).  
The colonic mucosa also consists of a single epithelial layer which consists of differentiated 
absorptive cells termed colonocytes, enteroendocrine cells and goblet cells which are the most 
abundant cell type comprising up to 50% of the large intestine epithelium (Figure 1.1). 
Similarly to the small intestine, stem cells are found at the base of the crypt, however unlike 
the small intestine, the large intestine is completely devoid of paneth cells (Williams et al., 
1989).  
1.2.3 The intestinal stem cell 
In the adult, stem cells are defined as pluripotent cells that maintain their own capacity for 
long-term self-renewal (Siminovitch and Axelrad, 1963). In all organs, stem cells are vital for 
tissue maintenance and homeostasis and it is hypothesised that the accumulation of 
mutations in these cells may result in the tumour-initiating cells that give rise to cancers. 
However, intestinal stem cells are thought to possess a number of protective mechanisms in 
order to prevent neoplastic growth. These include their propensity to be slow-cycling 
(quiescent) (Orford and Scadden, 2008), their ability to selectively sort damaged DNA to pass 
onto daughter cells which differentiate and migrate up the villus, and lastly their ability to 
readily undergo programmed cell death (apoptosis) after genetic insult (Potten et al., 1978).  
The location of the intestinal stem cell has been a widely debated issue in the field. The 
classical model put forward by Potten and colleagues described the location of the stem cells 
in the +4 cell region, relative to the base of the crypt. This was evidenced by a number of DNA 
labelling (using tritated thymidine- 3HTdR which incorporates into DNA during S phase) and 
irradiation experiments (to cause genetic insult) which showed the 3HTdR was incorporated 
into the DNA of stem cells that underwent regeneration, and could be visualised a number of 
weeks later (Potten 1974). This led to the identification of potential stem cell markers that 
were predominantly expressed in the +4 region including, mushashi-1 (Potten et al., 2003), 
Bmi1 (the polycomb ring finger oncogene) (Sangiorgi and Capecchi, 2008),  doublecortin and 
calcium/calmodulin-dependent protein kinase-like-1 (DCAMKL-1) (May et al., 2008) and CD133 
(Prominin-1) (Zhu et al., 2009) to study stem cell functionality. Functional lineage tracing 
experiments using conditional transgenic techniques in the mouse revealed that Bmi1 positive 
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cells can generate all intestinal cell types and a single Bmi1 positive cell can generate organoid 
structures when cultured in vitro (Sangiorgi and Capecchi, 2008). Since then, a number of 
other markers for the quiescent +4 cell have been identified including, the homeobox protein 
Hopx (Takeda et al., 2011), telomerase reverse transcriptase Tert (Montgomery et al., 2011) 
and the pan-ErbB inhibitor Lrig1 (Powell et al., 2012). More recently however, a plethora of 
new evidence demonstrated that the previously identified crypt based columnar cells (CBC 
cells) (Cheng and Leblond, 1974) can function as intestinal stem cells. Lineage tracing 
experiments identified the Wnt target gene leucine-rich repeat containing G-protein coupled 
receptor 5 (Lgr5) expressing CBC cells were actively cycling, and capable of generating all 
epithelial lineages over a 2 month period (Barker et al., 2007). Furthermore, when isolated and 
cultured in vitro, Lgr5 positive cells were able to generate organoid structures (Sato et al., 
2009).  
Together, the two areas of evidence led to the hypothesis of two pools of small intestinal stem 
cells, one quiescent pool in Bmi1 expressing cells at the +4 position and a second, in actively 
cycling Lgr5 expressing CBC cells. This model proposes the two populations have separate but 
cooperative functional roles as reciprocal back-up systems to provide a high rate of self-
renewal and flexible damage repair for the small intestine (Li and Clevers, 2010). Despite the 
validity of highly complex lineage tracing and in vitro culture experiments which gave rise to 
this hypothesis, a number of studies failed to corroborate the previous findings of specific 
markers of the quiescent ‘+4’ stem cell mentioned above, in particular, a study which failed to 
recapitulate the phenotype reported from Bmi1 driven lineage tracing experiments (Muñoz et 
al., 2012). This study conducted a transcriptome and proteomic analysis of Lgr5 positive CBC 
cells and found high levels of Bmi1, Hopx, Tert and Lrig1 in the Lgr5 positive cells and no 
specific enrichment of these markers in the Lrg5 negative stem cell zone. Whilst the authors 
argue that the presence and function of a quiescent stem cell pool cannot be excluded, they 
implying these markers solely cannot be used to identify the cells accurately. Instead, the 
authors allude to a concept first postulated by Cheng and Leblond and Potten and colleagues. 
This concept hypothesised that the transit amplifying cells above the stem cell zone may 
display plasticity when damaged and may be able to revert to stem cells to aid the 
regeneration process.   
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The small intestinal epithelium is made up of two compartments, the crypt and transit 
amplifying zone where stem cells and their progeny reside, and the villus, which constitutes 
differentiated cell types. Stem cells located at the bottom of the crypt give rise to immature 
progenitor cells which terminally differentiate as they migrate up the villus, before being shed 
into the lumen, with the exception of Paneth cells which migrate downwards and occupy the 
base of the crypt. The stem cell compartment found at the base of the crypt consists of paneth 
cells and stromal fibroblasts to create the stem cell niche.   
 
Figure 1.2 Schematic diagram of the small intestine 
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1.3 The stem cell niche and maintenance of homeostasis 
The stem cell niche can be defined as a local tissue microenvironment that hosts and 
influences the behaviour and characteristics of stem cells in order to maintain the balance 
between self-renewal and differentiation in the intestine, and therefore maintain homeostasis 
(Fuchs et al., 2004). This includes interactions between stromal fibroblasts found in the lamina 
propria through short-range signalling as well as interactions with the basement membrane 
and neighbouring epithelial cells. A number of signalling pathways have been implicated in 
maintenance of intestinal homeostasis and are discussed in detail below.  
1.3.1 The Canonical Wnt signalling pathway 
The Wnt signalling pathway plays an important role in regulation of cell proliferation and 
differentiation in a number of tissues including the skin, blood, brain and intestine. The 
canonical Wnt pathway, which regulates the ability of the β-catenin driven activation of target 
genes is better characterized and is strongly associated with initiation of colorectal cancer. The 
pathway is controlled at the cell membrane by Wnt ligands which bind to frizzled receptors (7 
pass transmembrane proteins). In the absence of cognate ligand, the protein dishevelled (Dsh) 
is recruited to the receptor preventing it inhibiting degradation of the transcriptional activator 
β-catenin in the cytoplasm by a destruction complex. This complex consists of Axis inhibitor 
(Axin) and adenomatous polyposis coli (Apc) proteins which form a scaffold and allow 
phosphorylation of β-catenin by glycogen synthase kinase 3β (Gsk3β). Phosphorylation marks 
the β-catenin protein for ubiquitination and subsequent proteosomal degradation. Binding of 
Wnt ligands to the receptor releases the Dsh protein from the receptor which is then able to 
bind to the destruction complex and prevent phosphorylation of β-catenin (summarised in 
Figure 1.3). This allows β-catenin to accumulate and enter the nucleus where it interacts with 
members of the T-cell factor and Lymphoid enhancer factor (Tcf/Lef) family to activate 
transcription of various Wnt target genes (reviewed in (Clevers, 2006).  
A number of elegant studies using mouse models have demonstrated the importance of 
precise Wnt signalling, for regulation of cell proliferation and maintenance of intestinal 
homeostasis. Initially, the role of Wnt signalling in the intestinal epithelium was determined by 
genetic alterations in Apc and β-catenin. This was shown to result in nuclear accumulation of 
β-catenin, constitutive activation of target genes associated with proliferation and subsequent 
formation of intestinal adenomas (Harada et al., 1999, Andreu et al., 2005). Similarly, 
homozygous loss of Apc in the intestine also resulted in rapid activation of the Wnt pathway 
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(Sansom et al., 2004). Accumulation of nuclear β-catenin here conferred a ‘crypt progenitor’ 
phenotype which led to mislocalisation of paneth cells, and increased proliferation and 
migration. Not surprisingly, inhibition of Wnt signalling has been shown to result in arrested 
epithelial cell proliferation, through ectopic expression of the secreted Wnt inhibitor 
Dickkopf1 (Dkk1) (Pinto et al., 2003) and can also lead to loss of the whole proliferative 
compartment as evidenced by deletion of the transcription factor Tcf (Korinek et al., 1998). Tcf 
is involved in activating transcription of a number of important genes including c-Myc, deletion 
of which leads to ablation of crypts in the mouse intestinal epithelium (Muncan et al., 2006). 
Concomitant deletion of c-Myc with Apc rescues the Apc ‘crypt progenitor’ phenotype 
highlighting its absolute requirement for development of the Wnt driven phenotype (Sansom 
et al., 2007). Furthermore, deletion of Wnt target genes EphB2 and EphB3 results in 
mislocalisation of paneth cells from their position at the bottom of the crypts, demonstrating 
requirement of Wnt signalling in correct migration and localisation of differentiated cell types 
(Batlle et al., 2002). These studies all highlight the importance of Wnt signalling in proliferation 
and differentiation and hence, appropriate control of Wnt signalling is required in the stem 
cell compartment and the stem cell niche, to maintain normal development and homeostasis. 
An extensive investigation of Wnt agonists and antagonists by in situ hybridisation techniques 
revealed a gradient of Wnt activity throughout the crypt-villus axis. Cells at the base of the 
crypt, where the stem cells reside, were shown to maintain a high level of Wnt activation 
whilst progenitors and differentiated cells migrating up the villus had no Wnt activation 
(Gregorieff et al., 2005). This discrete pattern of Wnt activation is regulated by a number of 
signalling pathways including those mentioned below to together maintain intestinal 
homeostasis. 
1.3.2 The Hedgehog signalling pathway 
Hedgehog signalling is a highly conserved signalling cascade, essential for embryonic 
development as well as differentiation, proliferation and maintenance of various adult tissues. 
Three Hedgehog genes exist in vertebrates which encode for three highly homologous ligands: 
Sonic Hedgehog (Shh), Indian Hedgehog (Ihh) and Desert Hedgehog (Dhh) (Echelard et al., 
1993). These are cleaved proteins released by Dispatched (Disp) from the cell membrane 
where they bind to Patched (Ptch), a 12-transmembrane receptor (Marigo et al., 1996). In the 
absence of Hh proteins, Ptch inhibits Hedgehog signalling by inhibiting activation of a 7-
transmembrane receptor, Smoothened (Smo). In the presence of Hh, inhibition on Smo is 
released and in turn, allows intracellular signal transduction via the Glioblastoma (Gli) family of 
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zinc finger transcription factors, Gli1, Gli2 and Gli3 (Ruiz i Altaba, 1999). These are able to 
translocate into the nucleus where they regulate target gene transcription of the Hedgehog 
pathway (summarised in figure 1.3).   
Indian Hh is the primary Hedgehog protein expressed in differentiated cells of the small 
intestine, and analysis of Hedgehog targets Ptch1 and Gli1 by in situ hybridization techniques 
revealed that Hedgehog signals exclusively in a paracrine fashion from epithelial to 
mesenchymal cells (van Dop et al., 2010). This in return has highlighted that Hedgehog 
responsive cells consist of smooth muscle precursor and differentiated cells, myofibroblast-
like cells and pericytes. A variety of studies have highlighted the role of Hedgehog signalling in 
regulating homeostasis of intestinal mesenchymal cells using transgenic mice. An increase in 
Hedgehog signalling via loss of Ptch, driven by the epithelial specific promoter VillinCre, led to 
an increase in the smooth muscle cell marker smooth muscle actin (α-Sma) positive cells in the 
mesenchyme (Zacharias et al., 2011). Additionally, overexpression of Ihh also by the Villin 
promoter resulted in an increase in smooth muscle precursors, differentiated smooth muscle 
cells as well as myofibroblast-like cells (van Dop et al., 2009). In another study by van Dop et 
al, the authors noted that deletion of Ihh from the intestinal epithelium resulted in a 
proliferative response mediated by increased Wnt signalling and loss of BMP signalling from 
the villus and loss of activin from the crypts. They also observed that prolonged loss of Ihh 
resulted in complete loss of smooth muscle precursor cells as well as complete loss of villus 
core support structure. Similarly, inhibition of Hedgehog signalling by overexpression of 
hedgehog-interacting protein (Hhip), leads to absence of villi and a highly proliferative crypt-
like intestine epithelium with activated Wnt signalling and a lack of differentiated cells 
(Madison et al., 2005). Therefore, the Hedgehog signalling pathway is crucial for formation of 
villi (through epithelial to mesenchymal signalling in the intervillus regions), restricting 
proliferation in the intervillus region as well as the crypt, and essential for maintaining spacing 
between crypts in the lamina propria. Taken together, it can be hypothesised that Hedgehog 
signalling acts from the epithelium to the mesenchyme as an inhibitor of Wnt signalling 
through upregulation of BMPs (described below in section 1.3.3) and may contribute to the 
tight control of Wnt activation in the normal intestinal epithelium.  
1.3.3 The TFGβ/BMP signalling pathway 
The Bone Morphogenetic Protein (BMP) pathway forms a large subgroup within the 
Transforming Growth Factor β (TFGβ) superfamily. Members of this family signal through a 
common mechanism in which the ligands bind to a complex of type 1 and type 2 
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transmembrane serine-threonine kinase receptors. This results in phosphorylation of the 
cytoplasmic domain of the type 1 receptor by the type 2 receptor, and leads to signal 
transduction via a family of proteins known as mothers against decapentaplegic, or Smads. 
Receptor regulated Smads (R-Smads) Smad 1, Smad 5 and Smad 8 are recruited to the 
receptor where they are activated by phosphorylation and in turn, able to complex with the 
common Smad (co-Smad), Smad 4. This association results in nuclear translocation of the 
complex where it interacts with co-activators and co-repressors of transcription to modulate 
target gene expression (summarised in figure 1.3) (Massagué, 1998).   
The BMP pathway was initially implicated in the initiation of CRC when inactivating mutations 
in BMP receptor type 1A (BMPR1A) and Smad4 were found in the majority of patients with 
Juvenile Polyposis Syndrome (JPS) (Howe et al., 1998, Zhou et al., 2001). JPS is a rare 
autosomal hamartoma syndrome in which patients can develop between 50-200 polyps which 
display gross chronic inflammation and expanded mesenchymal stoma (Roth and Helwig, 
1963). Investigation of various alterations of TGFβ/BMP signalling in the mouse intestine has 
generated a number of gastrointestinal phenotypes. Inhibition of BMP signalling in the villus 
by ectopic expression of Noggin (a secreted BMP inhibitor) led to de novo crypt formation, a 
JPS resembling phenotype and late forming adenomas (Haramis et al., 2004). Deletion of the 
Bmpr1a gene driven by an interferon-inducible promoter Mx1Cre (acts in the epithelium and 
the underlying stroma) also led to development of hamartomatous polyps as well as an 
expanded proliferative compartment in the intestine (He et al., 2004b). Deletion of Bmpr1a in 
the intestine driven by the epithelial-specific promoter VillinCre was not sufficient for the de 
novo crypt phenotype associated with JPS, but did lead to hyperproliferation of crypts and 
impaired terminal differentiation of cells from secretory lineages. Furthermore, stromal 
specific deletion of BMP receptor type 2 (Bmpr2) lead to development of hamartomas (Beppu 
et al., 2008) and T-cell specific deletion of Smad4 resulted in development of hamartomas 
which further developed into invasive carcinoma (Kim et al., 2006). Together, the studies 
outlined above highlight the importance of BMP signalling in the stroma and immune cells, 
and implicate a role in maintaining intestinal homeostasis.  
The BMP signalling pathway has a well defined role of establishing the crypt-villus axis in the 
intestine. BMP ligands, receptors and Smad proteins are found to be expressed in 
mesenchymal and epithelial cells whereas BMP antagonists are only found to be expressed in 
the mesenchyme (Li et al., 2007). Additionally, phosphorylated Smads 1, 5 and 8 can only be 
visualised in the nuclei of villus epithelial cells indicating BMP signals from the mesenchyme in 
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a paracrine fashion where mature epithelial cells are the main target (Haramis et al., 2004, He 
et al., 2004b). BMPs are also known to play an important role in controlling the proliferative 
compartment. Here, BMPs are found to directly inhibit Wnt activated and β-catenin driven 
proliferation, via intracellular mechanisms mediated by Pten, a negative regulator of the PI3K 
pathway (Tian et al., 2005). Additionally, BMP signalling has been shown to be required for full 
maturation of secretory lineages in vivo, an important function of the Notch signalling 
pathway (described below in section 1.3.4). Bmpr1a mutant mice were deficient in 
enteroendocrine cells, had immature-appearing paneth cells and goblet cell granuoles as well 
as reduced expression of secretory lineage gene expression, but did not affect absorptive cell 
maturation (Auclair et al., 2007). Taken together, these functions of BMP signalling imply an 
important role for BMP signalling in the lamina propria in regulating proliferation and lineage 
allocation in the intestine.      
1.3.4 The Notch signalling pathway 
The Notch signalling pathway, initially characterized in the 1980s plays a crucial role in 
regulating the balance between cell proliferation, differentiation, spatial patterning and 
apoptosis in a variety of tissues. Mammals possess four Notch genes, each of which encode a 
heterodimeric transmembrane receptor (Notch 1-4) with individual extracellular and 
cytoplasmic characteristics. Activation of Notch receptors by any one of five ligands (Delta like 
(Dll) 1, 3 and 4 and Jagged (Jag) 1 and 2) present on adjacent cells leads to proteolytic cleavage 
of the Notch intracellular domain (Nicd) by γ-secretases and metalloproteases into the 
cytoplasm. Nicd is then able to translocate into the nucleus where it binds to the transcription 
factor CBK1/RBP-Jk/Suppressor of Hairless/LAG-1 (Csl) to activate transcription of Hes (1, 5 
and 7), Hey (1, 2) and Heyl genes, encoding basic helix-loop-helix/orange domain 
transcriptional repressors (summarised in figure 1.3) (Radtke and Raj, 2003).   
Notch signalling in the intestine is restricted to the crypt region and to a lesser extent, the 
surrounding mesenchyme (Schröder and Gossler, 2002). The pathway governs cell fate in the 
intestinal epithelium by regulating differentiation predominantly between absorptive and 
secretory lineages. Overexpression of Nicd and hence aberrant activation of Notch signalling in 
the mouse intestinal epithelium, resulted in a reduced number of secretory cells (Fre et al., 
2005). Conversely, inhibition of the Notch pathway, either by deletion of the transcription 
factor Csl or inhibition of γ-secretases leads to an increase in the number of differentiated 
secretory cells (Fre et al., 2005, van Es et al., 2005). Notch is primarily expressed in the 
intestinal crypt and is thought to maintain the undifferentiated state by upregulation of Hes1 
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which is also only expressed in crypts. Animals deficient in Hes1 die perinatally due to 
neurological abnormalities. However, the developing intestines showed an increase in 
secretory cells at the expense of absorptive enterocytes (Jensen et al., 2000). Furthermore 
mice deficient in Math1, a target gene of Hes1 mediated repression, also have increased 
secretory goblet cells and reduced enteroendocrine cells (VanDussen and Samuelson, 2010). In 
accordance with previous data, a recent study in which Notch ligands Delta like (Dll) 1 and 4 
were deleted in the mouse intestinal epithelium resulted in an increase in secretory cell types. 
Interestingly however, unlike previous studies, mice died rapidly after loss of Dll1 and Dll4 due 
to crypt loss and ablation of the stem cell population. Together, these observations suggest 
that cells expressing Notch ligands are committed to a secretory cell fate and activate Notch 
signalling in their neighbouring cells in order to prevent their commitment to a secretory cell 
fate also. These observations also highlight the role of Notch signalling in maintaining the 
progenitor phenotype of cells in the crypt as well as stem cell maintenance, most likely 
through co-operation with the Wnt pathway (Peignon et al., 2011). Additional data to support 
this was recently reported in a study which showed Hath1 (the Drosophila Melanogaster 
homologue of Math1) expression is not only regulated by Notch, but also by the Wnt signalling 
pathway. This study showed that Math1 can be targeted for ubiquitination and subsequent 
proteosomal degradation by Gsk3-β when Wnt signalling is activated as opposed to targeting 
β-catenin for degradation in the absence of Wnt signalling (Tsuchiya et al., 2007). Moreover, 
other studies indicate Notch ligands Hes1 and Jag1 are also regulated by Wnt/β-catenin 
signalling, further highlighting the co-ordination between Notch and Wnt signalling in the 
maintenance of differentiation and homeostasis in the intestine (Rodilla et al., 2009).     
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Whilst Wnt signalling is crucial for regulating proliferation, the TGF-β/BMP and Hedgehog 
signalling pathways regulate Wnt pathway activation. Notch signalling influences 
differentiation of intestinal cell types and maintains an immature state in the crypt through 
high levels of Notch activity.   
Figure 1.3 Schematic representations of four main signalling pathways which regulate small 
intestinal homeostasis 
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1.3.5 Colorectal Cancer stem cells 
The identity of the cancer cell of origin and the mechanism by which a tumour is propagated 
has been a widely contentious issue in the field. This is because it has major implications on 
multiple aspects of cancer biology, including early cancer detection and prevention, 
therapeutic target discovery, drug resistance, as well as metastasis (Wicha et al., 2006). The 
original observations from tumour histology of heterogeneity in tumours alluded to a model 
whereby any cell type including stem cells, progenitors and early differentiated cells could be 
the cancer cell of origin (Little and Wright, 2003). It was also assumed that all cells had equal 
capacity to propagate the tumour by aberrantly proliferating. This model, currently termed the 
stochastic model was used to explain tumour heterogeneity as a consequence of genomic 
instability of tumour cells and microenvironmental factors affecting the tumour (Lobo et al., 
2007). Therefore from the stochastic model, obliteration of all cancer cells is required for 
successful treatment as any neoplastic cell can hypothetically propagate the tumour. 
Alternatively, substantial evidence for the existence of a discrete population of tumour cells 
capable of self-renewal and differentiation of multiple lineages has recently gained 
momentum. This theory is known as the cancer stem cell model (or the hierarchical model) 
and is now the more widely accepted notion used to explain the cancer cell of origin, tumour 
heterogeneity as well as tumour progression.  Due to their long-living, self-renewing and 
proliferative capacity, stem cells are favourable contenders for transformation into cell of 
origin for intestinal cancer. In this model, tumour cells maintain a hierarchical organisation 
whereby a population of cells (cancer stem cells) at the top of the hierarchy, are responsible 
for renewing cells. They can give rise to further cancer stem cells, progenitor cells with 
proliferative capacity as well as aberrantly differentiated cells with no proliferative capacity 
(Vries et al., 2010). Clinically, this implies that therapies targeting the cancer stem cells will 
eradicate the tumour  whereas those targeting the bulk tumour cells would be less successful, 
resulting in the cancer stem cells giving rise to more tumour cells and causing recurrence of 
the disease (He et al., 2009). However it is likely that selective killing of CSC within the tumour 
may create an opening for non-stem cell pools to revert to stem cell-like cells to help revive 
tumour growth. In this case, targeting CSCs and bulk tumour cells which provide a supporting 
microenvironment may be required for complete tumour eradication.        
There have been considerable efforts to identify the pools of cancer stem cells in order to 
isolate and confirm their ability to initiate tumourigenesis as well as develop therapeutics that 
could potentially target these cells.  The first cell surface marker to identify intestinal cancer 
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stem cells was CD133, also known as Prominin1. Identified in cells with a high proliferative 
capacity, CD133+ cells were found to be 200 fold enriched for tumour-initiating cells compared 
to CD133- cells as deduced upon transplantation into non-obese diabetic/severe combined 
immune deficiency (NOD/SCID) mice (O'Brien et al., 2007). Similarly, high expression of 
epithelial cell adhesion molecule (EpCAM) and CD44 were also identified as markers of 
tumour-initiating cells which when transplanted, formed lesions morphologically similar to the 
original human lesion (Dalerba et al., 2007).  Other intestinal cancer stem cell markers include 
CD166, CD29, CD24 and Lgr5, based on their expression in CD133+ cultures (Vermeulen et al., 
2008, Dalerba et al., 2007). Confirmation of these markers was achieved from transplantation 
of cell surface marker positive cells into immune-compromised mice, indicating 
CD133+/CD24+ and EpCAM high/CD44+/CD166+ populations to represent tumour initiating 
populations (Vermeulen et al., 2008, Dalerba et al., 2007). Previously used to isolate 
hematopoietic precursors, Aldehyde Dehydrogenase 1 (ALDH1) has also been shown to mark 
human CRC stem cells. Huang and colleagues isolated ALDH1+ CRC cells based on their 
enzymatic activity and showed they were capable of forming tumours when injected into 
NOD/SCID mice, whereas ALDH1- cells did not (Huang et al., 2009a). As ALDH1 functions as a 
detoxification enzyme (Riveros-Rosas et al., 1997), it is hypothesised that this could act to 
protect CSCs from oxidative insult, permitting longevity and increased proliferative capacity 
(Miyamoto and Rosenberg, 2011).   
Identification of these various cell surface markers allowed Barker and colleagues, and Zhu 
and colleagues to formally provide evidence for the small intestinal stem cell as the cell of 
origin for intestinal adenomas. These studies utilised conditional transgenic techniques to 
activate the Wnt pathway by loss of the tumour suppressor Apc in Lgr5 or CD133 expressing 
cells in the intestine. This led to efficient tumour formation which was not the case when Apc 
was lost in progenitor or differentiated cells (Zhu et al., 2009, Barker et al., 2009). Additionally, 
Schepers et al used a Confetti Cre-reporter allele to demonstrate that Lgr5+ cancer stem cells 
are able to fuel growth of established intestinal adenomas and give rise to additional Lgr5+ 
cells as well as other adenoma cell types (Schepers et al., 2012). Although it remains to be 
determined whether targeting Lgr5/CD133 expressing cells would be capable of causing 
tumour progression or chemo-refraction, the use of in vivo mouse models to investigate CSCs 
raise less caveats than those which utilise sorting of elusive cell surface markers in human 
CRCs and serial transplantations of these cells into immunodeficient mice. These caveats 
include extended culture of human cancer cells, transplantation of cells into foreign sites in 
immune-deficient mice, addition of multiple cocktails of growth factors and absence of any 
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natural tumour-host interactions. Although these experiments do provide valuable 
information on long term self-renewal of the cells, they fail to reflect the true physiological 
fate of cells in their natural environments.  
Additional evidence for the CSC hypothesis has recently been provided by Driessen and 
colleagues, utilising mouse models of benign papillomas and squamous skin carcinoma, and 
Chen and colleagues, using a mouse model of glioblastoma. Driessens and colleagues utilised 
genetic lineage tracing experiments to analyse clonal expansion in an established mouse 
model of benign papillomas. This study reported the presence of two distinct proliferative 
compartments, one which terminally differentiated, seldom cycled and had a limited 
proliferative potential and another with the capacity to persist long term, actively cycled and 
possessed more stem-cell like characteristics, reminiscent of the hierarchy found in normal 
tissue. Furthermore, the authors assessed similar features in invasive squamous cell 
carcinomas and found clonal expansion of a single proliferative population with reduced ability 
to undergo terminal differentiation. Together, these data are consistent with the CSC 
paradigm and highlight the differing hierarchy of tumour growth present in benign and 
invasive cancers (Driessens et al., 2012). Chen and colleagues also provided compelling 
evidence for the CSC hypothesis. In this study, the authors challenged murine glioblastomas 
with the standard cytotoxic temozolomide and found a small population of cells with similar 
properties to CSCs responsible for long term tumour re-growth through the production of 
highly proliferative cells. Additionally, the study found genetic targeting of glioblastoma CSCs 
together with cytotoxics for the bulk tumour cells significantly reduced growth of the 
established tumours, showing proof of concept of targeting CSC in vivo (Chen et al., 2012a). 
Although these studies provide strong evidence for the CSC hypothesis, a number of 
challenges within the area remain, including determining mechanisms involved in tumour re-
growth, the influence of external environment on tumour growth and progression and finally, 
identification of novel therapeutics which target these increasingly problematic cells.        
1.4 The genetic model of colorectal cancer progression 
Although tumourigenesis has long been thought a multistep process, the identification of key 
molecular events which underlie initiation and progression of tumourigenesis are not only vital 
for our understanding of tumourigenesis but are also imperative for the development of novel 
targeted therapeutics. The genetic model of CRC progression, first proposed over 20 years ago 
by Fearon and Vogelstein following a comprehensive review of available histopathological and 
genetic data, is currently coined the ‘classical model’ and is remarkably still valid today. Fearon 
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and Vogelstein proposed that the accumulation of multiple mutations leads to progression of 
a tumour from a dysplastic epithelium, to a benign adenoma through to metastatic carcinoma. 
Furthermore, they proposed that although the mutations often occur in a preferred sequence, 
it is the total accumulations of mutations rather than the order in which they accumulate that 
is responsible for the biological properties of a tumour (Fearon and Vogelstein, 1990). The 
model describes mutations in the APC gene as the initiating mutation of CRC, followed by 
subsequent mutations in Kirsten rat sarcoma viral oncogene homologue (KRAS), allelic loss of 
the 18q locus, and mutations in p53 which contribute to development of malignant disease 
(figure 1.4).      
As described previously, the Apc protein plays an important role in mediating the Wnt 
signalling pathway and is often regarded as the gatekeeper mutation, due to its central role in 
maintaining proliferation in the normal intestine (Powell et al., 1992, Kinzler and Vogelstein, 
1996). Understanding the molecular pathogenesis of the predisposition syndrome FAP where 
germline mutations in Apc resulted in hundreds of adenomas also implicated a role for Apc in 
initiation of CRC. Here, Apc mutations are not sufficient enough to cause progression of lesions 
and rather accumulations of other mutations leads to metastatic disease. Recently, the Cancer 
Genome Atlas Network identified altered Wnt signalling in 93% of all cases, with APC found to 
be inactivated in approximately 80% of cases, as well as CTNNB1 (which encodes β-catenin) 
mutations in up to 7% and finally AXIN2 mutations in up to 23% of cases (Network, 2012). This 
highlights the commonality of Wnt pathway mutations in colorectal tumourigenesis and 
implicates a role in the initiation of CRC. Additionally, APC loss is associated with Chromosomal 
instability (CIN), a process which increases chromosome rearrangements and hence promotes 
accumulation of further mutations. Fearon and Vogelstein hypothesised this as a mechanism 
to accumulate the 7 genetic alterations required for development and progression of 
tumourigenesis (loss of both alleles of 3 tumour suppressors and activation of 1 oncogene), a 
process which would normally take more than a lifetime given the mutation rates of the 
normal intestinal epithelium (Fodde et al., 2001).  
The acquisition of activating mutations in the RAS oncogene is regarded as the next step for 
adenoma progression. Fearon and Vogelstein noted that RAS mutations were more prevalent 
in larger adenomas and carcinomas as opposed to small adenomas indicating a role in tumour 
progression (Vogelstein et al., 1988). As further described in section 1.5.2, Kirsten-RAS (KRAS) 
is the RAS homologue most commonly mutated in CRC, and is a downstream mediator of the 
Mitogen activated protein kinase/Extracellular regulated MAP kinase (MAPK/ERK) pathway. 
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Manipulation of Apc and Kras in the murine intestine confirmed a role for Kras in tumour 
progression as mice developed more invasive intestinal lesions, and had a significantly reduced 
survival (Janssen et al., 2006, Sansom et al., 2006). Genomic analyses have indicted activation 
of KRAS in approximately 40% of CRC cases, and have also indicated a significantly higher 
frequency of mutations in Duke’s stage C tumours, confirming its association with tumour 
progression (Network, 2012, Smith et al., 2002).          
Fearon and Vogelstein also reported loss of the long arm of chromosome 18 in 70% of 
carcinomas and 50% of late adenomas (Vogelstein et al., 1988). This region was subsequently 
mapped and the tumour suppressor involved was termed Deleted in colorectal cancer (DCC) 
(Fearon et al., 1990). Despite its potential role in tumour progression, loss of Dcc failed to 
predispose mice to CRC and failed to promote tumour progression in Apcmin mice, indicating 
the role of Dcc currently remains unknown (Fazeli et al., 1997). The lack of phenotype 
observed by DCC mutants in the mouse may be attributed to the involvement of other genes 
at the 18q region, namely SMAD2 or SMAD4. As previously described, both mediate 
downstream signalling of the TGF-β/BMP pathway and are essential for maintenance of 
intestinal homeostasis through epithelial to mesenchymal signalling (section 1.3.3). Recent 
genomic analysis revealed the TGF-β signalling pathway to be altered in 27% of non-
hypermutated and 87% of hypermutated tumours, including mutations in Smad4 (20%) and 
Smad2 (13%) (Network, 2012) and establishing a major role for the pathway in colorectal 
tumourigenesis. 
Finally, Fearon and Vogelstein identified loss of the short arm of chromosome 17 as the final 
step for development of malignant disease. This region, lost in 75% of colorectal carcinomas, 
was mapped to the TP53 locus which encodes for a potent tumour suppressor, protein 53 
(p53) (Vogelstein et al., 1988). Furthermore, concomitant with loss of 17p, point mutations in 
the wild-type p53 gene have also been implicated in colorectal, breast, brain and bladder 
cancers where it was strongly associated with metastatic disease and poor prognosis 
(Iacopetta et al., 2006). Elegant evaluation of p53 using mouse models of CRC revealed loss of 
p53 had no effect on tumourigenesis or tumour progression; however mutant p53 promoted 
progression of Apc mutant colorectal tumours implicating the type of p53 mutation greatly 
impacts tumour biology (Clarke et al., 1995, Muller et al., 2009).  
Along with the Wnt, MAPK/ERK, TGF-β and p53 signalling pathways, the Phosphoinositide 3-
kinase (PI3K) pathway has also been implicated in colorectal tumourigenesis. As described in 
section 1.5.3, a number of elements along the pathway are mutated in CRC. A recent genomic 
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study of colorectal tumours found the PIK3CA gene, which encodes  the p110α protein- the 
catalytic subunit of PI3K, to be a ‘mountain’ in the cancer genome landscape, together with 
APC, KRAS and TP53 (Wood et al., 2007).  The implication from this study is that mutations in 
the PI3K pathway are likely to be ‘drivers’ of neoplastic processes rather than ‘passengers’ that 
provide no selective advantage to the tumour. This has been evidenced by a number of studies 
which implicate the pathway in mediating progression of tumours and poor prognosis (Yang et 
al., 2013). Activation of the PI3K pathway by loss of the tumour suppressor protein 
Phosphatase and tensin homolog (Pten) has been shown to promote invasion of Apc 
heterozygous intestinal tumours and also to synergise with oncogenic Kras in the small 
intestine to induce metastasis in vivo (Marsh et al., 2008, Davies et al., in press). The 
identification of various genetic events which underlie pathogenesis of CRC has not only 
helped our understanding of the disease but has also highlighted some credible therapeutic 
targets. 
 
Figure 1.4 Schematic outlining Fearon and Vogelstein model of colorectal cancer progression 
Fearon and Vogelstein proposed that accumulation of outlined mutations leads to progression 
of a benign lesion to metastatic carcinoma. Here, mutations the tumour suppressor APC are 
regarded as the initiating mutation of colorectal cancer, whilst mutations activating the 
oncogene KRAS and allelic loss of the 18q locus lead to progression of a tumour. Finally, 
mutations in the tumour suppressor protein p53 are associated with metastatic disease.  
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1.5 Novel targeted therapeutic strategies in pre-clinical and clinical development for CRC 
The notion of stratified medicine whereby the molecular definition of a tumour determines 
the choice of therapeutic strategy has been revolutionised by extensive analysis of molecular 
events underlying cancer development. Additionally, targeting patients on the basis of 
distinctive biological characteristics will identify enriched subpopulations that respond 
differently to treatment, leading to overall better treatment of cancer.   
1.5.1 Targeting developmental pathways and cancer stem cells: Wnt, Notch and 
Hedgehog pathways 
Since aberrant Wnt signalling is implicated in sporadic, familial and hereditary forms of CRC as 
well as FAP, there has been extensive interest in developing drugs which target the signalling 
cascade. Due to the complexity of Wnt signalling (discussed previously in section 1.3.1), 
intervention can occur at multiple levels including ligand expression, receptor-ligand 
interactions, as well as promote β-catenin degradation and disrupt Tcf/β-catenin interactions 
in the nucleus (Barker and Clevers, 2006). Human cancers with or without mutations in APC, 
AXIN or β-catenin may activate Wnt signalling by increasing expression of Wnt ligands or Fzl 
receptors (Rhee et al., 2002, He et al., 2005a, He et al., 2005b). He and colleagues recently 
developed a monoclonal antibody against Wnt-1 which has since been shown to effectively 
block Wnt signalling, halt proliferation and induced apoptosis in a number of human cancer 
cell lines including head and neck, non-small-cell lung, breast, mesothelioma and sarcoma cells 
(He et al., 2004a). Furthermore, the Wnt-1 antibody also induced apoptosis in colon cancer 
cells which had downstream activating mutations, most likely attributed to the rarity of null 
mutations (He et al., 2005b). Although encouraging, these preliminary results need further 
validation in animal models to determine true in vivo efficacy before further clinical 
development. Alternatively, a monoclonal antibody against sclerostin, a protein that inhibits 
the LRP5/6 receptors is currently undergoing clinical evaluation for osteoporosis (produced by 
Amgen) and may be an attractive therapeutic strategy if found to be tolerated well in patients 
(Rey and Ellies, 2010).  
Other strategies employed to inhibit Wnt signalling focus on targeting β-catenin for 
degradation or disrupting Tcf/β-catenin interactions in the nucleus. Two recent studies 
independently highlighted the role of poly-ADP-ribosylating enzymes tankyrase 1 and 2 (Tnks) 
in promoting degradation of Axin2. Enzymatic inhibition of Tnks by XAV-939 (Novartis) was 
able to stabilise Axin2 and promote degradation of β-catenin (Huang et al., 2009b, Chen et al., 
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2009) in Apc mutant cells, and may indeed hold some promise for anti-cancer therapy. 
Alternatively, targeting nuclear TCF/β-catenin interactions may yield more fruitful effects. A 
recent screen conducted by Emami and colleagues identified a number of TCF/β-catenin 
inhibitors including the lead compound ICG-001, which specifically inhibits the co-activator 
CREB binding protein (CBP). The compound has since been validated in vitro where it has been 
shown to preferentially induces apoptosis in colon cancer cells whilst sparing normal colon 
cells, and has also been assessed in vivo in human xenografts and the APCmin mouse model of 
human FAP  (Emami et al., 2004), showing some early promise.       
Despite the growing pharmaceutical interest and efforts into developing efficacious Wnt 
pathway inhibitors, a number of drugs already in the market, as well as many natural 
compounds, have been found to directly or indirectly target the Wnt pathway. These include 
Non-steroidal anti-inflammatory drugs (NSAIDs) such as aspirin and sulindac, both of which 
have chemopreventive effects by targeting cyclooxygenase (COX) enzymes which mediate Wnt 
pathway activation via Prostaglandin induced β-catenin degradation (Dihlmann et al., 2001, 
Boon et al., 2004). However, long term use of NSAIDs such as aspirin, can lead to severe 
intestinal bleeding and kidney damage. This has resulted in the development of novel NSAIDs 
which are hypothesised to have increased anti-tumour activity and limited toxic side effects 
(Barker and Clevers, 2006). Nitric Oxide-donating aspirin (NO-ASA) is an example of a safer, 
more effective NSAID that has been shown to reduce polyp formation in APCmin mice and 
reduce Wnt signalling in colon cancer cell lines by disrupting TCF/β-catenin interactions 
(Williams et al., 2004, Nath et al., 2003).  The Vitamin derivative retinoid, has also been used 
for pre-clinical therapy and chemoprevention whilst Vitamin A has been used against acute 
promyelocytic leukemia (APL), and active forms of Vitamin D have been shown to be 
chemopreventative in animal models of colorectal and breast cancers (Takahashi-Yanaga and 
Kahn, 2010, Pálmer et al., 2001). Various mechanisms have been proposed for the anti-tumour 
capabilities of vitamin derivatives including a study by Jiang et al, and Pendás-Franco et al, 
who evidenced vitamin A and D induced activation of Wnt/ β-catenin inhibitory proteins 
Disabled-2 (Dab2) and Dickkopf 1 and 4 (Dkk1, Dkk4) (Jiang et al., 2008, Pendás-Franco et al., 
2008). Additionally polyphenols, a chemical group found in plants and include compounds 
such as quercetin, curcumin and resveratrol, have all been implicated as Wnt inhibitors. 
Resveratrol, a compound extracted from grape skin and wine has been shown to reduce Wnt 
signalling and also CD133 expression in colonic epithelium when evaluated in a CRC prevention 
trial as a dietary supplement. Subsequently, this is currently under phase II clinical evaluation 
(Berge et al., 2011, Martinez et al., 2010). Although novel Wnt inhibitors have enormous 
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potential therapeutically, the Wnt pathway is critical to normal somatic stem cell maintenance 
and tissue homeostasis and therefore thorough evaluation will be required prior to integration 
with existing cancer treatments.  
Alternatively, the Hedgehog and Notch signalling pathways, also implicated in maintenance of 
cancer stem cells, may present as attractive therapeutic targets. The identity of cyclopamine, a 
naturally occurring hedgehog inhibitor found in Veratrum Californicum, has previously been 
utilised as an anti-cancer agent (Cooper et al., 1998). Despite potent anti-tumour activity in 
vitro and in vivo, cyclopamine was found to be highly insoluble and toxic. This led to the 
development of further compound screens to identify potent analogues (Teglund and 
Toftgård, 2010). Currently, the majority of Hedgehog inhibitors in pre-clinical and clinical 
evaluation from screening processes are Smoothened inhibitors. As described previously, 
Smoothened is a transmembrane receptor which is activated by a cognate transmembrane 
receptor Patched (PTCH), upon Hedgehog ligand binding. The smoothened inhibitor GDC-0449 
(vismodegib, Genentech) demonstrated potent single agent activity in patients with PTCH1 
mutant medulloblastoma and basal cell carcinoma (BCC) (Von Hoff et al., 2009), and 
subsequently resulted in FDA approval (in 2012) as the first agent approved for metastatic and 
inoperable locally advanced BCC. Interestingly, although mutations in Hedgehog signalling 
occur much less frequently in human malignancies of other origins including colorectal, 
ovarian, prostate and pancreatic cancer, in vitro studies have shown a lack of correlation 
between hedgehog pathway activation and response to pathway inhibitors, suggesting that 
hedgehog inhibition may be beneficial for other tumour settings (Yauch et al., 2008). This is 
thought to be attributed to the role of hedgehog signalling in the mesenchyme and the 
tumour microenvironment i.e. tumour stroma. Evidence for this was formally provided from a 
genetically engineered mouse model of pancreatic cancer where smoothened inhibition 
resulted in enhanced delivery and response to chemotherapeutics by depleting tumour 
associated stromal tissue (Olive et al., 2009). Promisingly, the lead Smoothened inhibitor 
vismodegib is currently in Phase I/II evaluation in gastrointestinal and pancreatic malignancies.   
The Notch signalling cascade has been implicated in maintenance of cancer stem cells and 
chemoresistance in a number of human malignancies. Furthermore, genetic alterations that 
implicate the Notch pathway have been detected in some cancers, in particular, T-cell acute 
lymphoblastic leukemia (T-ALL) in which 50% of cases are attributable to chromosomal 
translocations that activate Notch1 (Weng et al., 2004). The Notch pathway is also activated in 
CRC, where upregulation of NOTCH-1, JAGGED-1 and JAGGED-2 ligands have previously 
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observed in human intestinal adenomas, implicating the pathway in early stages of tumour 
growth (Reedijk et al., 2008). Furthermore, expression of NOTCH-1 was highest in liver 
metastases suggesting its requirement in tumour progression (Meng et al., 2009). 
Chemotherapeutics including oxaliplatin and 5-flurouracil have also been shown to indirectly 
induce NCID and HES-1 expression through increased γ-secretase activity, suggesting notch 
inhibition may act as a potent chemo-sensitizer (Meng et al., 2009).  The majority of Notch 
pathway inhibitors are γ-secretase inhibitors (GSIs) which block proteolytic cleavage of the 
Notch receptor and NICD (described previously in 1.3.4). GSIs were initially developed to treat 
or prevent Alzheimer’s disease however significant toxicity evidenced by gastrointestinal 
bleeding and diarrhoea, observed in animal experiments and early human trials, ceased 
further development and forced development of less cytotoxic agents (Searfoss et al., 2003). 
Various novel agents are currently under clinical evaluation, including the third generation GSI- 
R04929097, currently in phase I evaluation in combination with the anti-EGFR agent cetuximab 
and in phase II evaluation as a single agent for third-line treatment of metastatic CRC. 
Furthermore, oxaliplatin-induced activation of Notch signalling was reduced by simultaneous 
GSI treatment and resulted in an increased anti-tumour effect, indicating promising potential 
of targeting the Notch signalling pathway (Meng et al., 2009).  
 
1.5.2 Mitogen-Activated Protein Kinase Pathway (MAPK/ERK) pathway 
The MAPK/ERK pathway is stimulated by Receptor Tyrosine Kinases (RTK), Integrins and influx 
of calcium ions. Downstream of RTKs such as EGFR, are RAS proteins which belong to a larger 
family of small guanosine-5’-triphosphate binding proteins (GTPases) (Schubbert et al., 2007). 
This includes HRAS, KRAS and NRAS, all of which are crucial in mediating intracellular 
responses to extracellular stimuli, such as growth factor signalling. RAS is often localised to the 
membrane by farnesylation, a process that adds a 15-carbon isopropene chain to the C-
terminal CAAX (Downward, 2003, Sebti and Der, 2003). Once membrane bound, activation of 
the Growth-factor receptor binding protein 2 (GRB2) leads to subsequent activation of 
Sevenless homolog (SOS), which in turn leads to full activation of RAS by facilitating 
dissociation of GDP and binding of GTP to RAS. Immediately downstream RAS are RAF proteins 
(A-RAF, B-RAF and C-RAF) which are serine/threonine protein kinases, and whose 
phosphorylation leads to further downstream activation of Mitogen Activated Kinase 1/2 
(MEK1/2). These in turn act as catalytic substrates for extracellular signal-related kinase 1/2 
(ERK1/2) (Figure 1.5). Phosphorylation of ERK leads to nuclear translocation where key cell 
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cycle regulators are targeted including c-jun and cyclin D, as well as MAPK-interacting kinases 
(MNK1 AND MNK2), stress activated kinases (MSK1and MSK2) and various transcription 
factors (Maekawa et al., 2002, Roux et al., 2004, Ledwith et al., 1990). All of these targets are 
pivotal in regulating various cellular processes including proliferation, survival, apoptosis and 
migration. 
KRAS has been implicated in the oncogenesis of many tumour types including non-small-cell 
lung, pancreatic, papilliary and colon cancer (Sebolt-Leopold and Herrera, 2004), and is the 
most commonly mutated protein in the MAPK pathway. Approximately 40% of CRCs present 
with mutations in KRAS, the majority of which occur in codon 12 and 13 (Bos et al., 1987, 
Smith et al., 2002). These mutations often involve glycine-to-valine substitutions at the 
catalytic sites of amino acids which subsequently lead to loss of GTPase activity and therefore 
continuous binding of GTP to RAS (Yokota, 2012). Importantly, retrospective studies have 
found mutations in KRAS to be the key negative predictor for response to anti-EGFR antibodies 
for CRC, and currently patients are screened prior to cetuximab treatment to ensure absence 
of KRAS mutations (Karapetis et al., 2008). The MAPK pathway is also activated following 
mutations in B-RAF, most of which occur at the V600E kinase domain. This mutation involves a 
valine-to-glutamic acid substitution in the kinase activation loop resulting in constitutive 
activation of B-RAF (Ikenoue et al., 2003). The V600E mutation occurs in approximately 15% of 
CRCs and is also a negative predictor of anti-EGFR therapy. Subsequently, although mutations 
activating KRAS and B-RAF are mutually exclusive (Rajagopalan et al., 2002), together can 
identify up to 55% of non-responders to anti-EGFR therapy. This also highlights a large 
population of patients that could potentially benefit from agents targeting the MAPK pathway 
downstream of EGFR.  
Efforts to target the MAPK pathway have yielded agents targeting RAS and RAF proteins, but 
more fruitfully, MEK1/2. As RAS requires membrane localisation via farnesylation, much effort 
and early promise focused on inhibiting this process with selective farnesyltransferase 
inhibitors (FTIs) with hope to target a number of malignancies with KRAS mutations. Several 
compounds entered clinical trials including R115777 (Tipifarnib, Zanestra), however concerns 
developed when higher concentrations of FTIs were required to inhibit oncogenic KRAS, in 
comparison with wild-type RAS or oncogenic HRAS (End et al., 2001). Furthermore, 
disappointing results from trials in KRAS mutant pancreatic cancers provided further evidence 
against the use of FTIs. Here, the lack of response in KRAS mutant tumours was thought to be 
31 
 
attributable to geranylation, an alternative activating mechanism adopted by KRAS mutant 
tumours to ensure membrane localisation (Berge et al., 2011).  
Much interest into inhibiting RAF proteins stemmed from the discovery of the protein 
functioning as an effector downstream RAS. Additionally, oncogenic B-RAF mutations are 
present in a number human malignancies including melanoma, ovarian, thyroid and colon 
cancers (Davies et al., 2002, Singer et al., 2003, Cohen et al., 2003). Hence there are a number 
of promising BRAF inhibitors at various stages of clinical development, including PLX4032 
(Vemurafenib, Plexxicon) and XL281 (Excelexis), both of which target the V600E mutant form, 
and are proving well tolerated with mild toxicities in patients with a number of malignancies 
including colorectal cancer (Falchook et al., 2012) Despite this, a number of pre-clinical studies 
have recently reported compensatory activation of MAPK signalling through negative feedback 
loops activating EGFR in B-raf mutant tumours, in response to selective B-raf inhibition 
(Prahallad et al., 2012, Corcoran et al., 2012). Nevertheless, these studies show B-raf inhibition 
is well tolerated and suggest combination therapy with EGFR inhibitors could be beneficial for 
this patient population. 
As most mutations activating MAPK signalling occur in RAS or RAF proteins, targeting the 
pathway immediately downstream these effectors in an attractive strategy. This has led to the 
development of inhibitors targeting MEK1/2, dual specificity kinases which phosphorylate 
ERK1 and ERK2 at Threonine 202/Tyrosine 204 and Threonine185/Tyrosine187 respectively 
(Haystead et al., 1992). The high degree of homology between the MEK1 and MEK2 is 
promising for a small molecule inhibitor to potently target both kinases. Early MEK inhibitors, 
including CI-1040 and PD0325901, showed some promise in vivo in terms of inhibiting colon 
tumour growth, however were soon abandoned due to lack of efficacy during phase II trials 
(Allen et al., 2003, Rinehart et al., 2004). Nevertheless, target validation studies showed 
effective inhibition of ERK signalling, and the observation that these compounds were well 
tolerated in patients, spurred further pharmaceutical development of MEK inhibitors (Sebolt-
Leopold and Herrera, 2004). Furthermore, structural analysis of MEK inhibitors identified these 
to be non-competitive and to avoid perturbation of the ATP binding site, indicating selectivity 
of targeting MEK kinases only (Sebolt-Leopold and Herrera, 2004). Currently, third generation 
MEK inhibitors are in clinical development and are showing promise in combination with other 
targeted agents as well as standard chemotherapy. These include AZD6244 (selumetinib, Astra 
Zeneca), GSK1120212 (GSK) and MEK162 (Novartis Pharmaceuticals) and are currently 
undergoing extensive pre-clinical evaluation for a number of different human malignancies.  
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1.5.3 Phosphoinositide-3-kinase (PI3K) pathway  
The PI3K pathway is one of the most frequently deregulated pathways in cancer. Similarly to 
the MAPK pathway, downstream signalling is activated by RTKs, integrins and cytokine 
receptors but also indirectly by KRAS which activates the catalytic p110 subunit of the PI3K 
protein (Engelman, 2009, Kurosu et al., 1997). PI3Ks are heterodimers made up of a regulatory 
subunit (p85α, p55α, p50α, p85β, p55γ) and a catalytic subunit (p110α, p110β, p110δ). The 
main function of PI3Ks is to phosphorylate the 3’hydroxyl group of phosphatidylinositol 4,5-
bisphosphate (PI[4,5]P2 or PIP2) to phosphatidylinositol 3,4,5-triphosphate (PI[3,4,5]P3 or PIP3). 
The 3’phosphatase PTEN dephosphorylates PIP3 terminating PI3K signalling. Accumulation of 
PIP3 however acts as a crucial secondary messenger and recruits AKT to the membrane where 
it is phosphorylated and activated by phosphoinositide-dependent protein kinase 1 (PDK1) at 
threonine 308 (in the activation loop of AKT) and by mechanistic target of rapamycin complex 
2 (mTORC2) at serine 473 (in a hydrophobic motif of AKT) to fully activate the protein kinase 
(Figure 1.5) (Engelman, 2009). AKT is then able to phosphorylate several cellular proteins 
(shown in figure 1.5) and regulate important processes including proliferation, cell survival, 
protein synthesis and glucose metabolism (Engelman et al., 2006).  
All of the major elements of the PI3K pathway, from receptor to protein kinase, have been 
found to be altered in an extensive range of human malignancies. The PIK3CA gene which 
encodes the p110α catalytic subunit is mutated in 14% of CRC as well as breast, endometrial, 
urinary and ovarian cancer (www.sanger.ac.uk/genetics/CPG/cosmic). Mutations in this gene 
cluster in two conserved regions which encode the kinase and helical domains that confer 
constitutive kinase activity (Yuan and Cantley, 2008). The antagonist of the PI3K pathway, the 
phosphatase and tensin homologue (PTEN), is often mutated or lost in both heritable and 
spontaneous cancers. Germline mutations of this gene are associated with hamartoma tumour 
syndromes (Blumenthal and Dennis, 2008) whereas sporadic mutations are associated with 9% 
CRCs as well as endometrial, skin, prostate and breast cancers (Salmena et al., 2008). More 
recently, somatic mutations in AKT have been identified in 6% of CRCs as wells as ovarian and 
breast cancers (Carpten et al., 2007) and amplifications of the gene have been identified in 
pancreatic, ovarian and head and neck cancers (Engelman et al., 2006).  
With a number of elements in the complex PI3K pathway found to be altered in human 
cancers, an increasing number of strategies are available to target this pathway. The four main 
classes of inhibitors currently in clinical development include dual PI3K/mTOR inhibitors, 
isoform-specific and pan PI3K inhibitors, AKT inhibitors as well as mTOR inhibitors. Several 
33 
 
small molecules target both PI3K and the PI3K related kinase (PKK) mTOR as they share similar 
ATP-binding site structures (Garcia-Echeverria and Sellers, 2008). These inhibitors target all 
isoforms of the p110 subunit as well as both mTORC1 and mTORC2 and offer the advantage of 
complete signalling shutdown. There are currently a number of compounds in Phase I/II 
clinical trials producing promising results, including NVP-BEZ235 and NVP-BGT226 (Novartis 
Pharmaceuticals) as well as XL765 (Exelixis) and SF1126 (Semafore).  
One concern however is that PI3K targeted therapy could mediate insulin resistance in insulin 
sensitive tissues given the role of the pathway in insulin signalling and glucose metabolism. It 
is thought that isoform-specific or pan-PI3K inhibitors may provide the solution as selective 
but transient target inhibition may be better tolerated and more effective clinically (Engelman, 
2009). Pan-PI3K inhibitors currently in phase I/II clinical development include XL147 (Exelixis) 
for endometrial cancers, GDC0941 (Genentech) for metastatic breast cancer as well as 
BKM120 (Novartis) for a variety of solid tumours. A number of studies have highlighted the 
importance of individual isoforms in a subset of malignancies for example, p110α was found to 
be crucial for breast cancers with ERBB2 amplifications (Torbett et al., 2008) and p110β in 
PTEN deficient cancers (Jia et al., 2008). Indeed these highlight a specific group which may 
benefit from isoform specific inhibitors, but there is a concern that other isoforms may simply 
compensate for the targeted isoform. Nevertheless, these inhibitors hold potential for further 
development predominantly in combination with other targeted therapeutics including MAPK 
inhibitors.  
Given the central role of AKT in the PI3K pathway, a number of pharmaceutical companies 
have developed allosteric and non-catalytic site inhibitors of the kinase. Allosteric inhibitors 
prevent recruitment of AKT to the membrane by interfering with binding of the crucial PH 
domain of the kinase to phophoinositides involved in phosphorylation of AKT (She et al., 
2008). Alternatively, inhibitors may not affect phosphorylation of AKT and may instead 
prevent phosphorylation of AKT substrates including AKT substrate 1 (AKTSI/PRAS40), 
glycogen synthase kinase 3 (GSK3) and forkhead box transcription factors (Engelman, 2009). 
One agent in particular Perifosine (Keryx), showed early promise with an overall response rate 
of 20% vs. 7%, and mild toxicity, when combined with capecitabine in phase I trials, and is 
currently in phase III trials with capecitabine (Bendell et al., 2011).  As one of the major 
downstream effectors of AKT, mTORC1 is an attractive therapeutic target as it integrates 
growth factor signalling with energy sensing and other cellular processes such as protein 
synthesis. mTOR was originally identified as the target of a molecule known as rapamycin, a 
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potent anti-proliferative agent (Laplante and Sabatini, 2012). Despite the anti-tumour activity 
of rapamycin, it was found to primarily target mTORC1 and the presence of multiple feedback 
loops in the mTOR pathway (mainly through mTORC2 phosphorylating AKT at serine 473), 
limited the therapeutic efficacy of it (Harrington et al., 2005, O'Reilly et al., 2006). This 
provided the rationale for targeting both mTORC1 and mTORC2 to improve the impact on 
cancer cells. Several compounds have been developed including AZD8055 (Astra Zeneca) an 
ATP-competitive inhibitors of mTOR as well as OSI-027N and OXA-01 (Astellas Pharma Inc). 
The later compounds function by preventing phosphorylation of effectors downstream 
mTORC1 and mTORC2 to impair growth and proliferation better than rapamycin (Falcon et al., 
2011). Despite this, there are concerns that inhibition of phosphorylation of AKT at serine 473 
is not sufficient enough to completely inhibit AKT signalling (Jacinto et al., 2006). Nevertheless, 
targeting PI3K signalling holds great promise for the treatment of cancer given the high 
prevalence of mutations activating this signalling cascade in human cancers.   
Whilst targeting the MAPK and PI3K signalling pathways independently may be clinically 
beneficial in some settings, concurrent pathway activation frequently occurs in cancer and in 
CRC, a third of all cases present with KRAS and PI3K pathway mutations (Cancer Genome Atlas 
Network, 2012). This may be due to the extensive cross-talk between the two pathways as 
well as convergence on at least two downstream targets, mTORC1 and the BH3 family of 
proteins, namely BCL-2-associated antagonist of cell death (BAD) and BCL-2-interacting 
mediator of cell death (BIM), which regulate cell growth and apoptosis respectively (Figure 
1.5) (Engelman, 2009). Extensive evidence of pathway regulation is also evident, indicating a 
highly complex system of interactions. Whilst KRAS is known to lead to activation of the PI3K 
pathway through direct interactions with the p110 subunit (Kodaki et al., 1994), ERK and its 
kinase substrate p90RSK also inhibit GSK3 function, a negative regulator of the PI3K antagonist 
PTEN, subsequently resulting in reduced PI3K signalling (Cohen and Frame, 2001, Al-Khouri et 
al., 2005). Furthermore, regulation of PI3K signaling can positively or negatively influence 
MAPK signalling. Here, PIP3 accumulation can recruit the Grb-2 associated binding partner 
(GAB), IRS and Grb7 scaffold proteins which following subsequent phosphorylations, can 
interact with a number of molecules including ERK to mediate MAPK signalling (Wöhrle et al., 
2009). Also, PIP3 can stimulate PAK signalling which is crucial for phosphorylation of the MAPK 
effector RAF at Serine 388, which is essential for full activation of RAF (Chaudhary et al., 2000, 
Xiang et al., 2002). PI3K signalling can also influence MAPK effectors downstream AKT through 
mTOR and p70RSK proteins (Kiyatkin et al., 2006). These are able to negatively regulate GAB 
and IRS proteins which result in reduced tyrosine phosphorylations at the receptor and 
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subsequently impair ability to sustain and amplify ERK phosphorylations. Despite this, AKT can 
also positively regulate MAPK signalling, through multiple protein phosphatises (MKPs). 
Suppression of GSK-3 by AKT results in downregulation of MKPs which subsequently prevent 
inactivation of phosphorylated ERK (Aksamitiene et al., 2010). Together these interactions 
highlight the complex cross-talk between the two cascades but suggest the potential benefits 
of concomitant pathway inhibition, given these pathways govern crucial processes such as 
growth, cell survival and apoptosis in cancer cells. Subsequently, evidence for targeting both 
signalling pathways has been emerging from pre-clinical studies, in particular from genetically 
engineered mouse models (GEMMs) of lung (Engelman et al., 2008), ovarian (Kinross et al., 
2011) and thyroid cancer (Miller et al., 2009) which show activation of both signalling 
pathways.  
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MAPK pathway inhibitors include farnesyltransferase inhibitors (FTIs) which prevent membrane localisation of RAS, specific RAF inhibitors (RAF-i) such as B-
RAF inhibitors which target the V600E mutant form, and MEK1/2 inhibitors which as catalytic site inhibitors, prevent phosphorylation and activation of ERK. 
PI3K pathway inhibitors include isoform specific p110 inhibitors, pan-PI3K inhibitors, dual PI3K/mTOR inhibitors which target all isoforms of p110 as well as 
both mTORC1 and mTORC2, AKT inhibitors (AKT-i) which are either allosteric or catalytic site inhibitors, and finally mTOR inhibitors which inhibit individual 
or both complexes of mTOR.         
Figure 1.5 Schematic representation of the MAPK and PI3K signalling cascades (adapted from Engelman et al, 2006) and agent available to target various 
molecules involved in the respective signalling cascades 
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1.5.4 Anti-cancer prodrugs 
Despite the increasing number of promising avenues for developing targeted therapeutics, 
chemotherapy remains the backbone of cancer treatment. Many efforts are striving to 
improve the efficacy of standard cytotoxics and significantly decrease their toxicity. One large 
area of research is currently adopting the prodrug approach which via simple chemical 
modifications, aims to increase solubility, stability, permeability as well as reduce side effects 
of chemotherapy (Mahato et al., 2011). This is an attractive approach as due to poor 
selectivity, chemotherapy targets many rapidly proliferating cells including bone marrow, hair 
follicle, blood and intestinal cells leading to unpleasant side effects including hair loss, nausea, 
skin rashes and immunosuppression. Additionally, high doses of chemotherapy are often 
required for highly proliferative solid tumours leading to rapid toxicity and often 
discontinuation of treatment (Keefe and Bateman, 2012). Prodrugs currently represent 5-7% 
of all approved drugs worldwide and are becoming increasingly attractive therapeutic 
approaches (Ettmayer et al., 2004). Prodrugs typically are designed as biologically inert small 
molecules which are transformed in vivo to release the pharmacologically active components 
(Knox and Connors, 1997). They can be designed to target specific antigens, peptide 
transformers or enzymes overexpressed in tumour cells. The design of prodrugs is highly 
variable but often consists of combinations of the following components: the parent drug or a 
close derivative, a chemical linker, a cleavable spacer designed to release the drug in the 
presence of specific conditions (for example an enzyme or specific pH) and a targeting part to 
aid specific delivery to tumour cells (Mahato et al., 2011). An example of a successful anti-
cancer prodrug is capecitabine, an oral prodrug of 5-Flurauracil (5-FU). Capecitabine is thought 
to be absorbed in the small intestine where it undergoes a cascade of three enzyme 
bioconversions to release active 5-FU, with almost 100% bioavailability and minimising 
systemic toxicity (Miwa et al., 1998, Walko and Lindley, 2005).  In the absence of the essential 
enzymes required for prodrug bioconversion, numerous modes of delivering exogenous 
enzymes are under investigation and currently include the use of antibodies and gene vectors. 
Here, an antibody-enzyme complex is initially delivered to bind to tumour-specific antigens, 
then the inactive prodrug is administered with the aim for it to be activated in vivo by the 
localised enzyme (Sharma et al., 2005). Similarly, genes encoding a specific enzyme can also be 
utilised by means of a vector to deliver the gene to specific tumours (Dachs et al., 2005). These 
systems raise a number of caveats including immunogenicity of the enzyme/gene-antibody 
complex, random activation of prodrugs by unbound enzyme/gene-antibody circulating in the 
blood and conjugation heterogeneity, all of which are caveats which require addressing prior 
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to safe usage of this technology. However despite the limitations, the main advantage of these 
systems is the hope for limited toxicity and since a number of enzymes are overexpressed in 
tumours, it is anticipated this will lead to the development of potent anti-cancer agents. 
Overall, the prodrug approach is a novel and versatile method which could be applied to a 
wide range of parental molecules to improve their efficiency and limit toxicity.        
 
1.6 Preclinical mouse models of colorectal cancer and their value to study translational 
research 
1.6.1 Genetically engineered mouse models as useful tools for translational research 
Despite the significant progresses made in understanding the molecular mechanisms required 
for tumourigenesis and subsequent development of novel anti-cancer drugs, for CRC, only 1 in 
10 compounds successful at phase I evaluation are eventually approved by regulators 
(Johnston and Kaye, 2001). This is largely attributed to the drug development strategies 
adopted and lack of accurate guidance from preclinical studies which often leads to major 
failures at phase II evaluations (Robles and Varticovski, 2008). In most drug development 
strategies, target validation and compound discovery is initially assessed in a variety of human 
cancer cell lines. These are immortalized cell lines isolated and propagated from a variety of 
human cancers, decades ago. Although they provide a useful, rapid and inexpensive approach 
to identify lead compounds, they also suffer from a number of inadequacies. Cancer cell lines 
maintained under culture conditions may be highly susceptible to genetic drift due to genomic 
instability in cancer cells and this may affect reproducibility of experiments. Furthermore, in 
vitro conditions lack exposure to certain growth factors, interactions with stromal cells and the 
extracellular matrix, all of which may contribute to survivability of cancer cells in vivo (Watt 
and Driskell, 2010). For years, the preclinical testing of lead compounds has relied on 
xenotransplantation (xenograft) models. Xenotransplantation procedures usually involve a 
subcutaneous injection of human cancer cells into the flanks of immune-compromised mice. 
Here, lesions develop rapidly and are subsequently utilised to investigate the ability of 
compounds to reduce or halt tumour growth. Although this system addresses some of the 
caveats raised by in vitro experiments, it still does not recapitulate a number of key processes 
in cancer development. These including the sporadic nature of tumour formation, the native 
tumour microenvironment, angiogenesis required for survival, or a host immune response to 
tumour development, all of which contribute to the characteristics of the primary tumour and 
39 
 
its response to treatment. Most of these issues may be resolved by using genetically 
engineered mouse models (GEMM) of cancer which more accurately recapitulate many 
aspects of the disease. GEMMs have the potential to model cell-intrinsic and cell-extrinsic 
factors that drive de novo tumour formation and their progression to metastatic disease. 
Furthermore, these are useful for validating candidate genes involved in cancer development, 
and also provide a valuable platform for drug testing and defining mechanisms of resistance 
(van Miltenburg and Jonkers, 2012).  
An increasing number of novel therapeutic agents have been evaluated in clinically relevant 
GEMMs and together, these highlight some exciting new avenues which should be explored 
clinically. GEMMs have been used to assess a number of novel combination treatments, for 
example, Engelman and colleagues showed that Kras mutant lung tumours efficiently regress 
in response to combined PI3K/mTOR and MEK inhibitor treatment (Engelman et al., 2008). 
Similarly, De Raedt and colleagues evidenced combination of HSP90 inhibitor the IPI-504 with 
the mTOR inhibitor rapamycin as effective treatment against Kras driven tumours (De Raedt et 
al., 2011). Olive and colleagues showed the benefits of adding a novel therapy to a cytotoxic to 
improve outcome. Here, pre-treatment of mice with a smoothened inhibitor depleted tumour 
stroma and increased chemotherapy delivery in a mouse model of pancreatic cancer (Olive et 
al., 2009).  Furthermore, Singh and colleagues showed that Kras mutant non-small-cell lung 
cancer (NSCLC) and pancreatic adenocarcinoma mouse models mimic clinical response to 
EGFR and VEGF inhibitors, highlighting the use GEMMs in predicting clinical response (Singh et 
al., 2010). More recently, Chen and colleagues conducted a mouse ‘co-clinical’ trial which 
mirrored an ongoing human trial testing the efficacy of MEK inhibitor AZD6244 with standard 
of care treatment docetaxel, for patients with Kras mutant lung cancer. They demonstrated 
that concomitant loss of Lkb1, a potent tumour suppressor and not p53 impaired response of 
Kras mutant lung cancers to the combination treatment. As most patients recruited to clinical 
trials are stratified according to single oncogenic drivers, the study by Chen and colleagues 
highlighted variation within the stratified group and explored key mutations underlying this 
variation (Chen et al., 2012b).  
Not only are GEMMs useful for identifying novel therapeutic strategies and mimicking the 
human situation, but they are also powerful tools for studying acquired drug resistance and 
may provide insights into the underlying mechanisms of this. Gilbert and Hemann showed that 
stromal factors released from thymic endothelial cells created a chemoresistant niche for 
lymphoma cell survival following chemotherapy, allowing relapse in a mouse model for 
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Burkitt’s lymphoma (Gilbert and Hemann, 2010). Additionally, a recent study using the 
doxycycline-inducible oncogenic PIK3CAH1047R mutant breast cancer GEMM identified Myc 
activation as a mechanism of resistance to PIK3CAH1047R de-activation, elegantly indicating this 
may induce resistance to PI3K targeted therapies (Liu et al., 2011).  
Despite this, genetically engineered tumour models also have their intrinsic shortcomings. 
Generating GEMMs with multiple driver mutations is not only time consuming and costly but 
transgene expression in many GEMMs often surpasses levels of proteins ever observed in 
patients (Lin, 2008). Furthermore not all pre-clinical studies using GEMMs have predicted 
clinical response in humans. For example, although Olive et al identified the hedgehog 
inhibitor Vismodgib to deplete stomal tissue and improve Gemcitabine delivery in a mouse 
pancreatic ductal adenocarcinoma model, the combination of these compounds in a human 
phase II clinical trial detrimentally reduced survival of patients by 6 month in comparison to 
the control arm of Gemcitabine only therapy (http://www.olivelab.org/ipi-926-03.html).  
As such, an increasing number of pre-clinical studies employ the use of patient derived tumour 
xenograft (PDX) models. These models involve immediate transplantation of resected patient 
tumours into immunocompromised mice, eliminating an intermediate in vitro propagation 
step (Parmar et al., 2002, Kuperwasser et al., 2004). Furthermore, PDX models allow ongoing 
propagation of tumour lines within murine hosts without the compromising conditions 
encountered by continuous in vitro culturing (Jin et al., 2010). These models have been shown 
to remain faithful to cellular complexity and heterogeneity, tumour architecture including 
vasculature and supporting stromal tissue, as well as chromosomal architecture (Daniel et al., 
2009). PDX models of melanoma, breast, pancreatic, ovarian, lung and colorectal cancer have 
been successfully established and have also been shown to display similarities to the donating 
patients with regards to chemotherapy response, adding credence to these models (Decaudin, 
2011). Nevertheless, PXD models also have their shortcomings. The engraftment frequency 
and growth rate is known to vary considerably between patients perhaps suggesting 
dependence of some tumours on the surrounding tumour microenvironment. Other factors 
likely to contribute to ineffective tumour engraftment include the time inbetween resection 
and implantation, lack of supportive growth factors and perhaps an inhospitable site for a 
particular tumour type. Furthermore, these models heavily rely on patient material which may 
not be readily accessible (reviewed in Williams et al., 2013). Despite this, PDX models 
represent an exciting avenue in cancer research, particularly for translational studies as they 
allow direct evaluation of patient material within a laboratory setting.    
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1.6.2 Overview of conditional transgenesis techniques 
The genetic modification techniques developed in the 1980s by Capecchi, Evans and Smithies 
to generate mice with targeted disruptions has indisputably revolutionised biomedical 
research (Evans and Kaufman, 1981, Thomas and Capecchi, 1987, Doetschman et al., 1987). 
Since then, numerous constitutive gene knockout mice have been generated to study gene 
function in vivo. Although this has provided some useful insights into the physiological role of 
many genes, a large number of genes involved in tumourigenesis are also required for normal 
development and hence manipulation of these results in embryonic or perinatal lethality. To 
circumvent this, the heterozygous form is often studied however this is frequently insufficient 
for tumour formation. Additionally, constitutive knockout mice display phenotypes in a 
number of tissues as the gene manipulation is cell autonomous and not limited to a specific 
tissue type and so, may mask tissue specific effects. Since then, a number of techniques have 
been adopted to investigate tissue specific gene manipulation and include Tet-on and Tet-off 
systems as well as site-specific recombination techniques (Miller, 2011).  
The Tetracycline Operator (TetO) system developed by Bujard and Gossen, is a reversible 
method used to control temporal and spatial expression of target genes. It has two variants: 
the tetracycline controlled transactivator (tTA) or the Tet-off system, and the reverse-tTA 
(rtTA) or the Tet-on system. Here, the tTA made up of a tetracycline repressor protein (TetR) 
and the VP16 protein produced by Herpes Simplex Virus, is placed under control of a tissue 
specific promoter. The expressed protein is able to bind its target- a 19bp Tetracycline 
operator (TetO) sequence in a separate transgene and in doing so, allows expression of the 
target gene of interest downstream of the operator. Tetracycline derivatives such as 
doxycycline are used to antagonise this system as they are able to bind to the tTA protein and 
prevent it binding to the TetO sequence, therefore doxycycline addition switches off target 
gene expression. Alternatively, the Tet-On system utilises the rtTA which is capable of binding 
to TetO sequences only in the presence of doxycycline and hence the addition of doxycycline 
in this system initiates target gene expression (Gossen and Bujard, 1992).  
Site-specific DNA recombination systems are also used to manipulate the mouse genome in a 
temporal and spatial manner. The Cre-loxP (causes recombination (Cre) – locus of crossover of 
bacteriophage P1 (loxP)) system involves addition of Cre, a DNA recombinase under the 
control of a chosen promoter, and loxP sites which are 34 base pair sequences from 
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bacteriophage P1(Sauer and Henderson, 1988). Induction of cre recombinase activity, usually 
using a xenobiotic, will catalyse recombination between loxP sites and usually orientation of 
loxP sites determines either inversion or excision of the flanked DNA fragment. Most 
commonly, loxP sites flank the essential part of a gene or flank a transcription terminating 
stop-cassette. This will either excise the essential part of the gene and hence inactive the 
gene, or, excise the transcriptional stop-cassette and activate the gene (Orban et al., 1992). 
This system is most commonly used to exploit inducible promoters and tissue specific 
promoters. Inducible promoters which are transcriptionally silent under normal physiological 
conditions can be activated at a given time by administration of a xenobiotic. Tissue specific 
promoters on the other hand are often manipulated using post-translational approaches to 
offer temporal control. An example of a post-translational approach most commonly used is 
the CreERT transgene (Feil et al., 1997). This transgene encodes for a cre recombinase-
estrogen receptor fusion protein which is only activated in the presence of the estrogen 
antagonist tamoxifen and not endogenous oestrogen. Tamoxifen is able to bind to the ER 
domain of the fusion protein and allow nuclear localisation where it is able to catalyse 
recombination between loxP sites. Finally, both systems can be integrated to create tighter 
control of inducible promoters which are commonly expressed in a number of tissues. This 
avoids expression of inducible promoters during development as complete cre induction 
would require both xenobiotic and tamoxifen administration (Kemp et al., 2004). 
An alternative to the Cre-loxP system is the FLP-FRT system which works in the same manner. 
FLP is a recombinase extracted from yeast saccharomyces cerevisiae and is inserted as a 
transgene into the mouse genome along with FLP recognition target (FRT) sites which flank the 
gene of interest in the same manner as loxP sites (O'Gorman et al., 1991, Dymecki, 1996). 
Additionally, a FLP-ER transgene has also been developed to enable tighter control of 
recombination, much like the Cre-ER transgene.  
In addition to temporal and spatial gene manipulation, Tet based systems and Cre-loxP 
systems can be integrated to include lineage-specific gene expression in mice. These systems 
whilst require complex breeding programs and an extensive number of transgenes integrated 
into one mouse, rely on promoter specificity of the Cre transgene to determine where the Tet-
based system is active. Nevertheless, this system provides additional control over where the 
transgene is activated and the period of time for which it is activated, providing a powerful 
tool for lineage tracing experiments (Sun et al., 2007).  
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1.6.3 Modelling colorectal cancer in the mouse 
Before the advent of conditional transgenesis techniques, much of cancer research relied upon 
chemical mutagenesis screens to cause random disruptions in the mouse genome which then 
randomly gave rise to tumours. From this, emerged the first mouse model of human FAP, the 
ApcMin mouse (Su et al., 1992). These mice have a germline mutation in the tumour suppressor 
Apc, and heterozygous mice develop numerous polyps in the small and large intestines. 
Although this model has proven to be widely useful in investigating various candidate cancer 
genes and therapeutic regimens, it is limited in its ability to model other aspects of 
tumourigenesis such as tumour progression and metastasis.  
The availability of a number of inducible and tissue specific promoters as well as various loxP 
targeted tumour suppressors and oncogenes has allowed more faithful mouse models of 
human CRC to be developed. Most commonly, the tissue specific promoter VillinCre (el Marjou 
et al., 2004) and the inducible promoter AhCre (Kemp et al., 2004)are used in developing CRC 
GEMMs. AhCreER mediated heterozygous deletion of Apc and homozygous deletion of Pten 
leads to development of invasive adenocarcinoma in the small intestine (Marsh et al., 2008). 
Similarly, heterozygous of deletion Apc and oncogenic activation of Kras driven by VillinCreER 
also leads to invasive adenocarcinomas of the small intestine (Janssen et al., 2006). 
Furthermore, Ink4a/Arf deletion in the presence of oncogenic Kras driven by VillinCreER leads 
to development of metastasis (Bennecke et al., 2010). A recent study in the lab investigating 
the synergy between Pten deletion and Kras activation in the murine intestine found in the 
presence of a heterozygous Apc mutation, this lead to rapid onset of tumourigenesis however, 
in the absence of Apc, mice developed metastatic carcinoma over a long latency (Davies EJ, 
unpublished). These models not only provide valuable tools for investigating progression of 
tumourigenesis but they also represent differing stages of the disease in particular metastasis 
which could be hugely beneficial for testing novel therapeutics.                   
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1.7  Aims and Objectives 
The main aim of this thesis was to evaluate novel therapeutic strategies for CRC utilising valid 
mouse models of the disease. For this, I first aimed to evaluate PI3K and MEK inhibitors for 
Pten and Kras mutant CRCs in ‘a mouse clinic’ setting to explore their clinical application and 
secondly, to characterise novel ProTide agents aimed to overcome 5-FU resistance in CRCs.  
To address the first objective I aimed to utilise four GEMMs of CRC mutant for combinations of 
Apc, Pten and Kras, to investigate inhibition of the MAPK pathway through the MEK inhibitor 
MEK162, and inhibition of the PI3K pathway through the dual PI3K/mTOR inhibitor NVP-
BEZ235 (both supplied by Novartis pharmaceuticals). The four mouse models used here 
represent four clinically relevant tumour genotypes for human CRC. I aimed to explore the 
short term anti-tumour activity of single-agent treatment at various time points following 
administration, in each genotype as well as early pharmacodynamic effects of agents through 
assessing their effect on signal transduction. I also aimed to evaluate the therapeutic potential 
of MEK and PI3K/mTOR inhibition by conducting long term treatment experiments to 
investigate the impact of continuous drug administration on survival and tumour burden of 
mice. Furthermore, given the extensive cross-talk between MAPK and PI3K pathways, I also 
aimed to investigate the therapeutic potential of combined MEK and PI3K/mTOR inhibition in 
the genetically differing tumour models. These investigations are described in chapters 3-6.  
The second objective of this thesis addressed resistance to the most commonly used 
chemotherapeutic agent for CRC, 5-flurauracil (5-FU). A key enzyme implicated in the 
resistance to 5-FU is Thymidylate synthase (TS). Tumours become resistant by upregulation of 
TS and therefore the main objective here was to develop and characterize novel ProTides, 
similar to prodrugs, which could potentially target the increased TS in resistant tumours and 
result in an increased anti-tumour activity. The ProTide compounds designed and synthesised 
by Prof Chris McGuigan’s group (Department of Pharmacy, Cardiff University), use the anti-
viral compound Brivudin (BVDU) as the parent compound. The BVDU metabolite BVdUMP is a 
substrate of TS however the charge of BVdUMP prevents passive entry into cells. The ProTide 
method temporarily masks the charge on compounds to allow entry of the compound into the 
cell through the addition of additional chemical groups which are subsequently cleaved upon 
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entry into the cell to release the active compound. The hypothesis therefore suggested 
ProTide agents would present with increased anti-tumour activity in TS upregulated settings. 
ProTides with differing structures were synthesised by collaborators and first evaluated in vitro 
in normal and TS upregulated cancer cells using cell viability and colony forming assays to 
identify compounds potent in cancer cells but also those more potent in TS overexpressing 
cells. A handful of lead compounds were then assessed in vivo in a short time point 
experiment to investigate the in vivo potential of agents. Two potent compounds were then 
selected for long term treatment in an invasive mouse model of CRC to investigate long term 
the effect on survival of mice. Additionally, I aimed to model upregulation of TS through long 
term administration of 5-FU. The aim here was to investigate the anti-tumour effects of the 
selected compounds in a TS upregulated tumour setting. This work is described in chapter 7.  
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2 Materials and Methods 
 
2.1 Experimental Animals 
2.1.1 Animal Husbandry 
All experiments involving animals were carried out in accordance with national Home Office 
regulations (Animals (Scientific Procedures) Act 1986), under valid project and personal 
licences.  
2.1.2 Colony Maintenance 
All mice used in this thesis were of an outbred background. Mice had access to diet (Special 
diets service UK, PM3[E]) and fresh drinking water ad libitum.  
2.1.3 Breeding 
Adult animals of known genotypes were bred in trios consisting of one male and two females. 
Pups were weaned at around 4 weeks of age and ear biopsies were taken for identification 
and genotyping purposes. All mice were genotyped to determine the correct alleles were 
present before being used for experimental or breeding purposes.  
2.1.4 Genetic Mouse Models 
A number of transgenic mouse models were used for this study (origin of alleles used is 
outlined in table 2.1 below). Two Cre recombinase transgenes were used in this study, 
VillinCre, which is expressed in the intestinal epithelium, and AhCre, which is also expressed in 
the intestinal epithelium as well as the liver and skin. Both Cre recombinase transgenes are 
fused to a mutated estrogen receptor protein. This ensures that the Cre recombinase protein 
will only translocate to the nucleus in the presence of tamoxifen. Mice bearing the Cre 
recombinase transgene were crossed with mice bearing one or more targeted alleles including 
Apc, Pten and an oncogenic Kras knock in allele. Fig 2.1 is a schematic representation of how 
gene knock-in and knockout was controlled.   
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Transgene  Transgene details 
AhCreER (Ireland H et al., 2004)  Intestinal epithelium, liver and skin cells  
VillinCre ER (El Marjou et al., 2004)  Intestinal epithelium  
LoxP targeted Apc allele (Shibata et al., 
1997)  
Endogenous Apc allele bearing loxP sites flanking exon 14  
LoxP targeted Pten allele (Suzuki et al., 
2001)  
Endogenous Pten allele bearing loxP sites flanking exons 4 
and 5  
Kras knock-in (Guerra et al., 2003)  Mutated (G12V) Kras allele bearing loxP sites flanking a 
transcriptional stop cassette in the 5’UTR replacing the 
endogenous allele  
Table 2-1 Outline of transgenic mice used in this thesis 
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Mice that bore loxP flanked genes and the Cre recombinase transgene were generated for 
experimental use. Conditional knockout mice such as Apc and Pten had the endogenous allele 
replaced by one which contained loxP sites flanking essential exons of the gene. When 
activated, Cre recombinase recombined DNA at loxP sites causing deletion of essential exons 
simulating gene knockout. For conditional knock-in mice such as the oncogenic Kras knock-in 
mouse, one endogenous allele is replaced with an oncogenic version whereby in this case 
Glycine is replaced with Valine at codon 12 resulting in a missense mutation. A transcriptional 
stop cassette flanked by loxP sites is inserted upstream this gene. Activation of Cre 
recombinase causes recombination between loxP sites resulting in deletion of the 
transcriptional stop cassette and expression of the oncogenic Kras allele.   
Figure 2.1 Schematic representation of transgenic mouse techniques used in this thesis 
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2.2 Experimental Procedures 
2.2.1 Ear Biopsies 
Ear biopsies were taken using a 2mm ear punch (Harvard Apparatus) from individual mice and 
used for identification purposes as well as DNA genotyping of individual mice.    
2.2.2 Administration of Tamoxifen 
Animals expressing VillinCre-Estrogen Receptor (VilCreER) fusion protein were induced by 
Tamoxifen treatment. Corn oil (Sigma Aldrich) was heated to 80°C in a water bath and 
powdered Tamoxifen (Sigma Aldrich) was added to give a concentration of 10mg/ml. The 
solution was further heated until the Tamoxifen had dissolved and was kept at this 
temperature until just prior to administration. A dose of 80mg/kg was administered by intra-
peritoneal (i.p) injection to each animal, once daily for four consecutive days. 
2.2.3 Administration of beta-Napthoflavone and Tamoxifen 
Animals expressing the AhCreER transgene were induced by Tamoxifen dissolved in beta-
napthoflavone (βNF, Sigma Aldrich). Initially, to make up βNF, corn oil was heated to 99°C in a 
water bath and powder βNF was added to give a concentration of 10mg/ml. The solution was 
further heated until the βNF had dissolved completely. Aliquots were frozen in small amber 
glass bottles at -20°C and defrosted as required. The βNF solution was defrosted and heated to 
80°C in a water bath to which powdered Tamoxifen was added to give a concentration of 
10mg/ml. A dose of 80mg/kg was administered by i.p injection to each animal, once daily for 
four consecutive days.    
2.2.4 Treatment strategy for NVP-BEZ235 and MEK162 
To investigate the therapeutic potential of PI3K/mTOR and MAPK inhibition in the various 
mouse models, two main methods were utilised.  
1) To assess the early pharmacodynamic effects of respective drugs, mice were exposed 
to respective inhibitors for a series of time point (4, 8 or 24 hours were used, n≥3 
mice). This would provide valuable insight into immediate anti-tumour effect drug 
administration had on various tumour types.  
2) To investigate the long term therapeutic potential of respective inhibitors, a time 
point was chosen to start continuous treatment when mice were known to have a 
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significant tumour burden to avoid prophylaxis treatment. Treatment was continued 
(as specified for each cohort) until a defined end point.  
The schematic in figure 2.2 describes acute and chronic treatment regimens used in this study 
and table 2.2 outline details for chronic treatment regimens for individual mouse models.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Outline of treatment regimens used to investigate therapeutic potential of inhibitors. For 
investigation of immediate anti-tumour and pharmacodynamic effects of inhibitors, an acute 
treatment strategy was used (as outlined in section 2.2.4). To determine whether continuous 
treatment improved survival of mice, a chronic treatment strategy was undertaken whereby 
mice were started on daily treatment at a chosen start point following induction (as outlined 
in table 2.2) 
Figure 2.2 Schematic description of treatment regimens used in this thesis 
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2.2.4.1 Short term administration of compounds 
Mice which presented with symptoms of intestinal tumour burden, indicated by pale feet, 
bloating or rectal bleeding were exposed to a single dose of 35mg/kg NVP-BEZ235 or 30mg/kg 
MEK162 by oral gavage and were culled at either 4, 8  or 24 hour time points following drug 
administration.  
For short term combination studies 3 differing treatment strategies were employed: 
1. Combo 1: mice were exposed to 35mg/kg NVP-BEZ235 first followed by 30mg/kg 
MEK162 1 hour after, and culled 4 hours following last drug administration.  
2. Combo 2: mice were exposed to 30mg/kg MEK162 first followed by 35mg/kg NVP-
BEZ235 1 hour after, and culled either 4 or 24 hours following last drug administration. 
3. Combo 3: mice were exposed to 35mg/kg NVP-BEZ235 followed immediately by 
30mg/kg MEK162 and culled 4 hours following drug administration.  
2.2.4.2 Long term administration of NVP-BEZ235 
NVP-BEZ235 (Novartis Pharmaceuticals) was resuspended in 0.5% Methyl cellulose (MC, Sigma 
Aldrich) and vortexed to form a milky solution. The solution was then administered at 
35mg/kg once daily (O-D) or twice-daily (T-D) by oral gavage (Harvard apparatus) according to 
cohorts.  
Mouse model  Median survival 
(days post induction)  
Chronic treatment start point 
(days post induction)  
VillinCreER Apcf/+  270  220  
AhCreER Apcf/+ Ptenf/f  100  77  
VillinCreER Apcf/+ KrasLSL/+ 153  100  
VillinCreER Apcf/+ Ptenf/f KrasLSL/+ 41  22 
Table 2-2 Outline of chronic treatment start points for each mouse model used in this study 
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2.2.4.3 Long term administration of MEK162 
MEK162 (Novartis Pharmaceuticals) was suspended in 1% Carboxy-methyl cellulose (CMC, 
Sigma Aldrich) in 0.5% Tween80 (Sigma Aldrich) and vortexed to form a transluscent solution. 
The solution was then administered at a dose of 30mg/kg once daily (O-D) or twice-daily (T-D) 
by oral gavage (Harvard Apparatus) according to cohorts. 
2.2.4.4 Long term administration of Combination 
NVP-BEZ235 and MEK162 were prepared as outlined above in section 2.2.4.2 and 2.2.4.3 
respectively. The NVP-BEZ235 solution was administered at 35mg/kg first followed by MEK162 
administered an hour later at 30mg/kg once-daily or twice-daily according to cohorts.  
2.2.4.5 Vehicle treatment for NVP-BEZ235 and MEK162 
Controls of 0.5% MC (Sigma Aldrich) were administered by oral gavage (Harvard Apparatus) 
according to the volume administered for the drug counterpart.  
2.2.5 Treatment strategy for BVDU ProTide compounds 
2.2.5.1 Short term administration of selected compounds 
Selected ProTides and Thymectacin (synthesised by Stephanie Rats and Sahar Kandil, Cardiff 
University) were dissolved in a 50:40:10 [w/w/w] PEG300 (Sigma Aldrich):Ethanol:Tween 80 
(Sigma Aldrich) solution to give a 50mg/ml stock solution, which was stored at 4°C. For 
administration of 50mg/kg, the stock was diluted 1/20 in 1X Phosphate Buffered Solution (PBS, 
Invitrogen). AhCreER Apcf/+ Ptenf/f mice aged 85 days post induction were administered  at 
500µl/25g mouse by oral gavage (Harvard Apparatus) once daily for 4 days (n=4 mice per 
cohort). Mice were sacrificed 6 hours after the final dose and were also administered BrdU 2 
hours prior to culling as described in section 2.2.6.   
2.2.5.2 Long term administration of selected compounds 
CFP472, CFP3172 and Thymectacin (synthesised by Sahar Kandil, Cardiff University) were 
prepared as outlined above to form a stock of 75mg/ml, which was stored at 4°C for 5 days. 
The stock was then diluted and administered as outlined above. AhCreER Apcf/+ Ptenf/f mice 
aged 77 days post induction were treated daily until a survival end point (n=15 mice per 
cohort).   
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2.2.6 Administration of BrdU 
Where indicated, mice received an excessive dose of 5-Bromo-2-deoxyuridine (BrdU, 
Amersham Biosciences) in order to label cells in the S-phase of the cell cycle. Mice received 
10ml/kg BrdU by i.p injection 2 hours prior to culling.  
 
2.3 Polymerase Chain Reaction (PCR) genotyping 
2.3.1 DNA extraction from ear biopsies 
Mouse ear biopsies were collected after weaning and stored at -20°C for DNA extraction. The 
tissue was digested in 250µl lysis buffer (Purgene) containing 0.4mg/ml Proteinase K (Roche), 
overnight at 37°C with agitation. Protein was then precipitated by addition of protein 
precipitation solution (Purgene). The solution was mixed by inversion and protein and any 
remaining debris was pelleted by centrifugation at 14000 x g for 10 minutes. The supernatant 
was added to 250µl isopropanol to precipitate the DNA. The mixture was then inverted and 
centrifuged at 14000 x g for 15 minutes to pellet the DNA. The supernatant was discarded and 
the pellet was allowed to air dry for 2 hours before resuspending in 250µl of PCR grade water 
(Sigma Aldrich). 
2.3.2 Generic PCR genotyping protocol 
PCR reactions were carried out to detect the presence of loxP sites in targeted alleles. The PCR 
primers used in each reaction were designed using the web based program Primer 3. 
Reactions were carried out on 96 well PCR plates (Greiner Bio-One). 2.5µl of genomic DNA 
(gDNA) extracted from individual ear biopsies or control PCR grade water was pipetted into 
individual wells, and a PCR master mix containing PCR grade water (Sigma Aldrich), magnesium 
chloride (Promega), dNTPs (25mM dATP, dTTP, dCTP, dGTP (Bioline)), DNA polymerase (either 
Dream Taq (Fermentas) or GO taq (Promega)), PCR buffer (Promega) and gene specific primers 
(Sigma Genosys) were added to each well to make a final volume of 50µl (primer sequences 
and reaction mixtures for each PCR are outlined in table 2.3). The 96 well plates were then 
sealed with aluminium foil seals (Greiner Bio-One), and air bubbles were eliminated by tapping 
the sealed wells of the plate on a hard surface. The reactions were run in a GS4 thermocycler 
(G storm), individual reaction cycling times are described in table 2.4. 
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2.3.3 Visualisation of PCR products 
PCR reaction products were visualised by gel electrophoresis. 2% agarose gels were made by 
dissolving agarose (Eurogentech) 2% [w/v] in 1X Tris Borate EDTA (TBE) buffer (Sigma Aldrich) 
and heated in a microwave until boiling. Once boiling, the gel solution was quickly cooled 
under a running tap and 14µl of Safe View (NBS biological) was added per 400ml of gel 
solution (Safe View is a nucleic acid stain which allows visualisation of DNA as it binds to DNA 
and fluoresces under UV light). The gel was then poured into clean moulds (Bio-Rad) and 
combs were placed to create wells. Once set, the gels were placed into gel electrophoresis 
tanks (with their moulds to prevent slippage) and covered with 1X TBE (Sigmal Aldrich), Safe 
View (NBS Biologicals) was also added to the buffer. 5µl of loading dye (50% Glycerol (Sigma 
Aldrich), 50% ultrapure dH20, 0.1%[w/v] bromophenol blue (Sigma Aldrich)) was added to each 
PCR product sample, mixed by pipetting and then added to individual wells. A molecular 
weight marker was added to one well to ensure correct PCR product size. The gel was then run 
at 120V for approximately 30 minutes. Following this, PCR products were visualised using a 
GelDoc UV Transilluminator (Bio-Rad) and images were captured using GelDoc software (Bio-
Rad). PCR product sizes are outlined in table 2.5. 
DNA extraction, PCR and visualisation of PCR products by gel electrophoresis was repeated for 
all experimental animals once dissected to re-confirm original PCR genotyping. 
Gene  Forward primer sequence (5’-3’)  Reverse primer sequence (5’-3’)  
Cre specific  TGACCGTACACCAAAATTTG  ATTGCCCCTGTTTCACTATC  
Apc-loxP  GTTCTGTATCATGGAAAGATAGGTGGTC  CACTCAAAACGCTTTTGAGGGTTGATTC  
Pten-loxP  CTCCTCTACTCCATTCTTCCC  ACTCCCACCAATGAACAAAC  
Kras-loxP-
stop  
AGGGTAGGTGTTGGGATAGC  CTGAGTCATTTTCAGCAGGC  
Table 2-3 Primer sequences used for gene specific PCRs 
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 Cre specific  Apc-loxP  Pten-loxP  Kras-loxP-
stop  
PCR reaction Mix      
gDNA  
PCR grade water 
GO Taq PCR buffer 
1.5mM MgCl2 
dNTPs  
Primer 1 (100mM) 
Primer 2 (100mM) 
Taq DNA polymerase 
Brand of Taq polymerase 
2.5µl 
31.7µl 
10µl 
5µl 
0.4µl 
0.1µl 
0.1µl 
0.2µl 
GO Taq  
2.5µl 
31.7µl 
10µl 
5µl 
0.4µl 
0.1µl 
0.1µl 
0.2µl 
Dream Taq  
2.5µl 
31.7µl 
10µl 
5µl 
0.4µl 
0.1µl 
0.1µl 
0.2µl 
Dream Taq  
2.5µl 
31.7µl 
10µl 
5µl 
0.4µl 
0.1µl 
0.1µl 
0.2µl 
Dream Taq  
PCR cycling conditions      
Initial denaturation 
Cycle number 
Step 1: denaturation 
Step 2: annealing 
Step 3: extension 
Final extension  
3 min, 94°C 
30 at: 
30 sec, 95°C 
30 sec, 55°C 
1 min, 72°C 
5 min, 72°C 
Hold at 15°C 
3 min, 94°C 
30 at: 
30 sec, 95°C 
30 sec, 60°C 
1 min, 72°C 
5 min, 72°C 
Hold at 15°C 
3 min, 94°C 
35 at: 
1 min, 94°C 
1 min, 58°C 
1 min, 72°C 
5 min, 72°C 
Hold at 15°C 
3 min, 94°C 
30 at: 
1 min, 94°C 
1 min, 60°C 
1 min, 72°C 
5 min, 72°C 
Hold at 15°C 
Table 2-4 Outline of PCR reaction mixtures, cycling conditions 
PCR product size 
(bp) 
Cre specific  Apc-loxP  Pten-loxP  Kras-stop-
loxP  
Wild-type   266  228  403  
Targeted transgene  1000  315  335  621  
Table 2-5 Outline of PCR product sizes 
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2.4 Tissue sample preparation  
All tissues were dissected immediately after animal sacrifice to avoid degradation of RNA, 
protein and phospho-proteins. 
2.4.1 Dissection of Organs 
Mice were culled by cervical dislocation and placed on their backs. 70% ethanol was sprayed 
over the abdomen and the abdominal cavity was opened first by cutting through the skin and 
then through the muscle wall. The stomach and intestines were first dissected out (below, 
section 2.4.2), the stomach was opened longitudinally and contents removed prior to fixing. 
The kidneys, liver, spleen, pancreas and a small section of the abdominal skin were then 
dissected out and fixed along with the stomach (described in section 2.5).  
2.4.2 Dissection of intestines 
The intestines were first removed along with the stomach. The attachment between the 
stomach and the oesophagus was cut and the stomach was gently pulled out of the mouse 
taking along the intestines carefully removing all attached mesentery. Once the whole 
intestine was removed, the stomach was cut at the ileal-caecal junction and the caecum was 
cut from the small intestine and the colon. The contents of the small intestine and colon were 
removed by flushing with cold water and fixed as described in section 2.5. Prior to fixing and if 
required, the intestines were opened longitudinally and small intestine tumours, a small 
section of normal small intestine, colon polyps and a section of normal colon were dissected 
out and immediately placed into clean microtubes and quickly snap frozen in liquid nitrogen 
for either protein or RNA extraction.   
 
2.5 Fixation of tissues 
2.5.1 Formalin fixation 
Most tissues dissected were ‘quick fixed’ in 10% neutral buffered formalin (Sigma Aldrich) for 
24 hours, as majority of commercially available antibodies for immunohistochemistry analysis 
work well with formalin fixed tissues. This included the liver, pancreas, spleen, kidneys and 
stomach as well as the intestines which after flushing with water, were cut into 10cm lengths, 
opened longitudinally and rolled into ‘swiss rolls’ secured with needles. This allowed end-on 
sectioning of the intestine.  
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2.5.2 Methacarn fixation of intestines 
To allow analysis of total macroscopic tumour number and size, a methacarn solution (a 4:2:1 
ratio of methanol, chloroform and glacial acetic acid) was used for fixation. Once flushed with 
cold water, the small intestine and colon were opened longitudinally on blotting paper and 
placed into a methacarn bath overnight. Tumour number and size were accurately measured 
using a ruler before rolling the intestines into ‘swiss rolls’ and placing into 70% ethanol.    
2.5.3 Processing of fixed tissue 
After fixation for 24 hours, all tissues were removed from fixative solutions, placed in a 
cassette (Fisher) and processed using an automatic processor (Leica TP1050). This involved 
dehydrating the samples through increasing gradient of alcohols (70% ethanol for 1 hour, 95% 
ethanol for 1 hour, 2x 100% ethanol for 1 hour 30 minutes, 100% ethanol for 2 hours) and 
finally soaking in xylene (2x xylene for 2 hours). The tissues were then placed in liquid paraffin 
for 1 hour, then again twice for 2 hours. Finally, the tissue samples were removed from their 
cassettes and embedded in paraffin wax by hand and allowed to harden.  
2.5.4 Sectioning of fixed tissue 
Paraffin embedded tissues were cut into 5µm sections using a microtome (Leica RM2135), 
placed onto Poly-L-Lysine (PLL) coated slides and baked at 58°C for 24 hours. The sections 
were then used either for Haemotoxylin and Eosin (H&E) staining (described in section 2.6.4) 
or immunohistochemistry (IHC)(described in section 2.6.3).  
 
2.6 Histological Analysis 
2.6.1 Preparation of sections for staining or IHC 
Paraffin embedded tissue sections on PLL coated slides were first de-waxed by placing in two 
consecutive baths of xylene for 5 minutes each. The sections devoid of paraffin were 
rehydrated down a gradient of alcohol baths (2x 100% ethanol, 95% ethanol, 70% ethanol) for 
2 minutes each and then placed in a bath of distilled water in preparation for staining or IHC.    
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2.6.2 Immunohistochemistry (IHC) 
IHC was used to visualise the presence and localisation of various proteins on tissue sections. A 
generic IHC protocol is outlined in below in section 2.6.3 and specific conditions and antibody 
dilutions are detailed in table 2.6 
2.6.3 Generic IHC protocol 
2.6.3.1 Preparation of sections for IHC 
Paraffin embedded tissue sections on PLL coated slides were de-waxed and rehydrated as 
previously described in section 2.5.3. 
2.6.3.2 Antigen retrieval 
The antigen retrieval step was carried out to break cross-linking bonds formed between 
proteins during fixation and therefore unmask hidden antigens. This typically involved heating 
the tissue section slides in 1X citrate buffer (10X Sodium citrate, pH6, Thermo Scientific), 
either in a microwave, a pressure cooker or a water bath. After boiling, the slides were 
allowed to cool in solution for up to 1 hour before washing in distilled water.  
2.6.3.3 Blocking of endogenous peroxidases 
The antibody visualisation system used here involves an enzymatic reaction of 
3,3’diaminobenzidine (DAB) catalysed by horse radish peroxidase (HRP). Therefore, to avoid 
non-specific enzymatic action of endogenous peroxidases present in the tissue sample, a 
peroxidase block was utilised. Slides were incubated in a 3% hydrogen peroxide solution (30% 
stock, Sigma Aldrich) for 15 minutes at room temperature which irreversibly inactivates 
endogenous peroxidases. Slides were then washed in distilled water and then in wash buffer, 
each for 5 minutes.  
2.6.3.4 Blocking of non-specific antibody binding 
Non-specific binding of antibodies was blocked by incubating tissue sections with serum from 
a different animal to which the primary antibody used was raised in. A hydrophobic barrier 
pen was used to outline the tissue section on the PLL coated slides. Serum was then diluted in 
wash buffer to a known concentration which sufficiently prevents non-specific antibody 
binding and tissue sections were then incubated in serum block for an optimised period of 
time in a humidified slide chamber. Serum block was removed and tissue sections were 
incubated with primary antibody without washing. 
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2.6.3.5 Primary antibody incubation 
Tissue sections were incubated with primary antibody diluted in blocking serum (same 
concentration of serum in wash buffer used for blocking) at working concentrations (described 
in table 2.6). Incubation was carried out either for 1 hour at room temperature or overnight at 
4°C, in a humidified slide chamber. After incubation, slides were washed three times in wash 
buffer to remove residual unbound primary antibody.  
2.6.3.6 Secondary antibody incubation 
Tissue sections were then incubated with secondary antibody, typically a 1/200 dilution in 
normal serum diluted in wash buffer. The secondary antibody used, was raised in the same 
animal in which the primary antibody was raised in to ensure specific binding only to the 
antigen of interest. Secondary antibodies were typically incubated for 30 minutes in a 
humidified slide chamber. The slides were then washed three times in wash buffer.  
Most secondary antibodies used were biotinylated, and therefore an additional signal 
amplification step was required to allow HRP binding to the secondary antibody. Other 
protocols required use of the Envision plus kit (DAKO) in which tissue sections were incubated 
in a pre-diluted secondary antibody conjugated to HRP, in which case a signal amplification 
step was not required and antibody binding could be immediately visualised after washing off 
excess secondary antibody (signal detected described in section 2.6.3.7) 
2.6.3.7 Signal amplification 
Signal amplification was required for biotinylated secondary antibodies. This involved 
formation of a complex called avidin, which was bound to the HRP, using the Vectastain 
Avidin-Biotin Complex (ABC) kit (Vector labs). The ABC reagent was prepared following 
manufacturer’s instructions in wash buffer 30 minutes prior to use to allow structure 
formation. Tissue sections were then incubated in the ABC reagent for 30 minutes at room 
temperature in a humidified slide chamber before being washed three times in wash buffer. 
Sections were then ready for signal detection.  
2.6.3.8 Detection of signal 
The antigen of interest was visualised by the production of a coloured stain. This was 
produced as a result of a substrate-enzyme reaction. The substrate used here was 3’3-
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diaminebenzidine (DAB) which was catalysed by the HRP enzyme bound to the secondary-
primary antibody complex to produce a brown coloured stain. The DAB reagents (DAKO) were 
prepared by following manufacturer’s directions just prior to incubation. Tissue sections were 
incubated with DAB reagents for 2-10 minutes at room temperature. Excess DAB reagent was 
removed by washing tissue sections in distilled water.  
2.6.3.9 Counterstaining and cover slip mounting 
Tissue sections were incubated in Mayer’s Haemalum (R. A. Lamb) for 1 minute to stain nuclei 
and then washed under a running tap for 5 minutes. The slides were then dehydrated through 
an increasing gradient of alcohols (1X 70% ethanol, 1X 95% ethanol, 2X 100% ethanol) for 2 
minutes each and finally cleared in 2X xylene baths for 5 minutes each. Slides were removed 
from xylene, mounted in DPX medium (R. A. Lamb) and an appropriate sized cover slip as 
placed on the tissue section before being left to air dry in a fume hood.  
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Primary antibody  Manufacturer  Antigen retrieval 
conditions  
Non-specific signal block  Wash buffer  Primary 
antibody 
conditions  
Secondary antibody  Signal 
amplification 
step  
Anti-BrdU  BD 
Biosciences 
#347580  
20mins, 100°C 
water bath  
Peroxidase: envision 
+block (DAKO) 20mins  
Serum: 1%BSA  
1hr both at RT  
PBS 3X 5min 
washes  
1:150 in 1% 
BSA for 1hr at 
RT  
Envision+ HRP-
conjugated anti-
mouse (DAKO) 30mins 
at RT  
N/A  
Anti-Cleaved caspase 3 
(Asp175)  
Cell Signaling 
Technology 
#9661  
15mins at pressure  
using pressure 
cooker 
Peroxidase: 3% H2O2 
10mins  
Serum: 5% NGS 
1hr both at RT  
TBS/T 3X 
5min washes  
1:200 in 
5%NGS for 
48hrs at 4°C  
Biotinylated anti-
rabbit 1:200 (Vector 
Labs) 30mins at RT  
ABC kit (Vector 
Labs)  
Anti-phospho Akt 
(Ser473) XP  
Cell Signaling 
Technology 
#4060  
30mins, 100°C 
water bath  
Peroxidase: 3 H2O2 10mins  
Serum: 5% NGS 1hr  
Both at RT  
TBS/T 3X 
5min washes  
1:50 in 
5%NGS O/N 
at 4°C 
Biotinylated anti-
rabbit 1:200 (Vector 
Labs) 30mins at RT  
ABC kit (Vector 
Labs)  
Anti-phospo44/42 MAPK 
(phospho-ERK1/2) 
(Thr202/Tyr204)  
Cell Signaling 
Technology 
#4376  
15mins in boiling 
bath microwave  
Peroxidase: 1.5 H2O2 
10mins  
Serum: 10% NGS 
1hr both at RT  
TBS/T 3X 
5min washes  
1:75 in 
10%NGS O/N 
at 4°C 
Biotinylated anti-
rabbit 1:200 (Vector 
Labs) 30mins at RT  
ABC kit (Vector 
Labs)  
Anti-phospho S6 
ribosomal protein  
Cell Signaling 
Technology  
15mins in boiling 
bath microwave  
Peroxidase: 3 H2O2 10mins  
Serum: 10% NGS 45 mins   
Both at RT  
TBS/T 3X 
5min washes  
1:100 in 
10%NGS O/N 
at 4°C 
Biotinylated anti-
rabbit 1:200 (Vector 
Labs) 30mins at RT  
ABC kit (Vector 
Labs)  
Table 2-6 Outline of antibodies and conditions for immunohistochemistry (IHC) 
Key: BSA – Bovine Serum Albumin, RT – Room temperature, PBS – Phosphate buffered solution, NGS – Normal goat serum, TBS/T – Tris buffered solution with 
0.1% Tween, O/N – Over night.   
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2.6.4 Haematoxylin and Eosin (H&E) stain 
Tissue sections were stained with haematoxylin to mark nuclei and eosin to stain the cytoplasm 
of cells in order to visualise tissue sections for phenotypic analysis. Paraffin embedded tissue 
sections on PLL coated slides were de-waxed and rehydrated as previously described. The 
sections were then stained by immersing in a bath of Mayer’s Haemalum (R. A. Lamb) for 45 
seconds and then, washed under a running tap for 5 minutes, followed by counter staining in an 
aqueous solution of 1% Eosin (R. A. Lamb) for 5 minutes, and finally washing under a running tap 
water for 30 seconds. The tissue sections were then ready to be dehydrated, cleared and 
mounted as described previously. 
2.7 Scoring 
Scoring was undertaken to reveal potential anti-tumour activity of therapeutics assessed. 
Typically, five random fields per tumour were assessed, also counting the total number of cells 
per field to accurately assess the percentage per total number of cells. All tumours present and 
at least three biological replicates per cohort were assessed.  
2.7.1 Apoptosis and mitosis scoring 
H&E stained sections were used to assess the number of apoptotic bodies and mitotic figures 
present in vehicle and drug treated tissue.  
2.7.2 BrdU Scoring 
Animals were administered a pulse of BrdU as described in section 2.2.6. The incorporation was 
visualised by IHC (section 2.6.3) and positive cells were counted as above. 
2.7.3 Cleaved caspase 3 scoring 
Cleaved caspase 3 IHC was performed on tissue sections as described in section 2.6.3 and 
positive staining was scored as detailed above. 
2.7.4 Tumour severity grading 
Tumour grading was carried out on long term drug and vehicle treated cohorts. Multiple H&E 
stained sections of swiss-rolled intestines per mouse were examined under the microscope. The 
number of lesions and severity of tumour invasiveness was assessed according to criterion 
outlined in table 2.7 and figures 2.3 and 2.4 below. All mice assigned to the various drug and 
vehicle cohorts were examined.   
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Tumour stage Description  
microadenoma (mAd) Small lesions, often observed within the villi 
adenoma (Ad) Larger lesions that do not invade into the underlying submucosa 
Early invasive 
adenocarcinoma (EIA) 
Tumour displaying evidence on invasion into the underlying 
submucosa but does not infiltrate the smooth muscle of the 
intestine 
Advanced invasive 
adenocarcinoma (AIA) 
Tumour displaying evidence on invasion through the smooth 
muscle layer and local invasion in the peritoneum 
Table 2-7 Scoring system used for grade severity of lesions 
 
 
 
 
 
 
 
 
 
 
 
 
H&E stained sections of the whole colon were examined for the level of progression of each 
tumour. This was staged according to the criteria on table 2.7 
Figure 2.3 Stages of colon tumour progression 
hh 
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H&E stained sections of the whole small intestine were examined for the level of progression of 
each tumour. This was staged according to the criteria on table 2.7. (Dashed lines follow the 
smooth muscle wall to demonstrate invasion through the muscle wall) 
Figure 2.4 Stages of intestinal tumour progression 
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2.8 Protein Extraction and Western Blot Analysis 
Protein was extracted from tumour samples which were snap frozen during dissection in liquid 
nitrogen and stored at -80°C prior to protein extraction.  
2.8.1 Protein extraction 
Tumours were removed from frozen storage and placed in dry ice to keep frozen. 200µl of lysis 
buffer (20mM Tris-HCl pH8.0, 2mM EDTA pH8.0, 0.5% [v/v] NP-40 (Sigma Aldrich)) containing 
protease inhibitors (Complete mini protease inhibitor tablets, one per 5ml lysis buffer (Roche)), 
and phosphatase inhibitors (25mM sodium beta-glycerophosphate (Calbiochem), 100mM 
sodium fluoride (Sigma Aldrich), 20nM Calyculin A from Discodermia calyx (Sigma Aldrich) and 
10mM sodium pyrophosphate (Sigma Aldrich)) was added to homogenising lysing matrix D tubes 
(MP Biomedicals) and kept cold on ice. Individual tumours were carefully placed into individual 
homogeniser tubes containing lysis buffer and extra care was taken to ensure samples do not 
defrost during the process. Whilst the tumour defrosted, cells were homogenised using a 
Precellys 24 Homogeniser (Bertin Technologies) at 6000 RPM for 2 cycles of 45 seconds. The 
samples were then further lysed by shear action by passing sample through a 21 or 23 gauge 
needle 10 times. The samples were then transferred to clean microtubes and centrifuged at 
10000 x g for 10 minutes at 4°C. Centrifugation allowed formation of a pellet of insoluble 
material. The supernatant was removed and aliquoted before snap freezing in liquid nitrogen 
and storing at -80°C.                        
2.8.2 Determination of protein concentration 
An aliquot of each protein sample extracted was used for protein quantification using the 
Bicinchoninic Acid (BCA) method. The BCA method uses the biuret reaction in which Cu2+ ions 
are reduced to Cu1+ ions to produce a purple colour. The extent to which the copper ions are 
reduced can be quantified by colourimetric detection in a linear fashion as the BCA reagent 
strongly absorbs light at 562nm. Reactions were conducted in colourless, flat bottom 96 well 
plates (Greiner Bio-One). Each protein sample was measured in duplicate, 2µl was added to 
198µl 1X Phosphate Buffer Solution (PBS) (10X stock, Invitrogen), mixed and serially diluted 
twice to produce three concentrations (1/100, 1/200 and 1/400) in a final volume of 100µl. A 
standard curve was created using Bovine Serum Albumin (BSA) diluted from a stock of 2mg/ml 
to 100mg/ml in lysis buffer. The diluted BSA was further diluted in PBS to generate a 
concentration range of 5µmg/ml to 35µg/ml. BCA reagents were made up following 
manufacturer’s instructions (Pierce), 100µl was added to each sample and mixed by pipetting. 
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The plate was sealed using a foil lid and incubated at 37°C for 1 hour with slight agitation or 
overnight at room temperature. The absorbance of each sample was read using a plate reading 
spectrophotometer ELx800 (Biotek), at the nearest wavelength to the optimum (562nm) at 
590nm. Concentrations of each diluted sample were calculated using the standard curve.  
2.8.3 Preparation of protein samples for western blot analysis 
Protein samples were removed from -80°C storage and defrosted on ice. 30µg of protein from 
each sample was made up to 15µl with extraction buffer and a further 15μl of Laemmli buffer 
(Sigma Aldrich) was added. The samples were heated at 95°C for 10 minutes to denature 
proteins and then quenched on ice. Samples were briefly centrifuged prior to loading into wells.  
2.8.4 Casting of polyacrylamide gels 
The Mini-Protean III (Bio-Rad) gel casting apparatus was used to prepare 1.5mm thick 
polyacrylamide gels. Glass plates were rinsed with distilled water, cleaned with 70% ethanol, 
dried and assembled into the casting apparatus. Extra care was taken to ensure all seals were 
tight at the bottom of the glass plates. Gel solutions were made up to produce 10% resolving gel 
and 5% stacking gel without the addition of TEMED (recipes for resolving and stacking gel 
outlined on table 2.7). TEMED was first added to the resolving gel solution (in the fume hood), 
quickly mixed and poured into the glass plates, leaving approximately 2cm on top for the 
stacking gel.  1ml of distilled water was placed on top of the resolving gel solution to ensure the 
surface of the gel was flat and the gel was left to set. The remaining resolving gel solution was 
used to determine when the gel was set. Once set (approximately 30 minutes), the water was 
poured off onto tissue paper. TEMED was then added to the stacking gel solution, mixed 
thoroughly and pipetted onto the resolving gel up to the top of the glass plates and an 
appropriate comb inserted between the glass plates to create wells. Once set, the combs were 
removed and gel plates were placed into sodium dodecyl sulphate-polyacrylamide gel 
electrophoresis (SDS-PAGE) apparatus. Running buffer was added into the tank to create a 
buffer dam for the electric current to pass through and wells were flushed with running buffer 
to remove excess gel.  
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10% resolving polyacrylamide gel (2 gels)  5% stacking polyacrylamide gel (2 gels)  
6.8ml Ultrapure double deionised H2O 
8.4ml 30% acrylamide/bisacrylamide (Sigma 
Aldrich) 
9.4ml 1M Tris-HCL pH8.8 
250µl 10% [w/v] Sodium Dodecyl Sulphate 
(SDS, Sigma Aldrich) 
72µl 25% [w/v] Ammonium persulphate (APS, 
Sigma Aldrich) 
13.2µl N,N,N’,N’-teramethylethylenediamine 
(TEMED, Sigma Aldrich)  
6.9ml Ultrapure double deionised H2O 
1.7ml 30% acrylamide/bisacrylamide (Sigma 
Aldrich) 
1.3ml 1M Tris-HCL pH8.8 
100µl 10% [w/v] Sodium Dodecyl Sulphate 
(SDS, Sigma Aldrich) 
66µl 25% [w/v] Ammonium persulphate (APS, 
Sigma Aldrich) 
13.2µl N,N,N’,N’-teramethylethylenediamine 
(TEMED, Sigma Aldrich)  
Table 2-8 Recipes for resolving and stacking gels 
5X Running buffer 
(1L)  
1X Transfer buffer 
(1L)  
1X Stripping buffer (1L)  
950ml distilled H2O 
15.1g Tris base 
(Fisher Scientific) 
94g Glycine (Fisher 
Scientific) 
50ml 10% [w/v] 
Sodium Dodecyl 
Sulphate (SDS, 
Sigma Aldrich)  
800ml distilled H2O 
200ml Methanol 
(Fisher Scientific) 
2.9g Tris base 
(Fisher Scientific) 
14.5g Gycine (Fisher 
Scientific)  
60ml Tris 1M pH 6.8 
20g Sodium Dodecyl Sulphate 
(SDS, Sigma Aldrich)  
Make up to 1L 
Prior to use: add 350µl β-
mercapthoethanol (Sigma 
Aldrich) to 50ml stripping 
buffer  
Table 2-9 Recipes for buffers used during SDS-PAGE 
 
2.8.5 SDS-PAGE 
Once the apparatus was set up, 6µl of pre-stained full-range Rainbow molecular weight ladder 
(GE Healthcare) was added to the first well. Prepared protein samples (as described above in 
section 2.8.3) were loaded into individual wells and the gels were run at 130-200V, until the dye 
reached the end of the gel.  
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2.8.6 Protein transfer to nitrocellulose membrane 
After proteins had separated in the polyacrylamide gel, the gels were removed from the SDS-
PAGE tank and from the glass plates, and placed into transfer buffer before removal of the 
stacking gel. Amersham Hybond-ECL nitrocellulose membrane (GE Healthcare) was cut to size 
and also placed in transfer buffer until assembly of ‘transfer sandwiches’. The gel and 
membrane were ‘sandwiched’ between two sheets of 3MM blotting paper (cut to size) on each 
side, as well as one piece of sponge either side (all pre-soaked in transfer buffer). Extra care was 
taken to ensure no air bubbles were present in between the polyacrylamide gel and the 
nitrocellulose membrane, as these prevent the transfer of proteins to the membrane. The 
‘sandwich’ was placed into plastic transfer supports before being placed into the transfer tank, 
orientated so that the current runs through the gel towards the nitrocellulose membrane (- to +) 
to transfer negatively charged proteins to the nitrocellulose membrane. 1L of transfer buffer 
was added to the tank, which was then placed into an ice bucket and allowed to run at 100V for 
1 hour. After transfer, the nitrocellulose membrane was carefully removed from the sandwich 
and placed in wash buffer, 1X TBS/T (Tris Buffered Saline with 0.1%Tween (10X stock, Cell 
signalling Technology)) in a clean container.    
2.8.7 Primary and Secondary antibody probing on nitrocellulose membrane 
The nitrocellulose membrane was blocked in 5% [w/v] non-fat dry milk (Marvel) in TBS/T for 1 
hour at room temperature with slight agitation to prevent non-specific antibody binding. The 
membrane was then washed once in wash buffer before addition of the primary antibody 
diluted either in 5% non-fat dry milk or 5% Bovine Serum from Albumin (BSA) in TBS/T. The 
primary antibody was incubated either overnight at 4°C or 1 hour at room temperature, both 
with gentle agitation. The membranes were then washed three times for 5 minutes in wash 
buffer before incubation with HRP-linked secondary antibody diluted in 5% non-fat dry milk in 
TBS/T for 1 hour at room temperature with gentle agitation. The secondary antibody used was 
raised in the same animal as the primary antibody and was typically diluted 1/2000. The 
membrane was then washed three times for 5 minutes with wash buffer prior to signal 
detection 
2.8.8 Signal detection 
The electrochemiluminescence (ECL) reagent kit (GE Healthcare) was used for detection of 
antibody signal. The reagents utilise a chemifluorescent reaction catalysed by HRP exposed to X-
ray film. The ECL reagents were prepared according to manufacturer’s instructions just before 
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use. The ECL reagent was added to membranes and incubated according to manufacturer’s 
instructions before draining excess solution and placing membranes into a light-proof cassette. 
The cassette was then taken to the dark room where under safelight conditions, X-ray film 
(Fujifilm Super RX, blue background) was exposed and processed using an automatic processor 
(Xograph Compact X4 automatic X-ray film processor). A number of X-rays were exposed at 
varying times to ensure clear images were generated. The films were then placed on top of the 
membranes and molecular weight ladder was used to confirm presence of correct protein band 
size.  
2.8.9 Confirmation of equal loading 
Membranes were then washed to remove excess ECL reagents before re-probing with an 
antibody for β-actin (conditions in table 2.9), a house keeping gene often used to confirm equal 
loading of proteins. Often for phosphorylated proteins, in order to confirm the difference in 
phosphorylated proteins was not due to a higher or lower abundance of the unphosphorylated 
protein, samples from one stock solution were often run on two separate gels which were 
simultaneously transferred and incubated with either the phosphorylated or the total protein. 
Alternatively, membranes were stripped of bound antibody, using a stripping buffer (described 
in table 2.8) to re-probe at the same region. For this, each membrane was incubated in 50mls of 
stripping buffer with 350μl β-mercapthoethanol at 55°C for 30 mins. Following this, membranes 
were washed in wash buffer and then subjected to normal protocols for antibody probing as 
outlined in section 2.8.7.     
2.8.10 Densitometry Analysis 
For densitometry analysis, protein bands were quantified by measuring the intensity of bands on 
images of western blots, using Image J software. The quantity of protein was determined 
relative to the loading control (β-actin) and represented as relative to control samples.  
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Key: TTM – Non-fat dry milk, TBS/T – Tris buffered solution with 0.1% Tween, BSA – Bovine 
Serum Albumin, RT – Room temperature, O/N – Over night, ECL - Electrochemiluminescence.   
 phospho-
Akt473  
phospho-
Akt308  
Total Akt  phospho-
Erk  
Total Erk  phospho-S6 
Ribosomal Protein  
phospho-
4EBP1  
P110α  β-actin  
Manufacturer 
Catalogue #  
Cell 
signaling 
Technology 
4060 
Cell 
signaling 
Technology 
13038 
Cell 
signaling 
Technology 
4685 
Cell 
signaling 
Technology 
4377 
Cell 
signaling 
Technology 
4695 
Cell signaling 
Technology 4856 
Cell 
signaling 
Technology 
2855 
Cell signaling 
Technology 
4249 
Sigma 
Aldrich 
A5441 
Block  5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
5% TTM/ TBS/T  5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
5% TTM/ 
TBS/T  
Primary 
antibody 
dilution 
Conditions 
1:1000 in 
5%BSA/ 
TBST 
O/N at 4°C  
1:500 in 
5%BSA/ 
TBST  
O/N at 4°C 
1:1000 in 
5%BSA/ 
TBST  
O/N at 4°C 
1:1000 in 
5%BSA/ 
TBST  
O/N at 4°C 
1:1000 in 
5%BSA/ 
TBST  
O/N at 4°C 
1:500 in 5%BSA/ 
TBST  
O/N at 4°C 
1:500 in 
5%BSA/ 
TBST  
O/N at 4°C 
1:500 in 
5%BSA/ TBST  
O/N at 4°C 
1:4000 in 
5%TTM/ 
TBST 
1hr at RT  
Secondary 
antibody  
dilution 
Conditions  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-rabbit 
1:2000 
1hr at RT  
Anti-mouse 
1:2000 
1hr at RT  
Signal 
detection  
ECL  ECL  ECL  ECL  ECL  ECL  ECL  ECL  ECL  
Table 2-10 Outline of antibodies and conditions for protein analysis 
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2.9 Maintenance and culture of cells 
2.9.1 Experimental cell lines 
The MCF7 cell line is a human breast cancer cell line (obtained from Prof Jan Balzarini, Rega 
Institute, Netherlands) isolated from an invasive breast ductal carcinoma by the Michigan 
Cancer Foundation in 1970. The MCFTDX cell line (also obtained from Prof Jan Balzarini, Rega 
Institute, Netherlands) is a stable Tomudex resistant cell line created by continuous exposure to 
2µM Tomudex by Patrick Johnston and colleagues in 1995.  
2.9.2 Maintenance of cell lines 
Both MCF and MCFTDX cell lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Invitrogen) supplemented with 10% [v/v] Fetal Bovine Serum (FBS, Sigma Aldrich), 1% [v/v] 
Hepes buffer (Invitrogen), 2mM L-glutamine (Invitrogen) and 50 units/ml penicillin-streptomycin 
(Invitrogen).  
Cell lines were maintained in a sterile, humidified 37°C incubator and CO2 levels were 
maintained at 5%. Both cell lines were routinely cultured in T25 tissue culture flasks (Corning 
Ltd). Cells were passaged when they reached confluency of 80-90% on a split ratio of 1/6-1/12. 
For cell passaging, all media was removed, cells were washed in sterile 1X Phosphate-Buffered 
solution (PBS, Invitrogen) and incubated in 0.05% Trypsin/EDTA (Invitrogen) (normally 2mls of 
trypsin/T25 flask) for 5 minutes at 37°C. Cells were then checked under the microscope to 
ensure detachment before being diluted in culture medium to the appropriate splitting ratio and 
transferred to a clean flask. Cell lines were not split for more than 25 recorded passages.  
2.9.3 Long term cell storage 
Cells were routinely frozen and cryo-stored in order to have sufficient aliquots of cell lines with 
low passage numbers. Confluent T75 flasks (Corning Ltd) of cells were detached by trypsin 
resuspended in 10mls of culture medium and transferred to a clean 15ml falcon tube. Cells were 
then pelleted by centrifugation at 1100rpm for 3 minutes. The cells were then resuspended in 
10mls of freezing medium (culture medium with 10% [v/v] dimethyl sulfoxide (DMSO, Sigma 
Aldrich)) and aliquoted into 1ml cryo-tubes (Nunc). The tubes were placed in a freezing 
container filled with iso-propanol to facilitate slow freezing at -80°C overnight. Cyro-tubes 
containing cells were then transferred into liquid nitrogen storage.  
When required, cells were retrieved from liquid nitrogen storage and kept on dry ice until prior 
to defrosting. Cells were quickly defrosted in a 37°C water bath and immediately resuspended 
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into 10mls of culture medium in a 15ml falcon tube and pelleted by centrifugation at 1100rpm 
for 3 minutes. The pellet was then resuspended in 7mls of culture medium and cultured in T25 
flasks.  
2.9.4 Collection of cells for RNA extraction 
For RNA extraction, media from confluent T25 flasks of cells was removed and cells were 
washed twice with sterile 1X PBS (Invitrogen). 5mls of PBS was then added to each flask and cells 
were scraped off the surface of the plate with a cell scraper (Nunc). The cell solution was then 
transferred into a clean 15ml falcon tube and cells were pelleted by centrifugation at 1100rpm 
for 3 minutes. The supernatant was discarded and the pellet was immediately snap frozen in 
liquid nitrogen and stored at -80°C.  
2.9.5 Cell Titer Blue cell viability assay 
To assess the anti-cancer activity of BVDU ProTides in MCF7 and MCFTDX cell lines, the Cell Titer 
Blue cell viability assay was used. T25 flasks of 50% confluent MCF7 and MCFTDX cells were 
incubated with 0.05% trypsin-EDTA (Invitrogen) to detach cells as previously described. Cells 
were then transferred into clean 15ml falcon tubes and pelleted by centrifugation at 1100rpm 
for 3 minutes. The pellet was resuspended in 1ml of culture media and dissociated to ensure a 
single cell suspension was achieved. Cells were then counted utilising a haemocytometer cell 
counting chamber (Thermo Scientific) three times, and the average calculated. The total number 
of cells per ml could then be calculated by multiplying the average number of cells per square by 
104. Both MCF7 and MCFTDX cells were then seeded at a density of 5000 cells per 100µl into flat 
bottomed clear 96 well plates (Corning Ltd).  
After 24 hours at 37°C with 5% CO2, cells were treated with decreasing concentrations of 
individual ProTide compounds (using an initial stock of 25mM in DMSO (Sigma Aldrich)) in 6 well 
repeats. Concentrations used ranged between 250µM and 0.25µM. DMSO only controls as well 
as equivalent Thymectacin and BVDU concentrations were used to compare each ProTide 
compound tested. Cells were incubated with compounds for 72 hours at 37°C with 5% CO2.  
Following 72 hours of incubation, the viability of cells was determined using Cell Titer Blue 
(Promega), a reagent which allows measurement of cell metabolic activity. Viable cells which are 
metabolically active will have the ability to convert resazurin (the indicator dye used in this 
assay) into resofurin, a highly fluorescent product. Viability of cells is then determined by 
measuring fluorescent levels after incubation with the substrate. Prior to use, the Cell Titer Blue 
reagent was thawed at room temperature. Once thawed, 20µl was added per well and 
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incubated at 37°C with 5% CO2 for 1 hour. The fluorescence was then measured at the 
excitation/emission wavelength of 560/590nm on a Flurostar Optima plate reader (BMG 
Labtech). The percentage of viable cells was then calculated relative to DMSO controls and 
plotted against concentration to determine the half maximal Inhibition Concentration (IC50).  
2.9.6 Colony forming assay 
For colony forming assays, MCF7 and MCFTDX cells were detached and dissociated from T25 
flasks as previously described in section 2.9.2 and seeded in clear, flat bottomed 6 well plates at 
a density of 6000 cells per well. After 24 hours at 37°C with 5% CO2, cells were treated in 
duplicates with decreasing concentrations of ProTides, Thymectacin or DMSO controls. 
Concentrations used ranged from 150µM to 5µM. Cells were incubated with drugs for 72 hours 
at 37°C with 5% CO2 after which fresh culture media was added and subsequently changed every 
3 days. Colonies were left to grow for 14 days after which they were fixed with a 1:1 
methanol:acetone solution for a few seconds. Cells were then air dried, rinsed with distilled 
water and finally stained with Giemsa Stain (Sigma Aldrich) diluted 1/10 in distilled H2O for 1 
minute. Excess stain was rinsed off with distilled water and allowed to dry.   
 
2.10 RNA extraction and Gene expression analysis 
2.10.1 RNA isolation and quantification 
RNA was isolated from MCF7 and MCF7-TDX cell lysates (preparation detailed in section 2.9.4) 
as well as normal intestine and tumour tissue snap frozen in liquid nitrogen during dissection. 
The samples were stored at -80°C prior to RNA extraction 
2.10.2 Homogenisation of cells 
Cell lysates were added to 1ml Trizol (Invitrogen) in homogenising lysing matrix D tubes (MP 
Biomedicals). Normal small intestine and tumours were removed from storage and placed on 
dry ice to prevent defrosting. Whilst still frozen, tissue was carefully placed in 1ml Trizol in 
homogenising lysing matrix D tubes (MP Biomedicals). The samples were all homogenised from 
frozen using a Precellys 24 homogeniser (Bertin Technologies) at 6000 RPM for 2 cycles of 45 
seconds.   
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2.10.3 RNA extraction and purification 
All samples were kept on ice during RNA isolation. After homogenisation, the solution was 
centrifuged at 10 000 x g for 10 minutes to pellet insoluble material. The supernatant was then 
transferred to RNAse/DNAse free 1.5ml microcentrifuge tubes before adding 200µl of 
chloroform to each sample. The samples were shaken vigorously by hand before being 
incubated at room temperature for 3 minutes. The samples were then centrifuged at 10 000 x g 
for 15 minutes 4°C to separate the aqueous phase from the organic phase. 400µl of the aqueous 
phase was transferred to clean microcentrifuge tubes and an equal volume of isopropanol was 
added and mixed to precipitate the RNA. The RNeasy Minikit (Qiagen) was then used to isolate 
and purify the RNA. The RNA containing solution was added to RNeasy mini spin columns and 
centrifuged at 10 000 x g for 30 seconds at 4°C and the filtrate discarded. The RNA in the column 
was consecutively washed by adding 500µl RPE buffer containing ethanol (RNeasy Mini kit, 
Qiagen) once at 10 000 x g for 30 seconds at 4°C and filtrate discarded, and again at 10 000 x g 
for 2 minutes at 4°C and filtrate discarded. The column was centrifuged without RPE buffer at 10 
000 x g for 1 minute at 4°C to ensure elimination of wash buffer. The column was then incubated 
with 50µ of RNase-free H2O (RNeasy Mini kit, Qiagen) for 3 minutes on ice, placed in clean 
RNase/DNase free 1.5ml microcentrifuge tubes and centrifuged at 10 000 x g for 1 minute at 4°C 
to elute the RNA. The RNA was finally quantified in a 1µl sample using a NanoDrop 1000 
(Thermo Scientific), and treated to eliminate from DNase contamination.  
2.10.4 DNase treatment 
The TURBO DNA-free kit (Applied Biosystems) was used to eliminate DNase contamination from 
the RNA sample. 0.1 volume 10X Turbo DNase buffer and 1µl Turbo DNase was added to the 
RNA sample, gently mixed and incubated at 37°C for 20-30 minutes. 0.1 volume DNase 
Inactivation Reagent was added to the RNA samples and incubated for 5 minutes at room 
temperature with occasional mixing. The samples were then centrifuged at 10 000 X g for 1.5 
minutes, the supernatant transferred to a clean eppendorf and the RNA concentration 
quantified again in a 1µl sample using a NanoDrop 1000 (Thermo Scientific).  
2.10.5 cDNA synthesis 
cDNA was synthesised from 1µg of RNA using Superscript II reverse transcriptase (Invitrogen). 
First, random hexamers (Promega) were annealed to the RNA. For this, 1µg of RNA was pipetted 
into strip tubes (Greiner Bio-One), 5µl of random hexamers (Promega) was added to each 
sample and the volume was made up to 20µl with RNAse free dH2O. The samples were 
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incubated in a PTC-100 Thermocycler (MJ Research) at 70°C for 10 minutes followed by 25°C for 
10 minutes. The samples were then held at 4°C whilst a further 20µl of reverse transcriptase 
enzyme mix was added to each sample (outlined in table 2.11). Reverse transcription was 
carried out under the following conditions: 25°C for 10 minutes, 37°C for 45 minutes, 42°C for 45 
minutes and finally 70°C for 15 minutes. After completion of cDNA synthesis, 160µl of RNAse 
free dH2O was added to each sample to dilute the cDNA.  
Q-PCR enzyme mix (per sample)  
5X first strand buffer 8µl 
DDT  4µl 
dNTPs 0.8µl 
Superscript II 1µl 
Ultrapure double deionised H20 6.2µl 
Table 2.11 Recipe for qRT-PCR mix 
2.10.6 Design of quantitative real-time (qRT) PCR primers 
Primer sets for qRT-PCR reactions were designed across exon boundaries to avoid amplification 
of genomic DNA and designed to ensure a resulting product between 100-200 bp in size. The 
Primer3 web-based design program was used for this (http://frodo.wi.mit.edu/), checked using 
the BLAST engine against the Ensembl database (http://www.ensembl.org/Multi/blastview) for 
mis-priming and subsequently synthesised by Sigma Genosys. Primer sequences used can be 
found in Table 2.10. 
Gene  Forward Primer Sequence  Reverse Primer Sequence  Product 
size  
β-actin  TGTTACCAACTGGGACGACA  GGGGTGTTGAAGGTC TCAAA  166  
thymidylate 
synthase  
ATCATCATGTGTGCCTGGAA  GCATAGCTGGCAATGTTGAA  164  
Table 2-11 Outline of primer sequences used for qRT-PCR analysis 
76 
 
2.10.7 Syber green gene expression analysis 
All qRT-PCR reactions were run on the StepOnePlus real-time PCR system. Each reaction was 
performed in triplicate, with a minimum of three biological replicates and samples devoid of 
cDNA controls were used to ensure no contaminants of genomic DNA were present in cDNA 
samples. Typically, the housekeeping gene β-actin was simultaneously run during each 
experiment as the reference gene.  
Reactions were run utilising the DyNAmo HS SYBR Green qPCR kit (Finnzymes) according to 
manufacturer’s instructions. For this, equal quantities of forward and reverse primers were 
mixed (10mM final concentration per reaction). For all reactions, 4μl of cDNA was loaded per 
well into a thin wall 96 well PCR plate (Applied Biosystems) and 16μl of master mix containing 
both primers, was subsequently added. Plates were sealed using optically clear sealing film 
(Applied Biosystems), centrifuged and run using the following cycling conditions: 95°C for 10 
minutes, followed by 40 cycles of 95°C for 15 seconds, 60°C for 30 seconds, 72°C for 30 seconds. 
To ensure a single product was amplified, a melt curve was run after cycling from 60°C to 95°C 
with a 0.3°C increment.           
2.10.8 Analysis of qRT-PCR data 
The data from each qRT-PCR run was automatically collected using StepOne software (Applied 
Biosystems). The data was examined prior to analysis to ensure amplification of one fluorescent 
product, the fluorescence vs cycle plots for each triplicate were comparable and there was no 
fluorescent product in the (no) cDNA controls. Differences between target gene expression 
between each cohort was assessed by comparing the changes in the number of cycles required 
for the fluorescent product to reach exponential phase, i.e. the higher the abundance of target 
gene, the lower the cycles required for the level of fluorescence to reach the exponential phase. 
Fluorescence vs. cycle number plots were generated and the threshold for the exponential 
phase was set automatically by software. Cycle times (CT) and differences in cycle times (∆CT) 
values were calculated and normalised to β-actin control values. The ∆∆CT was then calculated 
for each experimental sample (normalised to the average of control groups). Subsequently fold 
change differences were calculated using the equation 2^(-x) whereby x represents the ∆∆CT 
values.    
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2.11 Data Analysis and Statistical analysis 
2.11.1 Mann Whitney U test 
The Mann Whitney U two-tailed test was conducted to detect statistical differences between 
most non-parametric data sets and was conducted using Minitab statistics package. A significant 
difference between data sets was accepted given p values were less than or equal to (≤) 0.05. 
For analysis of acute drug time points, analysis was conducted on individual tumours, at least 4 
tumours from 3 or more mice, whereas for chronic treatment analyses, n denotes the number of 
mice per cohort. To detect statistical differences between densitometry analyses, the Mann 
Whitney U one-tailed test was utilised as only three data points were available. A significant 
difference between data sets was accepted given p values were less than or equal to (≤) 0.05. 
 
2.11.2 Kaplan Meier survival analysis 
Survival curves were generated using SPSS statistical software. Statistical analysis was conducted 
using Minitab statistics package using the Log-Rank method and the wilcoxon test for 
significance. A significant difference between data sets was accepted given p values ≤ 0.05.
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3 Evaluating MEK and PI3K/mTOR inhibition in the Wnt activated, Apcf/+ tumour 
model 
 
3.1 Introduction 
Mutations in the APC gene which encodes for the Adenomatous polyposis coli tumour 
suppressor protein is recognised as the key initial event in the development of sporadic CRC, 
with mutations occurring in up to 80% of cases (Wood et al., 2007). Furthermore, germline 
mutations in APC characterise Familial Adenomatous Polyposis (FAP), an autosomal syndrome 
characterised by hundreds of colorectal lesions (Kinzler and Vogelstein, 1996). In vivo models 
of Apc mutant CRC are therefore highly relevant and have proved particularly useful in 
characterising the role of other tumour suppressor proteins and oncogenes in tumourigenesis, 
as well as the effect of novel therapeutic strategies on tumour development. The models 
utilised for this include the multiple intestinal neoplasia (Min) or Apcmin/+ mouse model, 
initially generated by random mutagenesis using N-ethyl-N-nitrosourea (ENU), this model 
carries a transversion at codon 850 causing truncation of one copy of the gene and requires 
loss of heterozygosity for development of benign intestinal lesions (Su et al., 1992). 
Additionally, other studies have used heterozygous deletion of the Apc580s allele driven by 
intestinal specific AhCre or VillinCre recombinase transgene to mimic spontaneous tumour 
formation over a long latency (Sansom et al., 2006, Davies et al., in press, Janssen et al., 2006). 
Tumours which develop in these models are often benign adenomas as Apc mutations are 
associated with initiation of tumourigenesis and accumulation of further mutations are 
required for progression of disease (Fearon and Vogelstein, 1990). Nevertheless, these can be 
useful tools to investigate novel therapeutic strategies for the early disease setting.   
Since its identification, aberrant activation of the Epidermal growth factor receptor (EGFR) has 
been associated with numerous cancer phenotypes including cellular proliferation, migration, 
metastasis, angiogenesis as well as escape from apoptosis (Gschwind et al., 2004). Binding of 
ligands to the extracellular receptor domain leads to activation of internal tyrosine kinase 
domains, which following a number of autophosphorylations at tyrosine residues, serve as 
binding sites for several adaptor proteins (Zhang et al., 2006). This includes GRB2, which leads 
to activation of RAS-RAF-ERK signalling and p85 which together with p110, activates PI3K/AKT 
signalling (Hynes and Lane, 2005). The observation that EGFR is often overexpressed in CRC 
warranted investigation of its therapeutic targeting in CRC (Resnick et al., 2004). Despite the 
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availability of numerous EGFR antagonists including cetuximab and panitumumab, and 
exhaustive investigation of these for therapeutic intervention, patients with CRC often display 
no or modest benefits, and subsequently develop resistance to treatment through up-
regulation of MAPK or PI3K signalling (Benvenuti et al., 2007, Di Nicolantonio et al., 2008). 
Furthermore, extensive retrospective analyses have identified mutations in KRAS, B-RAF and 
those activating the PI3K pathway such as PTEN, to predict non-response to anti-EGFR 
therapies (Lièvre et al., 2008, Frattini et al., 2007, Perrone et al., 2009, Bardelli and Siena, 
2010). Given these findings, targeting of MAPK and PI3K signalling downstream the pathway 
appears a more rational therapeutic strategy for wild-type tumours.  
In this chapter, I aimed to investigate the therapeutic potential of MAPK and PI3K inhibition in 
a mouse model of CRC mutant for the tumour suppressor protein Apc1. Here, heterozygous 
deletion of Apc is driven by the VillinCreER transgene and results in small intestinal and colonic 
tumours over a long latency. To antagonise the MAPK and PI3K pathways, I used the MEK1/2 
inhibitor MEK162 and the dual PI3K/mTOR inhibitor NVP-BEZ235, respectively (both provided 
by Novartis Pharmaceuticals). For these investigations, I employed two main strategies. Firstly, 
tumour bearing VillinCreER Apcf/+ (referred to as Apcf/+ here forth) mice were administered a 
single dose of MEK162 or NVP-BEZ235 and harvested 4 hours later to evaluate the immediate 
pharmacodynamic and anti-tumour effects. Secondly, to evaluate the therapeutic potential of 
each treatment, Apcf/+ mice were continuously administered treatment, from a chosen time 
point post induction until a survival end point (i.e when mice were symptomatic of disease) or 
the experimental end point of 500 days post induction. These later experiments were 
conducted to investigate the effect of treatment on survival of mice as well as tumour burden. 
Additionally in this chapter, I assessed activation status of MAPK and PI3K signalling in other 
transgenic mouse models of CRC mutant for the oncogene Kras and the tumour suppressor 
protein Pten, which are crucial for mediating MAPK and PI3K signalling respectively.  
3.2 Results   
3.2.1 Mek inhibitor MEK162 elicits no anti-tumour effect on Apcf/+ colon polyps however, 
in small intestinal tumours increases proliferation and apoptosis 
To investigate the immediate anti-tumour and pharmacodynamic effects of MEK162 in Apcf/+ 
tumours, 10 week old Apcf/+ mice were induced and monitored until symptomatic of disease 
(pale feet, bloating, blood in faeces, etc.). Mice were then administered a single dose of either 
                                                          
1
 Some data analysis presented in this chapter was conducted by Tanya Davies under my supervision 
79 
 
0.5% Methylcellulose (MC, Vehicle) or 30mg/kg MEK162 and harvested 4 hours later. 
Additionally, an excessive dose of BrdU was administered 2 hours prior to culling to label cells 
in S phase of the cell cycle. Dissection was conducted as previously described (methods section 
2.4.2) whereby the intestines were rolled into ‘swiss-roll’ like structures and quick fixed in 
formalin, in preparation for H&E staining and IHC. 
Following exposure to a single dose of MEK162, the immediate anti-tumour effects were first 
evaluated through scoring of histological mitosis and apoptosis from H&E stained sections of 
Apcf/+ colonic and small intestinal tumours (SITs). Scoring of mitotic figures in colon tumours 
and SITs revealed no significant alterations in MEK162 treated cohorts in comparison with 
vehicle controls (veh colon = 0.22 ± 0.11, MEK162 colon = 0.19 ± 0.12, p value = 0.583, veh SIT 
= 0.18 ± 0.064, MEK162 SIT = 0.26 ± 0.15, p value = 0.298, n≥4 tumours, 3 mice, Mann Whitney 
U test) (Figure 3.1 A). Additionally, quantification of apoptotic bodies in colon polyps and SITs 
revealed no significant alterations in MEK162 treated samples (veh colon = 0.77 ± 0.31, 
MEK162 colon = 0.72 ± 0.32, p value = 0.815, veh SIT = 0.32 ± 0.25, MEK162 SIT = 0.34 ± 0.27, p 
value = 0.930 n≥4 tumours, 3 mice, Mann Whitney U test) (Figure 3.1 B) indicating no 
immediate anti-tumour effects. 
To further evaluate the immediate effects of ME162 in Apcf/+ tumours, IHC for BrdU and 
cleaved caspase 3 were carried out and scored. Quantification of BrdU positive cells revealed 
no significant alterations in colon polyps or SITs, in keeping with scoring of mitosis (veh colon = 
16.1±7.1, MEK162 colon = 17.3 ± 5.9, p value = 0.954, veh SIT = 24.5 ± 16.1, MEK162 SIT = 21.8 
± 10.9, p value = 0.911, n≥4 tumours, 3 mice, Mann Whitney U test) (Figure 3.2 A). Scoring of 
cleaved caspase 3 staining also revealed no significant alterations in colon polyps, in 
corroboration with previous scoring of histological apoptosis, however did reveal a significant 
increase in cleaved caspase 3 staining in SITs 4 hours post exposure to MEK162 (veh colon = 
0.47 ± 0.38, MEK162 colon = 0.31 ± 0.33, p value = 0.378, veh SIT = 0.89 ± 0.59, MEK162 SIT = 
2.42 ± 1.54, p value = 0.034, n≥4 tumours, 3 mice, Mann Whitney U test) (Figure 3.2 B).  
In summary, the above observations indicate that MEK162 had no significant anti-tumour 
effect on Apcf/+ colon tumours at the 4 hour time point investigated as no alterations in 
proliferation or apoptosis were detected. Apcf/+ SITs appeared moderately sensitive to MEK162 
as a significant pro-apoptotic effect was detected 4 hours post exposure, indicating some 
favourable anti-tumour effects.  
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Figure 3.1 The anti-tumour effects of MEK162, characterised by scoring of histological 
mitosis and apoptosis in Apcf/+ colon polyps and small intestine tumours (SITs), 4 hours post 
exposure 
Scoring of mitotic figures (A) and apoptotic bodies (B) revealed a single dose of 30mg/kg 
MEK162 had no effect on colon polyps or SITs, although MEK162 led to a trend towards 
increased mitoses in SITs 4 hours after exposure. (p value ≥ 0.05, n ≥ 4 tumours, 3 mice, Mann 
Whitney U test). Error bars represent standard deviation 
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Figure 3.2 MEK162 has no effect on BrdU positive cells in Apcf/+ colon polyps or small 
intestine tumours (SITs) but increased cleaved caspase 3 in SITs only 
Quantification of IHC for BrdU and cleaved caspase 3 revealed a single dose of MEK162 at 
30mg/kg had no effect on BrdU positive cells in colon polyps or SITs. Additionally, MEK162 had 
no effect on cleaved caspase 3 scoring in colon polyps, but did significantly increase cleaved 
caspase 3 levels in SITs 4 hours post exposure (*p value ≤ 0.05, n ≥ 4 tumours, 3 mice, Mann 
Whitney U test). Error bars represent standard deviation.  
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3.2.2 MEK162 reduces MAPK signalling through pERK and also reduces PI3K signalling 
To investigate whether MEK162 lead to inhibition of MAPK signalling in Apcf/+ tumours, IHC 
against the phosphorylated and hence activated form of the MAPK effector protein ERK was 
carried out (Figure 3.3, 3.4). Immunostaining revealed a reduction in nuclear staining of pERK 
in colon polyps post exposure to MEK162 and a reduction in nuclear and cytoplasmic pERK 
staining in SITs, in comparison with vehicle treated tumours. These findings suggest that 
exposure to MEK162 for 4 hours is sufficient to inhibit MAPK signalling through pERK in Apcf/+ 
tumours and specifically in SITs, this may translate to biological activity, as an increase in 
apoptosis by cleaved caspase 3 staining was detected.  
 Given the close association and convergence between MAPK signalling through RAS-RAF-ERK 
and PI3K signalling through AKT and mTOR (Ma et al., 2007, Ma et al., 2005), the effects of 
MEK inhibition on the PI3K pathway was also assessed to determine whether this resulted in 
compensatory activation of PI3K signalling. For this, immunostaining of the phosphorylated 
form of AKT (pAKT) the PI3K signalling effector, and phosphorylated S6-ribosomal protein 
(pS6RP) which transduces signals downstream of mTOR were carried out (Figure 3.3, 3.4). 
Surprisingly, a reduction in membrane and cytoplasmic pAKT staining (Ser473) as well as a 
marked reduction in membrane, cytoplasmic and nuclear staining of pS6RP was observed in 
MEK162 treated colon polyps, indicating inhibition of PI3K signalling. Interestingly, a reduction 
in the cytoplasmic and nuclear staining of pAKT was also detected in SITs, however no 
alterations in pS6RP immunostaining were detected here. These observations again reflect 
differential sensitivities of colon polyps and SITs to MEK162; however surprisingly suggest 
activation of mechanisms to also inhibit PI3K signalling.  
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IHC for pERK, pAKT at Ser473 and pS6RP was carried out in MEK162 treated and control colon 
polyp samples. A reduction in nuclear and cytoplasmic pERK immunostaining reveals inhibition 
of MAPK signalling downstream MEK. Additionally, Immunostaining for pAKT473 and pS6RP 
appears reduced indicating inhibition of parallel PI3K/mTOR signalling pathway.     
 
 
 
Figure 3.3 IHC reveals MEK162 reduces MAPK and PI3K signalling in colon polyps 4 hours post 
exposure 
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Figure 3.4 IHC for pERK, pAKT473 and pS6RP in small intestinal tumours (SITs) 4 hrs following 
a single dose of MEK162 
Immunostaining for pERK in SITs following a single dose of 30mg/kg MEK162 reveals reduced 
levels of cytoplasmic and nuclear pERK, indicating inhibition of MAPK signalling. IHC showed 
reduced immunostaining for pAKT at Ser473 but not for pS6RP indicating partial PI3K pathway 
inhibition.  
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3.2.3 Continuous MEK162 treatment increases longevity of Apcf/+ mice  
To further evaluate the therapeutic potential of MEK162 in Apcf/+ mice, a long term treatment 
experiment was undertaken in tumour bearing mice to determine the effect of treatment on 
overall survival and tumour burden of mice. For this, Apcf/+ mice were induced and aged to 
allow for tumour development. Given the long tumour latency period in Apcf/+ mice (Figure 
3.5), 220 days post induction was chosen as an appropriate intervention start point. At this 
point, mice were randomly selected to either receive 30mg/kg MEK162 twice-daily (n=10 
mice) or 0.5% MC twice daily (n=5 mice) by oral gavage. To increase the number of mice in the 
control cohort, untreated mice which were monitored until symptomatic of disease and 
subsequently administered a short term dose of treatment were also used for survival 
analyses. Mice were treated daily until a survival end point (anaemia, bloating and ≥10% loss 
of body weight) or the experimental end point of 500 days post induction. 
Continuous daily treatment of MEK162 in Apcf/+ mice was found to be well tolerated and 
significantly increased longevity of mice (median survival of MEK162 mice = 401 vs vehicle = 
270, p value = 0.011 Log-Rank and p value = 0.007 Wilcoxon test, n≥9 per cohort) (Figure 
3.5).This indicates that whilst MEK162 in the immediate setting displayed only modest anti-
tumour activity, chronic administration is beneficial in Apcf/+ tumour bearing mice. Further 
evaluation of tumour burden following MEK162 treatment is described in section 3.2.7. 
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Figure 3.5 Kaplan Meier survival analysis of Apcf/+ mice on twice daily 30mg/kg MEK162 and 
vehicle controls from 220 days post induction 
Apcf/+ mice were induced and aged to 220 days post induction, at which point mice were 
randomised to receive either 0.5% Methyl cellulose (or remained untreated, controls) or  
30mg/kg MEK162 twice daily by oral gavage, either until a survival end point or an 
experimental end point of 500 days post induction. Continuous MEK162 treatment was found 
to significantly increase median survival of mice from 270 days post induction to 401 days post 
induction (p value ≤ 0.001, n≥8 mice per cohort, Log-Rank and Wilcoxon test). 
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3.2.4 The acute effects of NVP-BEZ235 in Apcf/+ colon polyps and SITs 
As described previously, EGFR mediates growth signals not only through the MAPK signalling 
cascade, but also through PI3K/AKT/mTOR signalling. To elucidate the therapeutic potential of 
inhibiting the later signalling pathway in Apcf/+ tumours, the biological effects of the dual 
PI3K/mTOR inhibitor NVP-BEZ235 were first evaluated in a short term setting. Similarly to 
section 3.2.1, Apcf/+ mice were induced and aged to allowed for symptoms of tumour burden 
to develop, at which point they received a single dose of 35mg/kg NVP-BEZ235 and were 
culled 4 hours after, as previously described methods 2.4.2. Additionally, a dose of BrdU was 
administered 2 hours prior to culling to label cells in S phase of the cell cycle. Vehicle controls 
for this experiment are identical to those used previously in section 3.2.1.  
The immediate anti-tumour activity of NVP-BEZ235 in Apcf/+ mice was initially evaluated by 
examination of H&E stained sections of colon polyps and SITs for histological mitosis and 
apoptosis. Quantification of mitotic figures in Apcf/+ colon polyps revealed no significant 
alterations 4 hours post exposure to NVP-BEZ235 (veh colon = 0.22 ± 0.11, NVP-BEZ235 colon 
= 0.21 ± 0.10, p value = 0.866, n≥4 tumours, 3 mice Mann Whitney U test) (Figure 3.6 A). 
Similarly, no significant effect on mitosis was detected in SITs following NVP-BEZ235 (veh SIT = 
0.18 ± 0.064, NVP-BEZ235 SIT = 0.23 ± 0.17, p value = 0.621, n≥4 tumours, 3 mice Mann 
Whitney U test) (Figure 3.6 A). Scoring of histological apoptosis revealed no statistical 
differences, although a trend towards reduced apoptosis in colon polyps exposed to NVP-
BEZ235 compared to vehicle controls was observed (veh colon = 0.77 ± 0.31, NVP-BEZ235 
colon = 0.57 ± 0.35, p value = 0.0585, n≥4 tumours, 3 mice, Mann Whitney U test) (Figure 3.6 
B). In contrast however, a significant increase in apoptosis was observed in SITs 4 hours post 
exposure to NVP-BEZ235, indicating anti-tumour activity in Apcf/+ mice (veh SIT = 0.32 ± 0.25, 
NVP-BEZ235 SIT = 0.55 ± 0.4, p value = 0.0307, n≥4 tumours, 3 mice, Mann Whitney U test) 
(Figure 3.6 B).  
Additionally to scoring of histological mitosis and apoptosis, IHC against the proliferation 
marker BrdU and the apoptosis marker cleaved caspase 3 were carried out and quantified to 
further characterise the anti-tumour activity of NVP-BEZ235 in Apcf/+ tumours. Scoring of BrdU 
positive cells revealed no significant alterations in colon polyps or SITs exposed to NVP-BEZ235 
in comparison to vehicle treated tumours, supporting mitosis scoring (veh colon = 16.1 ± 7.1, 
NVP-BEZ235 colon = 17.0 ± 5.9, p value = 0.493, veh SIT = 24.5 ± 16.1, NVP-BEZ235 SIT = 22.9 ± 
8.5, p value = 0.609, n≥4 tumours, 3 mice Mann Whitney U test) (Figure 3.7 A). Scoring of 
cleaved caspase 3 staining in colon polyps exposed to NVP-BEZ235 also revealed no significant 
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alterations (veh colon = 0.47 ± 0.38, NVP-BEZ235 colon = 0.38 ± 0.35, p value = 0.178, n≥4 
tumours, 3 mice, Mann Whitney U test) (Figure 3.7 B). Interestingly however, a significant 
reduction in the number of cleaved caspase 3 bodies was scored in SITs exposed to NVP-
BEZ235 indicating an anti-apoptotic effect (veh SIT = 0.89 ± 0.59, NVP-BEZ235 SIT = 0.44 ± 
0.46, p value = 0.0293, n≥4 tumours, 3 mice, Mann Whitney U test) (Figure 3.7 B).  
In summary, characterisation of proliferation and cell death in Apcf/+ tumours post exposure to 
NVP-BEZ235 revealed differences in sensitivities in colon polyps and SITs, as detected 
previously with MEK162 treatment. NVP-BEZ235 failed to induce any favourable anti-tumour 
effects in colon polyps at the 4 hour time point, but did induced both pro and anti-apoptotic 
effects in SITs.  To further characterise the immediate effects of NVP-BEZ235, PI3K signalling 
was next evaluated post exposure to NVP-BEZ235, as described below.        
3.2.5 NVP-BEZ235 preferentially reduces signalling downstream mTOR and not PI3K 
To determine target inhibition in Apcf/+ tumours following NVP-BEZ235 administration, IHC for 
pAKT at Ser473 and pS6RP were carried out to determine inhibition of signalling downstream 
PI3K and mTOR. Immunostaining of colon polyps exposed to NVP-BEZ235 revealed no obvious 
difference in pAKT473 staining however, a marked reduction in membrane, cytoplasmic and 
nuclear staining of pS6RP at the 4 hour time point (Figure 3.8). Interestingly, these 
observations were also notable in SITs, in comparison with vehicle treated tumours (Figure 
3.9). Downstream of PI3K, mTOR exists in two complex forms - mTOR complex 1 (mTORC1) 
which controls regulation of pS6RP, and mTOR complex 2 (mTORC2) which regulates activation 
of pAKT at Ser473 (Jacinto et al., 2006). Observations here indicate that in Apcf/+ NVP-BEZ235 
may preferentially inhibit mTORC1 rather than mTORC2 in Apcf/+ tumours. 
Furthermore, to determine the effect of NVP-BEZ235 on closely associated MAPK signalling, 
IHC for pERK was carried out. Immunostaining for pERK in colon polyps and SITs revealed no 
obvious alterations indicating NVP-BEZ235 had no compensatory effects on MAPK signalling at 
the 4 hour time point investigated (Figure 3.8, 3.9).  
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Scoring of mitotic figures (A) and apoptotic bodies (B) 4 hours following a single dose of 
35mg/kg NVP-BEZ235 reveals no significant alterations in colon polyps or SITs however, did 
reveal a significant increase in apoptosis in SITs, in comparison with vehicle controls (*p value 
≤ 0.05, n ≥ 4 tumours, 3 mice, Mann Whitney U test). Error bars represent standard deviation.  
Figure 3.6 The anti-tumour effects of NVP-BEZ235, determined by scoring of histological 
mitosis and apoptosis in Apcf/+ colon polyps and small intestine tumours (SITs) at a 4 hour time 
point following exposure 
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Figure 3.7 BrdU scoring revealed no significant alterations following NVP-BEZ235 treatment, 
cleaved caspase 3 scoring showed no significant differences in colon polyps but a significant 
reduction in small intestine tumours (SITs) 
Scoring of IHC for BrdU positive cells (A) and cleaved caspase 3 staining (B) 4 hours following a 
single dose of 35mg/kg NVP-BEZ235 reveals no significant alterations in colon polyps. Similarly, 
no significant alterations were detected in SITs with BrdU scoring however, NVP-BEZ235 led to 
a significant reduction in cleaved caspase 3 staining (*p value ≤ 0.05, n ≥ 4 tumours, 3 mice, 
Mann Whitney U test). Error bars represent standard deviation.  
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Figure 3.8 Immunostaining for PI3K pathway effectors reveals a reduction in levels of pS6RP 
only and no effect on MAPK signalling in colon polyps, in response to NVP-BEZ235 
IHC for effectors of PI3K/mTOR signalling revealed no notable alterations in pAKT 
immunostaining at Ser473, however did reveal a reduction in pS6RP staining indicating 
inhibition downstream AKT signalling at mTORC1 in colon polyps, 4 hours following a single 
dose of 35mg/kg NVP-BEZ235. Additionally, IHC for pERK was conducted to detect changes in 
MAPK signalling but revealed no notable changes.  
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Figure 3.9 IHC for PI3K pathway and MAPK pathway effectors in small intestine tumours 
(SITs) 4 hours post exposure to NVP-BEZ235 
Similar to Apcf/+ colon polyps, immunostaining for pAKT at Ser473 revealed no notable 
differences in Apcf/+ SITs exposed to a single dose of NVP-BEZ235 at 35mg/kg. Despite this,  
reduced pS6RP immunostaining was notable indicating inhibition of signalling downstream 
AKT in response to NVP-BEZ235. IHC for pERK revealed no alterations and hence no effect on 
MAPK signalling following NVP-BEZ235 exposure.  
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3.2.6 NVP-BEZ235 significantly increases survival of Apcf/+ mice 
Following from the short term evaluation of NVP-BEZ235 in Apcf/+ mice, the effects of long 
term NVP-BEZ235 treatment were assessed through a chronic exposure experiment, similar to 
that in described section 3.2.3. This would examine the effects of continuous pathway 
inhibition on survival and tumour burden of Apcf/+ mice.  For this, a cohort of mice (n=10) were 
appropriately induced and aged to 220 days post induction from which point they received 
35mg/kg NVP-BEZ235 twice daily by oral gavage until a survival end point (anaemia, bloating 
and ≥10% loss of body weight) or until the experimental end point of 500 days post induction. 
Controls used for this experiment are those described previously in section 3.2.3. 
Chronic NVP-BEZ235 administration was well tolerated (indicated by monitoring of body 
weight) by Apcf/+ mice and Kaplan-Meier survival analysis revealed treatment significantly 
increased longevity of mice (median survival of NVP-BEZ235 treated mice = 371 vs vehicle = 
270, n≥10 per cohort, p value = 0.018 for Log-Rank and p value = 0.049 for Wilcoxon test) 
(Figure 3.10). These findings indicate that chronic NVP-BEZ235 treatment is beneficial for 
Apcf/+ mice, despite the lack of favourable anti-tumour activity detected from acute NVP-
BEZ235 treatment. Interestingly, although the median survival of Apcf/+ mice on MEK162 
treatment is approximately 30 days longer than the NVP-BEZ235 cohort, this was not 
statistically more beneficial (median survival of NVP-BEZ235 mice =371, MEK162 mice = 401, p 
value = 0.926 Log-Rank and p value = 0.534 Wilcoxon test), indicating equipotent effects. The 
effects of both chronic treatments on tumour burden at death are evaluated in section 3.2.7.  
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Figure 3.10 Kaplan Meier survival analysis of Apcf/+ mice on twice daily 35mg/kg NVP-BEZ235 
and vehicle controls from 220 days post induction 
A cohort of 10 Apcf/+ mice were induced and aged to 220 days post induction, at which point 
they received 35mg/kg NVP-BEZ235 twice daily by oral gavage either until a survival end point 
or the experimental end point of 500 days post induction. Continuous NVP-BEZ235 treatment 
was found to increase survival of mice from a median of 270 days post induction to 371 days 
post induction (p value ≤ 0.001, n≥8 mice per cohort, Log-Rank and Wilcoxon test). 
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3.2.7 Analysis of tumour burden in Apcf/+ mice on various treatments 
To investigate the effects of long term treatments on tumour burden, a number of parameters 
of tumour burden were assessed in comparison with the vehicle treated cohort. These 
parameters include the total number of tumours present at death, as scored from H&E stained 
sections of colon and small intestine tissues. For each sample, 3 H&E stained sections were 
scored and subsequently averaged per mouse, and then per cohort. Secondly, macroscopic 
tumours were measured from methacarn fixed colon and small intestine tissues and the total 
tumour area (mm2) was calculated per mouse in each cohort. Finally, tumours were staged 
according to severity and invasive features, as outlined previously in methods section 2.7.4, to 
determine whether treatment had any effect on tumour progression.  
In the colon, neither MEK162 nor NVP-BEZ235 treatment significantly altered the total number 
of tumours present per mouse (median number of tumours: vehicle = 3, MEK162 = 3, p value = 
0.784, NVP-BEZ235 = 3, p value = 0.947, n≥4, Mann Whitney U test) (Figure 3.11 A). 
Additionally, both long term treatments had no significant effect on the total colon tumour 
area in Apcf/+ mice (median tumour area: vehicle = 71.5, MEK162 = 29.9, p value = 0.194, NVP-
BEZ235 = 42.4, p value = 0.111, n≥4, Mann Whitney U test) (Figure 3.11 B). Colon tumours 
were also staged according to severity and revealed presence of benign microadenoma or 
adenoma lesions only. Scoring here identified no significant alterations in the proportions of 
microadenomas and adenomas present in both MEK162 and NVP-BEZ235 treated cohorts 
(Proportion mAds: vehicle = 0.45, MEK162 = 0.69 p value = 0.055, NVP-BEZ235 = 0.47 p value = 
0.316; proportion of Ads: vehicle = 0.55, MEK162 = 0.55 p value = 0.055, NVP-BEZ235 = 0.53 p 
value = 0.32, n≥4, Mann Whitney U test) (Figure 3.11 C). Therefore, as analysis of colon 
tumour burden at the end of MEK162 and NVP-BEZ235 treatment revealed no significant 
differences in comparison with the vehicle treated cohort, it can be hypothesised that both 
treatments delay tumour growth given the increased survival of mice.  
Analysis of tumours in the small intestine revealed both MEK162 and NVP-BEZ235 treatment 
also had no significant effect on the total number of small intestinal lesions present in Apcf/+ 
mice at death (median tumour number: vehicle = 3, MEK162 = 4, p value = 0.523, NVP-BEZ235 
= 6, p value = 0.540, n≥4, Mann Whitney U test) (Figure 3.12 A). Analysis of total small 
intestine tumour area revealed no significant difference with MEK162 treatment but 
interestingly, revealed a trend towards reduced tumour area in NVP-BEZ235 treated mice 
(median tumour area: vehicle = 51.1, MEK162 = 50.7, p value = 1.00, NVP-BEZ235 = 0.92, p 
value = 0.462) (Figure 3.12 A). The paradoxical trend for increased number of lesions but 
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reduced tumour size in NVP-BEZ235 treated mice may be explained by staging of tumour 
severity (Figure 3.12 C). This revealed a significant increase in the proportion of 
microadenomas present at death and a reduction in the proportion of adenomas (proportion 
of mAds: vehicle = 0.24, NVP-BEZ235 = 0.88 p value = 0.0085; proportion of Ads: vehicle = 
0.47, NVP-BEZ235 = 0.08 p value = 0.0085; proportion of EIAs: vehicle = 0.24, NVP-BEZ235 = 
0.02 p value = 0.35; proportion of AIAs: vehicle = 0.06, NVP-BEZ235 = 0.04 p value = 0.865, 
n≥4, Mann Whitney U test). As microadenomas are not visible macroscopically, this may 
explain the trends for increased number of lesions scored from H&E stained slides but the 
reduced overall SIT area in these mice. These later observations indicate that NVP-BEZ235 
treatment may halt tumour progression in the small intestine of Apcf/+ mice. Assessment of 
tumour severity in MEK162 treated Apcf/+ mice revealed no statistically significant alterations 
however did indicate an increasing trend for more invasive lesions, in particular those 
characterised by invasion through the muscle wall of (mAds: vehicle = 0.24, MEK162 = 0.31 p 
value = 0.915; proportion of Ads: vehicle = 0.47, MEK162 = 0.36 p value = 0.3374; proportion 
of EIAs: vehicle = 0.24, MEK162 = 0.11 p value = 915; proportion of EIAs: vehicle = 0.06, 
MEK162 = 0.21 p value = 0.393, n≥4, Mann Whitney U test) (Figure 3.12 C).  
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 (A) Boxplot showing number of colon tumours present at death, as scored from H&E stained 
sections of colon tissue. No differences were detected in either MEK162 or NVP-BEZ235 
treated cohorts (
. 
indicates outlier). (B) Dot plot showing total tumour area per mouse, as 
scored from methacarn fixed tissue, post dissection. No significant alterations were detected 
here, although MEK162 and NVP-BEZ235 treatment trended to reduce total tumour area. (C) 
Key: mAd = microadenoma, Ad = Adenoma. No significant alterations were detected from 
staging of tumour severity according to invasiveness (all p values ≥ 0.05, n≥ 4, Mann Whitney 
U test).  
Figure 3.11 Analysis of colon tumour burden in Apcf/+ mice on various treatments. 
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(A) Boxplot showing number of SITs present at death, as scored from H&E stained sections of 
tissue samples. No differences were detected in either MEK162 or NVP-BEZ235 treated 
cohorts, although a trend towards increased number of tumours was observed in NVP-BEZ235 
treated cohorts (B) Dot plot showing total tumour area per mouse, as scored from methacarn 
fixed tissue, post dissection. No significant alterations were detected in either treated cohorts 
(C) Key: mAd = microadenoma, Ad = Adenoma, EIA = early invasive adenocarcinoma, AIA = 
Advanced invasive adenocarcinoma. No significant alterations were detected from staging of 
tumour severity according to invasiveness in MEK162 treated mice. A significant increase in 
the proportion of mAds and a significant reduction in Ads was detected in NVP-BEZ235 treated 
mice (* p value ≤ 0.05, n≥ 4, Mann Whitney U test).  
Figure 3.12 Analysis of small intestinal tumour (SIT) burden in Apcf/+ mice on various 
treatments. 
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3.2.8 Comparison of MAPK and PI3K activation in colonic and small intestinal tumours in 
alternative models of intestinal cancer 
Despite the validity of the Apcf/+ tumour model to assess MEK and PI3K/mTOR inhibition in this 
chapter, tumours harbouring specific mutations in oncogenes or tumour suppressor proteins 
resulting in activation of these pathways may be more sensitive to anti-MEK and anti-PI3K 
targeted agents. Recent studies within the Clarke lab have investigated the effect of oncogenic 
Kras and loss of the tumour suppressor protein Pten independently and also concurrently, on 
Apc driven tumourigenesis (Sansom et al., 2006, Marsh et al., 2008, Davies et al., in press). 
Here, Marsh et al showed that homozygous loss of the Pten allele accelerated Apc driven 
tumourigenesis through increased activation of pAKT (Marsh et al., 2008). The study by Davies 
et al supported previous findings of oncogenic Kras in accelerating Apc driven intestinal 
tumour development (Sansom et al., 2006, Janssen et al., 2006), but also found that 
concomitant deletion of Pten further accelerated tumourigenesis and shortened survival of 
mice compared to Apc Pten and Apc Kras controls (Davies et al., in press).   
To confirm activation status of corresponding signalling pathways in the tumour models 
described above, cohorts of Apcf/+, Apcf/+ KrasLSL/+, Apcf/+ Ptenf/f and Apcf/+ Ptenf/f KrasLSL/+ mice 
were generated. Apcf/+, Apcf/+ KrasLSL/+ and Apcf/+ Ptenf/f KrasLSL/+ manipulations are driven by 
the VillinCreER transgene whereas the Apcf/+ Ptenf/f deletions were driven by the AhCreER 
transgene. Cohorts of n=3 mice were induced and monitored for symptoms of tumour burden 
to develop (anaemia, bloating and blood in faeces). Upon development of these symptoms, 
mice were culled and dissected as described previously (methods section 2.4.2). Specifically 
tumours from the colon where appropriate, and the small intestine were snap frozen in liquid 
nitrogen in preparation for protein extraction and subsequent western blot analysis. For Apcf/+ 
and Apcf/+ KrasLSL/+ colon and SITs, lysates from 3 tumours were pooled (per well) whereas for 
Apcf/+ Ptenf/f and Apcf/+ Ptenf/f KrasLSL/+ SITs, 6 tumours lysates were pooled for western blot 
analysis of MAPK and PI3K pathway components. Antibodies against pERK, pAKT (at both 
Ser473 and Thr308) and pS6RP were used to investigate activation of MAPK and PI3K/mTOR 
pathways respectively. Immunoblotting for pERK revealed an increase in Apcf/+ KrasLSL/+ colon 
polyps and SITs, indicating activation of MAPK signalling (Figure 3.13). Interestingly, MAPK 
signalling through pERK was found to be more activated in colonic tumours in comparison to 
SITs. Surprisingly, levels of pERK in Apcf/+ Ptenf/f SITs were found to be elevated compared to 
controls and Apcf/+ KrasLSL/+ tumours, but Apcf/+ Ptenf/f KrasLSL/+ SITs did not show activation of 
pERK despite mutational activation of Kras (Figure 3.13). These findings corroborate previous 
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findings by IHC as reported by Davies et al (Davies et al., in press).  Immunoblotting for 
pAKT473 and pAKT308 revealed activation of PI3K signalling in Apcf/+ KrasLSL/+ colon polyps, but 
not in SITs (Figure 3.13). Both Apcf/+ Ptenf/f and Apcf/+ Ptenf/f KrasLSL/+ SITs show increased levels 
of pAKT473 and pAKT308 compared to Apcf/+ and Apcf/+ KrasLSL/+ controls however 
interestingly, oncogenic activation of Kras does not result in hyperactivation of PI3K signalling 
in Apcf/+ Ptenf/f SITs despite the observation that Kras activation increases PI3K signalling in 
mutant colon polyps (Figure 3.13). To further investigate signalling downstream PI3K and AKT 
at mTOR, levels of pS6RP were probed in colon tumour and SIT lysates. In keeping with 
activation of PI3K signalling in Apcf/+ KrasLSL/+ colon polyps, levels of pS6RP were found to be 
increased here. Surprisingly, no alterations in pS6RP levels were found in Apcf/+ KrasLSL/+, Apcf/+ 
Ptenf/f or Apcf/+ Ptenf/f KrasLSL/+ in comparison with Apcf/+ SITs (Figure 3.13), indicating perhaps 
co-operation between MAPK and PI3K signalling at mTORC1.  
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Figure 3.13 Western blot analysis indicating activation of PI3K and MAPK signalling in 
additional models of intestinal cancer 
Pooled colon tumour and small intestine tumour (SIT) lysates (n=3-6 tumours from n=3 mice) 
from Apcf/+, Apcf/+ KrasLSL/+, Apcf/+ Ptenf/f and Apcf/+ KrasLSL/+ Ptenf/f mouse models were 
subjected to western blot analysis and subsequent immunoblotting with the MAPK effector 
pERK and the PI3K pathway effectors pAKT473, pAKT308 and pS6RP. Apcf/+ KrasLSL/+ colon 
tumours display strong activation of MAPK and PI3K signalling whereas interestingly, Apcf/+ 
KrasLSL/+ SITs only show mild activation of MAPK signalling, in comparison with Apcf/+ controls. 
Apcf/+ Ptenf/f and Apcf/+ KrasLSL/+ Ptenf/f SITs both display activation of PI3K signalling in 
comparison with Apcf/+ and Apcf/+ Kras LSL/+ controls however surprisingly, Apcf/+ Ptenf/f and not 
Apcf/+ KrasLSL/+ Ptenf/f SITs show increased MAPK signalling.  
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3.3 Discussion 
3.3.1 MEK inhibition by MEK162 increases survival of Apcf/+ mice and results in tumour 
growth stasis 
Given that overexpression of EGFR is observed in a number of human malignancies including 
CRC (Ciardiello et al., 1991), drug development strategies and pre-clinical research have 
justifiably focused extensive efforts to target this receptor in order to inhibit downstream 
signalling. EGFR mediates aberrant pro-survival and anti-apoptotic signalling in cancer cells 
through a number of signalling pathways including the MAPK and PI3K cascades (Zwick et al., 
1999). Despite the early promise of anti-EGFR antagonists including cetuximab and 
panitumumab for CRC, and gefitinib and irressa for non-small-cell-lung carcinoma, it quickly 
became apparent that pre-existing mutations activating MAPK and PI3K signalling predicted 
non-response to anti-EGFR therapies (Lièvre et al., 2008, Frattini et al., 2007, Perrone et al., 
2009). Tumours determined wild-type for KRAS, B-RAF, PIK3CA or PTEN have also been shown 
to acquire mutations in these proteins resulting in resistance to anti-EGFR antagonists 
(Benvenuti et al., 2007, Di Nicolantonio et al., 2008, Diaz et al., 2012). Other mechanisms of 
resistance include strong activation of cognate receptors, including HER2, HER3 and cMET 
(Wheeler et al., 2008), and whilst targeting these with multiple anti-HER agents may be a 
rational therapeutic strategy, it was hypothesised that inhibition of signalling downstream 
EGFR, namely MEK inhibition for MAPK signalling and PI3K/mTOR inhibition for PI3K signalling, 
may also be an attractive therapeutic strategies for KRAS and PI3K pathway wild-type CRCs. To 
address these hypotheses in this chapter, I utilised the Apcf/+ tumour model driven by the 
intestinal specific transgene VillinCreER where induction with tamoxifen, results in formation 
of lesions within the small intestine and colon over a long latency. Two approaches were taken 
for investigations in this chapter. Firstly, to determine the immediate anti-tumour effects of 
MEK (MEK162) or PI3K/mTOR (NVP-BEZ235) inhibitors, aged mice presenting with symptoms 
of tumour burden were administered a single dose and culled 4 hours later. Alternatively, to 
address whether these agents provide any benefits to survival of Apcf/+ mice, a chronic 
treatment strategy was undertaken whereby mice received daily treatment from a chosen 
intervention start point, until a survival end point or the experimental end point of 500 days.  
The therapeutic effects of MEK inhibition by MEK162 were first assessed to determine 
whether as hypothesised, this would be beneficial for Apcf/+ tumours. From acute treatment of 
MEK162, Apcf/+ SITs appear more sensitive to MEK162 than colon polyps, as at 4 hours post 
treatment, MEK162 resulted in a pro-apoptotic effect, whereas no discernible anti-tumour 
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effects were detected in colon polyps from the same animals (Figure 3.1, 3.2). Although these 
findings indicate MEK162 treatment did have an effect on tumours, investigation of additional 
time points following treatment, for example 8, 12 or 24 hours, could provide more insightful 
information regarding the anti-tumour effects of MEK162 in Apcf/+ tumours over an extended 
period of time.  
Despite the lack of favourable anti-tumour activity in Apcf/+ colon polyps and the modest 
effects on SITs, IHC performed for pERK in colon polyps and SITs exposed to MEK162 revealed 
a marked reduction in immunostaining, indicating target inhibition (Figure 3.3, 3.4). Given the 
cross-talk between MAPK and PI3K/mTOR signalling (Ma et al., 2007, Ma et al., 2005), 
activation status of the later was also assessed post MEK162 administration. In doing so, a 
reduction in pAKT and pS6RP immunostaining was noted in colon polyps and SITs, indicating 
inhibition of the PI3K/mTOR axis also (Figure 3.3, 3.4). Although the changes in PI3K signalling 
detected here by immunostaining do require further confirmation and quantification by 
western blot analysis. The reduction in PI3K/mTOR signalling mediated by MEK inhibition may 
be attributable to a number of factors including p90 ribosomal S6 kinases (RSK1-4) which have 
previously been reported to mediate signals downstream pERK (Sturgill et al., 1988). These 
serine/threonine kinases regulate a number of cellular processes including proliferation, 
survival and growth through phosphorylation of a number of diverse substrates (Romeo et al., 
2012). Interestingly, the RSK consensus phosphorylation motif is shared by other kinases 
including AKT and S6 kinase 1 (S6K1) (Romeo et al., 2012). Substrates targeted by AKT 
including TSC2, Bad, GSK3, p27 and S6RP are also phosphorylated by RSKs (Roux et al., 2004, 
Shimamura et al., 2000, Torres et al., 1999, Roux et al., 2007) and may account for the 
MEK162 mediated reduction in pS6RP levels observed in Apcf/+ colon and SITs. Additionally, 
RSK1/2 protein kinases have been shown to phosphorylate Raptor, the key component of the 
rapamycin-sensitive mTOR complex – mTORC1 which is known to control phosphorylation of 
S6RP through S6K1 (Park et al., 2002). Although the reduction of pS6RP immunostaining may 
be explained by the interactions between ERK and mTORC1, the mechanism for reduced 
immunostaining of pAKT473 remain to be elucidated. Furthermore, the regulation of mTORC2 
which is responsible for the phosphorylation of AKT at Ser473 is currently unknown however, 
it has been hypothesised that mTORC2 responds to growth signals mediated through receptor 
tyrosine kinase receptors and that this could lead to reduced pAKT473 staining in Apcf/+ 
tumours following MEK inhibition (Oh and Jacinto, 2011).     
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Nevertheless, the therapeutic benefits of MEK inhibition in Apcf/+ mice determined through 
continuous administration of MEK162, substantially increased median survival of Apcf/+ mice 
from 270 to 401 days post induction (Figure 3.5). The favourable effects in this case may be 
attributable to inhibition of MAPK signalling but also to inhibition of PI3K and mTOR inhibition. 
Additionally, although analysis of tumour burden in Apcf/+ mice post MEK162 treatment 
revealed no significant alterations in either total tumour number, area nor severity of tumours 
in either colon polyps or SITs, these findings suggest chronic MEK162 resulted in tumour 
growth stasis (Figure 3.11, 3.12). Importantly, these findings corroborate a number of previous 
studies which promote suppression of MAPK signalling as a rational therapeutic strategy for 
CRC. Sebolt-Leopold et al evaluated the MEK inhibitor PD-184352 in a number of tumour 
models including two xenograft models of CRC and similarly reported growth inhibition 
following 2 weeks of twice-daily treatment (Sebolt-Leopold et al., 1999). Yeh et al. also 
investigated MEK inhibition with AZD6244 in the HT-29 CRC xenograft model and found this to 
result in growth inhibition (Yeh et al., 2007). Furthermore, Lee and colleagues investigating the 
role of ERK activation in intestinal tumourigenesis of Apcmin/+ mice found that treatment with 
MEK inhibitor PD0325901 from 10 weeks of age resulted in 100% survival whereas all vehicle 
treated animals succumbed to disease by 27 weeks of age, suggesting treatment inhibits 
tumour growth (Lee et al., 2010). Together, these investigations support the hypothesis for 
MAPK inhibition as a rational therapeutic strategy for CRC.     
3.3.2 NVP-BEZ235 treatment in Apcf/+ mice also increases longevity of mice and prevents 
tumour progression 
The therapeutic effects of the dual PI3K/mTOR inhibitor NVP-BEZ235 were next assessed in 
the Apcf/+ tumour model to evaluate this as a rational therapeutic strategy for this tumour 
subgroup. As with MEK162 experiments, the initial effects of NVP-BEZ235 were characterised 
4 hours after a single dose, in this case 35mg/kg of NVP-BEZ235. Characterisation of anti-
tumour effects i.e. proliferative and apoptotic effects in colon polyps and SITs post treatment 
revealed no significant alterations in colon polyps in comparison with vehicle controls, but 
contrasting effects with regards to apoptotic signalling in SITs (Figure 3.6, 3.7). Here, a 
significant increase in apoptotic bodies was scored from H&E stained sections but a significant 
reduction in cleaved caspase 3 staining was scored from IHC, with no effect on proliferation 
(Figure 3.6, 3.7). Although contrasting, scoring of both histological apoptosis and cleaved 
caspase 3 are relevant indicators of apoptosis, cleaved caspase 3 as an earlier indicator whilst 
histological apoptosis is often regarded as later marker of apoptotic signalling. Investigation of 
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alternative time points post NVP-BEZ235 treatment for example, 2, 8, 12 or 24 hours in Apcf/+ 
tumours may provide further insightful information regarding the immediate effects of NVP-
BEZ235 on apoptotic signalling, as well as proliferation. Previous findings by Maira et al. 
suggest that NVP-BEZ235 does result in reduced cell proliferation in colorectal cancer cell 
lines, however this did not amount to a decline in cell viability as no difference in total cell 
number was observed (Maira et al., 2008). Despite this, Haagensen et al found NVP-BEZ235 to 
be cytotoxic to HCT116 and HT29 colorectal cancer cell lines (Haagensen et al., 2012), 
indicating that the effects of NVP-BEZ235 may be context dependent.  
Further to the effects of NVP-BEZ235 on biological processes in tumours, the effect on PI3K 
signal transduction was evaluated by IHC for pAKT (Ser473) and pS6RP to assess target 
inhibition. Interestingly, reduction in pS6RP was observed in both colon polyps and SITs 
following NVP-BEZ235 administration, but no notable effects on pAKT473 immunostaining 
(Figure 3.8, 3.9). These findings suggest that at a 4 hour time point, Apcf/+ tumours are more 
sensitive to mTORC1 inhibition, which results in reduction of pS6RP rather than mTORC2 
which mediates phosphorylation of pAKT at Ser473. A study by Roper et al. corroborates these 
findings where by treatment of DLD-1, HCT116 and SW480 colorectal cancer cell lines with 
NVP-BEZ235 resulted in more transient inhibition of pAKT but sustained inhibition of pS6RP 
(Roper et al., 2011). This was also the case in a study by Haagensen et al. in which HT29 and 
HCT116 cell lines were used to evaluate the effects of NVP-BEZ235. Here, NVP-BEZ235 
reduced levels of pS6RP and p4EBP1, downstream of mTORC1, more effectively than pAKT 
(Haagensen et al., 2012). Together these data suggest reduced sensitivity to NVP-BEZ235 
mediated PI3K and mTOR inhibition. Moreover, these findings are consistent with the view of 
Maira et al, who noted that Pten-null cell lines may be more susceptible to the effects of NVP-
BEZ235 in comparison with controls (Maira et al., 2009).  
Additionally to the acute investigations of NVP-BEZ235, the therapeutic potential of 
PI3K/mTOR inhibition was assessed in a chronic treatment experiment in Apcf/+ animals, from 
220 days post induction. Continuous administration of NVP-BEZ235 significantly prolonged 
survival of mice indicating this as an effective treatment option for this subgroup of tumours 
(Figure 3.10). Interestingly, although long term treatment of MEK162 resulted in a longer 
median survival, this was not statistically more beneficial than chronic NVP-BEZ235 exposure 
in Apcf/+ mice. These findings suggest equal dependence of Apcf/+ tumours on MAPK and PI3K 
signalling and also propose combinatorial use of these targeted agents may provide further 
therapeutic benefits. Furthermore, although analysis of tumour burden yielded no significant 
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alterations in terms of total tumour number, tumour area or tumour severity in colon polyps 
(Figure 3.11), NVP-BEZ235 appeared to halt tumour progression in the small intestine (Figure 
3.12). This was characterised by a significant increase in the proportion of single crypt lesions 
or microadenomas, and a reduction in the proportion benign adenomas. Together, these data 
indicate beneficial therapeutic effects of NVP-BEZ235 in Apcf/+ mice. Previously, evaluation of 
NVP-BEZ235 in the adenovirus-inducible Cre recombinase model of Apc mutant colorectal 
cancer showed effective regression of colonic tumours as measured through consecutive 
colonoscopies (Roper et al., 2011). Together, these findings provide strong evidence for NVP-
BEZ235 as a rational therapeutic strategy for PI3K pathway and KRAS wild-type tumours.     
3.4 Summary 
To summarise, MAPK targeting through the MEK inhibitor MEK162 in tumour bearing Apcf/+ 
mice significantly prolonged longevity of mice despite lack of immediate anti-tumour activity 
detected at a 4 hour time point. Similarly, the dual PI3K/mTOR inhibitor NVP-BEZ235 
equipotently increased survival of Apcf/+ mice indicating equivalent dependence of Apcf/+ 
tumours on both signalling cascades. Together, these findings evidence therapeutic targeting 
of MAPK and PI3K pathways as beneficial therapeutic strategies, but also suggest that in 
combination, MEK162 and NVP-BEZ235 may together provide further therapeutic benefit. 
3.5 Further work 
3.5.1 Further investigation of anti-tumour effects of MEK162 and NVP-BEZ235 in Apcf/+ 
mice 
In this chapter, the immediate anti-tumour and pharmacodynamic effects of MEK162 and 
NVP-BEZ235 were only assessed at a 4 hour time point post drug administration. As only mild 
pro-apoptotic effects were detected in tumours at this time point, additional shorter and 
longer time points for example, 2, 8, 12 or 24 hours post treatment may provide additional 
information regarding anti-tumour effects of MEK162 and NVP-BEZ235 in this setting. 
Furthermore, the effects of MEK162 and NVP-BEZ235 on MAPK and PI3K signalling by western 
blot analysis would provide quantitative data into the duration of pathway inhibition and 
hence create a profile of drug activity in Apcf/+ tumours.  
3.5.2 Acute and chronic combination therapy in Apcf/+ mice 
As described previously, both MEK and PI3K/mTOR inhibition through MEK162 and NVP-
BEZ235 equally increased longevity of Apcf/+ mice. This suggests combinatorial therapy may 
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provide further benefits in increasing longevity. Initially, the anti-tumour and 
pharmacodynamic effects of combination therapy would be assessed at short time points (4, 
8, 24 hours) to ensure inhibition of both pathways as well as favourable anti-tumour effects. 
Following this, an appropriate dosing regimen would be required to ensure tolerability (as 
determined by weight loss). Nevertheless, given the benefits of single-agent therapy, I 
hypothesise the combination therapy to provide further therapeutic benefits for Apcf/+ mice.        
3.5.3 MEK and PI3K/mTOR inhibition in MAPK and PI3K-activated tumour settings 
Despite the validity of the Apcf/+ model to evaluate MEK and PI3K/mTOR inhibition as 
therapeutic strategies for MAPK and PI3K wild-type colorectal cancer, these types of lesions 
are often associated with early stage disease which are often effectively treated with adjuvant 
or neo-adjuvant chemotherapy and tumour resection. Colorectal cancer is often detected at 
late stages, due to mild symptoms, and often these lesions have accumulated further 
mutations, including those in the KRAS oncogene and those in genes activating the PI3K 
pathway- such as PTEN and PIK3CA. Therefore, it is hypothesised that MEK and PI3K/mTOR 
inhibition may be more beneficial in lesions presenting with mutations activating these. In this 
chapter, I assessed activation of MAPK and PI3K signalling in three models mutant for Kras and 
Pten and confirmed activation of associated signalling pathways. Following this, in chapters 4-
6 I explored therapeutic targeting of MEK through MEK162 and PI3K/mTOR through NVP-
BEZ235 as monotherapies and in combination to evaluate these as rational therapeutic 
strategies for Kras and Pten mutant intestinal tumour models.  
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4 Investigating PI3K/mTOR inhibition and MEK inhibition in the Apcf/+ Ptenf/f 
colorectal cancer mouse model 
 
4.1 Introduction  
Findings in chapter 3 indicate that targeting PI3K and mTOR in the absence of mutational 
activation of the pathway results in a significant survival benefit. Nevertheless, the rationale 
behind pathway-specific inhibitors is that these would be more effective for tumours with 
specific mutations which lead to activation of the respective pathway. Alterations in the PI3K 
pathway occur in a wide range of human malignancies and are often associated with 
progression of disease and metastasis, as well as poor prognosis for patients (Parsons et al., 
2005). Mutations in the PI3K pathway are known to occur at every major node including the 
receptor tyrosine kinases upstream PI3K, the p110α subunit of PI3K, the negative regulator 
PTEN, and at the downstream kinase AKT (Engelman, 2009). Furthermore, in the clinical 
setting, mutations in the PIK3CA gene (which encodes the p110α subunit) or PTEN loss are 
consistently associated with lack of response to anti-EGFR therapies, for example cetuximab 
and panitumumab which are both approved for third-line use of metastatic CRC (Bardelli and 
Siena, 2010). Together, this has led to a surge in the assessment of pharmacological inhibitors 
of the PI3K pathway specifically targeting tumours which present with pathway mutations as a 
stratified treatment strategy.    
Several pre-clinical studies have reported efficacy of a number of novel inhibitors of the 
PI3K/mTOR pathway in a range of human colorectal cancer cell lines. Herlund et al. evaluated 
the dual PI3K/mTOR inhibitor NVP-BEZ235 in a 3D colon carcinoma model and found this to 
potently inhibit cell proliferation and induce apoptosis in cancer cells, and also after prolonged 
use of cytotoxics (Hernlund et al., 2012). Furthermore, Blaser et al. reported NVP-BEZ235 and 
a novel ATP-competitive inhibitor of mTOR PP242 (Merck) were more effective than the 
allosteric mTOR inhibitor rapamycin at reducing growth and proliferation of colon cancer cells 
and xenografts (Blaser et al., 2012). In addition, Mueller et al. showed that NVP-BEZ235 and 
the novel pan-PI3K inhibitor BKM120 had an increased pro-apoptotic effect in colon cancer 
cell lines with PI3KCA mutations (Mueller et al., 2012). These studies all highlight the benefits 
of targeting the PI3K pathway and suggest further development of these in human clinical 
trials.  
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However, although cancer cell lines are valuable tools for quickly determining anti-tumour 
activity and evaluating the pharmacodynamics of novel agents, given that the main aim of 
pathway-targeted agents is to specifically target oncogenic proteins driving tumourigenesis, 
many studies crucially fail to evaluate mutation status of the PI3K pathway in the cancer cell 
lines used (Haagensen et al., 2012, Balmanno et al., 2009).  
In this chapter, I first evaluate the dual PI3K and mTOR inhibitor NVP-BEZ235 in an 
autochtonouse mouse model of colorectal cancer mutant for the tumour suppressor Pten. 
Here, AhCreER driven homozygous deletion of Pten and heterozygous deletion of Apc within 
the intestinal epithelium leads to invasive adenocarcinoma driven by activation of Akt.  
Mutations in the PI3K pathway have previously been shown to predict non-response to MEK 
mediated inhibition of the MAPK pathway (Balmanno et al., 2009, Chen et al., 2012b, Dry et 
al., 2010). However, a number of studies have recently reported that combined PI3K and MEK 
targeting results in synergistic pro-apoptotic effects in human colon cancer cell lines and 
xenografts (Haagensen et al., 2012, Migliardi et al., 2012). To further investigate this, I will also 
evaluate MEK inhibition using MEK162 as a single agent and also in combination with NVP-
BEZ235 in this Pten deficient tumour model.  
To evaluate the therapeutic potential of PI3K/mTOR, MEK and combined inhibition in the Pten 
deficient setting, I employed two main strategies. First, tumour-bearing AhCreER Apcf/+ Ptenf/f 
(referred to as Apcf/+ Ptenf/f hereon in) mice were administered a single dose of each treatment 
and culled 4, 8 or 24 hour time points post exposure to evaluate early pharmacodynamic and 
anti-tumour effects. Secondly, to investigate the long term effects of each treatment, tumour 
bearing mice were started on treatment at a defined time point following induction and 
treated daily to a survival end point i.e. when mice were symptomatic of disease, to 
investigate the effect of treatment on survival and tumour burden of Apcf/+ Ptenf/f mice.  
4.2 Results 
4.2.1 NVP-BEZ235 reduces proliferation, induces apoptosis and leads to inhibition of the 
PI3K and mTOR signalling cascade in Apcf/+ Pten f/f tumours 
For short term experiments, 10 week old Apcf/+ Ptenf/f mice were induced and monitored until 
symptomatic of disease (pale feet, bloating and blood in faeces). Mice (n≥3 per cohort) were 
then administered a single dose of 0.5% Methyl Cellulose (MC, Vehicle) and culled 4 hours 
later, or 35mg/kg NVP-BEZ235 and culled either 4, 8 or 24 hours later. Additionally, BrdU was 
administered to mice 2 hours prior to culling to label cells undergoing S phase of the cell cycle. 
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At dissection small intestinal tumours (SITs) were quickly dissected and snap frozen in liquid 
nitrogen for protein extraction, and the small intestine was ‘swiss-rolled’ and fixed in formalin 
in preparation for H&E staining and IHC (methods section 2.4.2).  
To characterise the immediate anti-tumour activity of NVP-BEZ235 in Apcf/+ Ptenf/f tumours, 
histological mitosis and apoptosis was scored in SITs from H&E stained slides. Quantification of 
mitotic figures (Figure 4.1 A), revealed no significant alterations at 4, 8 or 24 hours after a 
single dose of NVP-BEZ235, compared to vehicle (4hr NVP-BEZ235 = 0.548 ± 0.363, vehicle = 
0.407 ± 0.318, p value = 0.198, n≥15 tumours, 4 mice Mann Whitney U test). (8hr NVP-BEZ235 
= 0.311 ± 0.212, 24hr NVP-BEZ235 = 0.269 ± 0.303, vehicle = 0.407 ± 0.318, p value = 0.6004 
for 8hr NVP-BEZ235 and p value = 0.0844 for 24hr NVP-BEZ235, n≥15 tumours, 4 mice, Mann 
Whitney U test).  Similarly, scoring of apoptotic bodies in small intestine tumours indicated no 
significant alterations 4, 8 and 24 hours after a single dose of NVP-BEZ235 treatment 
compared to vehicle treated tumours (4hr NVP-BEZ235 = 1.871 ± 1.570, 8hr NVP-BEZ235 = 
1.2711 ± 0.766, 24hr NVP-BEZ235 = 1.409 ± 0.655, vehicle = 1.802 ± 1.123, p value = 0.951 for 
4hr NVP-BEZ235, p value = 0.295 for 8hr NVP-BEZ235, p value = 0.399 for 24hr NVP-BEZ235, 
n≥15 tumours, 4 mice, Mann Whitney U test) (Figure 4.1 B).  
In order to further characterise the biological effects immediately after a single dose of NVP-
BEZ235, IHC against BrdU and cleaved caspase 3 was carried out and scored (Figure 4.2 A, B). 
Quantification of BrdU staining revealed a significant decrease in number of BrdU positive 
tumour cells 4 and 8 hours post NVP-BEZ235 treatment (4hr NVP-BEZ235 = 14.877 ± 4.053, 8hr 
NVP-BEZ235 = 9.629 ± 3.105, vehicle = 30.7 ± 9.761, p value < 0.000 for 4hr NVP-BEZ235, p 
value = 0.0004 for 8hr NVP-BEZ235, n≥15 tumours, 4 mice, Mann Whitney U test), indicating a 
reduction in the number of cells in S phase of the cell cycle.  The number of BrdU positive cells 
24 hours after NVP-BEZ235 was not altered in comparison with vehicle cohorts (24hr NVP-
BEZ235 = 25.729 ± 10.341, vehicle = 30.7 ± 9.761, p value = 0.125, n≥15 tumours, 4 mice, 
Mann Whitney U test) indicating that NVP-BEZ235 initially induces a reduction in the number 
of cells in S phase of the cell cycle, however this returns to normal physiological levels 
between 8 and 24 hours after administration (Figure 4.2 A).    
Quantification of cleaved caspase 3 staining revealed a significant increase 4 hours post NVP-
BEZ235 exposure, (4hr NVP-BEZ235 = 5.631 ± 2.436, vehicle = 3.046 ± 2.298, p value = 0.0002 
n≥15 tumours, 4 mice, Mann Whitney U test) indicating an immediate pro-apoptotic effect. 
Cleaved caspase 3 scoring in SITs at further 8 and 24 hour time points following NVP-BEZ235 
treatment revealed a trend towards a reduction in cleaved caspase 3 at 8 hours and a 
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significant reduction at 24 hours (8hr NVP-BEZ235 = 2.247 ± 0.801, 24hr NVP-BEZ235 = 1.149 ± 
0.635, vehicle =  3.046 ± 2.297, p value = 0.544 for 8hr NVP-BEZ235, p value = 0.037 for 24hr 
NVP-BEZ235, n≥15 tumours, 4 mice, Mann Whitney U test), perhaps suggesting activation of 
compensatory mechanisms to reduce the increased apoptosis at 4 hours (Figure 4.2 B).  
To investigate whether the early anti-tumour effects of NVP-BEZ235 described above 
correspond to pathway inhibition, SIT lysates were subjected to western blot analysis (Figure 
4.3 A-C). Protein extracted from 6 small intestinal tumours from n=3 mice harvested 4, 8 and 
24 hours after a single dose of NVP-BEZ235, or 4 hours after vehicle treatment were pooled 
for analysis. Antibodies for the phosphorylated forms (and hence activated form) of AKT at 
Thr308 and Ser473 were probed to assess activation of PI3K signalling through PDK1 and 
mTORC2 respectively. Additionally, phospho S6 ribosomal protein (S6RP) at Ser235/236 and 
phospho 4EBP1 at Thr37/46 were also probed to investigate pathway activation status 
downstream of mTORC1. Western blotting and densitometry analysis revealed complete 
inhibition of the PI3K and mTOR signalling axis 4 hours after a single dose of NVP-BEZ235. This 
is evidenced through complete reduction in the abundance of pAKT at Ser473 and Thr308, as 
well as pS6RP and p4EBP1 (Figure 4.3, Table 4.1). Western blotting also revealed this inhibition 
is predominantly relieved by 8 hours post NVP-BEZ235 as tumours harvested 8 and 24 hours 
post NVP-BEZ235 administration show no obvious reduction in pathway effectors compared to 
vehicle controls. Interestingly, densitometry analysis revealed a significant 50% increase in 
abundance of pAKT Thr308, 8 hours post treatment (Figure 4.3, Table 4.2) and a trend towards 
reduced levels of p4EBP1 at 24 hours post treatment. These later changes suggest activation 
of a negative feedback loop activated by tumours in response to PI3K/mTOR pathway 
inhibition and may reflect a mechanism of rebalancing cell signalling to basal levels. 
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Figure 4.1 NVP-BEZ235 does not alter levels of mitosis and apoptosis in Apcf/+ Ptenf/f small 
intestine tumours 
Scoring of mitotic figures (A) and apoptotic bodies (B) revealed no significant alterations 4, 8 
or 24hrs after a single dose of 35mg/kg NVP-BEZ235 compared to vehicle (0.5% MC) however, 
there appears to be a trend towards a reduction in the number of mitotic figures 8 and 24hrs 
post NVP-BEZ235 exposure (p value ≥ 0.05, n ≥ 15 tumours, 4 mice, Mann Whitney U test). 
Error bars represent standard deviation.   
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Figure 4.2 NVP-BEZ235 reduces the number of cycling cells and induces apoptosis through 
cleaved caspase 3 in Apcf/+ Ptenf/f small intestine tumours (SITs) 
IHC against the proliferation marker BrdU and the apoptotic marker cleaved caspase 3 were 
carried out and quantified. (A) Scoring revealed a significant reduction in the number of BrdU 
positive cells 4 and 8 hours after exposure to NVP-BEZ235 indicating less cells going through 
the cell cycle (p value ≤ 0.0001 for 4hr, p value = 0.0004 for 8hr, n ≥ 3, Mann Whitney U test) 
as well as a pro-apoptotic increase in cleaved caspase 3 staining 4 hours after exposure (B) (p 
value = 0.0002, n ≥ 3, Mann Whitney U test). The initial anti-proliferative effect appears to 
return to baseline levels between 8 and 24 hours post exposure whereas cleaved caspase 3 
levels appear to further decrease 8 and 24 hours post exposure (p value ≥ 0.05, n ≥ 15 
tumours, 4 mice, Mann Whitney U test).  Error bars indicate standard deviation. 
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Figure 4.3 NVP-BEZ235 reduces PI3K and mTOR signalling in Apcf/+ Ptenf/f small intestine 
tumours (SITs) 4 hours post exposure 
 (A) 6 SIT lysates pooled from n=3 mice exposed to NVP-BEZ235 for varying time points were 
subjected to western blot analysis. Effectors of the PI3K and mTOR signalling pathways were 
probed and this revealed marked reduction of PI3K and mTOR signalling 4 hours post 
exposure.  Signalling mostly appeared to return to basal levels by 8 hours post exposure.  
Additionally, the MAPK pathway effector pERK was probed to assess activation of this 
pathway, no significant alterations were present here. (B + C) Densitometry was carried out to 
quantify differences observed from immunoblotting. These are normalised to β-actin as 
loading control and represented as relative to vehicle controls (*p value = 0.0404, n=3, Mann 
Whitney U test).  
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 Vehicle 4 hours post NVP-BEZ235 (p value) 
pAKT473 6804 ± 1921.9 131.7 ± 224.6 (0.0404) 
pAKT308 4770.1 ± 790.3 13.0 ± 22.5 (0.0404) 
pS6RP 12287.0 ± 92.6 863.6 ± 110.0 (0.0404) 
p4EBP1 1317.4 ± 1059.3 5.2 ± 1.3 (0.0404) 
pERK 10821.0 ± 3706.3 9873 ± 984.9 (0.5) 
Table 4-1 Raw densitometry values from western blot analysis of pooled Apcf/+ Ptenf/f SITs 4 
hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test was used for 
statistical analysis 
 Vehicle 8 hours post NVP-BEZ235 
(p value) 
24 hours post NVP-
BEZ235 (p value) 
pAKT473 9273.1 ± 1866.7 9826.7 ± 400.2 (0.3313) 8416.0 ± 963.9 (0.5) 
pAKT308 2933.2 ± 407.8 4526.0 ± 605.9 (0.0404) 2188.3 ± 417.4 (0.095) 
pS6RP 10963.3 ± 696.8 10430.6 ± 922.9 (0.1914) 11640.6 ± 112.4 (0.5) 
p4EBP1 10904.6 ± 4570.9 10944.3 ± 922.9 (0.5) 11640.6 ± 112.4 (0.095) 
pERK 12500.5 ± 908.6 10972 ± 822.4 (0.095) 10483.2 ± 2599.4 (0.5)  
Table 4-2 Raw densitometry values from western blot analysis of pooled Apcf/+ Ptenf/f SITs 8 
and 24 hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test was used 
for statistical analysis 
Additionally to investigating the effect of NVP-BEZ235 on PI3K and mTOR signalling, activation 
of the MAPK pathway through pERK was also assessed. Both pathways are known to converge 
at a number of downstream effectors and AKT is also known to lead to activation of MAPK 
signalling through RAF1 (Zimmermann and Moelling, 1999), upstream of MEK and 
downstream of RAS in the MAPK signalling cascade. Immunoblotting and subsequent 
densitometry analysis for pERK at Thr202/Tyr204 revealed no significant changes at either 4, 8 
or 24 hours after exposure to NVP-BEZ235 in comparison to vehicle treated tumours (Figure 
4.3, Table 4.1 and table 4.2), indicating no effect on MAPK signalling through phospho ERK in 
response to PI3K/mTOR inhibition by NVP-BEZ235. 
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In summary, acute NVP-BEZ235 exposure in Pten deficient SITs lead to effective inhibition of 
downstream pathway effectors (Figure 4.4). As PI3K signalling is known to be crucial for 
survival and apoptosis, the reduction in signalling may be responsible for the reduced 
proliferation and increased apoptosis in tumours as detected by BrdU and cleaved caspase 3 
quantification. 
 
At 4 hours post exposure, NVP-BEZ235 leads to a reduction in levels of pAKT at Ser473 and 
Thr308, pS6RP and p4EBP1 whereas at 24 hours post exposure, NVP-BEZ235 has no significant 
effect on PI3K/mTOR or MAPK signalling. 
 
    
 
 
 
 
 
Figure 4.4 Schematic showing the effects of NVP-BEZ235 on PI3K/mTOR and MAPK pathway 
components as detected through western blot analysis (Green denotes a reduction in 
protein levels). 
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4.2.2 Long term PI3K/mTOR inhibition through NVP-BEZ235 leads to a significant increase 
in survival of Apcf/+ Pten f/f mice  
To investigate the therapeutic potential of PI3K/mTOR inhibition in this Pten deficient tumour 
model, a chronic treatment experiment was conducted to determine the effect firstly upon 
longevity of mice, but also intestinal tumour burden (section 4.2.7). For this, 10 week old 
Apcf/+ Ptenf/f mice were induced and allowed to establish disease over an 11 week period (77 
days). Given that the majority of these mice become symptomatic of disease immediately 
after 11 weeks, a 77 days post induction (dpi) time point was chosen as an appropriate 
intervention start point. Mice (n≥15 per cohort) were randomised to receive either 0.5% MC 
(Vehicle) or 35mg/kg NVP-BEZ235 twice daily (weekdays only) by oral gavage until a survival 
end point (anaemia, bloating, ≥ 10% loss of body weight).  
Continuous twice daily treatment of NVP-BEZ235 in Apcf/+ Ptenf/f mice was well tolerated and 
led to a significant increase in survival of mice (median survival NVP-BEZ235 mice = 266 dpi, 
median survival Vehicle mice = 99 dpi, p value ≤ 0.001, n≥15, Log-Rank and wilcoxon test) 
(Figure 4.5) indicating this as a beneficial therapeutic strategy for Apcf/+ Pten f/f mice. Analysis 
of tumour burden at death following chronic NVP-BEZ235 treatment was also conducted 
(section 4.2.7) to further evaluate the effects of treatment.   
 
 
 
 
 
 
 
 
 
118 
 
Apcf/+ Ptenf/f  mice were induced and aged to 77 days post induction, at which point mice were 
randomised to receive either 0.5% Methyl cellulose (Vehicle control) or 35mg/kg NVP-BEZ235 
twice-daily by oral gavage until a survival end point. Continuous NVP-BEZ235 treatment was 
found to increase survival of mice from 99 days (vehicle controls) to a median of 266 days post 
induction (p value ≤ 0.001, n≥15 mice per cohort, Log-Rank and wilcoxon test).  
 
 
 
 
Figure 4.5 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f mice on NVP-BEZ235 compared to 
vehicle controls 
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4.2.3 Acute MEK inhibition through MEK162 reduces MAPK signaling and cellular 
proliferation in Apcf/+ Pten f/f tumours, but reduces apoptosis and increases PI3K 
signalling 
Similarly to section 4.2, mice for short term experiments were induced and aged to allow for 
development of intestinal tumours. Mice symptomatic of disease were subsequently 
administered with a single dose of 30mg/kg MEK162 and harvested either 4 or 24 hours later 
as described previously (section 2.4.2). Mice were also administered BrdU 2 hours prior to 
culling. Vehicle controls for this experiment are identical to those used in section 4.2.  
To investigate the immediate anti-tumour activity of MEK162 in Apcf/+ Ptenf/f tumours, mitotic 
figures and apoptotic bodies were scored in SITs from H&E stained slides (Figure 4.6 A, B). 
Quantification of mitotic figures revealed no significant alterations at either 4 or 24 hours post 
exposure to MEK162 (4hr MEK162 = 0.372 ± 0.137, 24hr MEK162 = 0.417 ± 0.271, veh = 0.407 
± 0.318, p value = 0.884 for 4hr MEK162 and p value = 0.774 for 24hr MEK162, n≥15 tumours, 
4 mice, Mann Whitney U test). However, scoring of apoptosis revealed a significant reduction 
in the number apoptotic bodies at both 4 and 24 hours following MEK162 exposure (4hr 
MEK162 = 0.645 ± 0.546, 24hr MEK162 = 0.8 ± 0.675, veh = 1.802 ± 1.123, p value = 0.0036 for 
4hr MEK162 and p value = 0.0072 for 24hr MEK162 n≥15 tumours, 4 mice, Mann Whitney U 
test) 
Furthermore, IHC for BrdU and cleaved caspase 3 was carried out and scored to further 
evaluate the anti-tumour effects of MEK162 (Figure 4.7 A,B). Scoring revealed a significant 
reduction in BrdU positive cells at both 4 and 24 hour time points post MEK162 exposure (4hr 
MEK162 = 17.65 ± 4.82, 24hr MEK162 = 15.614 ± 8.64, veh = 30.7 ± 9.761, p value = 0.0003 for 
4hr MEK162 and 0.001 for 24hr MEK162, n≥15 tumours, 4 mice, Mann Whitney U test) 
indicating an anti-proliferative reduction in cells undergoing S phase of the cell cycle. 
Quantification of cleaved caspase 3 bodies revealed no significant changes at both 4 and 24 
hours post MEK162 (4hr MEK = 2.76 ± 1.68, 24hr MEK = 4.036 ± 2.81, Veh = 3.046 ± 2.29, p 
value ≥ 0.05, n≥15 tumours, 4 mice, Mann Whitney U test) (Figure 4.7 B). 
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Figure 4.6 MEK162 resulted in a reduction of apoptotic bodies in Apcf/+ Ptenf/f small intestine 
tumours (SITs) 
Scoring of mitotic figures (A) and apoptotic bodies (B) by H&E examination revealed no 
significant alterations in the number of mitotic figures present, however revealed a significant 
reduction in the number apoptotic bodies 4 and 24 hours after a single dose of 30mg/kg 
MEK162 (p value = 0.0036 for 4hr and p value = 0.0072 for 24hr, n≥ 15 tumours, 4 mice, Mann 
Whitney U test). Error bars represent standard deviation.  
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Figure 4.7 MEK162 lead to a reduction in the number of BrdU positive cells however, no 
alterations in cleaved caspase 3 were detected in Apcf/+ Ptenf/f small intestine tumours (SITs) 
Quantification of IHC against the proliferation marker BrdU (A) and the apoptotic marker 
cleaved caspase 3 (B) revealed a significant reduction in BrdU positive cells 4 and 24 hours 
after a single dose of 30mg/kg MEK162 indicating less cells undergoing the cell cycle (p value = 
0.0003 for 4hrs and p value = 0.001 for 24hr, n≥ 3, Mann Whitney U test) however, no 
alterations were observed with regards to cleaved caspase 3 staining (p value ≥ 0.05, n≥ 15 
tumours, 4 mice, Mann Whitney U test). Error bars indicate standard deviation.   
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Mutations of the PI3K pathway have previously proved to be inherently impervious to MEK 
inhibition in other models of human cancer (Balmanno et al., 2009, Chen et al., 2012b, Dry et 
al., 2010). To evaluate the immediate pharmacodynamic effects of MEK162 in this Pten 
deficient and hence PI3K activated intestinal tumour setting, protein extracted from 6 SITs 
(from n=3 mice per cohort) were pooled and subjected to western blot analysis. 
Immunoblotting for pERK (Thr 202/Tyr204) revealed a marked reduction at 4 and 24 hours 
post MEK162 exposure, indicating prolonged target inhibition in the Pten deficient tumour 
setting (Figure 4.8 A-C, Table 4.3, Table 4.4). 
 Vehicle 4 hours post MEK162 (p value) 
pERK 10821.0 ± 3706.3 2961.3 ± 1120.1 (0.0404) 
pAKT473 6804.6 ± 192.9 6393.7 ± 545.1 (0.3313) 
pAKT308 4770.1 ±790.3 2907.8 ± 982.2 (0.0404) 
pS6RP 12287.0 ± 942.6 9954 ± 1462 (0.0404) 
p4EBP1 13174 ± 1059.3 15543 ± 2254.5 (0.0952) 
Table 4-3 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f SITs 4 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
 Vehicle 24 hours post MEK162 (p value) 
pERK 15657.0 ± 805.8 1451.5 ± 197.1 (0.0404) 
pAKT473 5420.1 ± 385.9 8678.3 ± 596.0 (0.0404) 
pAKT308 2754.0 ± 105.9 5483.5 ± 371.9 (0.0404) 
pS6RP 15479.0 ± 1066.3 7776.3 ± 2165.8 (0.0404) 
p4EBP1 7954.1± 618.5 43.3 ± 75.0 (0.0404) 
p110 818.8 ± 246.8 4399.2 ± 560.1 (0.0404) 
Table 4-4 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f SITs 24 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
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Given the extensive cross-talk between both pathways, the immediate effect of MEK inhibition 
on PI3K and mTOR signalling was explored through western blot analysis of antibodies against 
pAKT, pS6RP and p4EBP1 were probed. Subsequent densitometry analysis revealed no 
significant difference in pAKT473 or p4EBP1 abundance, but did show a significant reduction in 
pAKT308 and pS6RP abundance 4 hours post MEK inhibition, indicating partial inhibition of 
PI3K and mTOR signalling (Figure 4.8, Table 4.3). Together, these changes to PI3K signalling are 
surprising but highlight immediate modulation of the closely associated signalling cascades. 
Furthermore, western blotting of tumour samples from mice harvested 24 hours after MEK162 
exposure revealed additional modulation of PI3K signalling. Here, densitometry analysis 
revealed a significant increase in both pAKT 473 and 308 abundance but a significant reduction 
in levels of pS6RP and p4EBP1 (Figure 4.8, Table 4.4). The changes in PI3K signalling triggered 
through acute MEK inhibition may be attributable to convergence of both signalling cascades 
at mTOR or alternatively, activation of receptor tyrosine kinases through a feedback 
mechanism downstream of pERK may be responsible for activation of PI3K signalling. To 
further evaluate whether this was the case, western blotting of p110α was conducted. 
Interestingly, western blotting revealed a significant increase in p110α abundance 24 hours 
post MEK162 administration, correlating the increase in pAKT 473 and 308 abundance 
observed at this time point (Figure 4.9, table 4.4). 
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(A) 6 SITs pooled from n=3 mice exposed to MEK162 for either 4 or 24 hours were subjected to 
western blot analysis.  Immunoblotting revealed a reduction in pERK abundance compared to 
vehicle controls indicating inhibition of MAPK signalling. Effectors of PI3K and mTOR signalling 
were also probed to investigate cross-talk of pathways. PI3K/mTOR signalling was found to be 
predominantly reduced at 4 hours, however PI3K signalling (through pAKT) was found to be 
increased after 24 hours but mTOR signalling (through pS6RP and p4EBP1) was found to be 
reduced. (B + C) Densitometry was carried out to quantify differences observed from 
immunoblotting. These are normalised to β-actin as loading control and represented relative 
to vehicle controls (*p value = 0.0404, n=3, Mann Whitney U test).  
Figure 4.8 MEK162 leads to inhibition of MAPK signalling through pERK in Apcf/+ Ptenf/f small 
intestine tumours (SITs), however leads to differential modulation of PI3K and mTOR 
signalling 
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(A) Pooled SITs from mice culled 24 hours after exposure to MEK162 were subjected to 
western blotting and probed for p110α. Immunoblotting and subsequent densitometry 
analysis, (B) revealed a significant increase in p110α abundance. For densitometry, p110α 
bands were normalised to β-actin as loading control and represented relative to vehicle 
controls (*p value = 0.0404, n=3, Mann Whitney U test).  
 
 
 
   
 
 
Figure 4.9 MEK162 leads to a significant increase in p110α 24 hours post exposure in Apcf/+ 
Ptenf/f small intestine tumours (SITs) 
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In summary, the immediate consequences of MEK162 in Apcf/+ Ptenf/f SITs involved prolonged 
inhibition of MAPK signalling through pERK which may be responsible for the anti-proliferative 
effects observed by BrdU scoring. Interestingly however, MEK162 also led to modulation of 
PI3K and mTOR signalling further evidencing cross-talk between the two pathways. Here, an 
initial reduction in PI3K and mTOR signalling was observed at 4 hours post MEK162 exposure 
however at 24 hours, MEK162 leads to activation of p110α and AKT signalling but a significant 
reduction in levels of the mTORC1 effectors pS6RP and p4EBP1. 
 
At 4 hours post exposure, MEK162 leads to a reduction in levels of pERK, pAKT at Thr308 and 
pS6RP. At 24 hours post exposure, MEK162 reduced levels of pERK, pS6RP and p4EBP1 but led 
to increased levels of p110α and pAKT at Ser473 and Thr308. 
 
4.2.4 Chronic Mek162 treatment has no effect on longevity of Apcf/+ Pten f/f mice 
Similarly to section 4.2.2, 10 week old Apcf/+ Pten f/f mice were induced and aged to 77 dpi for 
long term treatment with MEK162. A cohort of 13 mice received 30mg/kg twice daily 
(weekdays only) by oral gavage until a survival end point (anaemia, bloating, ≥ 10% loss of 
body weight). Vehicle controls for this experiment are identical to those used in section 4.2.2. 
Chronic twice daily treatment of MEK162 although well tolerated (determined by body weight) 
in Apcf/+ Pten f/f mice, had no advantageous effect on median survival of mice (median survival 
of MEK162 mice = 101dpi, vehicle mice = 99dpi, n≥13, log rank p value = 0.224 and Wilcoxon p 
Figure 4.10 Schematic showing the effects of MEK162 on PI3K/mTOR and MAPK pathway 
components as detected by western blot analysis (Green denotes a reduction and red 
denotes an increase in protein levels). 
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value = 0.529) (Figure 4.11). Therefore, despite the immediate reduction in MAPK signalling, 
Apcf/+ Ptenf/f mice are unresponsive to long term MEK inhibition potentially due to immediate 
compensatory modulation of the PI3K signalling cascade.   
 
 
 
 
 
 
 
 
 
 
 
 
Apcf/+ Ptenf/f  mice were induced and aged to 77 days post induction, at which point mice were 
randomised to receive either 0.5% Methyl cellulose (Vehicle control) or 30mg/kg MEK162 
twice-daily by oral gavage until a survival end point. Continuous MEK162 treatment was found 
to have no benefit on survival of mice (p value = 0.224 Log-Rank, p value = 0.529 Wilcoxon 
test, n ≥13 mice per cohort).  
 
4.2.5 The sequence of NVP-BEZ235 and MEK162 administration is crucial for combined 
inhibition of PI3K and MAPK signalling in Apcf/+ Pten f/f mice  
Given the effectiveness of long term PI3K/mTOR inhibition in this Pten deficient tumour 
model, and the lack of response to chronic MEK inhibition, combined PI3K and MEK inhibition 
Figure 4.11 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f mice on MEK162 compared to 
vehicle controls 
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was then investigated to determine whether the effects of chronic single agent NVP-BEZ235 
could be improved upon. First however, it was crucial to determine the most effective manner 
of administering the combination therapy. Three differing dosing strategies were chosen (as 
outlined below, Table 4.5) and investigated in a short term setting to help identify the most 
effective strategy for administering the combination in the long term setting. A cohort of n≥3 
mice were administered with each strategy and harvested 4 hours after the final dose. The 
dosing strategies chosen differ in the order of inhibitors administered. Combination strategy 1 
(Combo 1) involved administration of MEK162 1 hour prior to NVP-BEZ235 whereas 
combination strategy 2 (Combo 2) involved administration of MEK162 1 hour following NVP-
BEZ235 treatment. The 1 hour time gap in between treatments was initially chosen to reduce 
the stress of oral gavage however to eliminate any effect this may have had on tumours, both 
inhibitors were also administered simultaneously in combination strategy 3 (Combo 3). Mice 
were also administered with a dose of BrdU 2 hours prior to culling and were dissected as 
previously described in section 4.2. Vehicle controls for short term combination experiments 
are identical to those described previously in section 4.2.   
Strategy Dosing schedule 
Combo 1 30mg/kg MEK162 followed by 35mg/kg NVP-BEZ235 1hr later 
Combo 2 35mg/kg NVP-BEZ235 followed by 30mg/kg MEK162 1hr later 
Combo 3 35mg/kg NVP-BEZ235 and 30mg/kg MEK162 at the same time 
Table 4-5 Outline of combination dosing strategies utilised for short term pharmacodynamic 
and anti-tumour evaluations 
To elucidate the immediate anti-tumour effect of each combination strategy, histological 
mitosis and apoptosis was scored from H&E stained slides (Figure 4.12) and also, IHC for brdU 
and cleaved caspase 3 was carried out and quantified (Figure 4.13). Scoring of mitotic figures 
in the Pten deficient SITs revealed no significant alterations following exposure to any of the 
three combinations in comparison to vehicle controls (4hr veh = 0.407 ± 0.318, combo 1 = 
0.347 ± 0.16, combo 2 = 0.138 ± 0.239, combo 3 = 0.393 ± 0.417, combo 1 p value = 0.897, 
combo 2 p value = 0.144, combo 3 p value = 0.778, n≥8 tumours, 4 mice, Mann Whitney U 
test). Quantification of apoptotic bodies revealed a significant increase in histological 
apoptosis only after exposure to combo 2 (4hr veh = 1.802 ± 1.123,combo 1 = 1.85 ± 1.141, 
combo 2 = 4.77 ± 0.406, combo 3 = 2.365 ± 1.102, combo 1 p value = 0.927, combo 2 p value = 
0.0058, combo 3 p value = 0.218, n≥8 tumours, 4 mice, Mann Whitney U test) (Figure 4.12).   
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IHC for BrdU and cleaved caspase 3 was carried out and quantified to further evaluate the 
immediate anti-tumour activity of the three combination strategies. Scoring of BrdU positive 
cells showed a significant reduction in positive cells following combo 1 and 2 but not with 
combo 3 (Veh = 30.7 ± 9.76 combo 1 = 13.65 ± 6.18, combo 2 = 10.45 ± 3.32, combo 3 = 26.93 
± 5.02, both p value ≤ 0.05, n≥8 tumours, 4 mice, Mann Whitney U test). Quantification of 
cleaved caspase 3 revealed a significant increase in staining in SITs exposed to all three 
combination strategies (4hr veh = 3.046 ± 2.297, combo 1 = 4.06 ± 1.38, combo 2 = 4.4 ± 
1.702, combo 3 = 9.567 ± 2.351, combo 1 p value = 0.0305, combo 2 p value = 0.0033, combo 
3 p value = 0.0009, n≥8 tumours, 4 mice, Mann Whitney U test) compared to vehicle treated 
tumours, although the levels of cleaved caspase 3 was higher in combo 3 treated tumours 
than combo 1 and 2 (Figure 4.13).    
As described previously, exposure to NVP-BEZ235 led to inhibition of a number of components 
along the PI3K/mTOR signalling cascade and similarly, exposure to MEK162 led to a reduction 
in MAPK signalling evidenced through a reduction in pERK. To determine whether combination 
of NVP-BEZ235 and MEK162 led to simultaneous inhibition of PI3K/mTOR and MAPK signalling 
in Apcf/+ Ptenf/f tumours, SITs harvested from mice exposed to the three combination 
strategies (Table 4.5) were subjected to protein extraction. For western blot analysis, 6 SITs 
per cohort were pooled and probed for components of the PI3K/mTOR and MAPK signalling 
pathways to build pharmacodynamic profiles of the three combination strategies.  
Surprisingly, immunoblotting for pathway components revealed notable differences between 
the three combination strategies with regards to pathway inhibition. Administration of 
MEK162 1 hour prior to NVP-BEZ235 (Combo 1) led to a reduction in levels of pERK, but 
differential modulation of PI3K/mTOR signalling, evidenced by partial inhibition of pAKT at 
Ser473 and Thr308 and p4EBP1, but complete reduction of pS6RP (Figure 4.14, Table 4.6). 
Interestingly, administration of NVP-BEZ235 1hr prior to MEK162 (Combo 2), led to potent 
inhibition of pERK and a number of PI3K pathway components including pAKT Ser473 and 
Thr308 and pS6RP (Figure 4.14, Table 4.7), suggesting that MEK inhibition prior to PI3K/mTOR 
inhibition may render Apcf/+ Pten f/f tumours insensitive to PI3K/mTOR inhibition whereas MEK 
inhibition post PI3K/mTOR inhibition results in a cooperative effect to inhibit both pathways. 
To evaluate whether the differences observed between combo 1 and combo 2 with regards to 
pathway inhibition were due to the order of which inhibitors were administered or whether 
this perhaps was due to the 1 hour time in between doses, both inhibitors were administered 
at the same time (combo 3) and tumours were similarly evaluated for differences in pathway 
output. Western blotting of these tumours revealed that administration of NVP-BEZ235 and 
130 
 
MEK162 at the same time lead to inhibition of MAPK signalling through reduced levels of 
pERK, but differential inhibition of PI3K/mTOR signalling. Here, a partial reduction in pAKT 
Ser473 levels, no difference in levels of p4EBP1 however, a considerable reduction in pAKT 
Thr308 and pS6RP was detected (Figure 4.14, Table 4.7). This later finding suggests that 
tumours exposed to combo 3 are no longer sensitive to potent PI3K/mTOR inhibition as 
observed by NVP-BEZ235 alone 4 hours after a single dose and that perhaps when 
administered at the same time, the effects of one agent negate the effects of the other.  
 Vehicle Combo 1 (p value) 
pERK 10280 ± 276 1852 ±390 (0.0404) 
pAKT473 8417 ± 798 5855 ±460 (0.0404) 
pAKT308 3461 ± 1562 2350 ± 743 (0.0404) 
pS6RP 5344 ± 1022 65 ± 39 (0.0404) 
p4EBP1 6614 ± 2694 2261 ± 671.9 (0.0404) 
Table 4-6 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f SITs 4 hours post exposure to combo 1, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
 Vehicle Combo 2 (p value) Combo 3 (p value) 
pERK  12689 ± 1257 1221 ± 352 (0.0404) 2683 ± 954 (0.0404) 
pAKT473 11861 ± 197 713 ± 280 (0.0404) 9521 ± 1283 (0.0404) 
pAKT308 5308 ± 574 No bands detected 2165 ± 423 (0.0404) 
pS6RP 16685 ± 854 386 ± 114 (0.0404) 1818 ± 814 (0.0404) 
p4EBP1 9452.9 ± 2308.1 13063.9 ± 1602.6 (0.0404) 11543.4 ± 2089.7 (0.1914) 
Table 4-7 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f SITs 4 hours post exposure to combo 2 and combo 3, n=3, One-tailed Mann Whitney 
U test was used for statistical analysis 
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In summary, western blotting of the three combination strategies chosen show that Apcf/+ 
Ptenf/f tumours are highly sensitive to the order of which inhibitor is administered, in order to 
achieve simultaneous inhibition of both pathways. 
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Figure 4.12 Sequencing of combination is important for anti-tumour effects in Apcf/+ Ptenf/f 
small intestine tumours (SITs) 
Scoring of mitotic figures (A) and apoptotic bodies (B) revealed a trend towards reduced 
mitotic figures only after combo 2 administration, but a significant increase in apoptosis 4 
hours after combo 2 exposure (p value ≤ 0.05, n≥8 tumours, 4 mice, Mann Whitney U test). 
Error bars represent standard deviation.   
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Figure 4.13 Sequencing of combination is important for anti-tumour effects in Apcf/+ Ptenf/f 
small intestine tumours 
Quantification of IHC against the proliferation marker BrdU (A) and the apoptotic marker 
cleaved caspase 3 (B) revealed a significant reduction in BrdU positive cells 4 after combo 1 
and 2, and increase in cleaved caspase 3 only after combo 3 administration. (*p value ≤ 0.05, 
n≥8 tumours, 4 mice, Mann Whitney U test). A trend towards an increase in cleaved caspase 3 
after combo 2 was also observed, however this was not significantly altered. Error bars 
indicate standard deviation. 
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Figure 4.14 Sequencing of combination is crucial for combined inhibition of PI3K/mTOR and 
MAPK signalling in Apcf/+ Ptenf/f small intestine tumours 
(A)6 small intestine tumours pooled from n=3 mice exposed to the differing combination 
strategies were subjected to western blot analysis and probed for effectors of PI3K/mTOR and 
MAPK signalling.  Immunoblotting revealed complete inhibition of PI3K/mTOR and MAPK 
signalling only with combo 2. Combo 1 and 3 led to substantial inhibition of MAPK signalling 
through pERK, but differential modulation of PI3K/mTOR signalling. (B + C) Densitometry was 
also carried out to quantify differences observed from immunoblotting. These are normalised 
to β-actin as loading control and represented relative to vehicle controls (*p value = 0.0404, 
n=3, Mann Whitney U test).  
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4.2.6 Combination strategy 2 results in prolonged inhibition of the PI3K/mTOR and MAPK 
signalling cascades  
The preferred combination strategy identified from short term 4 hour treatments (section 
4.2.5) was combo 2, given the increased anti-tumour effects and the favourable immediate 
pharmacodynamic effects. To investigate whether this was still the case at a 24 hour time 
point after a single dose of the combination, a cohort of n=4 tumour bearing Apcf/+ Ptenf/f mice 
were administered with combo 2 and culled 24 hours following the last dose. Mice were also 
administered a 2 hour pulse of BrdU to label cells in S phase of the cell cycle prior to culling. 
Mice were harvested as previously described and controls for this experiment are those used 
in section 4.2.  
H&E stained sections of the small intestine were used to assess histological mitosis and 
apoptosis in tumours, and IHC for BrdU and cleaved caspase 3 were also carried out to 
determine the biological effects of combo 2 24 hours after exposure (Figure 4.15). 
Quantification of mitotic figures here revealed no significant alterations (vehicle = 0.407 ± 
0.318, 24hr combo 2 = 0.418 ± 0.271, p value = 0.0932, n≥8 tumours, 4 mice, Mann Whitney U 
test) (Figure 4.15 A) however histological apoptosis was significantly reduced (vehicle = 1.802 
± 1.123, 24hr combo 2 = 0.800 ± 0.675, p value = 0.0243, n≥8 tumours, 4 mice, Mann Whitney 
U test) (Figure 4.15 B) indicating activation of a compensatory mechanism which results in 
reduced apoptosis following the 4-fold increase in apoptosis observed at 4 hours following 
combo 2 (section 4.2.5). The levels of BrdU positive cells was also significantly reduced (vehicle 
= 30.7 ± 9.761, 24hr combo 2 = 23.887 ± 5.011, p value = 0.0179, n≥8 tumours, 4 mice, Mann 
Whitney U test) indicating less S phase cells are present 24 hours post combo 2 treatment 
(Figure 4.15 C). Scoring of cleaved caspase 3 staining revealed no significant alterations (24hr 
vehicle = 3.046 ± 2.297, combo 2 = 2.203 ± 1.150, p value = 0.4365, n≥8 tumours, 4 mice, 
Mann Whitney U test) (Figure 4.15 D) consistent with levels 4 hours after combo 2 exposure 
(Figure 4.13 B).  
 
 
 
 
136 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.15 Biological effects of combo 2, 24 hours following NVP-BEZ235 exposure  in Apcf/+ Ptenf/f small intestine tumours (SITs).  Quantification of 
histological mitotic figures (A), apoptotic bodies (B), the proliferation marker BrdU (C) and the apoptotic marker cleaved caspase 3 (D) revealed a significant 
reduction in BrdU positive cells and surprisingly, a reduction in histological apoptotic bodies (*p value ≤ 0.05, n≥ 3, Mann Whitney U test). Error bars represent 
standard deviation. 
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Given that PI3K/mTOR signalling was not reduced 24 hours after exposure to single agent NVP-
BEZ235 and MEK162 caused significantly varied modulation of PI3K/mTOR signalling 24 hours 
after administration, it was important to examine the pharmacodynamic effects of combo 2 24 
hours post exposure. For this, tumours harvested from mice were subjected to whole cell 
protein extraction and 6 SITs were pooled for western blot analysis of downstream signalling 
components. Western blotting and subsequent densitometry analysis revealed a significant 
reduction of all components of the PI3K/mTOR signalling cascade probed including, pAKT at 
Ser473 and Thr308, pS6RP and p4EBP1 as well as the MAPK pathway component pERK, 
indicating efficient and prolonged inhibition of both pathways (Figure 4.16, Table 4.8). 
 
 
 
 
 
 
 
Table 4-8 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f SITs 24 hours post exposure to combo 2, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
These results reveal combo 2 effectively delivers prolonged reduction of MAPK and 
PI3K/mTOR signalling in Pten deficient tumours and suggests this may be more advantageous 
in a long term treatment setting, as explored next.      
 
 
 
 
 
 Vehicle 24 hours post Combo 2 (p value) 
pERK 5296 ± 457.97 393.20 ± 64.03 (0.0404) 
pAKT473 3730.6 ± 303.1 134.69 ± 26.48 (0.0404) 
pAKT308 1491.01 ± 254.09 No bands detected 
pS6RP 4893.369 ± 428.92 No bands detected 
p4EBP1 2031.21 ± 125.08, No bands detected 
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(A) 6 SITs were pooled from n=3 mice exposed to combo 2 for 24 hours were subjected to 
western blot analysis and probed for effectors of PI3K/mTOR and MAPK signalling. 
Immunoblotting revealed substantial inhibition of both PI3K/mTOR and MAPK signalling 
cascades. (B) Densitometry analysis was carried out to quantify differences observed from 
immunoblotting. These are normalised to β-actin as loading control and represented relative 
to vehicle controls (*p value = 0.0404, n=3, Mann Whitney U test). 
 
 
 
Figure 4.16 Sequencing of combination is crucial for prolonged inhibition of PI3K/mTOR and 
MAPK signalling in Apcf/+ Ptenf/f small intestine tumours (SITs) 
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4.2.7 Combined PI3K/mTOR and MEK inhibition increases longevity of Apcf/+ Ptenf/f mice 
however it does not provide any additional benefit compared to dual PI3K/mTOR 
inhibition by NVP-BEZ235 
Given the importance of scheduling when administering the combination of PI3K/mTOR and 
MEK inhibitors in Apcf/+ Ptenf/f mice in the short term setting, combination strategy 2 (combo 
2) was chosen for the chronic treatment regimen to achieve concomitant pathway inhibition. 
For all single agent long term treatments, inhibitors were administered as a twice daily 
regimen and so to be comparative, the combination would also require twice daily dosing of 
both inhibitors (despite effective inhibition of pathways for 24 hours after a single dose of 
combo 2 – section 4.2.5 and 4.2.6). However, it was not known whether administering combo 
2 twice-daily would be well tolerated by mice. To test this, a cohort of n=4 wild type mice were 
subjected to daily treatment of twice daily combo 2 treatment from 12 weeks of age for a 2 
month (8 week) period. Mice were monitored daily and overall body weight was recorded 
throughout the treatment period. As shown on figure 4.17, the combo twice-daily regimen 
proved toxic to wild-type mice as overall body weight was shown to be dramatically reduced 
(approximately 20% reduced) after only 4 days of treatment. Therefore, although this regimen 
was initiated as an 8 week experiment, as Home Office guidelines prohibit weight loss of more 
than 20%, mice had to be culled prior to the experimental end point. Of the 4 mice in this 
cohort, 2 were culled before the experimental end point due to excess weight loss and 
therefore due to toxicity. Despite reaching the experiment end point, the 2 remaining mice did 
demonstrate fluctuations in weight – usually weight loss during weekdays whilst on treatment 
after which weight would increase during the weekend whilst not receiving treatment. This 
was a clear indication of treatment induced toxicity. Additionally, when compared to relative 
weights of Apcf/+ Ptenf/f mice on twice daily 35mg/kg NVP-BEZ235 treatment, the combo twice 
daily regimen was more variable and therefore a less desirable chronic treatment option.  
In light of this toxicity issue, I next investigated a reduced combination dose. NVP-BEZ235 at 
35mg/kg twice daily previously demonstrated efficacy in Apcf/+ Ptenf/f mice (Figure 4.4) and so 
to be comparable, this dose was kept constant. MEK162 at 30mg/kg twice daily showed no 
survival benefit (Figure 4.11) and so this dose was reduced to once daily administration 1 hour 
after the first NVP-BEZ235 dose. This reduced combination dose was administered to a cohort 
of 13 Apcf/+ Ptenf/f mice aged to 77 days post induction, as a chronic treatment experiment, to 
a survival end point.  During the experiment, mice were closely monitored and body weights 
recorded. As depicted in figure 4.17, mice still showed some fluctuations in body weight; 
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however this was not as extreme as in the combo 2 twice-daily cohort and was well tolerated 
by the majority of mice.  
Chronic administration of 35mg/kg NVP-BEZ235 twice daily plus 30mg/kg MEK162 once daily 1 
hour after the first NVP-BEZ235 dose by oral gavage, significantly increased median survival of 
Apcf/+ Ptenf/f mice from 99 dpi to 270 dpi (Figure 4.18) (median survival combination mice = 
270 dpi, median survival Vehicle mice = 99 dpi, n≥15, p value ≤ 0.001, Log-Rank and wilcoxon 
test). Interestingly however, this treatment showed no significant additional benefit compared 
to single agent NVP-BEZ235 and in fact the two treatments resulted in comparable median 
survivals (median survival combination mice = 270dpi, median survival NVP-BEZ235 mice = 
266dpi, n≥15, p value = 0.201 Log Rank test and p value = 0.514 Wilcoxon test). This result 
indicates a lack of additional synergy from the combination therapy with regards to the 
survival of animals, despite the favourable short term pharmacodynamic effects. Despite this, I 
next investigated whether the combination therapy may have had more subtle effects on 
tumour burden of mice at point of culling as described in section 4.2.8.  
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Figure 4.17 Twice-daily combo 2 administration resulted in significant weight loss in wild 
type mice and so a reduced combination dose, which was better tolerated, was chosen for 
long term treatment for the Apcf/+ Ptenf/f tumour model 
To investigate whether administration of combo 2 twice-daily would be well tolerated by mice, 
n=4 wild type mice were dosed the regimen from 12 weeks of age for an 8 week period prior 
to usage of this combination regimen in tumour models.  This led to significant fluctuations in 
body weight and n=2 mice were sacrificed due to severe weight loss prior to the 8 week 
experimental end point. Therefore, a reduced combination dose of 35mg/kg NVP-BEZ235 
twice-daily plus 30mg/kg MEK162 once daily (1 hour after first NVP-BEZ235 dose) was utilised. 
This appeared to be better tolerated compared to twice daily combination. Single agent NVP-
BEZ235 twice daily was well tolerated in Apc f/+ Pten f/f mice and so was chosen as a 
comparison.  
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Figure 4.18 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f mice on combination therapy 
compared to vehicle and single agent controls 
Apcf/+ Ptenf/f  mice were induced and aged to 77 days post induction, at which point mice were 
randomised to receive either 0.5% Methyl cellulose (Vehicle control) or combination (35mg/kg 
NVP-BEZ235 twice daily plus 30mg/kg MEK162 once daily, 1 hour after the first NVP-BEZ235 
dose) by oral gavage until a survival end point. Continuous combination (combo) 
administration significantly increased longevity of mice from 99 days (Vehicle) to 270 days 
post induction (p value ≤ 0.001 Log-Rank and Wilcoxon test n ≥15 mice per cohort). This was 
also significantly better than single agent MEK162 administration p value ≤ 0.001 Log-Rank and 
Wilcoxon test n ≥13 mice per cohort) however, combo was not significantly different in 
comparison to single agent NVP-BEZ235 treatment (p value = 0.201 Log-Rank, p value = 0.514 
Wilcoxon test, n ≥15 mice per cohort).  
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4.2.8 Tumour burden analysis of Apcf/+ Ptenf/f mice on long term treatments 
Long term treatment with single agent NVP-BEZ235 and combined NVP-BEZ235 plus MEK162 
significantly increased longevity of Apcf/+ Ptenf/f mice compared to vehicle treated mice, 
whereas MEK162 failed to show any efficacy in this setting. To establish the effects of these 
chronic treatment strategies on tumour burden at the end of treatment, tumours were 
counted, measured for size and staged according to severity (methods section 2.7.4). 
Additionally, as intervention with the various treatment regimens was started at a chosen time 
point, the parameters of tumour burden outlined above were also scored in a cohort of mice 
culled at day 77 post induction (treatment start time) as a measure of basal levels.  The 
number of tumours present at death for all cohorts was scored on 3 H&E stained slides of 
small intestine rolls per sample.  
At 77dpi (start of treatment) Apcf/+ Ptenf/f mice possessed a median of 3 tumours per mouse 
whereas vehicle treated mice at death had a median of 6 lesions (Figure 4.19 A). Importantly, 
this shows that tumours are present at the start of treatment and although new lesions 
develop during the course of vehicle treatment, the number of tumours between the two 
cohorts was not significantly different (p value = 0.1134, n≥11, Mann Whitney U test). Apcf/+ 
Ptenf/f mice on NVP-BEZ235 treatment possessed a median of 2 tumours at time of death 
which is significantly reduced compared to vehicle but not to the start of treatment (p value = 
0.0291 compared to vehicle, p value = 0.2857 compared start cohort), suggesting that NVP-
BEZ235 may function by halting initiation of further lesions (Figure 4.19 A). Scoring of lesions 
in MEK162 treated mice reveal a median of 5 lesions and as expected, this is not significantly 
altered from the vehicle or start of treatment cohorts (p value = 0.287 for vehicle, p value = 
0.325 for start, n≥11 for each cohort, Mann Whitney U test). Similarly to the NVP-BEZ235 
treated cohort, long term combo 2 treated mice possessed significantly reduced tumours at 
death in comparison to vehicle treated mice and not in comparison to the start cohort 
(median number of lesions at death combo = 4, vehicle = 6, start cohort = 3, p value = 0.0362 
for vehicle, p value = 0.584 for start, n≥11, Mann Whitney U test). This again suggests 
treatment has an effect on further tumour initiation (Figure 4.19 A). Interestingly, there is no 
significant difference between NVP-BEZ235 treated and combination treated mice with 
regards to tumour number at death, further suggesting lack of cooperation or synergy in the 
context of Pten deficient tumours (number of lesions at death: NVP-BEZ235 = 2, combo = 4 p 
value = 08183, n≥11, Mann Whitney U test).  
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To address whether the size of lesions was affected by treatment, macroscopic tumours were 
measured from methacarn fixed small intestines and the total tumour area (in mm2) was 
calculated per mouse in each cohort (Figure 4.19 B). Apcf/+ Ptenf/f mice on vehicle treatment 
trended to possess larger tumours at death compared to the start cohort, however this was 
not significantly different (start = 37.8 ± 39.38 n=13, vehicle = 53.21 ± 32.48 n = 4, p value = 
0.174, Mann Whitney U test). Similarly, a trend for larger small intestinal tumours at death 
was observed in NVP-BEZ235 and combination treated mice compared to vehicle and the start 
cohort, but again this was not significant (vehicle = 53.21 ± 32.48 n = 4, NVP-BEZ235 = 81.57 ± 
44.76 n = 7 and p value = 0.508, combo = 108.23 ± 81.28 n = 5 and p value = 0.2207 Mann 
Whitney U test), due to large variation within the cohorts. As expected, tumours in mice on 
long term MEK162 treatment were not significantly altered in size compared to vehicle treated 
or the start cohort (vehicle = 53.21 ± 32.48 n = 4, mek162 = 66.61 ± 26.2 n=4, p value = 0.665 
Mann Whitney U test) (Figure 4.19 B).  
Lastly, for tumour burden analysis, tumours on H&E stained sections of the small intestine 
were staged according to severity and invasive characteristics as described in section 2.7.4. 
These stages refer to microadenomas (mAd) or single crypt lesions, benign adenomas (Ad) 
with no signs of invasion, early invasive adenocarcinomas (EIA) identified by submucosal 
invasion, and advanced invasive adenocarcinomas (AIA) characterised by invasion into the 
muscle wall and the underlying serosa. The average number of these per cohort were 
calculated and displayed in figure 4.17 C as a proportion of the total number of tumours 
scored. This was due to a difference in the total number of tumours observed between the 
various treatment cohorts, as described previously (figure 4.19 B). The proportion of 
microadenomas observed was found to be unchanged between all groups: 17.4% in the start 
cohort (n=11), 19.3% in the vehicle cohort (n=15), 14.3% in NVP-BEZ235 treated mice (n=14), 
17.6% in MEK162 treated mice (n=11) and 25% in combination treated mice (n=14) (p value ≥ 
0.05 for all comparisons) (Figure 4.19 C).  The proportion of adenomas was found to be 
significantly reduced in all treated cohorts in comparison with the start cohort (start = 60%, 
vehicle = 44% p value = 0.027, NVP-BEZ235 = 33% p value = 0.0038, MEK162 = 41% p value = 
0.0086, combo = 12.5% p value = 0.0002, n≥8, Mann Whitney U test) and in combination 
treated mice, compared to the vehicle cohort (p value = 0.0011, n≥8, Mann Whitney U test). 
The proportion of EIAs is statistically unaltered in all cohorts however, a trend towards 
increased proportion of EIAs was notable in vehicle and MEK162 cohorts compared to the 
start cohort (Start cohort = 22%, vehicle = 28% p value = 0.161, NVP-BEZ235 = 20% p value = 
0.954 for start cohort and p value = 0.249 for vehicle cohort, MEK162 = 31% p value = 0.158 
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for start cohort and p value = 0.795 for vehicle cohort, combo = 23% p value = 0.743 for start 
cohort and p value = 0.126 for vehicle cohort, n≥8, Mann Whitney U test). Interestingly, a 
significant increase in the proportions of AIAs was observed in NVP-BEZ235 and combination 
treated cohorts, suggesting that a larger proportion of tumours were more invasive and that 
the Apcf/+ Ptenf/f mice were able to tolerate such an increase in severity of tumours 
(proportions of AIAs: start = 0, vehicle = 8%, NVP-BEZ235 = 33% p value = 0.0121, MEK162 = 
10% p value = 0.856, combo = 40% p value = 0.0095, n≥8, Mann Whitney U test) (Figure 4.19 
C).  
Interestingly at dissection, Apcf/+ Ptenf/f mice on NVP-BEZ235 were noted to have abnormal 
livers compared to vehicle treated animals, in which large macroscopic lesions were clearly 
identifiable. Closer pathological analysis of H&E stained sections of the liver identified the 
large white lesions as well differentiated hepatocellular tumours with trabecula scanti-mitosis, 
mild to moderate nuclear pleomorphisms and no definite invasion of adjacent parenchyma or 
of intra hepatic blood vessels however, occasional tumours showed focal necrosis2. Further 
comparisons of whole cohorts identified tumours to be present in 50% of animals exposed to 
chronic NVP-BEZ235 compared to none of the vehicle treated mice. Additionally, 
hepatocellular tumours were not identified in MEK162 mice however interestingly, only 7% of 
Apcf/+ Ptenf/f mice on combo treatment were identified to present with these tumours (Figure 
4.20).  
  
 
 
 
                                                          
2
 pathological description of hepatocellular tumours was provided by Professor Geraint Williams, Cardiff 
University, School of Medicine 
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(A) Apcf/+ Ptenf/f mice on NVP-BEZ235 and combo had significantly less tumours at death compared 
to vehicle controls (p value = 0.0291 for NVP-BEZ235 and p value = 0.0362 for combo, n ≥ 11, Mann 
Whitney U test). (B) No significant alterations were observed when comparing tumour area, 
however NVP-BEZ235 and combo treated mice trended to have larger tumours at death, compared 
to the start and vehicle treated cohorts (p value ≥ 0.05, n ≥ 4, Mann Whitney U test) . (C) Key: mAd 
– microadenoma, Ad – adenoma, EIA – early invasive adenocaricinoma, AIA – advanced invasive 
adenocarcinoma. Staging of tumours at death reveals no alterations in the proportions of 
microadenomas across the cohorts, a significant reduction in adenomas in all treated cohorts, in 
comparison with the start cohort but also the proportion of adenomas was reduced in combination 
treated mice, compared to the vehicle cohort (*p value ≤ 0.05, Mann Whitney U test). Additionally, 
although no significant differences were detected in the proportions of EIAs, the proportion of AIAs 
was significantly increased in NVP-BEZ235 and combo treated mice. 
Figure 4.19 Analysis of tumour burden in Apcf/+ Ptenf/f  mice 
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(A) Analysis of liver tissue indicated 50% of mice on NVP-BEZ235 developed hepatocellular 
tumours, approximately 7% of mice on Combo had liver lesions whereas none of the mice on 
Vehicle or MEK162 developed HCC (B) H&E image of hepatocellular tumour (dashed lines used 
to highlight an example of a lesion).  
Figure 4.20 Incidence of liver tumours in Apcf/+ Ptenf/f mice on long term treatment 
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4.3 Discussion 
4.3.1 NVP-BEZ235 leads to inhibition of PI3K and mTOR signalling whilst imposing anti-
proliferative and pro-apoptotic effects in Pten deficient small intestinal tumours and 
long term, substantially increasing longevity of mice 
The therapeutic potential of targeting the PI3K pathway in the context of PI3K activated CRC 
was assessed in the AhCreER Apcf/+ Ptenf/f mouse model (Marsh et al., 2008) using the potent 
dual PI3K/mTOR inhibitor NVP-BEZ235. The mouse model used in this chapter is a robust and 
relatively quick model of invasive adenocarcinoma driven by activation of AKT and mice 
usually succumb to disease by 100 days post induction. Therefore, the main aim of this 
chapter was to inhibit the primary pathway driving tumourigenesis in this model. For all 
experiments described in this chapter, 10 week old mice were induced via i.p. injections of 
Tamoxifen and βNF and aged, either until symptomatic of disease or until the chosen 
treatment start point. Mice which presented with symptoms of tumour burden were also 
administered short term doses of NVP-BEZ235 to investigate anti-tumour and 
pharmacodynamic effects.  
NVP-BEZ235 resulted in complete inhibition of PI3K and mTOR signalling, as observed by the 
reduction in levels of pAKT at Ser473 and Thr308, pS6RP and p4EBP1 4 hours after exposure 
(Figure 4.3). As described previously, the serine-threonine kinase AKT is a major effector of 
PI3K signalling and has well established roles in mediating cellular growth and survival. AKT is 
known to bind to accumulated PIP3 at the plasma membrane which in turn allows PDK1 into 
the ‘activation loop’ of AKT where it is able to phosphorylate Thr308 and hence activate AKT 
(Alessi et al., 1997). This, in turn, is sufficient to activate a number of proteins including 
mTORC1 (complex 1) which mediates activation of S6RP and 4EBP1, important for a number of 
cellular processes including, translation of mRNAs that encode cell cycle regulators such as 
MYC and cyclin D1 (Rini, 2008).  For full activation of AKT, phosphorylation at Ser473 in the 
carboxy-terminal hydrophobic motif by mTORC2 is required and is thought to lead to a 
number of substrate-specific phosphorylation events including phosphorylation of pro-
apoptotic FOXO proteins (Guertin et al., 2006). As well as inhibition of signalling, NVP-BEZ235 
in Pten deficient tumours also induced potent anti-tumour effects, evidenced by a reduction in 
BrdU positive cells and an increase in cleaved caspase 3 4 hours after administration (Figure 
4.2). This is in accordance with previous studies which have reported the cytotoxic effects of 
NVP-BEZ235 in a number of cell lines (Haagensen et al., 2012, Blaser et al., 2012), and also that 
Pten null cell lines are particularly sensitive to the compound (Maira et al., 2008). The later 
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observations were further corroborated by Mueller et al., in a study which found PI3K mutated 
cells to be more sensitive to the effects of NVP-BEZ235 than wild-type cells (Mueller et al., 
2012). These anti-tumour effects may be attributable to inhibition of signalling given the role 
of the PI3K cascade in promoting cellular growth and inhibition of apoptosis (Cantley, 2002).  
Given that pathway inhibition and anti-tumour effects of NVP-BEZ235 were only detected 4 
hours after exposure, and that the majority of these had reached basal levels by 8 and 24 
hours (Figure 4.3), a twice-daily administration regimen was anticipated to lead to potent anti-
tumour effects long term. Mice were randomised at 77 days post induction to receive 0.5% 
Methyl cellulose (MC, Vehicle) or 35mg/kg NVP-BEZ235 by oral gavage to firstly evaluate the 
long term therapeutic potential of PI3K/mTOR inhibition by NVP-BEZ235 and secondly to 
determine its effect on tumour burden. Chronic administration of NVP-BEZ235 led to a 
significant increase in survival of mice from a median of 99 days to 266 days post induction, 
clearly indicating the benefits of PI3K and mTOR inhibition in this Pten deficient tumour setting 
(Figure 4.5). Additionally, at death, mice possessed fewer tumours than vehicle treated mice 
indicating treatment prevented growth of further tumours. Despite the fact that mice bore 
fewer tumours, these tumours trended to be larger than vehicle treated mice and 
proportionally, more invasive lesions were detected. This suggests that the rate of tumour 
growth is reduced, however as mice survived longer, tumours at death are larger as they have 
had a longer period in which to grow and become invasive (Figure 4.19). Given the trend 
towards increased tumour area following long term NVP-BEZ235, the component of stromal 
tissue within the tumours was also evaluated to investigate whether treatment influenced the 
stromal component of tumours (data not shown). This included scoring of total stromal tissue 
versus epithelial tissue and evaluation of vascularisation through scoring of CD31 positive 
vessels. Although no significant difference was detected between vehicle and NVP-BEZ235 
treated tumours in this case, the importance of drug treatment on tumour stroma is well 
documented within the literature.  Cancer cells are known to alter their stroma and supportive 
environment to allow tumour progression or regression by modulating production of stroma 
modulating factors such as basic FGF, VEGF, PDGR, EGFR, interleukins, colony stimulating 
factors, etc (Mueller and Fusenig, 2004). These factors are known to disrupt tissue 
homeostasis in a paracrine manner and can lead to stromal reactions such as angiogenesis and 
inflammatory responses(Bergers and Benjamin, 2003, Coussens and Werb, 2002).  
Alterations of the PI3K pathway have been implicated in tumour development and progression 
of human cancer for some time now, and this has rightfully led to a surge in development of 
inhibitors which target multiple components of the pathway. However, the evaluation of PI3K 
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inhibitors for PI3K mutant cancers is limited, primarily as these mutations tend to co-exist with 
those activating MAPK signalling for example Ras and B-raf. NVP-BEZ235 has previously been 
assessed in the autochtonous p110α H1047R mouse model of lung cancer where acutely, 
treatment led to reduced PI3K/mTOR signalling through pAKT, pS6RP and p4EBP1 and long 
term, NVP-BEZ235 led to reduced 18FDG avidity measured by PET imaging, as well as reduced 
tumour size (Engelman et al., 2008). The evidence presented in this chapter is the first study in 
an autochtonous model that establishes activity against PI3K activated intestinal cancer. 
Together, these studies provide rationale for stratification of PI3K mutant tumours in clinical 
trials.  
4.3.2 MEK inhibition through MEK162 reduces MAPK signalling in Pten deficient tumours, 
however does not increase survival of mice potentially through increased PI3K 
signalling 
Having established that targeting PI3K signalling using the dual PI3K/mTOR inhibitor NVP-
BEZ235 is beneficial in this Pten deficient mouse model of colorectal cancer, concomitant 
inhibition of MAPK signalling was next investigated. Prior to that however, the effects of single 
agent MEK inhibition was established in this model. This involved short term experiments with 
MEK162, to investigate pharmacodynamic and anti-tumour effects, as well as a long term 
therapeutic intervention study to investigate the effect on survival and tumour burden.  
Interestingly, a single dose of MEK162 led to prolonged reduction in cellular proliferation 
observed by a reduction in BrdU positive cells, and prolonged pathway inhibition evidenced by 
reduction of pERK abundance in this Pten deficient setting (Figure 4.7, 4.8). This is contrary to 
a number of previous reports which have found mutations activating the PI3K pathway to be 
intrinsically resistant to MEK inhibition (Balmanno et al., 2009, Chen et al., 2012b, Dry et al., 
2010). Interestingly, MEK162 initially lead to a reduction in PI3K and mTORC1 signalling 
evidenced through reduced pAKT308 and pS6RP at 4 hours after exposure. However, MEK162 
then lead to an increase in PI3K signalling through pAKT at Ser473 and Thr308 but a reduction 
in mTORC1 signalling through pS6RP and p4EBP1 at 24 hours post MEK162 exposure (Figure 
4.8). There are a number of mechanisms reported in the literature, by which ERK regulates 
PI3K/AKT signalling. Reduction of pERK through inhibition of MEK has previously shown to lead 
to an increase in EGF stimulated association of GAB1 which in turn was shown to increase PI3K 
activity and AKT signalling (Yu et al., 2002). Also, MEK inhibition has previously led to 
downregulation of mTORC1 signalling, therefore relieving feedback inhibition of PI3K signalling 
through IGFR-1R/IRS and subsequently leading to activation of PI3K signalling (Ebi et al., 2011). 
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Additionally, pERK has been shown to directly regulate tyrosine phosphorylation of EGFR in 
the context of a Ras mutation and subsequently increase signalling downstream the receptor 
(Wong et al., 2002). Although it remains unclear as to the mechanism through which PI3K 
signalling is increased in response to MEK inhibition 24 hours post exposure, the observation 
that p110α was found to be increased, together with the corresponding increase in pAKT, 
suggests the mechanism may be any one of those highlighted above (Figure 4.9).  
Additionally, the mechanism by which MEK162 administration reduces PI3K and mTOR 
signalling (observed at 4 hours following MEK162 exposure) is also unknown. Both pERK and 
one of its substrates p90RSK have been shown to phosphorylate and inhibit activity of Gsk3 
(Cohen and Frame, 2001). Gsk3 functions as a negative regulator of Pten and has previously 
been shown to alleviate Pten inhibition and decreasing PI3K signalling (Al-Khouri et al., 2005). 
Despite this, complete deletion of Pten in these tumours suggests Gsk3 may not be 
responsible for the reduced PI3K signalling. Interestingly, similar effects were observed in 
Apcf/+ colon tumours following acute MEK162 exposure, in section 3.2.2. It was previously 
suggested this could be due to the alternative effects of the p90RSK downstream pERK, as was 
described previously in chapter 3.3.1, and may be responsible for the similar effects observed 
in the Pten deficient tumours in this chapter.  
Nevertheless, despite the initial inhibition of MAPK signalling, long term MEK inhibition proved 
to be ineffective in Pten deficient tumours, in accordance with previous reports (Balmanno et 
al., 2009, Chen et al., 2012b, Dry et al., 2010). This is at least, with respect to survival (Figure 
4.9), the end number of tumours, tumour area and tumour severity profiles (Figure 4.17). 
However, given a number of studies have reported synergistic effects with simultaneous 
PI3K/Akt and MEK/ERK inhibition (Haagensen et al., 2012, Martinelli et al., 2013), this was next 
investigated in the context of Pten deficient intestinal tumours. 
4.3.3 Sequencing of PI3K/mTOR and MEK inhibitors is crucial for concomitant inhibition of 
signalling cascades  
The hypothesis for combined targeting of PI3K/AKT and RAS/MEK/ERK signalling is well 
documented, given the close association and convergence of the two pathways (Aksamitiene 
et al., 2012). A number of studies have assessed this hypothesis in cell lines (Haagensen et al., 
2012, Liu and Xing, 2008, Yu et al., 2008, Martinelli et al., 2013) and murine models of human 
cancer including a Pten null and Kras activated ovarian cancer model (Kinross et al., 2011), 
PIK3CA and KRAS mutant lung cancer model (Engelman et al., 2008) and in PIK3CA and KRAS 
activated colon, pancreatic and lung cancer xenografts (Halilovic et al., 2010). However, 
152 
 
evaluation of the combination therapy has been less well characterised for only Pten deficient 
and hence PI3K activated only tumour settings. 
 To evaluate combination therapy in our Pten deficient mouse model, I first performed short 
term pharmacodynamic and anti-tumour experiments to identify the most desirable dosing 
strategy. Interestingly, western blotting revealed that Apcf/+ Ptenf/f SITs are particularly 
sensitive to the scheduling of both inhibitors (Figure 4.14). Administration of NVP-BEZ235 1 
hour prior to MEK162 completely inhibited PI3K/mTOR and MAPK signalling for 24 hours 
(Figure 4.14, 4.16), whereas MEK162 administered 1 hour prior to or at the same time as NVP-
BEZ235 resulted in less effective pathway inhibition. This was surprising, particularly given 
modulation of PI3K and mTOR signalling observed immediately following MEK inhibition. The 
reasons for this are currently unclear however it may be possible that PI3K signalling was 
efficiently reduced within the first hour following administration of NVP-BEZ235 and so 
therefore, MEK inhibition simply added to this inhibition of signalling given that reduction in 
pAKT Thr308 and pS6RP was observed following single agent MEK inhibition 4 hours after 
administration (Figure 4.8).  
Previous studies investigating the acute effects of combined PI3K/mTOR and MEK inhibition in 
CRC have predominantly evaluated effects on signalling in cancer cell lines which differ in 
mutation status of the PI3K pathway. Martinelli et al. reported effective inhibition of pERK and 
pAKT, reduced pS6RP and p4EBP1 levels, reduced cell cycle progression and increased 
apoptosis with combinations of the MEK inhibitor Pimasertib and PI3K inhibitor MSC 2208382, 
mTOR inhibitor everolimus and multi-kinase inhibitors Sorafenib and regorafenib in HT15 
cancer cells (Kras and PI3KCA mutant) (Martinelli et al., 2013). Interestingly, Haagensen et al 
found moderate inhibition of pAKT and pERK with combinations of the dual PI3K/mTOR 
inhibitor NVP-BEZ235 and MEK inhibitor PD0325901 in HCT116 (Kras and PIK3CA mutant) and 
HT29 (B-raf and PIK3CA mutant) cell lines. The effects of this combination in comparison with 
combination of PI3K inhibitor GDC-0941 and MEK inhibitor PD0325901 was markedly reduced 
suggesting a role for additional mTOR inhibition in reducing the synergy between PI3K and 
MEK inhibitors. Addition of the mTOR inhibitor KU0063794 to the later combination (PI3K and 
MEK) provided further evidence of compromised synergy suggesting that mTOR dependent 
inhibition of p4EBP1 may be responsible for preventing synthesis of proteins that negatively 
regulate cell cycle progression, causing synergy between PI3K and MEK inhibitors to be 
compromised (Haagensen et al., 2012). Despite this, the authors provide no indication of 
which proteins may be responsible for this. The observations from acute combination studies 
in this chapter have not previously been reported. This may be due to differences in 
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compounds or experimental systems used, for example in vivo metabolism of the compounds 
in combination may affect their target inhibition ability in comparison with in vitro culture 
systems in which compounds are administered to cells much quicker. Although further 
evaluation of PI3K and MAPK signalling components is required to determine the distinct 
mechanism behind the differential effects of combined NVP-BEZ235 and MEK162 in Apcf/+ 
Ptenf/f tumours, the modulation of signalling observed here is novel and highlights the 
necessity of such experiments, especially when the pathways targeted are closely associated.  
Despite this, when taken forward for the long term survival experiment, combination therapy 
failed to provide any additional benefit compared to single agent NVP-BEZ235 treatment 
(Figure 4.18, 4.19). Mice on long term NVP-BEZ235 and combination had similar median 
survivals (NVP-BEZ235 = 266 days vs combo = 270 days post induction) and the number of 
tumours at death were not significantly altered (NVP-BEZ235 = 2 vs combo = 4 tumours). 
Similarly, although there was a trend towards an increase in total tumour area, this was not 
significantly different (median tumour size: NVP-BEZ235 = 81.6mm2 vs combo = 108.2 mm2) 
and finally, assessment of tumours revealed the profiles did not differ with regards to 
invasiveness (Figure 4.19).   
One stark difference observed at dissection and subsequent analysis was that the incidence of 
HCC was dramatically reduced in mice which received long term combo compared to those of 
long term NVP-BEZ235 (Figure 4.20). Although the AhCreER transgene is predominantly used 
to drive recombination in the small intestinal epithelium, it is also known to drive 
recombination in a number of other tissues including the liver, fore stomach, gall bladder and 
prostate (Ireland et al., 2004). In the liver, AhCreER driven Pten loss has previously been 
shown to result in liver steatosis and hepatomegaly (Marsh et al, unpublished observations) 
and in one case, this lead to HCC. These findings corroborate previous phenotypes reported in 
the literature from hepatocyte specific deletion of Pten using a cre recombinase transgene 
driven by the Albumin gene (Horie et al., 2004, Stiles et al., 2004). Interestingly, the Wnt 
signalling pathway is also known to have a major role in development of HCC. Here, abnormal 
regulation of the transcription factor β-catenin appears to be a major early event in HCC 
development (de La Coste et al., 1998). Additionally, mutations in Axin1 and promoter 
methylation of Apc which lead to gene inactivation are also implicated in HCC (Taniguchi et al., 
2002, Yang et al., 2003) however importantly, these are not sufficient to cause HCC. The lack 
of HCC in compound Apcf/+ Ptenf/f mice is most likely due to the severe intestinal tumour 
phenotype, therefore it is hypothesised that mice with increased survival due to NVP-BEZ235 
treatment had a longer period in which to allow development of HCC phenotypes. It was 
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surprising however to find that although mice on NVP-BEZ235 and combination treatments 
had a comparable median survivals, combination treated mice had a substantially lower 
incidence of HCC (7% of combo treated mice compared to 50% of NVP-BEZ235 treated mice) 
(Figure 4.20). These findings suggest perhaps MEK inhibition in liver cells prevented growth of 
tumours. Although RAS and RAF mutations are rare in HCC, the importance of MAPK signalling 
in HCC has previously been highlighted by preclinical studies showing that the MEK inhibitor 
AZD6244 displayed significant anti-tumour activity in primary HCC cells and xenografts (Huynh 
et al., 2007b, Huynh et al., 2007a).  
4.3.4 Summary 
In summary, the work described in this chapter highlights the benefits of targeting PI3K and 
mTOR signalling through NVP-BEZ235 for Pten deficient intestinal tumours. Furthermore, I 
provide evidence corroborating previous findings that mutations activating the PI3K pathway 
predict non-response to MEK inhibition. Finally, although combinatorial MEK and PI3K 
inhibition failed to provide any additional benefit for Pten deficient tumours with respect to 
survival of mice, work in this chapter describes novel sensitivities of Pten deficient tumours to 
the sequence of combination drug administration to achieve concomitant inhibition of both 
PI3K/mTOR and MAPK signalling pathways.  
4.4 Further work 
4.4.1 Mechanisms of resistance to chronic single agent NVP-BEZ235 
The findings in this chapter highlight PI3K and mTOR targeting to be a beneficial therapeutic 
strategy for Pten deficient and hence PI3K activated intestinal tumours. Despite this, 
resistance to targeted agents is a common obstacle in the success of these agents and so 
further characterisation of Apcf/+ Ptenf/f tumours exposed to long term NVP-BEZ235 treatment 
may provide insightful observations. IHC for PI3K pathway effects together with scoring of 
proliferation and apoptosis could identify whether tumours were still responding to NVP-
BEZ235 at death. Furthermore, this could be correlated to tumour severity to determine 
whether tumour progression is associated with non-response of tumours to NVP-BEZ235.    
4.4.2 Further evaluation of the differential sensitivities to acute combination treatment 
Investigation of the three combination strategies in Apcf/+ Ptenf/f tumours revealed that 
administration of MEK162 1 hour prior to, or at the same time as NVP-BEZ235 prevented 
effective inhibition of both PI3K and MAPK signalling pathways 4 hours following the final 
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dose. Investigation of signalling components and potential mechanisms of cross-talk at 4 hours 
and further time points for example 1, 2, 3, 8 or 12 hours following exposure may help identify 
the mechanism behind these observations.  
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5 Investigating MEK inhibition and PI3K/mTOR inhibition in the Apcf/+ KrasLSL/+ 
colorectal cancer mouse model 
 
5.1 Introduction 
In chapter 3, I described work indicating that MEK inhibition leads to a significant survival 
benefit in the absence of hyper-activated MAPK signalling through the RAS-RAF-MEK-ERK 
kinase cascade. This pathway is known to be crucial for mediating signals that regulate 
proliferation, differentiation, apoptosis and cellular growth, and is often found to be 
deregulated in a number of human cancers, including pancreatic, lung and ovarian cancer 
(Downward, 2003).  The oncogene KRAS is frequently altered in cancer and in particular, is 
found to be mutationally activated in approximately 50% of human CRC (Bos et al., 1987). 
Oncogenic Kras has been implicated in the activation of PI3K signalling through direct 
interaction with the p110 catalytic subunit of PI3K (Kodaki et al., 1994) and MAPK signalling 
through subsequent phosphorylations of RAF, MEK and ERK. Thus, the notion (and 
confirmation of this in Kras mutant colon tumours, as observed in chapter 3) that aberrant 
activation of Kras results in a ‘double hit’ causing activation of both PI3K and MAPK signalling 
in cancer cells, has led to the investigation of MAPK and PI3K inhibitors as rational therapeutic 
strategies for Kras mutant cancers.  
Several studies have evaluated inhibition of MAPK and PI3K signalling independently and 
concurrently in Kras mutant tumour models. Perturbation of MAPK signalling through potent 
MEK1/2 inhibitors, has been well characterised in the Kras driven genetically engineered 
mouse model for lung cancer  (Engelman et al., 2008, Holt et al., 2012, Chen et al., 2012b, 
Simmons et al., 2012, Corcoran et al., 2013). Furthermore, these studies have also investigated 
combined PI3K or mTOR inhibition. The study by Engelman et al. found that addition of dual 
PI3K/mTOR inhibitor NVP-BEZ235 enhanced activity of the MEK inhibitor AZD6244 in this 
setting and similarly, Simmons et al. highlighted that addition of the dual PI3K/mTOR PF-
04691502 to MEK inhibitor PD-0325901 increased target inhibition and further reduced 
tumour burden in the same tumour model (Engelman et al., 2008, Simmons et al., 2012). A 
recent study by Holt et al. found that combination of MEK inhibitor AZD6244 and mTOR 
inhibitor AZD0855 was well tolerated and increased anti-tumour efficacy in NSCLC xenograft 
models (Holt et al., 2012). Interestingly, a Kras driven GEMM for pancreatic cancer was found 
to be more sensitive to MEK inhibition (through AZD6244) than PI3K inhibition (through 
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GDC0941), but that the combination of inhibition resulted in an enhanced effect (Hofmann et 
al., 2012). Furthermore, Williams et al. found that the radiosensitising activity of MEK inhibitor 
PD0325901 was potentiated by the AKT inhibitor AP1-2 in Kras mutant pancreatic xenografts 
(Williams et al., 2012). For CRC however, the evaluations of MEK and PI3K inhibitors in the Kras 
mutant setting is mostly limited to studies in cancer cell lines and xenograft models.  A recent 
study by Jing J et al. profiled sensitivity to the MEK inhibitor GSK1120212 in over 200 cancer 
cell lines and identified that RAS/RAF mutations were strong predictors of sensitivity whereas 
PI3K/PTEN mutations conferred cytostatic responses in CRC cell lines (Jing et al., 2012). 
Additionally, Tentler et al. found that Kras mutant colon cancer cell lines, xenografts and 
patient derived xenografts were most likely to respond to the MEK inhibitor AZD6244 (Tentler 
et al., 2010). Furthermore, Yeh et al. evaluated Kras as a biomarker for MEK inhibition and 
found mutations in Kras tend to predict response to MEK inhibition in cancer cell lines. 
Although the observations from studies outlined here allude to the benefits of MEK inhibition 
in the Kras mutant setting, the proof of principle experiment in an autochtonous mouse model 
has yet to be reported. Additionally, the therapeutic potential of PI3K signalling alone and 
concurrently with MAPK inhibition has yet to be evaluated in the Kras mutant intestinal cancer 
setting.   
In light of these observations, in this chapter, I aimed to evaluate MEK inhibition and 
PI3K/mTOR inhibition as monotherapies and in combination in a clinically valid mouse model 
of intestinal cancer mutant for Kras. Here, the activation of the endogenously expressed G12V 
(glycine to valine at codon 12) mutant Kras allele and heterozygous deletion of Apc within the 
intestinal epithelium driven by the VillinCreER transgene leads to a reduced lifespan and 
progression of both colonic and small intestinal lesions (Janssen et al., 2006). Therefore, I first 
evaluated acute MEK inhibition by MEK16 in the resulting Kras mutant colon and small 
intestinal tumours (SITs) to investigate the anti-tumour and pharmacodynamic effects, 
followed by a long term dosing experiment to deduce the therapeutic potential of MEK 
inhibition for Kras mutant cancer using this autochtonous genetically engineered mouse 
model (GEMM). 
Given the role of mutant Kras in activating PI3K signalling, I next evaluated targeting this 
pathway utilising the dual PI3K and mTOR inhibitor NVP-BEZ235 (Novartis Pharmaceuticals) 
alone and in combination with MEK162. Similarly, acute and chronic administration methods 
were utilised to investigate the potential in vivo anti-tumour and pharmacodynamic effects, 
and survival benefit respectively.  
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Similarly to chapters 3 and 4, two main strategies were employed for these investigations. 
Firstly, tumour bearing VillinCreER Apcf/+ KrasV12LSL/+ mice (hereon in referred to as Apcf/+ 
KrasLSL/+mice) were administered a single dose of MEK162, NVP-BEZ235 or a combination of 
both and harvested at 4 or 24 hour time points to investigate the immediate anti-tumour and 
pharmacodynamic effects. To evaluate the effect of treatment on survival, tumour bearing 
Apcf/+ KrasLSL/+mice were started on daily treatment at a chosen time point either until a 
survival end point (when mice were symptomatic of disease defined by pale feet, anal 
bleeding, bloating, weight loss) or until an experimental end point of 500 days post induction. 
Similarly in chapter 3, a 500 days post induction time point was chosen due to the increased 
latency Apcf/+ KrasLSL/+ mice have for tumour development and subsequent death, in 
comparison to Apcf/+ Ptenf/f mice. Therefore, it was hypothesised that a 500 day window 
following induction was sufficient time to observe any significant survival benefit.  
5.2 Results 
5.2.1 MEK162 results in a pro-apoptotic effect in Apcf/+ KrasLSL/+tumours and reduces MAPK 
signalling through reduced phosphorylated ERK     
For all short term experiments described in this chapter, 10 week old Apcf/+ KrasLSL/+ mice were 
induced using tamoxifen (methods 2.2.2) and aged until symptomatic of disease (pale feet, 
bloating, blood in faeces). A cohort of n ≥3 mice were then administered 0.5% MC (vehicle) 
and culled 4 hours after, or 30mg/kg MEK162 and harvested at either 4 or 24 hour time points. 
Additionally, a dose of BrdU was administered to mice 2 hours prior to culling. At dissection, 
colon and SITs were quickly snap frozen in liquid nitrogen and the whole colon and small 
intestine was ‘swiss-rolled’ and fixed in formalin in preparation for H&E staining and IHC, as 
outlined in section 2.4. 
To evaluate the anti-tumour activity of MEK162 in Apcf/+ KrasLSL/+ colon and SITs, mitotic figures 
and apoptotic bodies were scored from H&E stained slides. Interestingly, quantification of 
mitotic figures revealed a trend towards an immediate increase in mitosis in colon polyps (4hr 
MEK162 polyps = 0.36 ± 0.176, vehicle polyps = 0.199 ± 0.169, p value = 0.072, n≥8 tumours, 3 
mice, Mann Whitney U test) (Figure 5.1 A) however no significant alteration in proliferation in 
SITs was observed 4 hours post MEK162 exposure (4hr MEK162 SIT = 0.193 ± 0.113, vehicle SIT 
= 0.258 ± 0.154, p value = 0.672, n≥5 tumours, 3 mice, Mann Whitney U test) (Figure 5.1 A). At 
24 hours post exposure, no significant alteration in mitotic figures were observed in colon 
polyps (24hr MEK162 polyps = 0.316 ± 0.265, vehicle polyps = 0.199 ± 0.169, p value = 0.508, 
159 
 
n≥8 tumours, 3 mice, Mann Whitney U test), or in SITs (24hr MEK162 SIT = 0.329 ± 0.222, 
vehicle SIT = 0.258 ± 0.154, p value = 0.523, n≥5 tumours, 3 mice, Mann Whitney U test) 
(Figure 5.1 A).  
Scoring of apoptotic bodies in colon polyps and SITs following MEK162 exposure indicated an 
increase in apoptosis at the 4 hour time point but a reduction at 24 hours, suggesting tumours 
return to normal physiological levels by 24 hours following MEK162 administration (4hr 
MEK162 polyps = 2.67 ± 1.153, 24hr MEK162 polyps = 0.768 ± 0.424, vehicle polyps = 0.508 ± 
0.49, p value = 0.0014 for 4 hrs MEK162 and p value = 0.129 for 24hr MEK162; 4hr MEK162 SIT 
= 2.606 ± 1.723, 24hr MEK162 SIT = 0.932 ± 0.607, vehicle SIT = 0.522 ± 0.333, p value = 0.001 
for 4hr MEK162 and p value = 0.201 for 24 hour MEK162, n≥5 tumours, 3 mice, Mann Whitney 
U test) (Figure 5.1 B).  
In order to further characterise anti-tumour effects following MEK162 exposure in Apcf/+ 
KrasLSL/+ lesions, IHC against BrdU and cleaved caspase 3 were carried out and scored. 
Quantification of BrdU positive cells revealed no significant difference in the number of BrdU 
positive cells in colon polyps 4 and 24 hours after MEK162 exposure (4hr MEK162 polyps = 
13.45 ± 4.07, 24hr MEK162 polyps = 13.914 ± 10.35, vehicle polyps = 10.686 ± 7.059, p value = 
0.316 for 4hr, p value = 0.651 for 24hr, n≥8 tumours, 3 mice, Mann Whitney U test) (Figure 5.2 
A), corroborating previous scoring of mitosis. BrdU scoring in SITs revealed no significant 
alteration in staining 4 hours post exposure to MEK162 but a significant increase in BrdU 
positive cells in SITs 24 hours after MEK162 (4hr MEK162 SIT = 8.848 ± 3.066, 24hr MEK162 SIT 
= 24.743 ± 7.863,vehicle SIT = 10.188 ± 5.617, p value = 0.589 for 4hr, p value = 0.0298 for 
24hr, n≥5 tumours, 3 mice, Mann Whitney U test) (Figure 5.2 A), indicating an increase in the 
number of cells in S phase of the cell cycle.  
For further characterisation of anti-tumour effects, cleaved caspase 3 scoring was performed. 
This revealed an increase in staining at 4 hours post MEK162 in colon polyps, but no significant 
difference in SITs (4hr MEK162 polyps = 8.002 ± 4.83, vehicle polyps = 0.977 ± 0.609, p value = 
0.0011; 4hr MEK162 SIT = 2.397 ± 0.885, vehicle SIT = 1.792 ± 1.029, p value = 0.159, n≥8 
tumours, 3 mice, Mann Whitney U test) (Figure 5.2 B). This was also the case at 24 hours post 
MEK162 exposure, whereby a significant increase in cleaved caspase 3 staining was observed 
in colon polyps but no difference was detected in SITs (24hr MEK162 polyps = 2.875 ± 1.722, 
vehicle polyps = 0.977 ± 0.609, p value = 0.0138; 24hr MEK162 SIT = 2.656 ± 1.654, vehicle SIT 
= 1.792 ± 1.029, p value = 0.524, n≥5 tumours, 3 mice, Mann Whitney U test) (Figure 5.2 B). 
For the colon polyps exposed to MEK162, these observations indicate that the initial pro-
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apoptotic effect observed at 4 hours post exposure may be returning to basal physiological 
levels by 24 hours. However, as apoptosis is still significantly increased compared to vehicle 
treated tumours, it can be concluded that MEK162 induces a prolonged pro-apoptotic effect in 
Kras mutant colon polyps. For the SITs, it is possible that a significant increase in cleaved 
caspase 3 staining may be observed at a time point between 4 and 24 hours as an increase in 
histological apoptosis was previously observed.   
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Scoring of mitotic figures (A) and apoptotic bodies (B) in colon polyps and SITs by H&E 
examination revealed no significant alterations in the number of mitotic figures present, 
however revealed a significant increase in the number of apoptotic bodies 4 hours after a 
single dose of 30mg/kg MEK162 (p value = 0.0014 for 4hr polyps and p value = 0.001 for 4hr 
SIT, n≥ 5 tumours, 3 mice, Mann Whitney U test). Error bars represent standard deviation.  
 
 
Figure 5.1 MEK162 had no effect on mitosis but increased apoptosis in Apcf/+ KrasLSL/+ colon 
polyps and small intestinal tumours (SITs) 
162 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scoring of IHC against BrdU (A) and cleaved caspase 3 (B) in Apcf/+ KrasLSL/+ colon polyps and 
SITs revealed a significant increase in BrdU positive cells in SIT 24 hours after MEK162 
exposure. A significant increase in cleaved caspase 3 was observed 4hrs after MEK162 in colon 
polyps. (p value = 0.0298 for 24hr SIT BrdU and p value = 0.0011 for 4hr polyp cleaved caspase 
3, n≥ 5 tumours, 3 mice, Mann Whitney U test). The levels of cleaved caspase 3 appears to 
have been reduced 24 hours after exposure, however the trend towards an increase 
compared to vehicle controls remains. Error bars represent standard deviation.  
Figure 5.2 MEK162 also increased BrdU positive cells in small intestinal tumours (SITs) and 
cleaved caspase 3 staining in colon polyps 
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To investigate whether the anti-tumour effects described above correspond with pathway 
inhibition, colon polyps and SIT lysates were subjected to western blot analysis. Protein 
extracted from individual colon polyps and SITs from n=3 mice harvested 4 or 24 hours after 
exposure to MEK162 were compared to corresponding tumours harvested 4 hours post 
vehicle treatment. Activation status of the MAPK pathway was assessed utilising an antibody 
against the phosphorylated form (and hence activated form) of the MAPK Kinase- ERK at 
Thr202/Tyr204. Immunoblotting and subsequent densitometry analysis revealed a significant 
reduction in the levels of pERK in colon polyps 4 and 24hrs indicating prolonged inhibition 
(Figure 5.3, Table 5.1, Table 5.2). Here, levels of pERK were difficult to detect at 4 hours post 
exposure and was still reduced to approximately 50% at the 24 hour time point, indicative of 
prolonged but reduced inhibition of MAPK signalling. A significant reduction in levels of pERK 
was detected at 4 hours post exposure in SITs however no difference was observed 24 hours 
post exposure indicating return to basal levels by this time point (Figure 5.4, Table 5.3, Table 
5.4). These observations confirm target inhibition by MEK162 in Kras mutant tumours but 
suggest that colon polyps may be more sensitive to the effects of MEK162 than SITs, perhaps 
due to increased signalling through pERK, as observed in chapter 3 section 3.2.8.   
Given the convergence of MAPK and PI3K signalling at a number of downstream nodes and the 
role of Kras in activation of PI3K signalling, it was hypothesised that inhibition of MAPK 
signalling in the context of activated Kras may lead to increased activation of PI3K signalling as 
a compensatory mechanism. To investigate this, status of PI3K pathway signalling was 
assessed by western blotting. Antibodies described previously in section 4.2.1 were used to 
investigate complete activation of pAKT and signalling downstream of mTOR. Immunoblotting 
revealed an increasing trend, although not significant, in PI3K signalling through pAKT473, 
pAKT308 and pS6RP in colon polyps 4 hours after MEK162 exposure (Figure 5.3, Table 5.1). 
Interestingly, further modulation of PI3K signalling was observed at 24hrs post MEK162 
exposure. Here, levels of pAKT308 were increased approximately 50%, however all other 
downstream effectors of PI3K signalling probed appeared reduced (Figure 5.3, Table 5.2) and 
may simply reflect a mechanism of rebalancing cell signalling to basal levels. 
The initial effect of MEK inhibition on PI3K signalling in SITs appears to be contrasting to colon 
polyps. Overall, a trend towards reduced PI3K signalling at 4 hours post MEK162 was observed 
however a significant reduction was only detected in levels of pAKT473 (Figure 5.4, Table 5.3). 
No significant alteration in PI3K signalling was observed at 24 hours post exposure with the 
exception of pS6RP which was found to be significantly reduced (Figure 5.4, Table 5.4). 
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(A)Individual colon tumours lysates from n=3 mice exposed to 30mg/kg MEK162 for 4 or 24 hours were subjected to western blot analysis. Immunoblotting 
with the MAPK effector pERK revealed significant reduction in abundance at 4 and 24 hours after exposure. Additionally, effectors of PI3K and mTOR 
signalling probed revealed a trend towards increased signalling at 4 hours but a trend towards reduced signalling at 24 hours, with the exception of 
significantly increased pAKT308 at 24 hours post exposure. (B + C) Densitometry was carried out to quantify differences observed from western blotting. 
These are normalised to β-actin as loading control and represented as relative to vehicle controls (*p values = 0.0404, n=3, Mann Whitney U test).  
Figure 5.3 MEK162 reduces MAPK signalling in Apcf/+ KrasLSL/+ colon polyps , however  leads to modulation of PI3K and mTOR signalling. 
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 (A) Individual SIT lysates from n=3 mice exposed to 30mg/kg MEK162 for 4 or 24 hours were subjected to western blot analysis. Western blotting for the 
MAPK effector pERK revealed significant reduction in abundance at 4 hours post exposure. Immunoblotting of PI3K and mTOR pathway effectors probed to 
investigate cross-talk of pathways revealed a significant reduction in pAKT473 4 hours post exposure and pS6RP 24 hours post exposure. (B + C) 
Densitometry was carried out to quantify differences observed from western blotting. These are normalised to β-actin as loading control and represented 
as relative to vehicle controls (*p value = 0.0404, n=3, Mann Whitney U test).  
Figure 5.4 reduces MAPK signalling in Apcf/+ KrasLSL/+ small intestine tumours (SITs) and partial inhibition of PI3K and mTOR signalling. 
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Colon polyps Vehicle 4 hour MEK162 (p value) 
pERK 4126 ± 2113 211.5 ± 184.8 (0.0404) 
pAKT473 1062.2 ± 138 1362 ± 596.9 (0.3313) 
pAKT308 716.9 ± 230 1496.2 ± 1217.1 (0.3313) 
pS6RP 1407.2 ± 655.6 2043.4 ± 1680.8 (0.3313) 
p4EBP1 3128.4 ± 630.2 2132.6 ± 177.4 (0.3313) 
Table 5-1 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polpys 4 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
Colon polyps Vehicle 24 hour MEK162 (p value) 
pERK 4988 ± 452.4 2751.5 ± 736.9 (0.0404) 
pAKT473 4421.3 ± 268.7 4314.7 ± 748.9 (0.1914) 
pAKT308 1523.1 ± 114.1 2619.7 ± 593.5 (0.0404) 
pS6RP 3511± 333.1 1634 ± 2253.4 (0.3313) 
p4EBP1 6881 ± 1037 5399 ± 1942.3 (0.0952) 
Table 5-2 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polyps 4 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
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Small intestinal tumours Vehicle 4 hour MEK162 (p value) 
pERK 4101.8 ± 748 42.5 ± 14.7 (0.0404) 
pAKT473 2160.7 ± 185.9 1686 ± 612.7 (0.0404) 
pAKT308 525.4 ± 131.9 566.6 ± 212.7 (0.1914) 
pS6RP 4015.2 ± 602.4 3221.8 ± 1407.7 (0.0952) 
p4EBP1 5671.9 ± 284.7 4759 ± 2357 (0.0952) 
Table 5-3 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
SITs 4 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was used for 
statistical analysis 
 
 
 
 
 
 
 
In summary, the observations above highlight favourable anti-tumour activity of MEK162 in 
the Kras mutant setting, however also identify as hypothesised, activation of closely related 
PI3K signalling (summarised in Figure 5.5, 5.6). Nevertheless, the long term therapeutic 
efficacy of MEK162 in Kras mutant tumours was further probed below in section 5.2.2. 
 
 
Small intestinal tumours Vehicle 24 hour MEK162 (p value) 
pERK 4923.5 ± 195.8 4200.6 ± 2513.8 (0.0404) 
pAKT473 3763 ± 212.9 3929 ± 844.9 (0.1914) 
pAKT308 916.2 ± 268.7 991.8 ± 684.8 (0.1914) 
pS6RP 4199 ± 445.1 1082.3 ± 370.7 (0.0404) 
p4EBP1 5286 ± 828.7 5702.2 ± 1899.6 (0.0952) 
Table 5-4 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polyps 24 hours post exposure to MEK162, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
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MEK162 leads to a reduction in levels of pERK at 4 and 24 hours post exposure and 
significantly increases levels of pAKT at Thr308 24 hours post exposure. 
 
 
 
 
 
 
 
 
 
 
MEK162 leads to a reduction in levels of pERK and pAKT473 at 4 hours post exposure and 
reduces levels of pS6RP 24 hours post exposure. 
 
Figure 5.5 Schematic showing the effects of MEK162 on MAPK and PI3K/mTOR pathway 
components in Apcf/+ KrasLSL/+ colon polyps detected through western blot analysis 
(Green denotes a reduction whereas red indicates an increase) 
Figure 5.6 Schematic showing the effects of MEK162 on MAPK and PI3K/mTOR pathway 
components in Apcf/+ KrasLSL/+  SITs detected through western blotting (Green denotes a 
reduction whereas red indicates an increase). 
169 
 
5.2.2 MEK162 increases survival of Apcf/+ KrasLSL/+ mice  
To investigate the therapeutic potential of MEK inhibition as a rational therapeutic strategy for 
Kras mutant tumours, a chronic treatment experiment was conducted to elucidate the effect 
of MEK162 upon survival and also to determine the effect on intestinal tumour burden. 10 
week old Apcf/+ KrasLSL/+ mice were induced and allowed to develop disease over 
approximately 14 weeks. Given that the tumour latency period of untreated mice (Davies EJ, 
unpublished) is between 80 and 250 days post induction, 100 days post induction was chosen 
as an appropriate intervention start point. Presence of tumours at this point was confirmed in 
a cohort of mice culled at 100 days post induction (section 5.2.8). Subsequently, mice (n=12 
per cohort) were randomised to receive either 0.5% MC (vehicle) or 30mg/kg MEK162 twice 
daily (weekdays only) by oral gavage, until a survival end point (anaemia, bloating, ≥10% loss 
of body weight) or the experimental end point of 500 days post induction.  
Continuous twice daily administration of MEK162 in Apcf/+ KrasLSL/+ mice was well tolerated 
(defined by weight during treatment) and led to a significant increase in survival of mice with 
2/12 mice culled at the experimental end point of 500 days (median survival MEK162 mice = 
287 days vs vehicle = 153 days post induction, p value ≤ 0.0001, n=12, Log-Rank and Wilcoxon 
test) (Figure 5.7), indicating this as a beneficial therapeutic strategy. To further the 
investigations of chronic MEK162 treatment, the effect on tumour burden was assessed as 
described in section 5.2.8.  
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Apcf/+ KrasLSL/+ mice were induced and aged to 100 days post induction, at which point mice 
were randomised to receive either 0.5% Methyl cellulose (Vehicle control) or 30mg/kg 
MEK162 twice-daily by oral gavage until a survival end point or the experimental end point of 
500 days post induction. Continuous MEK162 treatment was found to significantly increase 
survival of mice from 153 days to 287 days post induction (p value ≤ 0.001 Log-Rank and 
Wilcoxon test, n ≥12 mice per cohort).  
5.2.3 NVP-BEZ235 increases apoptosis in Kras mutant tumours and significantly reduces 
signalling downstream PI3K and mTOR 
Given that oncogenic Kras also impinges on the PI3K signalling cascade, I next investigated the 
short term effects of pathway inhibition through the dual PI3K/mTOR inhibitor to ascertain 
whether this results in any favourable anti-tumour effects. Similarly to section 5.2.1, the initial 
effects of NVP-BEZ235 were assessed through short term exposure experiments. Mice were 
induced and aged to allow for symptoms of intestinal tumour burden. Subsequently, mice 
Figure 5.7 Kaplan-Meier survival analysis of Apcf/+ KrasLSL/+ mice receiving MEK162 compared 
to vehicle controls 
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were administered a single dose of 35mg/kg NVP-BEZ235 and culled either 4 or 24 hours post 
exposure as described previously (cohort of n ≥3 mice). Mice also received a dose of BrdU 2 
hours prior to killing. Vehicle treated controls for this experiment are identical to those used in 
section 5.2.1.  
To investigate the immediate anti-tumour activity of NVP-BEZ235 in Apcf/+ KrasLSL/+ tumours, 
the levels of mitosis and apoptosis were quantified by examination of H&E stained slides and 
IHC for BrdU and cleaved caspase 3. Quantification of mitotic figures revealed no significant 
alterations at either 4 or 24 hours post exposure to NVP-BEZ235 in either colon polyps or SITs 
(Colon polyps: 4hr veh = 0.198 ±0.169, 4hr NVP-BEZ235 = 0.213 ± 0.193, 24hr NVP-BEZ235 = 
0.432 ± 0.284, p value = 0.973 for 4hr NVP-BEZ235, p value = 0.059 for 24hr NVP-BEZ235, n≥ 9 
tumours, 4 mice, Mann Whitney U test) (SITs: 4hr veh = 0.258 ± 0.154, 4hr NVP-BEZ235 = 
0.346 ± 0.239, 24hr NVP-BEZ235 = 0.345 ± 0.416, p value = 0.672 for 4hr NVP-BEZ235, p value 
= 0.289 for 24hr NVP-BEZ235, n≥ 6 tumours, 4 mice, Mann Whitney U test) (Figure 5.8 A). 
However, a trend towards an increase in mitotic figures was observed 24 hours post exposure 
in colon polyps. Scoring of apoptotic bodies here revealed a significant increase 4 hours post 
exposure in both colon polyps and SITs (Colon polyps: 4hr veh =0.508 ± 0.490, 4hr NVP-BEZ235 
= 1.84 ± 1.823, p value = 0.0103, SITs: 4hr veh = 0.522 ± 0.33, 4hr NVP-BEZ235 = 1.75 ± 0.679, 
p value = 0.003, n≥ 6 tumours, 4 mice, Mann Whitney U test) (Figure 5.8 B). The initial increase 
at 4 hours was reduced by 24 hours, indicating a transient effect on apoptosis (Colon polyps: 
4hr veh =0.508 ± 0.490, 24hr NVP-BEZ235 = 0.558 ± 0.362, p value = 0.693, SITs: 4hr veh = 
0.522 ± 0.33, 24hr NVP-BEZ235 = 0.814 ± 0.416, p value = 0.0903, n≥ 6 tumours, 4 mice, Mann 
Whitney U test).  
Additionally, the anti-tumour properties of NVP-BEZ235 were further characterised through 
BrdU and cleaved caspase 3 scoring. Consistent with the histological characterisation of 
mitosis, the number of BrdU positive cells was unaltered in both colon polyps and SITs at 4 and 
24 hour time points post exposure (Colon polyps: 4hr veh = 10.686  ± 7.059, 4hr NVP-BEZ235 = 
6.757 ± 2.316, 24hr NVP-BEZ235 = 12.896 ± 4.716, p value = 0.374 for 4hr NVP-BEZ235, p value 
= 0.339 for 24hr NVP-BEZ235, n≥ 9 tumours, 4 mice, Mann Whitney U test) (SITs: 4hr veh = 
10.19 ± 5.62, 4hr NVP-BEZ235 = 17.71 ± 7.29, 24hr NVP-BEZ235 = 12.31 ± 3.32, p value = 
0.1939 for 4hr NVP-BEZ235, p value = 0.713 for 24hr NVP-BEZ235, n≥ 6 tumours, 4 mice, Mann 
Whitney U test) (Figure 5.9 A). Quantification of active caspase in Kras mutant tumours 
conducted through cleaved caspase 3 scoring revealed a significant increase in staining 4 and 
24 hours post NVP-BEZ235 exposure in colon polyps and a significant increase in staining at 24 
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hours post exposure in SITs (Colon polyps: 4hr veh = 0.977 ± 0.609, 4hr NVP-BEZ235 = 1.927 ± 
1.059, 24hr NVP-BEZ235 = 2.00 ± 1.37, p value = 0.0433 for 4hr NVP-BEZ235, p value = 0.0485 
for 24hr NVP-BEZ235, n≥ 9 tumours, 4 mice, Mann Whitney U test) (SITs: 4hr veh = 1.79 ± 
1.028, 4hr NVP-BEZ235 = 3.05 ± 1.69, 24hr NVP-BEZ235 = 2.99 ± 0.803, p value = 0.1599 for 
4hr NVP-BEZ235, p value = 0.0472 for 24hr NVP-BEZ235, n≥ 6 tumours, 4 mice, Mann Whitney 
U test) (Figure 5.9 B). These later findings corroborate previous analysis of histological 
apoptosis and highlight prolonged pro-apoptotic effects of NVP-BEZ235.  
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 (A) Quantification of mitotic figures and apoptotic bodies (B) in colon polyps and SITs of mice 
exposed to a single dose of 35mg/kg NVP-BEZ235. Scoring revealed a trend towards an 
increase in mitosis 4 and 24 hours after exposure and a significant increase in apoptotic bodies 
in both polyps and SITs, 4 hours post administration (p value = 0.0103 for 4hr polyps 
apoptosis, p value = 0.003 for 4hr SIT apoptosis, n≥ 6 tumours, 4 mice, Mann Whitney U test).  
The initial apoptotic effects appear reduced to baseline levels between 4 and 24 hours after 
exposure to NVP-BEZ235. Error bars represent standard deviation  
 
Figure 5.8 NVP-BEZ235 significantly increases apoptosis in Apcf/+ KrasLSL/+ colon polyps and 
small intestine tumours (SITs), but elicits no significant anti-proliferative effects. 
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To further evaluate the anti-tumour properties of NVP-BEZ235 in Apcf/+ KrasLSL/+ intestinal 
lesions, IHC against BrdU (A) and cleaved caspase 3 (B) were carried out and scored. Scoring of 
BrdU positive cells revealed no significant alterations at either 4 or 24 hours in colon polyps or 
SITs following exposure to NVP-BEZ235. Cleaved caspase 3 scoring was increased in colon 
polyps at both 4 and 24 hour time points, and at 24 hours in SITs (colon polyps: p value = 
0.0433 for 4hr, and p value = 0.0485 for 24hr; SITs: p value = 0.159 for 4hr, p value = 0.0472 for 
24hr, n≥ 6 tumours, 4 mice, Mann Whitney U test). Error bars represent standard deviation  
 
Figure 5.9 Further anti-tumour evaluation of NVP-BEZ235 revealed an increased pro-
apoptotic effect in Apcf/+ KrasLSL/+ colon polyps and small intestine tumours (SITs) 
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To explore the immediate effects of NVP-BEZ235 on PI3K and mTOR signalling in Apcf/+ KrasLSL/+ 
tumours, proteins extracted from individual colon polyps and SITs harvested from mice (n=3) 
at 4 and 24 hour time points post exposure to NVP-BEZ235, were subjected to western blot 
analysis. Immunoblotting and subsequent densitometry analysis of colon polyp samples with 
antibodies against the downstream PI3K targets, revealed a significant reduction in levels of 
pAKT473, pS6RP and p4EBP1 and a trend towards reduced pAKT308, 4 hours following 
exposure to NVP-BEZ235 (Figure 5.10, Table 5.5). A trend towards reduced PI3K signalling was 
still evident at 24 hours post exposure with a significant reduction in pAKT473, indicating 
prolonged inhibition of PI3K signalling (Figure 5.10, Table 5.6).  
Colon polyps Vehicle 4 hour NVP-BEZ235 (p value) 
pAKT473 1062.2 ± 137.8 460.8 ± 204.6 (0.0404) 
pAKT308 716.9 ± 230 443.6 ± 400.1 (0.3313) 
pS6RP 1407.2 ± 655.6 91.4 ± 66.1 (0.0404) 
p4EBP1 3128.4 ± 630.2 3128.4 ± 630 (0.0404) 
pERK 4125.7 ± 2118 4113 ± 1139.2 (0.5) 
Table 5-5 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polyps 4 hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test 
was used for statistical analysis 
Colon polyps Vehicle 24 hour NVP-BEZ235 (p value) 
pAKT473 4421.3 ± 268.7 3992.1 ± 494.8 (0.0404) 
pAKT308 1523.1 ± 114.1 1162.9 ± 477.4 (0.0952) 
pS6RP 3511± 333.1 3358.7 ± 1858.7 (0.5) 
p4EBP1 6881 ± 1037 6831 ± 984.7 (0.3313) 
pERK 4988 ± 452.4 6133.8 ± 588.7 (0.1914) 
Table 5-6 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polyps 24 hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test 
was used for statistical analysis 
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In SITs, analysis of PI3K and mTOR downstream effectors also revealed prolonged inhibition of 
PI3K and mTOR signalling evidenced through reduced levels of pAKT308, pS6RP and p4EBP1 4 
hours post exposure and significantly reduced levels of pAKT473 and pS6RP at 24 hours post 
exposure (Figure 5.11, Table 5.7, Table 5.8). Together, these observations confirm target 
inhibition and indicate that NVP-BEZ235 induced prolonged inhibition of PI3K signalling in this 
Kras mutant tumour setting similar to effects of MEK inhibition.   
Small intestinal tumours Vehicle 4 hour NVP-BEZ235 (p value) 
pAKT473 525.4 ± 131.9 601.6 ± 478.3 (0.3313) 
pAKT308 2160.7 ± 185.9 915.6 ± 407.4 (0.0404) 
pS6RP 4015.2 ± 602.4 1033.3 ± 224.1 (0.0404) 
p4EBP1 5671.9 ± 284.7 267.4 ± 863.3 (0.0404) 
pERK 4101.8 ± 748 4847.7 ± 621.5 (0.5) 
Table 5-7 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
SITs 4 hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test was used 
for statistical analysis 
 
 
 
 
 
 
 
Small intestinal tumours Vehicle 24 hour NVP-BEZ235 (p 
value) 
pAKT473 3763 ± 212.9 3290.6 ± 1176.7 (0.0404) 
pAKT308 916.2 ± 268.7 1214 ± 925.9 (0.5) 
pS6RP 4199 ± 445.1 2398.4 ± 1383.7 (0.0404) 
p4EBP1 5286 ± 828.7 6104.9 ± 3321.3 (0.5) 
pERK 4923.5 ± 195.8 6203.8 ± 738.7 (0.3313) 
Table 5-8 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ SITs 
24 hours post exposure to NVP-BEZ235, n=3, One-tailed Mann Whitney U test was used for 
statistical analysis 
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Given previous observations of cross-talk between MAPK and PI3K signalling in this study and 
elsewhere (Ma et al., 2005, Ma et al., 2007, Turke et al., 2012, Zimmermann and Moelling, 
1999), activation status of MAPK signalling was also interrogated in samples exposed to NVP-
BEZ235 through western blot analysis. Immunoblotting and subsequent densitometry analysis 
for pERK revealed no significant alterations in either colon polyps or SITs, 4 or 24 hours after 
exposure to NVP-BEZ235, indicating PI3K inhibition does not affect MAPK signalling in the Kras 
mutant setting (Figure 5.10, Figure 5.11, table 5.5- 5.8). Overall, these investigations reflect 
favourable anti-tumour and pharmacodynamic effects of NVP-BEZ235 in the Kras mutant 
setting (summarised in Figure 5.12) and warrant further investigation to determine whether 
continuous NVP-BEZ235 treatment can increase survival of tumour bearing mice.  
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 (A) Individual colon polyp lysates from n=3 mice exposed to 35mg/kg NVP-BEZ235 for 4 or 24 hours were analysed by western blotting.  A significant 
reduction in PI3K and mTOR signalling through pAKT473, pS6RP and p4EBP1 was observed 4 hours after exposure and overall, a trend towards reduced 
signalling at 24 hours with only a significant reduction of pAKT473. Additionally, MAPK pathway status was probed using pERK but showed no alterations at 
4 or 24 hours following NVP-BEZ235 exposure. (B + C) Densitometry was carried out to quantify differences observed from western blotting. These are 
normalised to β-actin as loading control and represented as relative to vehicle controls (*p value = 0.0404, n=3, Mann Whitney U test).  
Figure 5.10 NVP-BEZ235 significantly reduces signalling downstream PI3K and mTOR in Apcf/+ KrasLSL/+ colon polyps 
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(A) Analysis of individual SIT lysates from n=3 mice exposed to 35mg/kg NVP-BEZ235 for 4 or 24 hours by western blotting.  Immunoblotting for effectors of 
PI3K and mTOR signalling revealed a significant reduction in pAKT308, pS6RP and p4EBP1 4 hours after exposure and pAKT473 and pS6RP 24 hours after 
exposure to NVP-BEZ235. To investigate the effect of NVP-BEZ235 on MAPK signalling, antibody against pERK was probed. No significant alterations in the 
levels of pERK were observed either 4 or 24 hours after exposure. (B + C) Densitometry was carried out to quantify differences observed from western 
blotting. These are normalised to β-actin as loading control and represented as relative to vehicle controls (*p value = 0.0404, n=3, Mann Whitney U test). 
Figure 5.11 Figure 5.9 NVP-BEZ235 significantly reduces signalling downstream PI3K and mTOR in Apcf/+ KrasLSL/+  small intestine tumours (SITs) 
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NVP-BEZ235 leads to a reduction in levels of PI3K pathway components and does not have any 
effect on MAPK signalling 
 
Figure 5.12 Schematic showing the effects of NVP-BEZ235 on PI3K/mTOR and MAPK 
pathway components in Apcf/+ KrasLSL/+ colon polyps and SITs detected through western 
blotting (Green denotes a reduction). 
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5.2.4 NVP-BEZ235 significantly increases longevity of Apcf/+ KrasLSL/+ mice 
To investigate the therapeutic potential of NVP-BEZ235 in Apcf/+ KrasLSL/+ mice, 10 week old 
mice were induced and aged to 100 days post induction at which point they started long term 
treatment with NVP-BEZ235. A cohort of n=12 mice received 35mg/kg NVP-BEZ235 twice daily 
(weekdays only) by oral gavage until a survival end point (anaemia, bloating, ≥10% loss of body 
weight) or the experimental end point of 500 days post induction. Vehicle controls are 
identical to those used in section 5.2.2. 
As with MEK162 treatment, chronic twice-daily treatment of NVP-BEZ235 was well tolerated 
by Apcf/+ KrasLSL/+ mice and significantly increased survival of mice with 2/12 mice reaching the 
experimental end point of 500 days (median survival of NVP-BEZ235 mice = 343 days vs vehicle 
= 153 days post induction, n=12 mice per cohort, p value ≤ 0.0001 for Log-Rank and Wilcoxon 
test) indicating a therapeutic benefit (Figure 5.13). Comparison of both chronic treatments 
revealed no significant difference between the two, suggesting MEK162 and NVP-BEZ235 are 
equipotent with regards to survival benefit, in Apcf/+ KrasLSL/+ mice (median survival of MEK162 
mice = 287 days vs NVP-BEZ235 mice = 343 days post induction, n=12 per cohort, p value = 
0.523 for Log-Rank and p value = 0.818 for Wilcoxon test).    
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Apcf/+ KrasLSL/+ mice were induced and aged to 100 days post induction, at which point mice 
were randomised to receive either 0.5% Methyl cellulose (Vehicle control) or 35mg/kg NVP-
BEZ235 twice-daily by oral gavage until a survival end point or the experimental endpoint of 
500 days. Continuous NVP-BEZ235 treatment was found to significantly increase survival of 
mice from 153 days to 343 days post induction (p value ≤ 0.001 Log-Rank and Wilcoxon test, n 
≥12 mice per cohort).  
 
 
 
 
 
Figure 5.13 Kaplan-Meier survival analysis of Apcf/+ KrasLSL/+ mice receiving chronic NVP-
BEZ235 treatment compared to vehicle controls 
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5.2.5 Investigating the varied combination strategies in Kras mutant colon polyps and 
small intestinal tumours 
Given the effectiveness of both MEK162 and NVP-BEZ235 as single agents in Apcf/+ KrasLSL/+ 
mice, it was anticipated that combined inhibition of MAPK and PI3K signalling may result in an 
additive benefit in this tumour model. First however, given that Apcf/+ Ptenf/f mice were 
particularly sensitive to the scheduling of the combination (section 4.2.5), the three 
combination strategies were also investigated in a short term setting to determine whether 
Kras mutant tumours were similarly sensitive to the sequence of drug delivery. The three 
differing dosing strategies outlined in table 4.5 were used; a cohort of n≥3 mice were 
administered with each strategy, and culled 4 hours following the final dose. Mice were also 
administered with a dose of BrdU 2 hours prior to killing, and were dissected as previously 
described in section 2.4. Vehicle treated controls for this experiment are identical to those 
described in section 5.2.1.  
Firstly, to determine the anti-tumour effects of each combination strategy in Kras mutant 
lesions, histological mitosis and apoptosis were scored from H&E stained slides. Scoring of 
mitotic figures in both colon polyps and SITs revealed no significant differences between any of 
the combination strategies compared to vehicle controls (colon polyp samples: 4hr veh =0.199 
± 0.169, combo 1 = 0.405± 0.361, combo 2 = 0.281 ± 0.165, combo 3 = 0.201 ± 0.222, p value = 
0.291 for combo 1, p value = 0.329 for combo 2, p value = 0.753 for combo 3, n≥ 8 tumours, 4 
mice; SIT samples: 4hr veh = 0.258 ± 0.154, combo 1 = 0.283 ± 0.279, combo 2 = 0.252 ± 0.174, 
combo 3 = 0.299 ± 0.115, p value = 0.862 for combo 1, p value = 1 for combo 2, p value = 0.721 
for combo 3, n≥6 tumours, 4 mice, Mann Whitney U test) (Figure 5.14). Quantification of 
histological apoptosis however revealed significantly increased levels of apoptosis 4 hours 
following exposure to all three combination strategies, in both colon polyps and SITs indicating 
potent pro-apoptotic effects (colon polyp samples: 4hr veh = 0.508 ± 0.49, combo 1 = 10.63 ± 
5.51, combo 2 = 6.53 ± 4.58, combo 3 = 9.73 ± 5.68, p value = 0.0011 for combo 1, p value = 
0.002 for combo 2, p value = 0.0004 for combo 3, n≥8 tumours, 4 mice; SIT samples: 4hr 
vehicle = 0.52 ± 0.33, combo 1 = 6.57 ± 2.44, combo 2 = 6.94 ± 1.45, combo 3 = 7.09 ± 4.59, p 
value = 0.0015 for combo 1, p value = 0.0058 for combo 2, p value = 0.0034 combo 3, n≥6 
tumours, 4 mice, Mann Whitney U test) (Figure 5.14). 
IHC for BrdU and cleaved caspase 3 were quantified to further characterise the immediate 
anti-tumour activity of each combination strategy. Scoring of BrdU positive cells in Apcf/+ 
KrasLSL/+ colon polyps revealed no significant alterations (4hr veh = 10.69 ± 7.06, combo 1 = 
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12.58 ± 2.49, combo 2 = 14.92 ± 1.78 , combo 3 = 12.52 ± 4.23, p value = 0.377 for combo 1, p 
value = 0.337 for combo 2, p value = 0.331 for combo 3, n≥8 tumours, 4 mice, Mann Whitney U 
test) similar to mitosis scoring. Additionally in SITs, no significant effect was detected with 
combo 1 however a significant increase in BrdU positive cells was detected following combo 2 
and 3, indicating a pro-proliferative increase in the number of cells in S phase of the cell cycle 
(4hr veh = 10.19 ± 5.62, combo 1 = 13.45 ± 6.59, combo 2 = 18.96 ± 2.18, combo 3 = 27.28 ± 
7.45, p value = 0.3502 for combo 1, p value = 0.0304 for combo 2, p value = 0.0015, n≥6 
tumours, 4 mice, Mann Whitney U test) (Figure 5.15).  
Further to scoring of histological apoptosis, quantification of cleaved caspase 3 staining also 
revealed a significant increase in both colon polyps and SITs, in response to all three 
combination strategies (Colon polyps: 4hr veh = 0.978 ± 0.609, combo 1 = 17.876 ± 5.99, p 
value = 0.0014, combo 2 = 6.22 ± 1.91, p value = 0.142, combo 3 =16.53 ± 6.47, p value = 
0.0004, n≥ 8 tumours, 4 mice, Mann Whitney U test) (SIT: 4hr veh = 1.79 ± 1.029, combo 1 = 
24.14 ± 11.33, p value = 0.0015, combo 2 = 15.73 ± 4.74, p value = 0.0107, combo 3 = 14.16 ± 
9.66, p value = 0.0015, n≥ 6 tumours, 4 mice, Mann Whitney U test) (Figure 5.15). These 
surprisingly high levels of cleaved caspase 3 suggest long term combination treatment may be 
highly beneficial in killing tumour cells effectively. 
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Scoring of mitotic figures (A + C)  and apoptotic bodies (B + D) in colon polyps and SITs by H&E examination revealed no significant alterations in the levels 
of mitotic figures, however did reveal increased apoptosis in colon polyps and SITs following all three combination strategies (*p value ≤ 0.05 for all, n≥ 6 
tumours, 4 mice, Mann Whitney U test). Error bars represent standard deviation.  
Figure 5.14 Anti-tumour effects of different combination strategies in Apcf/+ KrasLSL/+ colon polyps and small intestinal tumours (SITs) 
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IHC for BrdU and cleaved caspase 3 was carried out and scored in colon polyps and SITs from mice following exposure to the three different combination 
strategies. Scoring of BrdU (A + C) revealed no significant alterations in colon polyps but increased BrdU staining in SITs following combo 2 and 3. 
Quantification of cleaved caspase 3 staining (B + D) revealed increased levels following all three combination strategies in colon polyps and SITs. (*p value ≤ 
0.05 for all, n≥ 6 tumours, 4 mice, Mann Whitney U test). Error bars represent standard deviation.  
Figure 5.15 BrdU and cleaved caspase 3 scoring of three combination strategies in Apcf/+ KrasLSL/+ colon polyps and small intestinal tumours (SITs) 
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To investigate whether the anti-tumour effects of the combination strategies described above 
correlate with pathway inhibition, both colon polyps and SITs samples from mice exposed to 
the different combinations were interrogated by western blot analysis for MAPK and PI3K 
pathway status. Immunoblotting and subsequent densitometry analysis of individual polyp 
lysates (from n=3 mice) revealed a marked reduction in the levels of pERK with all three 
combinations, however no significant alteration in levels of either pAKT473 or pAKT308 (Figure 
5.16, Table 5.9, Table 5.10). A significant reduction in levels of pS6RP was also observed with 
all three combinations but levels of p4EBP1 were found to be reduced only in response to 
combo 2 and 3 (Figure 5.16, Table 5.9, Table 5.10). Interestingly, the trends observed here with 
all three combination strategies suggest that addition of MEK162 to NVP-BEZ235, irrelevant of 
the order, eliminates the ability of NVP-BEZ235 to reduce levels of pAKT in colon polyps. The 
reason for this is currently unclear but may be attributable to an additive effect on levels of 
pAKT, whereby the increasing effects of MEK162 are negated by the reducing effects of NVP-
BEZ235, as previously observed.  
Colon 
polyps 
Vehicle Combo 1        (p value) Vehicle Combo 2 (p value) 
pERK 5903.6 ± 308.6 355.42 ± 91.97 
(0.0404) 
4264 ± 1238.9 20.8 ± 18.9 
(0.0404) 
pAKT473 2405.1 ± 947.8 1677.1 ± 901.8 
(0.1914) 
2453.5 ± 69.6 3024.9 ± 256.5 
(1.0) 
pAKT308 1844.9 ± 254.9 2780.7 ± 96.1 (0.0404) 1663.8 ± 277.7 1694.9 ± 598.8 
(0.6625) 
pS6RP 2152.4 ±1693.2 87.7 ± 59.3 (0.0404) 3570.9 ± 1445.1 1153.5 ± 472.5 
(0.0404) 
p4EBP1 4168.9 ± 1565.3 3268.7 ± 1218.9 
(0.3313) 
4189.9 ± 1565.3 1226.1 ± 682.9 
(0.0404) 
Table 5-9 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ 
colon polyps 4 hours post exposure to combo 1 and combo 2, n=3, One-tailed Mann Whitney 
U test was used for statistical analysis 
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Colon 
polyps 
Vehicle Combo 3        (p value) 
pERK 5876.9 ± 184.2 1216.1 ± 916 (0.0404)  
pAKT473 4178.5 ± 702.5 3351.9 ± 195.4 (0.0952) 
pAKT308 1661.1 ± 748.2 1790.1 ± 490.7 (1.0) 
pS6RP 1453.9 ± 813.8 16.2 ± 20.4 (0.0404) 
p4EBP1 5153.9 ± 765.2 3651.3 ± 320.9 (0.0404) 
Table 5-10 Outline of raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+  
colon polyps 4 hours post exposure to combo 3, n=3, One-tailed Mann Whitney U test was 
used for statistical analysis 
Western blot analysis of SITs from mice exposed to the varying combinations revealed a similar 
trend to that observed in colon polyps, with regards to pathway inhibition. A marked reduction 
in the levels of pERK was observed with all three combinations but no significant alterations in 
levels of pAKT473 or pAKT308 were observed (Figure 5.17, Table 5.11 and Table 5.12). Similarly 
to colon polyps, levels of pS6RP were found to be reduced with all three combinations 
whereas, p4EBP1 was found to be reduced with both combo 1 and combo 2 (Figure 5.17, Table 
5.11 and Table 5.12). Overall in SITs, the addition of MEK162 has also diminished the ability of 
NVP-BEZ235 to reduce PI3K signalling through pAKT (mainly pAKT308) however in this case, 
the observations cannot be attributed to an additive effect because MEK162 alone did not 
increase levels of pAKT308 but in fact led to a significant reduction in levels of pAKT308.  
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SITs Vehicle Combo 1 (p value) Vehicle Combo 2 (p value) 
pERK 3546.9 ± 1033.7 297.4 ± 35.9 (0.0404) 6274.9 ± 564.4 1054.7 ± 273.6 
(0.0404) 
pAKT473 1794.2 ± 340.2 1327.8 ±452.6 
(0.0952) 
3235.7 ± 470.2 3123.6 ± 647.8 
(0.0952) 
pAKT308 1993.2 ± 406.9 1459.1 ± 567.4 
(0.0952) 
1019.7 ± 333.9 2067.2 ± 913.3 
(0.1914) 
pS6RP 1544.0 ± 886.9 578.3 ± 147.9 
(0.0404) 
1544.0 ± 886.9 134.9 ± 125.9 
(0.0404) 
p4EBP1 5972.1 ± 1966.8 3827.0 ± 864.7 
(0.0404) 
5972.1 ± 1966.8 1795.9 ± 90.8 
(0.0404) 
Table 5-11 Raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+ SITs 4 hours 
post exposure to combo 1 and combo 2, n=3, One-tailed Mann Whitney U test was used for 
statistical analysis 
SITs Vehicle Combo 3 (p value) 
pERK 5158.9 ± 416.2 271.1 ± 159.2 (0.0404) 
pAKT473 2829.9 ± 681.7 2124.4 ± 1833.9 (0.3313) 
pAKT308 1711.9 ± 490.1 1249.8 ± 1061.7 (0.1914) 
pS6RP 5702.2 ± 884.9 1379.4 ± 842.5 (0.0404) 
p4EBP1 6585.9 ± 1256.2 4897.2 ± 3318.2 (0.1914) 
Table 5-12 Raw densitometry values from western blot analysis of Apcf/+ KrasLSL/+  SITs 4 
hours post exposure to combo 3, n=3, One-tailed Mann Whitney U test was used for 
statistical analysis 
Given the above observations, analysis of the three chosen combination strategies in Kras 
mutant colon and SITs revealed that all three were similar in terms of their anti-tumour and 
pharmacodynamics effects. In light of this, combination strategy 2 which was identified as the 
most effective in Apcf/+ Ptenf/f tumours in chapter 4, was chosen for all further experiments to 
remain consistent across the different genotypes of mice evaluated in this study. 
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Figure 5.16 sequencing of combination has no differential effect on signalling in Apc
f/+
 Kras
LSL/+ colon polyps. (A) Individual colon polyp lysates from n=3 mice exposed to 
the different combination strategies were analysed by western blotting for effectors of MAPK and PI3K/mTOR signalling. Significant reduction of pERK but no 
alterations in pAKT308 or pAKT473 was observed with all three combination strategies. Significant reduction of pS6RP an effector downstream of mTOR was also 
observed with all three combinations however, a significant reduction in p4EBP1 was only observed with combo 2 and 3.  (B + C) Densitometry analysis was carried out 
to quantify differences observed from western blotting. These are normalised to β-actin as loading control and represented as relative to vehicle controls (*p values = 
0.0404, n=3, Mann Whitney U test).  
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Figure 5.17 sequencing of combination has no differential effect on signalling in Apc
f/+
 Kras
LSL/+ small intestinal tumours (SITs). (A) To investigate the effects of the three 
combination sequences on downstream pathway signalling, individual tumour lysates from n=3 mice were analysed by immunoblotting.  Similarly to colon polyps, a 
significant reduction in levels of pERK were observed with all three combinations and no significant reduction of pAKT308 or pAKT473 were observed. Additionally, 
significant reduction of pS6RP was observed with all three combination strategies, but significant reduction of p4EBP1 only with combo 1 and 2. (B + C) Densitometry 
analysis was carried out to quantify differences observed from western blotting. These are normalised to β-actin as loading control and represented as relative to 
vehicle controls (*p values = 0.0404, n=3, Mann Whitney U test).  
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5.2.6 Long term combination results in an additive increase in survival in Apcf/+ KrasLSL/+ 
mice 
As described previously, investigation of twice-daily NVP-BEZ235 and MEK162 treatment in a 
short pilot experiment identified this regimen to be toxic (determined by weight loss) for wild-
type mice (Figure 4.16). Therefore, the combination dose was reduced and administered as 
twice-daily NVP-BEZ235 but only once-daily MEK162, which was found to be well tolerated in 
Apcf/+ Ptenf/f mice and increased lifespan of mice (Figure 4.18). Given these observations, the 
later combination regimen was chosen for long term treatment in Apcf/+ KrasLSL/+ mice. A 
cohort of 13 mice were induced and aged to 100 days post induction at which point they were 
administered with 35mg/kg NVP-BEZ235 twice-daily plus 30mg/kg MEK162 once daily (1 hour 
after the initial dose) and monitored closely until a survival end point. Shortly after the 
experiment began it became apparent that this regimen was toxic for Apcf/+ KrasLSL/+ mice as 
8/13 were culled due to substantial weight loss (weights of mice are shown on figure 5.18, 
survival of mice on figure 5.19). Despite this, 5/13 mice appeared to tolerate the treatment 
after some time and displayed a marginal survival benefit compared to vehicle controls (figure 
5.19), indicating the potential benefits of combination in the absence of toxic effects.  
In light of these additional toxicity issues, a second further reduced combination regimen of 
35mg/kg NVP-BEZ235 once daily plus 30mg/kg MEK162 once daily (1 hour after the first dose) 
– combo R2, was conducted, in an effort to elucidate the potential of long term combination 
treatment in the Kras mutant tumour setting. For this, a cohort of 12 mice were induced and 
aged to 100 days post induction at which point they were administered with the further 
reduced combination treatment (as above) until a survival end point, or until the experimental 
end point of 500 days post induction. Additionally, controls of 35mg/kg NVP-BEZ235 as once 
daily and 30mg/kg MEK162 as once daily treatments were also conducted. Interestingly, 
reduced once daily MEK162 treatment significantly increased survival of Apcf/+ KrasLSL/+ mice in 
comparison with vehicle controls, but not in comparison to twice daily administration of 
MEK162 (median survivals: MEK T-D = 287 days vs MEK O-D = 286 vs veh = 153 days post 
induction, p values ≤ 0.0001, Log-Rank and Wilcoxon test) (Figure 5.20), indicating that the 
maximal benefit with respect to survival benefit was reached with the once-daily regimen. 
Similarly, reduced NVP-BEZ235 to a once-daily regimen also significantly increased survival of 
Apcf/+ KrasLSL/+ mice in comparison with vehicle treated mice however, in this case, the effect 
on survival was found to be dose dependent  as the higher dose was found to increase survival 
further (median survivals: NVP-BEZ235 T-D = 343 days, NVP-BEZ235 O-D = 267 days, veh = 153 
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days post induction, p value = 0.019, n=12 mice per cohort, Log-Rank test) (Figure 5.20). 
Importantly, the reduced combination treatment in Apcf/+ KrasLSL/+ mice was found to be better 
tolerated than the first combination regimen (figure 5.18) and significantly increased longevity 
of Apcf/+ KrasLSL/+ mice from a median of 153 days to 389 days post induction (Figure 5.20). The 
combination treatment here was found to be significantly better than single agent NVP-
BEZ235 once-daily treatment (combo median survival = 389 vs NVP-BEZ235 median survival = 
267 days post induction, p value = 0.029 for Log-Rank and p value = 0.042 for Wilcoxon test) 
however, not significantly better in comparison with single agent MEK162 regardless of the 
100 days increase in median survival on combination treatment (MEK162 median survival = 
286 days vs combo = 389 days post induction, p value = 0.374 for Log-Rank and p value = 0.279 
for Wilcoxon test) (Figure 5.20). This was likely to be due to convergence of the two survival 
curves at 400 days post induction with both cohorts having 2/12 mice reach the experimental 
end point of 500 days. Nevertheless, the combination treatment resulted in an additive 
increase in median survival for Apcf/+ KrasLSL/+ mice, potentially indicating increased therapeutic 
benefits here.   
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Previously in figure 4.15, administration of 35mg/kg NVP-BEZ235 twice-daily plus 30mg/kg 
MEK162 once daily was shown to be well tolerated in Apcf/+ Ptenf/f  mice. Administration of this 
combination strategy in Apcf/+ KrasLSL/+   mice however, led to notable fluctuations in body 
weight, n=8/13 mice were culled due to weight loss of approximately 20% of the original body 
weight. A further reduced combination of 35mg/kg NVP-BEZ235 once daily plus 30mg/kg 
MEK162 once daily (1 hour later) was then conducted and was found to be better tolerated.  
Single agent NVP-BEZ235 twice daily was well tolerated in Apcf/+ KrasLSL/+ mice and so was 
chosen as a comparison. Error bars represent relative standard deviation  
 
 
 
 
 
 
Figure 5.18 Combination treatment was found to induce toxicity in Apcf/+ KrasLSL/+  mice. 
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Apcf/+ KrasLSL/+ mice were induced and aged to 100 days post induction, at which point mice 
were randomised to receive either 0.5% Methyl cellulose (Vehicle control) or  35mg/kg NVP-
BEZ235 twice daily plus 30mg/kg MEK162 once daily, 1 hour after the first dose, by oral 
gavage, until a survival end point or the experimental endpoint of 500 days. Continuous 
combination treatment (Combo R1) was shown to have no significant effect on median survival 
of mice in comparison to vehicle controls and approximately only 40% of mice appeared to 
have had some survival advantage. (Median survival: combo R1 = 150 days vs vehicle = 153 
days post induction, p values: Log-Rank = 0.41 and Wilcoxon test = 0.84, n ≥12 mice per 
cohort). Interestingly, single agent MEK162 and NVP-BEZ235 are equipotent in terms of 
survival benefit for Apcf/+ KrasLSL/+ mice ( Median survival: MEK162 = 287 days vs NVP-BEZ235 = 
343 days post induction, p values: Log-Rank = 0.523 and Wilcoxon test = 0.878, n ≥12 mice per 
cohort).  
 
Figure 5.19 Kaplan-Meier survival analysis of Apcf/+ KrasLSL/+ mice receiving long term 
combination treatment (Combo R1) compared to single agent NVP-BEZ235, MEK162 and 
vehicle controls 
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Induced and aged to 100 days post induction, Apcf/+ KrasLSL/+ mice were randomised to receive 
either 0.5% Methyl cellulose (Vehicle control), 30mg/kg MEK162 once daily, 35mg/kg NVP-
BEZ235 once daily or 35mg/kg NVP-BEZ235 once daily plus 30mg/kg MEK162 once daily (1 
hour after) by oral gavage, until a survival end point or the experimental endpoint of 500 days. 
Combo R2 treatment significantly increased survival of mice to a median of 389 days post 
induction, compared 153 days with vehicle controls (p values Log-Rank and Wilcoxon test ≤ 
0.0001, n ≥12 mice per cohort). Interestingly, combo 2 was significantly better than reduced 
single agent NVP-BEZ235, but not in comparison to reduced single agent MEK162 (median 
survival Combo R2 = 389 days vs NVP-BEZ235 = 267 days vs MEK162 = 286 days, p values for 
Combo R2 vs NVP-BEZ235: Log-Rank = 0.029 and Wilcoxon = 0.042, p values for Combo R2 vs 
MEK162: Log-Rank = 0.374 and Wilcoxon = 0.279).  
 
 
 
Figure 5.20 Kaplan-Meier survival analysis of Apcf/+ KrasLSL/+ mice receiving reduced 
combination treatment (Combo R2) long term compared to reduced single agent NVP-
BEZ235 and MEK162, and vehicle controls 
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5.2.7 Analysis of tumour burden following treatment in Apcf/+ KrasLSL/+ mice 
As well as the effect of treatment on survival of mice, the effect on tumour burden was also 
assessed following long term treatment. For this, tumours were counted, measured and staged 
according to severity (as described in methods section 2.7.4). As in section 4.2.8, these 
parameters of tumour burden were also assessed in a cohort of mice harvested at the 
treatment start point which in this case was 100 days post induction.  
5.2.7.1 Analysis of tumour number following treatment in Apcf/+ KrasLSL/+ mice 
The total number of tumours present at death was scored from H&E stained slides of colon 
and small intestine ‘swiss rolls’. For each sample three H&E stained slides were scored blind, 
the average calculated per mouse and subsequently averaged per cohort. At 100 days post 
induction, Apcf/+ KrasLSL/+ mice bore a median of 16 colon lesions and 33 SITs per mouse (n=4 
mice). Vehicle treated Apcf/+ KrasLSL/+ mice had a median of 30 colon lesions and 34 SITs (n=12 
mice) at death indicating that although the number of colon polyps significantly increased 
between the start and vehicle cohorts, tumours were present at the start of treatment 
confirming treatment was not in a prophylactic setting (start = 15.5 tumours vs vehicle = 30.3 
tumours, p = 0.0223, n≥6, Mann Whitney U test) (Figure 5.21, 5.22). The median number of 
colon polyps at death was significantly reduced in both MEK162 treatment cohorts (T-D and O-
D) compared to vehicle controls (vehicle = 30.3 vs MEK162 T-D = 7.7, p value = 0.0064, MEK162 
O-D = 13, p value = 0.0058, n≥6, Mann Whitney U test) (Figure 5.21) however, SITs were found 
to be reduced in MEK162 twice-daily treated mice (and not once-daily) in comparison with the 
start and vehicle treated cohorts (start = 32.5 veh = 34, MEK162 T-D = 12, p value = 0.050 
compared to start and p value = 0.026 compared to vehicle, MEK162 O-D = 14, p value = 0.058 
compared to start and p value = 0.057 compared to vehicle cohorts, n≥6, Mann Whitney U 
test) (Figure 5.22).  
Analysis of tumours present at death following long term NVP-BEZ235 treatment revealed that 
the median number of colon tumours at death was significantly increased with the once-daily 
(O-D) treatment, in comparison to with the start cohort but not in comparison with vehicle 
treated mice (Colon polyps: start = 15.5, vehicle = 30.3, NVP-BEZ235 O-D = 39, p value = 0.037 
for start and p value = 0.095 for vehicle comparisons, n≥6, Mann Whitney U test) (Figure 5.20). 
The number of SITs with once-daily NVP-BEZ235 treatment however, was found to be 
increased compared to vehicle but not in comparison with the start cohort (SITs: start = 32.5, 
vehicle = 34, NVP-BEZ235 O-D = 74, p value = 0.076 for start and p value = 0.023 for vehicle 
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comparison, n≥6, Mann Whitney U test) (Figure 5.22). Interestingly, no difference in the 
number of colon polyps or SITs was found with NVP-BEZ235 twice daily treatment in 
comparison with either the start or vehicle treated cohorts. (Colon polyps: start = 15.5, vehicle 
= 30.3, NVP-BEZ235 T-D = 26, p value = 0.089 for start and p value = 0.526 for vehicle cohort 
n≥6, Mann Whitney U test) (SITs: start = 32.5, vehicle = 34, NVP-BEZ235 T-D = 63, p value = 
0.289 for start and p value = 0.067 for vehicle comparison, n≥6, Mann Whitney U test) (Figure 
5.21, 5.22). These observations indicate that whilst twice-daily NVP-BEZ235 treatment had no 
effect on total tumour number, once-daily treatment resulted in increased tumour number 
which may reflect increased tumour burden with the increase in longevity.   
The median number of colon polyps was found to be significantly reduced with both 
combination strategies (R1 and R2) in comparison with vehicle treated mice but not in 
comparison with the start cohorts, suggesting tumour growth stasis (median number of colon 
polyps: start = 15.5, vehicle = 30.3, combo R1 = 17.5, p value = 0.777 for start and p value = 
0.026 for vehicle comparison, combo R2 = 5, p value = 0.396 for start and p value = 0.0086 for 
vehicle comparison, n≥6, Mann Whitney U test,) (Figure 5.21). Additionally, a trend towards 
reduced SITs was observed with both combo R1 and R2 although not found to be significant in 
comparison with either start or vehicle cohorts (start = 32.5, vehicle = 34, combo R1 = 25.8, p 
value = 0.808 for start and p value = 0.926 for vehicle comparison, combo R2 = 18.3, p value = 
0.299 for start and p value = 0.497 for vehicle comparison, n≥6, Mann Whitney U test) (Figure 
5.22). Overall, these observations are more relevant for the combo R2 treatment due to the 
significant increase in survival, however together they display the favourable effects of 
combination treatment in terms of reduced tumour numbers in Apcf/+ KrasLSL/+ mice.    
5.2.7.2 Analysis of total tumour area following treatment in Apcf/+ KrasLSL/+ mice 
To determine the effect of various long term treatments on total tumour area, macroscopic 
tumours were measured from methacarn fixed colon and small intestine tissues and the total 
tumour area (mm2) was calculated per mouse, per cohort. Apcf/+ KrasLSL/+ mice on vehicle 
treatment trended to have larger colon and SITs at death compared to the start cohort 
however, this was not significantly altered due to large variation within the cohorts (colon start 
= 12.8 ± 10.1, colon vehicle = 55.2 ± 44.7, p value = 0.194, SIT start = 43.8 ± 51.7, SIT vehicle = 
117.4 ± 51.7, p value = 0.112, n≥6, Mann Whitney U test) (Figure 5.21). Analysis of colon 
tumour area in all treatment cohorts revealed no significant alterations in comparison to the 
start cohort (start = 12.8 ± 10.1, MEK162 T-D = 21.5 ± 21.7 p value = 0.817, MEK162 O-D = 68.2 
± 90.6 p value = 0.269, NVP-BEZ235 T-D = 48.2 ± 59 p value = 0.508, NVP-BEZ235 O.D = 134.8 ± 
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105.6 p value = 0.126, combo R1 = 2.98 ± 6.3 p value = 0.123, combo R2 = 40.8 ± 58.9 p value = 
1.0, n≥6, Mann Whitney U test) (Figure 5.20). This was also the case in comparison to vehicle 
cohorts, with the exception of combo R1 treatment, after which mice presented with 
significantly reduced total tumour area (start = 12.8 ± 10.1, MEK162 T-D = 21.5 ± 21.7 p value = 
0.28, MEK162 O-D = 68.2 ± 90.6 p value = 0.932, NVP-BEZ235 T-D = 48.2 ± 59 p value = 0.777, 
NVP-BEZ235 O.D = 134.8 ± 105.6 p value = 0.35, combo R1 = 2.98 ± 6.3 p value = 0.0168, 
combo R2 = 40.8 ± 58.9 p value = 0.396, n≥6, Mann Whitney U test) (Figure 5.21). These 
observations suggest all long term treatment regimens resulted in tumour growth stasis as no 
reduction in tumour area was detected in comparison with the start cohort. An Interesting 
observation was that mice on all reduced treatments (once-daily) trended to have larger 
tumour areas than mice on their corresponding twice-daily treatment regimens and may 
indicate a dose-dependent effect.  
Analysis of SIT area in all long term treated cohorts revealed no significant differences in 
comparison to the start cohort (start = 43.8 ± 51.7, MEK162 T-D = 58.3 ± 34.1 p value = 0.699, 
MEK162 O-D = 46.1 ± 55.9 p value = 0.671, NVP-BEZ235 T-D = 9.2 ± 10.9 p value = 0.637, NVP-
BEZ235 O-D =20.7 ± 31.1 p value = 0.799, combo R1 = 1.18 ± 2.13 p value = 0.396, combo R2 = 
14.7 ± 26.1 p value = 0.488, n≥6, Mann Whitney U test) (Figure 5.22). Interestingly, all 
treatments except for MEK162 O-D, resulted in significantly reduced total SIT area in 
comparison with vehicle treated cohorts, suggesting tumour growth stasis, as tumour area was 
comparable in most cases with the start cohort (vehicle = 117.4 ± 26.9, MEK162 T-D = 58.3 ± 
34.1 p value = 0.037, MEK162 O-D = 46.1 ± 55.9 p value = 0.107, NVP-BEZ235 T-D = 9.2 ± 10.9 p 
value = 0.011, NVP-BEZ235 O-D =20.7 ± 31.1 p value = 0.0085, combo R1 = 1.18 ± 2.13 p value 
= 0.0069, combo R2 = 14.7 ± 26.1 p value = 0.0069, n≥3, Mann Whitney U test) (Figure 5.22).  
5.2.7.3 Analysis of tumour severity following treatment in Apcf/+ KrasLSL/+ mice 
To further characterise the effect of treatment on tumour burden in Apcf/+ KrasLSL/+ mice, 
tumours on H&E stained colon and small intestine sections were staged according to severity 
and invasive features to ascertain whether treatment had an effect on tumour progression. 
The criteria for scoring were described previously in methods section 2.7.4 and section 4.2.8. 
The average number of each tumour type was calculated and is displayed as a proportion of 
the total number of tumours, due to differences in total tumour numbers observed.  
For colon tumours, the general observations indicated a significant reduction in the 
percentage of microadenomas and a significant increase in the percentage of adenomas 
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compared to the start cohort. This was the case for all single-agent long term treatments, in 
comparison with the start cohort but not for combination treated cohorts. Furthermore, no 
significant differences were detected in tumour severity profiles of mice on any of the long 
term treated cohorts in comparison with vehicle treated mice (microadenomas: start = 93%, 
vehicle = 56% p value =0.005, MEK162 T-D = 58% p value = 0.019, MEK162 O-D = 59% p value = 
0.005, NVP-BEZ235 T-D = 72% p value = 0.0339, NVP-BEZ235 O-D = 58% p value = 0.0069; 
adenomas: start = 7%, vehicle = 41% p value = 0.005, MEK162 T-D = 36% p value = 0.0188, 
MEK162 O-D = 36% p value = 0.0188, NVP-BEZ235 T-D = 26% p value = 0.0339, NVP-BEZ235 O-
D = 40% p value = 0.0069, n≥6, Mann Whitney U test) (Figure 5.21). Therefore, although 
differences in total tumour number and area were observed as described previously, tumours 
in mice at death were of comparable severity indicating treatment had no effect on tumour 
severity.  
With long term combo R1 treatment, mice displayed no differences in the proportion of 
microadenomas and adenomas present at death in comparison with the start cohort however, 
mice did present with significantly fewer adenomas and more microadenomas in comparison 
with vehicle treated mice, indicating that treatment here halted progression of colon tumours 
even though no difference in survival was observed (microadenomas: start = 93%, vehicle = 
56%, combo R1 = 86% p value = 0.525 for start and p value = 0.0043 for vehicle comparison; 
adenomas: start = 7%, vehicle = 41%, combo R1 = 12%, p value = 0.832 for start and p value = 
0.0075 for vehicle comparison, n≥6, Mann Whitney U test) (Figure 5.21). Scoring the severity 
of tumours following combo R2 treatment showed no statistical alterations in comparison with 
both start and vehicle treated cohorts providing further evidence for tumour growth stasis 
(microadenomas: start = 93%, vehicle = 56%, combo R2 = 70% p value = 0.299 for start and p 
value = 0.651 for vehicle comparison; adenomas: start = 7%, vehicle = 41%, combo R2 = 29%, p 
value = 0.706 for start and p value = 0.365 for vehicle comparison, n≥6, Mann Whitney U test) 
(Figure 5.21). 
 Interestingly, grading of early invasive adenocarcinomas (EIAs) (characterised by submucosal 
invasion) identified a small proportion of these to be present in vehicle treated mice but not in 
the start cohort, indicating tumour progression (3% of tumours were EIAs in vehicle treated 
mice). A similar proportion of EIAs was observed in all drug treated cohorts (vehicle = 3%, 
MEK162 T-D = 5.5% p value = 0.358, MEK162 O-D = 4.9% p value = 0.325, NVP-BEZ235 = 1.5% p 
value = 0.13, NVP-BEZ235 O-D = 1.6% p value = 0.111, combo R1 = 2.3% p value = 0.149, 
combo R2 = 1.4% p value = 0.057, n≥6, Mann Whitney U test) indicating that although some 
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differences in tumour number and area as described previously, overall tumours at death were 
of comparable severity.  
Scoring of tumour severity in the small intestine revealed that the vehicle cohort at death had 
more invasive lesions than the start cohort indicating tumour progression between the two 
points. This was characterised by the presence of significantly less microadenomas and more 
adenomas and a trend towards increased advanced invasive (AIAs) lesions, compared to the 
start cohort (start mAd = 94%, vehicle mAd = 85% p value = 0.0223, start Ad = 3.4%, vehicle Ad 
= 12.7% p value = 0.0109, start EIA = 2%, vehicle = 1.5% p value = 1.00, start AIA = 0%, vehicle = 
0.8%, n≥6, Mann Whitney U test) (Figure 5.22).  
Furthermore in the small intestine, MEK162 treated cohorts (both once-daily and twice-daily 
cohorts) had significantly less microadenomas compared to the start cohort and trended to 
have more adenomas and invasive lesion, however this was not statistically significant 
(microadenomas: start = 94%, vehicle = 85% MEK162 T-D = 84% p value = 0.0265 for start and 
p value = 0.539 for vehicle, MEK162 O-D = 83% p value = 0.0312 for start and p value = 0.569; 
adenomas: start = 3.4%, vehicle = 12.6% MEK162 T-D = 11.2% p value =0.0583 for start and p 
value = 0.4727 for vehicle, MEK162 O-D = 13% p value = 0.078 for start and p value = 0.361 for 
vehicle, n≥6, Mann Whitney U test) (Figure 5.22). In comparison with vehicle treated mice, 
both MEK162 treatments had no statistically significant effect on tumour severity, although 
the proportion of invasive lesions (EIAs and AIAs) trended to be increased with both once-daily 
and twice-daily treatments (EIAs; start = 2%, vehicle = 1.5% p value = 1, MEK162 T-D = 1.2% p 
value = 0.648 for start and p value = 0.393 for vehicle, MEK162 O-D = 3.1% p value = 0.845 for 
start and p value = 0.896 for vehicle comparison, n≥6, Mann Whitney U test).  
Conversely to the observations above, mice on NVP-BEZ235 (once-daily and twice-daily 
treatments) and both combination regimens (combo R1 and R2) possessed less adenomas and 
more microadenomas in the small intestine. This was statistically significant in comparison 
with vehicle cohorts but not in comparison with the start cohort indicating stasis of tumour 
growth and progression with these treatments (microadenomas: start = 94%, vehicle = 85%, 
NVP-BEZ235 T-D = 90% p value = 0.289 for start p value = 0.0054 for vehicle comparison, NVP-
BEZ235 O-D = 95% p value = 0.396 for start and p value = 0.003 for vehicle comparison, combo 
R1 = 99% p value = 0.856 for start and p value = 0.0002 for vehicle comparison, combo R2 = 
90% P value = 0.508 for start and p value = 0.0185 for vehicle comparison; adenomas: start = 
3.4%, vehicle = 12.7%, NVP-BEZ235 T-D = 7.9% p value = 0.104 for start and p value = 0.0317 
for vehicle comparison, NVP-BEZ235 O-D = 5% p value = 0.143 for start and p value = 0.0098 
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for vehicle comparison, combo R1 = 0.8% p value = 0.762 for start and p value = 0.0002 for 
vehicle comparison, combo R2 = 7.9% p value = 0.508 for start and p value = 0.0185 for vehicle 
comparison, n≥6, Mann Whitney U test) (Figure 5.22).  
Finally, the proportion of EIAs and AIAs was also not significantly altered with either NVP-
BEZ235 or combination treatments providing further evidence for stasis of tumour progression 
with treatment (EIAs: start = 2%, vehicle = 1.5%, NVP-BEZ235 T-D = 0.13% p value = 0.734 for 
start and p value = 0.597 for vehicle comparison, NVP-BEZ235 O-D = 0.4% p value = 0.508 for 
start and p value = 0.224 for vehicle comparison; AIAs: vehicle = 0.85%, NVP-BEZ235 T-D = 
0.4% p value = 0.86, NVP-BEZ235 O-D = 0.3% p value = 0.939, combo R1 = 0.3% p value = 
0.601, combo R2 = 1.3% p value = 0.928, n≥6, Mann Whitney U test) (Figure 5.22).  
In summary, analysis of various parameters of tumour burden here indicate that whilst twice-
daily MEK162 treatment significantly reduced the number of small intestinal and colonic 
lesions and reduced total tumour area in the small intestine, treatment had no effect on 
progression of tumours. Also, although twice-daily NVP-BEZ235 treatment in Apcf/+ KrasLSL/+ 
mice had no effect on colon polyps with respect to the parameters of tumour burden analysed 
here, treatment did reduce tumour area and halts progression of lesions in the small intestine. 
These findings provide some insights into the importance of MAPK and PI3K pathways in Apcf/+ 
KrasLSL/+ tumours highlighting that MAPK signalling may be more important for growth of 
tumours whereas PI3K signalling may be more crucial for progression of tumours. 
Furthermore, tumour burden analyses in the combination treated cohorts corroborate these 
hypotheses as treatment resulted in fewer colon lesions. Also in the small intestine, reduced 
total tumour area was coupled with less invasive lesions in comparison with vehicle treated 
cohorts.  
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Figure 5.21 Colon tumour burden analysis of Apc
f/+
 Kras
LSL/+ mice on all long term treatments.  
(A) Apcf/+ KrasLSL/+ mice  on vehicle had significantly more colon tumours at death compared to a cohort 
of mice culled at the treatment start point. Mice on MEK162 T-D and O-D and combo R1 and R2 had 
significantly reduced tumours compared to vehicle treated mice, (B) In terms of tumour area, only 
Apcf/+ KrasLSL/+ mice on combination treatment which resulted in toxicity (combo R1) had significantly 
reduced total tumour area at death, (C) Key: mAd – microadenoma, Ad – adenoma, EIA – early invasive 
adenocaricinoma, AIA – advanced invasive adenocarcinoma. The proportion of mAds were found to be 
significantly reduced and adenomas were found to be significantly increased with all single-agent 
treatments in comparison to the start cohort. The opposite pattern was found with combo R1 
treatment compared to vehicle cohorts (* p value ≤ 0.05, n≥6, Mann Whitney U test).     
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Figure 5.22 Small intestinal tumour burden analysis of Apc
f/+
 Kras
LSL/+ mice on all long term treatments 
(A) Apcf/+ KrasLSL/+ mice on MEK162 T-D have significantly reduced tumours compared to the start cohort 
and vehicle treated mice, whereas mice on NVP-BEZ235 O-D had significantly more tumours at death 
compared to vehicle treated mice. (B) Assessment of tumour area following fixation revealed mice on 
all treatment cohorts except those on MEK162 O-D had significantly reduced tumour area compared to 
vehicle cohorts. (C) Key: mAd – microadenoma, Ad – adenoma, EIA – early invasive adenocaricinoma, 
AIA – advanced invasive adenocarcinoma. Mice on vehicle and both MEK162 treatments had 
significantly less mAds than the start cohort but only vehicle mice had significantly more Ads compared 
to the start cohort. Mice on MEK162 O-D, NVP-BEZ235 T-D and O-D, Combo R1 and mice on combo R2 
had significantly altered mAds and Ads compared to vehicle treated mice. (* p value ≤ 0.05, n≥6, Mann 
Whitney U test)     
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5.3 Discussion 
5.3.1 MEK inhibition lead to increased PI3K signalling in Kras mutant tumours, however 
still increases survival of Apcf/+ KrasLSL/+ mice 
The oncogene KRAS is one of the most frequently altered genes in human cancer and leads to 
aberrant activation of MAPK and PI3K signalling, both of which are crucial for a myriad of 
processes that regulate cancer cell survival (Sebolt-Leopold and Herrera, 2004, Engelman, 
2009). This has subsequently led to a surge in the development of targeted agents for these 
signalling pathways, and their investigation in KRAS mutant tumour settings as a stratified 
treatment approach. The main objective of this chapter was to investigate the therapeutic 
potential of targeting MAPK and PI3K signalling using a robust and clinically relevant model of 
CRC, driven by activation of oncogenic Kras. Here, concurrent heterozygous deletion of Apc 
and activation of oncogenic Kras (Janssen et al., 2006) leads to tumour progression driven by 
activation of ERK, a downstream effector in the RAS-RAF-MEK kinase cascade, and AKT, a 
downstream effector of PI3K signalling. Activation of these mutations driven by the intestinal 
specific VillinCreER recombinase transgene causes mice to succumb to disease by 
approximately 150 days post induction, at which point they present with lesions in both the 
colon and small intestine (Davies et al., in press, Janssen et al., 2006). For all experiments 
described in this chapter, 10 week old mice were induced by i.p. injections of Tamoxifen and 
aged. Mice were either aged until the chosen treatment start point of 100 days, or until they 
presented with symptoms of disease, at which point they received a single dose of treatment 
and were culled at defined short term time points to investigate the immediate anti-tumour 
and pharmacodynamic effects of treatment.  
Firstly, the effects of targeting the MAPK pathway using the MEK1/2 inhibitor MEK162 were 
assessed acutely and chronically in the Kras mutant tumour model to ascertain whether this 
could be beneficial therapeutically against Kras mutant CRC, as hypothesised. In colon polyps, 
acute MEK162 administration resulted in inhibition of phosphorylated ERK, the MAPK effector 
directly downstream MEK1/2. Here, levels of pERK were found to be reduced at both 4 and 24 
hour time points; however inhibition was less marked at 24 hours indicating reduced pathway 
inhibition (Figure 5.3). Western blot analysis also showed that SITs were less sensitive to MEK 
inhibition as pERK levels were only found to be reduced at 4 hours post exposure and not at 
the 24 hour time point (Figure 5.4). As described previously, phosphorylated and hence 
activated ERK1/2 acts as a catalyst for one branch of MAPK signalling where it is responsible 
for a number of cellular processes including proliferation, differentiation, survival and 
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apoptosis (Johnson and Lapadat, 2002). These functions are mediated in the cytoplasm or once 
translocated to the nucleus through direct interactions with transcriptional repressors or 
transcription factors of target genes including Fos, Myc and Jun (Murphy et al., 2004). As well 
as repressing signalling, MEK162 increased apoptosis in both colon polyps and SITs 4 hours 
following exposure with no discernable effect on mitosis, suggesting reduced cell number 
(Figure 5.1, 5.2). Concordantly, scoring of BrdU positive cells in tumours post MEK162 
exposure revealed no gross alterations at the 4 hour time point however, an increase in the 
number of BrdU positive cells was detected in SITs 24 hours post exposure to MEK162 (Figure 
5.2). The reasons for this are unclear, however may be attributable to a compensatory 
mechanism to overcome the initial increase in apoptosis or may reflect cells stuck in S phase of 
the cell cycle. 
Recently, a number of studies investigating the consequences of MEK inhibition in cancer cell 
lines have reported compensatory activation of the closely associated PI3K signalling pathway 
(Turke et al., 2012, Yuen et al., 2012). In this study, probing of PI3K pathway activity revealed 
differential effects in colon polyps and SIT exposed to MEK inhibition. In colon polyps, a trend 
towards an increase in PI3K signalling through pAKT473, pAKT308 and pS6RP was observed 4 
hours post exposure to MEK162 with a significant increase in pAKT308 at 24 hours post 
exposure (Figure 5.3). In contrast, a reduction in PI3K signalling was observed in SITs with 
MEK162 exposure, evidenced through reduced levels of pAKT473 and pS6RP at 4 and 24 hours 
post exposure respectively (Figure 5.4).  The mechanisms behind the contrasting response of 
tumours to MEK162 are currently unclear, however may be due to differences in basal 
pathway activation, as observed in chapter 3, where the MAPK and PI3K pathways were found 
to be increasingly activated in Apcf/+ KrasLSL/+ colon polyps in comparison to SITs (Figure 3.13). 
The mechanism behind the compensatory activation of PI3K signalling is currently unknown 
but may be due to divergence of the two signalling cascades at mTOR, through direct 
interactions between Kras and p110 (Kodaki et al., 1994), or negative feedback loops which 
directly affect signalling of PI3K cascade at receptor level as identified by Turke et al and Yuen 
et al. As such, Turke and colleagues found that MEK inhibition led to increased PI3K signalling 
through hyperactivation of ERBB3, which was due to loss of inhibitory threonine 
phosphorylation on membrane domains of EGFR and HER2 (Turke et al., 2012). Yuen et al 
show that MEK inhibition lead to activation of pAKT specifically in Kras mutant and not wild-
type cancer cell lines. The authors propose that MEK inhibition in Kras mutant cells is not 
sufficient to lead to apoptosis and hence leads to increased PI3K signalling as a feedback 
mechanism to protect cells from apoptosis (Yuen et al., 2012). Subsequently, combinatorial 
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inhibition here led to sustained inhibition of MAPK and PI3K signalling as well as an enhanced 
effect on apoptosis (Yuen et al., 2012).  
Nevertheless, continuous treatment of MEK162 in Apcf/+ KrasLSL/+ mice at a dose of 30mg/kg 
twice-daily, led to a significant increase in survival, extending lifespan of mice from a median 
of 153 days to 287 days post induction (Figure 5.7). The effect on tumour burden was also 
favourable, indicated by a reduction in the total number of colon polyps and SITs compared to 
vehicle treated mice (Figure 5.21, 5.22). Furthermore, the total SIT area was significantly 
reduced with MEK162 treatment. Interestingly, although no significant differences were 
detected with regards to tumour severity, a trend towards more advanced invasive 
adenocarcinoma, characterised through invasion into the smooth muscle wall, was observed in 
SITs exposed to long term MEK162, indicating potential resistant growth (Figure 5.22 C). 
Previous studies evaluating MEK inhibitors for Kras mutant CRC have reported moderate 
effects of anti-MEK monotherapy. Migliardi et al showed the MEK inhibitor AZD6244 resulted 
in tumour growth stasis in Kras mutant patient-derived xenografts (Migliardi et al., 2012) and 
Holt et al also reported AZD6244 to result in moderate efficacy in the Calu-6 xenograft model 
(Holt et al., 2012).  Both studies however reported increased efficacy of MEK inhibition in 
combination with PI3K or mTOR inhibitors, providing rationale for further evaluation of these 
in Apcf/+ KrasLSL/+ mice.  
Regardless of the observations from Migliardi et al and Holt et al., the beneficial effects of 
chronic MEK162 treatment were also observed in the reduced dose cohort. Here, Apcf/+ 
KrasLSL/+ mice were administered MEK162 at 30mg/kg once-daily (O-D) as a control single agent 
arm for the reduced combination therapy (Figure 5.20). Interestingly, the survival benefit 
observed here was comparable to that of the twice-daily treatment cohort (mice on MEK162 
once-daily had a median survival of 286 days post induction compared to 287 on twice-daily 
treatment). Furthermore, in terms of tumour burden, both cohorts presented with similar total 
tumour number, tumour area and invasiveness. Although the total tumour area of Apcf/+ 
KrasLSL/+ mice on MEK162 once-daily treatment trended to be increased, fewer advanced 
invasive lesions (muscle wall invasion) and more early invasive lesions (submucosal invasion) 
were present (Figure 5.22). This later observation either indicates less resistant tumour 
growth, or that treatment of the reduced dose did not promote tumour progression. Despite 
this, the fact that no dose-dependent effect was observed with regards to survival with 
MEK162 alludes to a maximal effect being achieved which may be a particularly favourable 
property of the drug for combinatorial experiments. Similar findings by Simmons et al. where a 
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reduced dose of the MEK inhibitor PD-0325901 at sub-MTD levels of just 1.5mg/kg showed 
efficacy in the Kras mutant GEM model of lung cancer (Simmons et al., 2012) corroborate 
findings that MEK inhibition is highly efficacious even at reduced doses.          
 
5.3.2 PI3K/mTOR inhibition through NVP-BEZ235 significantly increases survival of Apcf/+ 
KrasLSL/+ mice however, leads to increased tumour burden 
Given the promiscuous nature of Kras in activation of PI3K signalling, a number of previous 
studies have evaluated the effects of PI3K inhibition in this setting using a multitude of pre-
clinical platforms (Roberts et al., 2012, Hofmann et al., 2012, Simmons et al., 2012). 
Assessment of this in the Kras driven model of lung cancer by Engelman and colleagues 
identified that although the PI3K/mTOR inhibitor NVP-BEZ235 did not shrink tumours, levels of 
pAKT were found to be reduced indicating that whilst PI3K may be required for Kras induced 
tumourigenesis, it is less critical for maintenance of tumours, in the lung cancer setting 
(Engelman et al., 2008). For further investigation of this in a CRC context, I examined the 
effects of the PI3K/mTOR inhibitor NVP-BEZ235 in an autochtonous mouse model of intestinal 
cancer driven by activation of oncogenic Kras. In the acute setting, NVP-BEZ235 resulted in 
minimal and differential inhibition of the PI3K pathway through pAKT at both threonine 308 
and serine 473 phosphorylation sites in colon and small intestine lesions (Figure 5.10, 5.11). 
The majority of substantial alterations in signalling from NVP-BEZ235 however, were found to 
be downstream of mTOR. Phosphorylated-S6RP was found to be significantly reduced in colon 
polyps 4 hours post exposure and in SITs at both 4 and 24 hour time points (Figure 5.10, 5.11). 
Also downstream of mTOR, p4EBP1 was found to be significantly reduced in colon and small 
intestine tumours 4 hours after exposure to NVP-BEZ235 suggesting inhibition of protein 
synthesis (Bracho-Valdés et al., 2011). The majority of signalling effectors probed here were 
found to be unaltered 24 hours after exposure in colon polyps indicating the initial inhibitory 
effects were diminished and signalling was returned to basal levels (Figure 5.10, 5.11). It is 
interesting that an increase in MAPK signalling through pERK was not observed in response to 
the predominantly mTOR related inhibition by NVP-BEZ235 in this setting (Figure 5.10, 5.11). 
This has previously been reported by Carracedo et al and others, where inhibition of mTORC1 
led to activation of MAPK signalling through the S6 kinase – IRS-1 – PI3K feedback loop 
(Carracedo et al., 2008b, Chen et al., 2010).    
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The favourable pharmacodynamic effects described above correspond with encouraging anti-
tumour effects of NVP-BEZ235 in Kras mutant tumours. A significant increase in the levels of 
apoptosis observed in both colon and SITs 4 hours post NVP-BEZ235 administration, together 
with no alteration in the levels of mitosis potentially indicate reduced cell numbers (Figure 
5.8). These results were further investigated through BrdU and cleaved caspase 3 staining and 
tended to corroborate findings (Figure 5.9). Also, a significant increase in cleaved caspase 3 
levels was detected at 24 hours post exposure to NVP-BEZ235 indicating a sustained pro-
apoptotic effect (Figure 5.9). Together, the immediate effects of NVP-BEZ235 in Apcf/+ KrasLSL/+ 
mice appear favourable and warranted further long term investigations.  
For further evaluations, the effects of PI3K/mTOR inhibition by NVP-BEZ235 were evaluated in 
a survival setting to determine the potential of single agent as a therapeutic strategy. Here, 
Apcf/+ KrasLSL/+ mice were induced and aged to 100 days post induction at which point they 
were administered with 35mg/kg NVP-BEZ235 twice-daily until a survival end point or until the 
experimental end point of 500 days post induction. Treatment was found to significantly 
increase survival of Apcf/+ KrasLSL/+ mice from a median of 153 days to 343 days post induction 
demonstrating as described previously, strong dependence of Kras mutant tumours on PI3K 
signalling (Figure 5.13). Analysis of tumour burden showed twice-daily NVP-BEZ235 treatment 
had no significant effect on colon tumour number, total tumour area or tumour severity 
(Figure 5.21). These observations however, indicate reduced colon tumour growth rate as mice 
did have increased survival with drug treatment. With regards to SITs, no significant alteration 
in the number of lesions was scored however, the total tumour area measured was found to 
be reduced and tumours were characteristically less invasive compared to vehicle cohorts 
suggesting treatment halted SITs growth and progression of tumours (Figure 5.22).   
In comparison to the MEK162 twice-daily cohort, NVP-BEZ235 treatment was not significantly 
more beneficial (in terms of survival) even though the median survival of mice was 76 days 
increased (MEK162 T-D had a median survival of 287 days whereas NVP-BEZ235 had a median 
survival of 343 days post induction), suggesting equipotent effects of long term pathway 
inhibition on survival of tumour bearing mice. Despite this, there are notable differences with 
regards to tumour burden when comparing both cohorts, which could possibly allude to 
differing roles of both signalling pathways in the initiation, maintenance and progression of 
tumourigenesis. From the above observations, it can be deduced that therapeutic PI3K/mTOR 
inhibition elicited effects by delaying the tumour growth in the colon but also by preventing 
tumour progression in the small intestine. In this study, MEK inhibition was found to delay 
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tumour growth in the colon and significantly reduce total tumour area in the small intestine 
suggesting a role for MAPK signalling predominantly in promoting tumour growth. Colon 
tumours here were found to have the same histological profile of invasive tumours but small 
intestine tumours trended to be more invasive which could elude to resistant tumour growth 
given mice survive longer on daily MEK162 treatment. From the literature, the therapeutic 
effects of PI3K/mTOR and MEK inhibition on tumour growth stasis or shrinkage of tumours in 
Kras mutant setting, appears to be tissue specific. In the Kras mutant lung cancer model, 
monotherapy with PI3K/mTOR and MEK inhibitors was shown to lead to tumour growth stasis, 
but targeting both pathways independently led to tumour shrinkage in mouse models of Kras 
mutant melanoma (Engelman et al., 2008, Roberts et al., 2012). Furthermore, in the pancreatic 
cancer setting, Kras mutant tumours were more responsive to MEK inhibition than PI3K 
inhibition (Hofmann et al., 2012) in this case suggesting more dependence on MAPK signalling 
rather than PI3K signalling.  
Further investigation of NVP-BEZ235 in Apcf/+ KrasLSL/+ mice showed that similarly to reduced 
MEK162 administration, once-daily NVP-BEZ235 treatment as a control dose for combination 
studies, also increased survival. Mice had a median survival of 267 days post induction with 
treatment, compared to 153 days post induction with vehicle treatment (Figure 5.20). In 
contrast to the reduced MEK162 treatment however, the survival benefit with NVP-BEZ235 
was found to be dose-dependent in that mice on twice daily treatment had an increased 
survival benefit in comparison to mice on once daily treatment. Interestingly, tumour burden 
analysis of mice exposed to chronic NVP-BEZ235 revealed an increasing trend in colon tumour 
number and area however, no difference in the profile of tumour severity was observed, 
suggesting that treatment resulted in augmented tumour growth rate, in contrast with the 
effects of twice-daily dosing (Figure 5.21). Despite this, NVP-BEZ235 treatment in the small 
intestine reduced tumour growth and halted tumour progression as evidenced by an increase 
in the number of less invasive lesions and a reduction in the number of more invasive lesions 
(Figure 5.22). These conflicting observations suggest that small intestinal lesions may respond 
better to reduced PI3K inhibition and this may be due to the reduced activation of PI3K 
signalling in this tumour setting, in comparison with colon polyps (as observed in chapter 3, 
section 3.2.8). In comparison with the reduced MEK162 dose, the effects of NVP-BEZ235 were 
more favourable for SIT burden however, the opposite was the case for colon tumour burden. 
These observations suggest that combined inhibition may provide promising effects in terms of 
tumour burden.          
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5.3.3 Combination treatment leads to an additive increase in longevity for Apcf/+ KrasLSL/+ 
mice 
As described previously, the rationale for combination therapy is well documented in the 
literature, providing experimental evidence from both in vitro and in vivo studies (Yuen et al., 
2012, Turke et al., 2012, Engelman et al., 2008, Balmanno et al., 2009). In an effort to evaluate 
the potential of combined inhibition in our Apcf/+ KrasLSL/+ mouse model of intestinal cancer, I 
first evaluated the three combination strategies employed previously in chapter 4 to 
determine whether Kras mutant tumours are as sensitive to the schedule of drug 
administration as Pten deficient tumours were found to be (section 4.2.5). Pharmacodynamic 
evaluation of Kras mutant colon polyps and SITs exposed to the three combination strategies, 
by western blot analysis of effectors of MAPK and PI3K signalling, revealed no stark differences 
between the three combination strategies, indicating that Kras mutant tumours are not 
sensitive to the sequence of drug administration (Figure 5.16, 5.17). All three combination 
strategies resulted in substantial inhibition of MAPK signalling through pERK and inhibition of 
PI3K/mTOR signalling through pS6RP (Figure 5.16, 5.17). Combo 2 also resulted in inhibition of 
p4EBP1 in colon polyps whereas both combo 1 and 2 reduced abundance of p4EBP1 in SITs 
(Figure 5.16, 5.17). No significant alterations in the levels of pAKT were observed in either 
colon polyps or SITs, in response to the combination strategies suggesting that perhaps, in 
combination with MEK162, the ability of NVP-BEZ235 to reduce levels of pAKT is abrogated 
(Figure 5.16, 5.17). To determine the mechanism behind this, further investigation is required 
however, it is plausible that the phenotype in colon polyps is due to an additive effect of both 
inhibitors. As single agent MEK162 was found to increase PI3K signalling acutely and NVP-
BEZ235 was found to inhibit signalling at pAKT, the phenotype resulting from combination 
treatment may simply reflect an additive result. Nevertheless, combination therapy does lead 
to inhibition of both MAPK and PI3K/mTOR signalling albeit levels of all signalling components 
assessed were not completely reduced. Additionally as described previously, all three 
combination strategies significantly increased levels of apoptosis and cleaved caspase 3 
staining in both colon and SITs with no detectable effect on the level of mitosis, suggesting 
reduced cell number (Figure 5.14, 5.15). Therefore, to remain consistent between genotypes 
with regards to the long term combination treatment strategy, combo 2 was chosen as the 
method of administering combination therapy for long term survival experiments.  
As in Apcf/+ Ptenf/f mice, combination therapy here first involved administration of NVP-BEZ235 
twice-daily followed by MEK162 once daily (1 hour following the first dose). This however was 
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quickly found to be toxic for Apcf/+ KrasLSL/+ mice as the majority of mice were culled due to 
significant weight loss (Figure 5.18, 5.19). The lack of toxicity in Apcf/+ Ptenf/f mice compared to 
Apcf/+ KrasLSL/+ mice may be attributable to a number of factors. Firstly, the experimental 
system employed differed between the two mouse models. The AhCreER transgene used in 
the Apcf/+ Ptenf/f model results in lower levels of recombination within the intestine in 
comparison to the VillinCreER transgene used in the Apcf/+ KrasLSL/+ model, due to the 
requirement of both a xenobiotic and tamoxifen (el Marjou et al., 2004, Kemp et al., 2004). 
Therefore, less intestinal cells undergo recombination resulting in mutations with the AhCreER 
transgene in comparison to all intestinal cells which undergo recombination with the 
VillinCreER transgene. A recent study investigating the effect of heterozygous loss of Apc and 
activation of Kras in the normal intestinal epithelium found an increased number of cells per 
half villus and reduced enterodendocrine and paneth cells in comparison to controls (Davies 
EJ, unpublished). This therefore results in less absorptive cells within the intestinal epithelium 
which may lead to subtle metabolic changes (Guarner and Malagelada, 2003), which when 
challenged could affect absorption of food and water and subsequently result in weight loss. 
Despite this, no gross alteration in the histological architecture of the intestine was observed 
with combination therapy, indicating the toxic effect may be due to additional factors. Kras 
function has previously been found to be dispensable in a number of adult tissues including 
the intestine, which was unaffected by loss of Kras (Velho and Haigis, 2011). Additional studies 
investigating genetic inhibition of MAPK signalling found that although Erk-/- mice are fertile 
and present with no apparent abnormalities, they do have a reduction in the number of 
mature thymocytes, raising concerns of potential toxicity from inhibition of signalling (Pagès et 
al., 1999). Despite the later observation, long term MEK inhibition was well tolerated and 
Apcf/+ KrasLSL/+ mice displayed no signs of toxicity (detected by weight loss). Genetic 
experiments investigating inhibition of PI3K signalling have previously reported important roles 
of the signalling cascade in insulin signalling and energy sensing mediated through interactions 
with IRS-1 and mTOR signalling respectively (Engelman et al., 2006, Shaw, 2006). Furthermore, 
deletion of p110 causes lethality during embryogenesis and although Akt1 and Akt2 null mice 
are viable, they are smaller in size, have a shorter lifespan and are highly susceptible to 
apoptosis (Foukas et al., 2006, Chen et al., 2001). Nevertheless, single agent PI3K/mTOR 
inhibition was found to be well tolerated in Kras mutant mice, indicating the toxic effects may 
be due to combined inhibition and the presence of the Kras mutation. Previous studies 
investigating combined PI3K/mTOR and MEK inhibition have not reported any major toxicity 
issues however this may be due to differences in the doses administered and regimens used 
213 
 
for example, Kinross et al. assessed combined inhibition of PI3K/mTOR and MEK in models of 
ovarian cancer with PF-04691502 and PD-0325901 respectively. In this case, although the dual 
PI3K/mTOR inhibitor displayed some toxicity at higher doses, the combination therapy which 
involved reduced dose of 7.5mg/kg of the PI3K/mTOR inhibitor and 1.5mg/kg of the MEK 
inhibitor, was found to be well tolerated (Kinross et al., 2011). Additionally, Engelman et al 
investigating the combination therapy in the Kras mutant lung cancer model reported no toxic 
effects. Here, the dual PI3K/mTOR inhibitor NVP-BEZ235 was also used, together with MEK 
inhibitor AZD6244, at once daily doses of 35mg/kg and 25mg/kg respectively.  
In light of the previous toxicity issues, a further reduced combination dose was assessed in 
Apcf/+ KrasLSL/+ mice which involved once daily NVP-BEZ235 at 35mg/kg plus MEK162 at 
30mg/kg 1 hour following the initial dose. Interestingly, this was well tolerated by mice and no 
weight loss was observed indicating the toxic effects were no longer apparent. Reduced 
combination therapy (combo R2) increased survival of Apcf/+ KrasLSL/+ mice from a median of 
153 days to 389 days post induction, which also indicates an additive increase in median 
survival compared to single agents MEK162 and NVP-BEZ235 when administered once daily 
(Figure 5.20). The additive effect in median survival also supports the hypothesis regarding 
early pharmacodynamic effects from combination therapy as an additive effect. In terms of 
colon tumour burden, although the number of lesions scored was significantly reduced, total 
tumour area and the invasive characteristics of lesions were comparable to vehicle treated 
mice (Figure 5.21). Interestingly in the small intestine, fewer lesions were scored and were 
found to be reduced in terms of total tumour area as well as proportionally, lesions were less 
invasive, perhaps indicating reduced tumour burden (Figure 5.22). However, there was also a 
trend towards an increase in the number of advanced invasive adenocarcinomas, 
characterised by smooth muscle invasion and may potentially reflect resistant tumour growth. 
The increased beneficial effect of combinatorial therapy upon survival and tumour burden has 
previously been corroborated in other malignancies (Engelman et al., 2008, Migliardi et al., 
2012, Singh et al., 2010, Simmons et al., 2012) however, this study provides the first proof of 
principle evidence for combination therapy in an autochtonous mouse model of intestinal 
cancer driven by oncogenic Kras.           
5.4 Summary 
In summary, therapeutic targeting of MAPK signalling using the MEK inhibitor MEK162 in 
tumour bearing Apcf/+ KrasLSL/+ mice, significantly prolonged longevity of mice. Acutely 
however, tumours respond by compensatory modulation of PI3K signalling. Subsequently, 
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inhibition of signalling here using the dual PI3K/mTOR inhibitor NVP-BEZ235 was found to be 
equally beneficial for Apcf/+ KrasLSL/+ mice, indicating equivalent dependence of Kras mutant 
tumours on both signalling pathways. Together, MEK162 and NVP-BEZ235 resulted in an 
additive increase in survival for Apcf/+ KrasLSL/+ mice suggesting this as an effective therapeutic 
strategy for Kras mutant colorectal cancer.         
5.5 Further work 
5.5.1 Further investigation of mechanisms underlying the immediate response of Kras 
mutant tumours to combination therapy 
As described previously, combined MEK162 and NVP-BEZ235 abrogated the capability of NVP-
BEZ235 to reduce PI3K signalling though pAKT. I have proposed that this may be due to an 
additive effect as pAKT was increased immediately after MEK162 but reduced after NVP-
BEZ235 which additively, results in a null effect as observed with combination therapy. This 
was further supported by an additive increase in survival with combination therapy however 
this does not identify the mechanism underlying this. It would be insightful to investigate 
pharmacodynamics at shorter time points after administration, for example at 1,2 and 3 hours 
post exposure, to determine whether any differences in signalling can be determined which 
could provide the mechanism for this. Additionally, further investigation of intracellular 
signalling at convergence points would also provide insight into the additive interactions. This 
includes status of TSC2, the BH3 proteins which control apoptotic signalling BAD, BIM as well 
as Mcl-1. Additionally, status of negative regulators of the MAPK pathway- Dusp and Sprouty 
proteins, and negative regulators of PI3K signalling – IRS-1 and S6K would be informative.  
5.5.2 Further investigation to toxic effects of combination in Apcf/+ KrasLSL/+ mice and not 
Apcf/+ Ptenf/f mice 
As described previously, administration of PI3K/mTOR inhibitor NVP-BEZ235 twice daily plus 
MEK inhibitor MEK162 in Kras mutant mice led to substantial toxicity which was not observed 
in the Pten deficient setting. To further investigate whether this was due to detrimental effects 
on normal intestinal homeostasis, scoring of proliferation and apoptosis in the crypts (and villi) 
of the small intestinal and colonic epithelium could be carried out. Furthermore, 
characterisation of the stem cell compartment and the differentiated cell types within the 
epithelium in combination treated cohorts, compared to single agents could identify whether 
normal homeostasis was altered and may help to identify the detrimental effects of this 
combination regimen in the Kras mutant setting.   
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5.5.3 Mechanisms of resistance to combination therapy 
Given the prevalence of Kras mutations in human colorectal cancer, the lack of effective 
treatment for this sub-group of tumours indicates they still represent an unmet clinical need. 
Although this study has provided evidence for combined MEK and PI3K/mTOR inhibition as a 
highly effective therapeutic strategy, it remains imperative to further investigate the effect of 
this as a therapy, as tumours tend to evolve and develop resistance to therapy. Previously, I 
have hypothesised that in some cohorts where an increase in the severity of tumours is seen, 
this could be indicative of resistant tumour growth. To determine if this indeed is the case, 
immunohistochemistry for downstream effectors of both MAPK and PI3K signalling, together 
with scoring of proliferation and apoptosis, could be used to determine whether tumours are 
still responding to treatment. These two factors could then be correlated with the severity 
status of tumours to determine whether tumour progression is associated with resistant 
tumour growth.     
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6 Investigating PI3K/mTOR inhibition and MEK inhibition in the Apcf/+ Ptenf/f 
KrasLSL/+ colorectal cancer mouse model 
 
6.1 Introduction 
Work described in chapters 4 and 5 indicate that whilst inhibition of PI3K/mTOR signalling is an 
effective therapeutic strategy for Pten deficient tumours, combined targeting of MEK and 
PI3K/mTOR was most beneficial for Kras activated tumours. This is potentially due to the 
‘double-hit’ effect of Kras mutations, which were shown to activate both MAPK/ERK and 
PI3K/AKT signalling in chapter 3. Despite characterisation of targeted agents in Pten deficient 
and Kras mutant independent tumour models, concomitant mutations resulting in activation 
of PI3K and MAPK signalling have been shown to co-exist in approximately a third of all CRC 
cases (Network, 2012). Additionally, sequencing analysis has identified that mutations in APC, 
KRAS and PIK3CA are the most prevalent mutations in CRC. Furthermore, these mutations are 
associated with aggressive disease and a poor prognosis for cancer patients (Wood et al., 
2007, Ogino et al., 2009, Richman et al., 2009). Therapeutic investigation of targeted agents in 
models of cancer with activating mutations of PI3K signalling and concurrent Kras mutations 
have indicated beneficial effects in ovarian, lung and thyroid cancers (Kinross et al., 2011, 
Engelman et al., 2008, Miller et al., 2009). In light of these observations, I next investigated 
therapeutic targeting of PI3K and MAPK signalling in the context of concurrent Pten loss and 
Kras activation.   
A recent study in the Clarke lab investigating the synergy between Pten and Kras in the context 
of tumourigenesis revealed that compound deletion of Pten and activation of mutant Kras 
within the intestinal epithelium resulted in metastatic carcinoma. Here, mice had a median 
survival of 344 days post induction and presented with multiple intestinal phenotypes as well 
as metastatic lesions in the liver, pancreas, lung and lymph node (Davies EJ, unpublished). 
Although this tumour model is attractive for the evaluation of novel and targeted therapeutic 
strategies, a number of caveats render the model impractical. These include the long latency 
period of tumour development, multiple intestinal phenotypes and the fact that metastasis 
was not observed with 100% penetrance. However, Davies et al also found synergy between 
Pten loss and activation of Kras in the context of activated Wnt signalling through 
heterozygous deletion of Apc. Here, although ‘hyper-activation’ of PI3K signalling was not 
detected by IHC (also confirmed in chapter 3 by western blot analysis), mice had a significantly 
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reduced lifespan of only 41 days post induction and presented with more tumours at death 
(Davies EJ, unpublished). Given these later observations, the therapeutic potential of 
PI3K/mTOR and MEK inhibition in the mouse model mutant for Apc, Pten and Kras was next 
investigated.  
In this chapter, the therapeutic potential of PI3K/mTOR and MEK inhibition through NVP-
BEZ235 and MEK162 are evaluated independently, as well as in combination, in the Pten 
deficient and Kras activated tumour setting. Similarly to chapters 3-5, two main strategies 
were employed for these investigations. For evaluation of immediate anti-tumour and 
pharmacodynamic effects, tumour bearing VillinCreER Apcf/+ Ptenf/f KrasV12LSL/+ mice (hereon in 
referred to as Apcf/+ Ptenf/f KrasLSL/+ mice) were administered a single dose of NVP-BEZ235, 
MEK162 or combination and harvested 4 or 24 hours following. Additionally, the effect on 
survival was evaluated through daily administration of single agents and combination therapy 
from a chosen start point until a survival end point (when mice were symptomatic of disease 
defined by pale feet, anal bleeding, bloating, and weight loss). 
6.2 Results 
6.2.1 NVP-BEZ235 increases apoptosis in Apcf/+ Ptenf/f KrasLSL/+ tumours, inhibits PI3K and 
mTOR signalling, however also reduces MAPK signalling 
For all short term experiments described in this chapter, 10 week old Apcf/+ Ptenf/f KrasLSL/+ 
mice were induced and monitored for symptoms of tumour burden (paling feet, bloating, 
blood in faeces). A cohort of n≥3 mice were then administered a single dose of 0.5% Methyl 
cellulose (MC, vehicle) and harvested 4 hours later, or a single dose of 35mg/kg NVP-BEZ235 
and harvested 4 or 24 hours later. A dose of BrdU was also administered 2 hours prior to 
culling. At dissection, small intestinal tumours (SITs) were immediately snap frozen in liquid 
nitrogen before ‘swiss-rolling’ the whole small intestine and fixing in formalin for H&E staining 
and IHC (section 2.4).  
Following exposure to a single dose of NVP-BEZ235, the immediate anti-tumour effects were 
characterised in Apcf/+ Ptenf/f KrasLSL/+ SITs through assessment of histological mitosis and 
apoptosis from H&E stained slides. Scoring of mitotic figures revealed no significant alterations 
4 or 24 hours following NVP-BEZ235 compared to vehicle controls (4hr veh = 0.283 ± 0.192, 
4hr NVP-BEZ235 = 0.339 ± 0.202, p value = 0.328, 24hr NVP-BEZ235 = 0.357 ± 0.15, p value = 
0.104, n≤15 tumours, 4 mice, Mann Whitney U test) (Figure 6.1 A). Quantification of apoptotic 
bodies from H&E stained slides revealed a significant increase in levels of apoptosis at 4 hours 
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but a significant reduction at 24 hours post exposure in comparison to vehicle treated controls 
(4hr veh = 1.00 ± 0.515, 4hr NVP-BEZ235 = 2.281 ± 1.301, p value = 0.0001, 24hr NVP-BEZ235 = 
0.618, p value = 0.024, n≥ 15 tumours, 4 mice, Mann Whitney U test) (Figure 6.1 B). The 
observation that an initial wave of apoptosis at 4 hours is followed by a reduction in the levels 
of apoptosis at 24 hours suggests transient anti-tumour effects and subsequently, activation of 
a compensatory mechanism to restore levels of apoptosis.  
In addition to histological mitosis and apoptosis, IHC for BrdU and cleaved caspase 3 were 
carried out and quantified to further characterise the anti-tumour effects. Scoring of the 
proliferative marker BrdU revealed no significant difference at 4 hours following NVP-BEZ235 
but a significant increase at the 24 hour time point (4hr veh = 13.36 ± 4.13, 4hr NVP-BEZ235 = 
15.9 ± 4.42, p value = 0.2667, 24hr NVP-BEZ235 = 18.82 ± 4.30, p value = 0.006, n≥ 15 tumours, 
4 mice, Mann Whitney U test) (Figure 6.2 A). Scoring of cleaved caspase 3 staining in Apcf/+ 
Ptenf/f KrasLSL/+ tumours identified a significant increase in staining 4 and 24 hours post 
exposure to NVP-BEZ235 (4hr veh = 1.22 ± 0.56, 4hr NVP-BEZ235 = 2.46 ± 1.14, p value = 
0.0006, 24hr NVP-BEZ235 = 1.99 ± 1.097, p value = 0.0133, n≥15 tumours, 4 mice, Mann 
Whitney U test), indicating a prolonged pro-apoptotic effect (Figure 6.2 B).  
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Figure 6.1 NVP-BEZ235 results in a pro-apoptotic effect in Apcf/+ Ptenf/f KrasLSL/+  small 
intestinal tumours (SITs) 4 hours following exposure, but no effect on mitosis 
Following exposure to NVP-BEZ235, scoring of mitotic figures (A) and apoptotic bodies (B) in 
Apcf/+ Ptenf/f KrasLSL/+ tumours revealed no alterations in the levels of mitosis however, a 
significant increase in apoptosis 4 hours after exposure was revealed (p value = 0.0001, n ≥ 3, 
Mann Whitney U test). This immediate pro-apoptotic effect was found to be significantly 
reduced by 24 hours post exposure (p value = 0.024, n ≥ 15 tumours, 4 mice, Mann Whitney U 
test).  Error bars represent standard deviation  
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Figure 6.2 NVP-BEZ235 increases the number of cycling cells, but also increases apoptosis 
through cleaved caspase 3 in Apcf/+ Ptenf/f KrasLSL/+  lesions 
Scoring of IHCs for BrdU (A) and cleaved caspase 3 (B) revealed an anti-proliferative increase in 
the number of BrdU positive cells 24 hours after exposure to NVP-BEZ235, but also a pro-
apoptotic increase in cleaved caspase 3 staining 4 and 24 hours after exposure (p value = 0.006 
for 24hr BrdU, p value = 0.0006 for 4hr caspase and p value = 0.0133 for 24hr caspase, n ≥ 15 
tumours, 4 mice, Mann Whitney U test).  Error bars represent standard deviation  
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To investigate the effects of NVP-BEZ235 on PI3K and mTOR signalling in Apcf/+ Ptenf/f KrasLSL/+ 
tumours, western blotting was used to analyse SIT lysates. Proteins extracted from 6 SITs were 
pooled (per cohort) from n=3 mice exposed to either vehicle or NVP-BEZ235 and harvested 
either 4 or 24 hours following. For analysis of PI3K and mTOR signalling, antibodies against the 
phosphorylated (and hence activated forms) of AKT (Ser473 and Thr308) S6RP (Ser235/236) 
and 4EBP1 (Thr37/46) were used. Western blotting and subsequent densitometry analysis 
revealed subtle, yet significant reductions in the levels of pAKT473, pAKT308, and pS6RP 4 
hours post exposure to NVP-BEZ235 (Figure 6.3, Table 6.1). Although not significant, a trend 
for reduced p4EBP1 was also notable. Signalling at 24 hours post exposure to NVP-BEZ235 was 
generally augmented, as evidenced though significantly increased levels of pAKT473, pAKT308, 
and pS6RP and a trend towards an increase in p4EBP1, and may be responsible for the 
reduced levels of apoptosis observed previously (Figure 6.3, Table 6.1). 
 Vehicle 4hr NVP-BEZ235 (p value) 24hr NVP-BEZ235 (p value) 
pAKT473 4276.9 ± 181.2 3539.8 ± 128.8 (0.0404) 4960 ± 156.9 (0.0404) 
pAKT308 1791.3 ± 336.9 1003.1 ± 80.7 (0.0404) 3073.1 ±608.6 (0.0404) 
pS6RP 1572.9 ± 701.9 112.4 ± 81.9 (0.0404) 3367.9 ± 976.0 (0.0404) 
p4EBP1 4260 ± 1633.3 3111.2 ± 356.7 (0.1914) 4877.6 ± 569.5 (0.3313) 
pERK 6207.1 ± 727.9 3720.9 ± 647.9 (0.0404) 5805.6 ± 454.2 (0.1914) 
Table 6-1 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f KrasLSL/+ SITs 4 and 24 hours post exposure to NVP-BEZ235 , n=3, One-tailed Mann 
Whitney U test was used for statistical analysis 
Given the activation of mutant Kras in these tumours, activation status of MAPK signalling was 
subsequently analysed to investigate whether PI3K/mTOR inhibition led to compensatory 
increase in signalling through pERK. Immunoblotting and subsequent densitometry analysis 
revealed a surprising reduction in levels of pERK 4 hours post exposure to NVP-BEZ235 with 
levels returning to basal levels by 24 hours post exposure (Figure 6.3, Table 6.1).  
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(A) 6 SIT lysates pooled from n=3 mice exposed to NVP-BEZ235 for 4 or 24 hours were 
subjected to western blot analysis. Effectors of the PI3K and mTOR signalling pathways were 
probed and revealed marked reduction of pathway effectors 4 hours post exposure.  Signalling 
at 24 hours post exposure was found to be significantly increased through pAKT473, pAKT308 
and pS6RP.  Additionally, the MAPK pathway effector pERK was probed to assess pathway 
activation. This revealed a significant reduction at 4 hours, but no effect at 24 hours (B). 
Densitometry was carried out to quantify differences observed from immunoblotting. These 
are normalised to β-actin as loading control and represented as relative to vehicle controls (*p 
value = 0.0404, n=3, Mann Whitney U test). 
Figure 6.3 NVP-BEZ235 reduces PI3K and mTOR signalling in Apcf/+ Ptenf/f KrasLSL/+  tumours 4 
hours after exposure, however increases signalling  at a 24 hour time point 
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In summary, the immediate consequences of NVP-BEZ235 in Apcf/+ Ptenf/f KrasLSL/+ SITs involve 
reduction in PI3K and mTOR signalling (summarised in Figure 1.4) and induction of apoptosis. 
At 24 hours however, an increase in PI3K and mTOR signalling was observed and given the role 
of the pathway in controlling cellular proliferation and apoptosis, this may be attributable to 
the increased proliferation and reduced apoptosis observed here.   
 
At 4 hours post exposure, NVP-BEZ235 leads to a reduction in levels of pERK, pAKT at Ser473 
and Thr308 and pS6RP whereas at 24 hours post exposure, NVP-BEZ235 results in increased 
levels of pAKT at Ser473 and Thr308 and pS6RP. 
 
 
 
 
 
 
 
Figure 6.4 Schematic showing the effects of NVP-BEZ235 on PI3K/mTOR and MAPK pathway 
components as detected by western blot analysis (Green denotes a reduction whereas red 
indicates an increase). 
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6.2.2 Chronic NVP-BEZ235 significantly increases longevity of Apcf/+ Ptenf/f KrasLSL/+ mice 
To investigate the therapeutic potential of PI3K and mTOR inhibition using NVP-BEZ235 in a 
compound Pten deficient and Kras activated tumour setting, a long term treatment 
experiment was conducted to assess the effect on longevity and tumour burden of mice. For 
this, a cohort of 13 mice per cohort were induced and aged until the chosen intervention start 
point. Given these mice become symptomatic of disease from 3 weeks (21 days) following 
induction and have a median survival of just 41 days, a time point of 22 days post induction 
was chosen as the intervention start point. Mice were randomised to receive either 0.5% MC 
(vehicle) or 35mg/kg NVP-BEZ235 twice daily (weekdays only) by oral gavage, until a survival 
end point (anaemia, bloating, ≥10% loss of body weight). 
Chronic NVP-BEZ235 administration in Apcf/+ Ptenf/f KrasLSL/+  mice was found to be well 
tolerated by mice (determined by body weight) and led to a significant increase in survival of 
mice from 40 days to 104 days post induction (n≥ 13 per cohort, p value = 0.0001, Log-Rank 
and Wilcoxon test) (Figure 6.5). Long term NVP-BEZ235 treatment more than doubled lifespan 
of Apcf/+ Ptenf/f KrasLSL/+ mice indicating this as a beneficial therapeutic strategy.   
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Figure 6.5 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f KrasLSL/+ mice on NVP-BEZ235 
compared to vehicle controls 
Apcf/+ Ptenf/f KrasLSL/+ mice were induced and aged to 22 days post induction, at which point 
mice were randomised to receive either 0.5% Methyl cellulose (Vehicle control) or 35mg/kg 
NVP-BEZ235 twice-daily by oral gavage until a survival end point. Continuous NVP-BEZ235 
treatment was found to significantly increase survival of mice from 40 days (vehicle controls) 
to a median of 104 days post induction (p value ≤ 0.001, n≥13 mice per cohort, Log-Rank and 
wilcoxon test).  
 
 
 
 
 
 
226 
 
 
6.2.3 MEK162 increases cleaved caspase 3 in Apcf/+ Ptenf/f KrasLSL/+ tumours and prolonged 
inhibition of MAPK signalling, however also leads to modulation of PI3K/mTOR 
signalling 
Given that MEK inhibition induced favourable anti-tumour and pharmacodynamic effects in 
Apcf/+ KrasLSL/+ mice, I next investigated the immediate effects of MEK inhibition through 
MEK162 in the additional presence of Pten deletion. Similarly to section 6.2.1, for short term 
experiments, Apcf/+ Ptenf/f KrasLSL/+ mice were induced and aged until presented with 
symptoms of tumour burden. Mice were then administered with a single dose of 30mg/kg 
MEK162 and harvested either 4 or 24 hours post exposure as described previously in methods 
section 2.4. Mice were also administered a dose of BrdU 2 hours prior to culling. Vehicle 
controls used for this experiment were previously described in section 6.2.1.  
To explore the immediate anti-tumour activity of MEK162 in Apcf/+ Ptenf/f KrasLSL/+ tumours, 
mitotic figures and apoptotic bodies were scored from H&E stained slides. Quantification of 
mitosis in Apcf/+ Ptenf/f KrasLSL/+ SITs revealed no significant alterations at either 4 or 24 hours 
post exposure (4hr veh = 0.283 ± 0.192, 4hr MEK162 = 0.439 ± 0.293, p value = 0.0565, 24hr 
MEK162 = 0.288 ± 0.268, p value = 0.494, n ≥ 15 tumours, 4 mice, Mann Whitney U test) 
(Figure 6.6 A). Similarly, no significant alterations in apoptosis were observed at 4 or 24 hours 
post exposure to MEK162 (4hr veh = 1.00 ± 0.515, 4hr MEK162 = 1.416 ± 0.764, p value = 
0.073, 24hr MEK162 = 0.72 ± 0.346, p value = 0.138, n≥15 tumours, 4 mice, Mann Whitney U 
test) (Figure 6.6 B). 
In addition to scoring of histological mitosis and apoptosis, IHC against the proliferative marker 
BrdU and the apoptotic marker cleaved caspase 3 was carried out and scored. Quantification 
of BrdU positive cells revealed a significant increase in staining 4 hours after MEK162 exposure 
but no significant alteration at 24 hours (4hr veh = 13.36 ± 4.134, 4hr MEK162 = 19.57 ± 4.05, 
p value = 0.0017, 24hr MEK162 = 14.96 ± 4.94, p value = 0.521, n≥15 tumours, 4 mice, Mann 
Whitney U test) (Figure 6.7 A). This suggests possible compensatory activation of proliferation 
in response to MEK162 at 4 hours which is relieved by 24 hours. Scoring of cleaved caspase 3 
staining in these samples revealed a significant increase in staining at both 4 and 24 hour time 
points after MEK162 exposure (4hr veh = 1.219 ± 0.56, 4hr MEK162 = 7.028 ± 2.56, p value ≤ 
0.0001, 24hr MEK162 = 4.12 ± 2.68, p value = 0.0001, n≥15 tumours, 4 mice, Mann Whitney U 
test) (Figure 6.7 B). Although cleaved caspase 3 levels were found to be increased at both 4 
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and 24 hour time points, caspase 3 levels at the 4 hour time point appeared higher than at 24 
hours indicating transient anti-tumour effects (Figure 6.6).    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scoring of mitotic figures (A) and apoptotic bodies (B) revealed no significant alterations 4 or 
24 hours after a single dose of 30mg/kg MEK162 compared to vehicle (0.5% MC) (p value ≥ 
0.05, n ≥ 15 tumours, 4 mice, Mann Whitney U test). Error bars represent standard deviation.   
 
 
 
Figure 6.6 MEK162 has no effect on levels of mitosis or apoptosis in Apcf/+ Ptenf/f KrasLSL/+  
small intestine tumours (SITs) 
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IHC for BrdU (A) and cleaved caspase 3 (B) was carried out and quantified. Scoring revealed a 
significant increase in BrdU positive cells 4 hours post exposure and a significant increase in 
cleaved caspase 3 staining at 4 and 24 hours following exposure to a single dose of 30mg/kg 
MEK162 (p value ≥ 0.05, n ≥ 15 tumours, 4 mice, Mann Whitney U test). Error bars represent 
standard deviation.   
 
 
Figure 6.7 MEK162 significantly increases the number of BrdU positive cells and cleaved 
caspase 3 staining in Apcf/+ Ptenf/f KrasLSL/+  small intestine tumours (SITs) 
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As described in studies elsewhere (Wee et al., 2009) and in chapter 4, mutations resulting in 
activation of PI3K signalling are inherently resistant to MEK inhibition. Wee et al showed that 
activated PI3K signalling renders Kras mutant tumours (which would normally be sensitive) 
unresponsive to MEK inhibition (Wee et al., 2009). To investigate whether this is also the case 
in our Apcf/+ Ptenf/f KrasLSL/+ model, tumours harvested from mice 4 and 24 hours post MEK162 
were analysed for effectors of MAPK and PI3K signalling. Proteins extracted from 6 SITs (from 
n=3 mice) were pooled per cohort and subjected to western blot analysis (Figure 6.8). 
Immunoblotting and subsequent densitometry analysis revealed prolonged inhibition of MAPK 
signalling evidenced through reduced pERK abundance at both 4 and 24 hour time points 
(Figure 6.8, Table 6.2). Interestingly, investigation of PI3K signalling in response to MEK 
inhibition revealed a significant reduction in signalling through pAKT473, pAKT308 and pS6RP 
and a trend towards reduced p4EBP1 abundance. Furthermore, analysis of signalling at the 24 
hour post exposure time point revealed a trend towards increased PI3K/mTOR signalling 
through pAKT473 and pAKT308, with a significant increase in pS6RP and p4EBP1 (Figure 6.8, 
Table 6.2). As described previously, cross-talk between the MAPK and PI3K signalling cascades 
occurs through a number of mechanisms and these be responsible for the immediate 
modulations observed here. Nevertheless, the observation that acute MEK inhibition leads to 
reduced PI3K signalling in this model (summarised in Figure 6.9) warrants further exploration 
of MEK inhibition, given the increased benefit in survival following chronic PI3K/mTOR 
inhibition.  
 Vehicle 4hr MEK162 (p value) 24hr MEK162 (p value) 
pERK 5922 ± 1129 1240.2 ± 479.8 (0.0404) 706.3 ± 298.1 (0.0404) 
pAKT473 4746 ± 692.6 3409.3 ±531 (0.0404) 5156.7 ± 322 (0.1914) 
pAKT308 2234.6 ±307.2 923.7 ±598.6 (0.0404) 2934.2 ± 551.1 (0.1914) 
pS6RP 2139.1 ± 1349.3 39.8 ± 26.5 (0.0404) 4417 ± 271.8 (0.0404) 
p4EBP1 2387.8 ± 494.2 832.4 ±919.5 (0.0952) 3303.9 ± 598.5 (0.0404) 
Table 6-2 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f KrasLSL/+ SITs 4 and 24 hours post exposure to MEK162 , n=3, One-tailed Mann 
Whitney U test was used for statistical analysis 
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 (A)6 SIT lysates pooled from n=3 mice exposed to MEK162 for 4 or 24 hours were subjected to 
western blot analysis. Immunoblotting for the MAPK effector pERK revealed marked reduction 
at both 4 and 24 hour time points. Additionally, effectors of PI3K/mTOR signalling were 
probed to assess pathway cross-talk. This revealed inhibition of PI3K signalling 4 hours post 
exposure, however an increase in signalling 24 hours post exposure. (B) Densitometry was 
carried out to quantify differences observed from immunoblotting. These are normalised to β-
actin as loading control and represented as relative to vehicle controls (*p value = 0.0404, n=3, 
Mann Whitney U test). 
Figure 6.8 MEK162 induced prolonged inhibition of MAPK signalling in Apcf/+ Ptenf/f KrasLSL/+  
tumours and reduced PI3K signalling 4 hours after exposure, but increased levels of 
PI3K/mTOR signalling at the 24 hour time point 
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At 4 hours post exposure, MEK162 leads to a reduction in levels of pERK, pAKT at Ser473 and 
Thr308 and pS6RP whereas at 24 hours post exposure, MEK162 still reduces levels of pERK 
however also results in increased levels of pS6RP and p4EBP1. 
 
6.2.4 Chronic MEK162 has no beneficial effect on survival of Apcf/+ Ptenf/f KrasLSL/+ mice 
For chronic MEK162 treatment, a cohort of 10 week old Apcf/+ Ptenf/f KrasLSL/+ mice were 
induced and aged as described in section 6.2.2, to 22 days post induction. At this point mice 
received 30mg/kg MEK162 twice-daily (week days only) by oral gavage, until a survival end 
point. Vehicle controls for this experiment were also previously described in section 6.2.2.  
Chronic administration with MEK162 was found to be well tolerated in Apcf/+ Ptenf/f KrasLSL/+ 
mice, however treatment did not have any beneficial effect on survival of mice (median 
survival of MEK162 mice = 36 days vs vehicle mice = 40, n≥13 mice per cohort, p value = 0.547 
for Log-Rank and p value = 0.937 for Wilcoxon test) (Figure 6.10). Therefore, despite the 
favourable anti-tumour and pharmacodynamic modulating of PI3K signalling by MEK162, mice 
with tumours deficient for Pten and activation of Kras were not sensitive to long term MEK162 
treatment.  
 
Figure 6.9 Schematic showing the effects of MEK162 on MAPK and PI3K/mTOR pathway 
components as detected by western blot analysis (Green denotes a reduction whereas red 
indicates an increase). 
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Figure 6.10 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f KrasLSL/+  mice on MEK162 
compared to vehicle controls 
 Apcf/+ Ptenf/f KrasLSL/+ mice were induced and aged to 22 days post induction, at which point 
mice received 30mg/kg MEK162 twice-daily by oral gavage until a survival end point. 
Continuous MEK162 treatment was found to have no significant effect on survival of mice 
compared to vehicle controls (Median survival: MEK = 36 days vs veh = 40 days post induction, 
p values: Log-Rank = 0.547 and wilcoxon test = 0.937 n≥13 mice per cohort).  
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6.2.5 Investigation of short term combination treatment in Apcf/+ Ptenf/f KrasLSL/+ tumours 
As PI3K/mTOR inhibition significantly increased survival of Apcf/+ Ptenf/f KrasLSL/+ mice, but MEK 
inhibition failed to show any benefit on longevity, combined inhibition of PI3K/mTOR and 
MAPK signalling was next investigated to determine whether longevity of mice could be 
further improved upon. As with chapters 4 and 5, the three combination strategies were 
initially investigated to determine whether tumours are sensitive to the order of drug 
administration, as was observed with Apcf/+ Ptenf/f tumours (section 4.2.5), or not so, as 
observed with Apcf/+ KrasLSL/+ tumours (section 5.2.5).  
Similarly to previous short term experiments, mice were induced and aged until symptomatic 
of tumour burden. A cohort of n ≥3 mice were administered with the three differing 
combination strategies (outline in Table 4.5) and harvested 4 hours after the final dose. A dose 
of BrdU was also administered 2 hours prior to culling and mice were dissected and tissues 
were prepared as previously described in methods section 2.4. Vehicle controls used here 
were also described earlier in section 6.2.1.  
To explore the immediate anti-tumour activity of the three differing combination strategies, 
histological mitosis and apoptosis was scored from H&E stained sections of SITs. Furthermore, 
IHC for BrdU and cleaved caspase 3 was carried out and quantified to further inform on the 
anti-tumour effects of the combination strategies. Scoring of mitotic figures revealed no 
significant alterations after exposure to any of the three combinations compared to vehicle 
controls (4hr veh = 0.283 ± 0.192, combo 1 = 0.305 ± 0.265, p value = 0.99, combo 2 = 0.391 ± 
0.258, p value = 0.199, combo 3 = 0.2733 ± 0.209, p value = 0.766, n≥15 tumours, 4 mice, 
Mann Whitney U test) (Figure 6.11 A). Quantification of histological apoptosis in Apcf/+ Ptenf/f 
KrasLSL/+ SITs identified significant increase in levels in response to all three combination 
strategies (4hr veh = 1.00 ± 0.575, combo 1 = 3.272, p value = 0.0002, combo 2 = 4.146 ± 
2.045, p value ≤ 0.0001, combo 3 = 1.919 ± 0.951, p value = 0.0022, n≥15 tumours, 4 mice, 
Mann Whitney U test) (Figure 6.11 B).  
To further evaluate the anti-tumour properties of combination treatment, IHC for BrdU and 
cleaved caspase 3 were scored. Quantification of BrdU surprisingly revealed a significant 
increase in the number of positive cells scored after all three combination strategies (4hr veh = 
13.36 ± 4.13, combo 1 = 33.48 ± 9.61, p value = 0.0001, combo 2 = 27.03, p value = 0.0004, 
combo 3 = 20.05 ± 7.47, p value = 0.0452, n≥15 tumours, 4 mice, Mann Whitney U test) (Figure 
6.12 A), possibly indicative of compensatory actions which lead to increased proliferation in 
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response to treatment. Despite this, quantification of cleaved caspase 3 staining here revealed 
an increase in staining in samples from all three combination strategies (4hr veh = 1.22 ± 0.56, 
combo 1 = 11.86 ± 9.48, p value ≤ 0.0001, combo 2 = 7.42 ± 4.06, p value = 0.0002, combo 3 = 
10.31 ± 4.86, p value ≤ 0.0001, n≥15 tumours, 4 mice, Mann Whitney U test), corroborating 
the scoring of histological apoptosis (Figure 6.12 C). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
235 
 
A 
* 
* 
* 
B 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Scoring of mitotic figures (A) and apoptotic bodies (B) revealed no significant alterations in 
mitosis however, all three combinations significantly increased apoptosis, compared to vehicle 
controls (p value ≤ 0.05, n ≥ 15 tumours, 4 mice, Mann Whitney U test). Error bars represent 
standard deviation. 
 
Figure 6.11 All three combination strategies resulted in a pro-apoptotic effect in 
Apcf/+ Ptenf/f KrasLSL/+  but no effect on proliferation 
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Scoring of BrdU (A) and cleaved caspase 3 (B) staining from IHCs revealed a significant increase 
in BrdU positive cells and cleaved caspase 3 (p value ≤ 0.05, n ≥ 15 tumours, 4 mice, Mann 
Whitney U test). Error bars represent standard deviation. 
 
 
 
 
Figure 6.12 All combination strategies increased BrdU positive cells and cleaved 
caspase 3 staining in Apcf/+ Ptenf/f KrasLSL/+  tumours 
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To determine the short term pharmacodynamic effects of the three differing combination 
strategies, tumours harvested from Apcf/+ Ptenf/f KrasLSL/+ mice exposed to the combination 
strategies were subjected to western blot analysis. For each cohort, protein extracted from 6 
SITs were pooled (from n=3 mice) and probed for components of PI3K/mTOR and MAPK 
signalling pathways to build pharmacodynamic profiles for each combination strategy. 
Interestingly, immunoblotting for intracellular pathway components revealed subtle but 
notable differences between the three combination strategies on pathway inhibition (Figure 
6.13, Table 6.3, Table 6.4). Whilst all three combination strategies reduced levels of pERK to 
levels comparable to single agent MEK162, combo 3 also significantly reduced levels of total 
ERK protein (Figure 6.13, Table 6.3, Table 6.4). With respect to PI3K and mTOR signalling, 
combo 1 reduced pAKT473 whereas only combo 2 reduced pAKT308 levels (Figure 6.13, Table 
6.3, Table 6.4). Nevertheless, all three combinations reduced pS6RP levels indicating effective 
mTOR inhibition even though p4EBP1 was found not reduced only following combo 1.  
 Vehicle Combo 1 (p value) Combo 2 (p value) 
pERK 3599.9 ± 1925 15.8 ± 5.2 (0.0404) 17.9 ± 13.1 (0.0404) 
pAKT473 3026 ± 285.5 2257.7 ± 1107.3 (0.5) 4650.3 ± 636.8 (0.952) 
pAKT308 2057.2 ± 735.8 810.6 ± 686.5 (0.0404) 1566.7 ±99.5 (0.1914) 
pS6RP 5216.6 ± 1621.0 382.7 ± 169.9 (0.0404) 62.9 ± 33.9 (0.0404) 
p4EBP1 3426 ± 1392.7 3863.4 ± 1852.8 (0.5) 1217.5 ± 541.2 (0.0404) 
Table 6-3 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f KrasLSL/+  SITs 4 hours post exposure to combo 1 and combo 2, n=3, One-tailed Mann 
Whitney U test was used for statistical analysis 
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 Vehicle Combo 3 (p value) 
pERK 4235.1 ± 2772.8 29.9 ± 12.7 (0.0404) 
T ERK 7500.4 ± 395.3 5261.6 ± 243.1 (0.0404) 
pAKT473 5833.4 ± 291.8 2725.6 ± 291.8 (0.0404) 
pAKT308 1517.7 ± 707.2 594.3 ± 429.6 (0.1914) 
pS6RP 5816.0 ± 1622.0 280.5 ± 69.6 (0.0404) 
p4EBP1 3845.9 ± 3679.1 2137.9 ± 1147.8 (0.0404) 
Table 6-4 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f KrasLSL/+  SITs 4 hours post exposure to combo 3, n=3, One-tailed Mann Whitney U test 
was used for statistical analysis 
The overall trends observed from western blotting do not clearly identify one superior strategy 
out of the three evaluated, in terms of complete pathway inhibition. Concomitant inhibition of 
pERK and pS6RP was observed with all three combinations however, some subtle differences 
were apparent with regards to pathway output. Both combo 1 and 3 lead to reduction of four 
PI3K and MAPK effectors assessed whereas combo 2 led to reduction of three components 
(Figure 6.13, Table 6.3, Table 6.4). In this case, it was not known whether the number of 
components inhibited was more significant than the observation that both signalling pathways 
were terminally inhibited. Nevertheless, all three strategies increased apoptotic signals, and so 
to remain consistent with the two previous mouse models assessed (chapter 4 and 5), 
combination strategy 2 was chosen for all further short term and long term experiments in this 
cohort. 
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(A)6 SIT lysates pooled from n=3 mice exposed to the three different combination strategies 
were subjected to western blot analysis and probed for effectors of PI3K/mTOR and MAPK 
signalling. Immunoblotting revealed all three combination strategies reduced levels of pERK 
and pS6RP, however only combo 1 reduced levels of pAKT308 and combo 3 reduced levels of 
pAKT472. Both combo 2 and 3 reduced levels of p4EBP1. (B + C) Densitometry analysis was 
also carried out to quantify differences observed from western blotting. These are normalised 
to β-actin as loading control and represented as relative to vehicle controls (*p value = 0.0404, 
n=3, Mann Whitney U test). 
 
Figure 6.13 sequencing of combination results in differential inhibition of signalling 
downstream PI3K/mTOR and MEK in Apcf/+ Ptenf/f KrasLSL/+  tumours 
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6.2.6 Further analysis of combination strategy 2 in Apcf/+ Ptenf/f KrasLSL/+ tumours 
Combination strategy 2 where NVP-BEZ235 is administered 1 hour prior to MEK162 was 
chosen for all further combination experiments, and also to keep consistency between the 
different genotypes assessed in this thesis, to allow comparisons. To investigate whether 
combo 2 results in prolonged anti-tumour or favourable pharmacodynamic effects, n=4 mice 
were administered with combo 2 and harvested 24 hours following the final dose. Mice were 
also administered a pulse of BrdU 2 hours prior to culling, and were dissected as described in 
section 6.2.  
For evaluation of anti-tumour activity, histological mitosis and apoptosis was scored from H&E 
stained sections of SITs and IHC for BrdU and cleaved caspase 3 was carried out and quantified 
to further inform on the anti-tumour effects of combo 2 24 hours post exposure (Figure 6.14). 
In doing so, scoring of mitotic figures revealed a significant reduction in proliferation however 
no significant alteration in the levels of histological apoptosis (veh mitosis = 0.283 ± 0.192, 
24hr c2 mitosis = 0.0928 ± 0.082, p value = 0.002, veh apoptosis = 1.00 ± 0.515, 24hr c2 
apoptosis = 0.907 ± 0.681, p value = 0.336n≥3, Mann Whitney U test) (Figure 6.14 A, B), 
indicating an anti-proliferative effect. Furthermore, quantification of BrdU positive cells 
revealed no significant alterations compared to vehicle controls, but scoring of cleaved 
caspase 3 revealed a significant increase, indicating a pro-apoptotic effect of the combination 
24 hours after administration (veh BrdU = 13.36 ± 4.13, 24hr c2 BrdU = 13.29 ± 9.37, p value = 
0.678, veh caspase 3 = 1.22 ± 0.56, 24hr c2 caspase 3 = 4.16 ± 2.28, p value = 0.0025, n ≥3, 
Mann Whitney U test) (Figure 6.14 C, D).  
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Assessment of proliferation in Apcf/+ Ptenf/f KrasLSL/+  SITs 24 hours post exposure to combo 2 by quantification of histological mitosis (A) and IHC against BrdU (C) 
revealed a significant reduction in mitotic figures  only (p value = 0.0024, n≥15 tumours, 4 mice, Mann Whitney U test). Additionally, assessment of apoptosis here 
through quantification of histological apoptotic bodies (B)and IHC against cleaved caspase 3 staining (D) revealed a pro-apoptotic effect through a significant 
increase in cleaved caspase 3 staining (p value = 0.0025, n≥15 tumours, 4 mice, Mann Whitney U test). Error bars represent standard deviation.  
Figure 6.14 Biological effects of combo 2 24 hours post exposure in Apcf/+ Ptenf/f KrasLSL/+  small intestinal tumours (SITs) 
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Given that PI3K and mTOR signalling was increased 24 hours post exposure to NVP-BEZ235, 
and similarly MEK162 increased mTOR signalling through pS6RP and p4EBP1, it was pertinent 
to investigate whether the combination alleviate or exacerbated this effect. For this, snap 
frozen tumours from mice harvested 24 hours post combo 2 were subjected to protein 
extraction and analysis through western blotting. Proteins from 6 SITs were pooled and 
following western blot analysis, were incubated with antibodies against various effectors of 
MAPK and PI3K signalling (Figure 6.15). This, and subsequent densitometry analysis revealed a 
significant reduction in the phosphorylated and total ERK protein, indicating prolonged 
inhibition of MAPK signalling. However, a minimal yet significant increase in pAKT473 and 
large 2.5 fold increase in pAKT308 levels were observed (Figure 6.15, Table 6.5). Despite the 
increase in PI3K signalling through pAKT, no significant alterations were observed with regards 
to pS6RP and p4EBP1 which signal downstream of the AKT substrate, mTOR, potentially 
indicating synergy to stabilise mTOR signalling (Figure 6.15, Table 6.5). These investigations 
indicate that combo 2 results in prolonged anti-proliferative and pro-apoptotic effects, and 
when compared to single agents, reduce MAPK signalling and prevent strong activation of PI3K 
signalling. Whether this results in a beneficial effect long term is addressed in section 6.2.7.  
 
 Vehicle 24hr Combo 2 (p value) 
pERK 4235.1 ± 2772.8 344.7 ± 205.6 (0.0404) 
T ERK 7500.4 ± 395.3 4816.3 ± 261.1 (0.0404) 
pAKT473 5833.4 ± 291.8 6631 ± 102.1 (0.0404) 
pAKT308 1517.7 ± 707.2 4094.6 ± 492.6 (0.0404) 
pS6RP 5816.0 ± 1622.0 4589.5 ± 1001.5 (0.1914) 
p4EBP1 3845.9 ± 3679.1 5960.1 ±2216.3 (0.5) 
Table 6-5 Outline of raw densitometry values from western blot analysis of pooled Apcf/+ 
Ptenf/f KrasLSL/+ SITs 24 hours post exposure to combo 2, n=3, One-tailed Mann Whitney U 
test was used for statistical analysis 
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(A) 6 SITs pooled from n=3 mice culled 24 hours following exposure to combo 2 were 
subjected to western blot analysis and probed for effectors of PI3K/mTOR and MAPK 
signalling. Immunoblotting revealed substantial inhibition of MAPK signalling, however, an 
increase in PI3K signalling through pAKT473 and pAKT308. (B) Densitometry analysis was 
carried out to quantify differences observed from immunoblotting. These are normalised to β-
actin as loading control and represented relative to vehicle controls (*p value = 0.0404, n=3, 
Mann Whitney U test).  
 
Figure 6.15 Combo 2 led to inhibition of MAPK signalling but increased PI3K signalling 24 
hours following exposure 
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6.2.7 Chronic treatment of combined NVP-BEZ235 and MEK162 results in a synergistic 
survival benefit in Apcf/+ Ptenf/f KrasLSL/+ mice 
Previously in sections 4.2.7 and 5.2.7, reduced combined treatment of NVP-BEZ235 and 
MEK162 (at 35mg/kg NVP-BEZ235 twice daily plus 30mg/kg MEK162 once daily) was found to 
be well tolerated in Apcf/+ Ptenf/f mice but not in Apcf/+ KrasLSL/+ mice. To investigate the 
combination treatment in Apcf/+ KrasLSL/+ mice, the dose of combination was further reduced 
(to 35mg/kg NVP-BEZ235 once daily plus 30mg/kg MEK162 once daily) to ensure tolerability, 
and this led to an additive increase in survival in comparison to single agent therapy. However, 
it was not known whether the first combination treatment regimen would be tolerated by 
Apcf/+ Ptenf/f KrasLSL/+ mice therefore, a cohort of 11 mice were induced and aged until 22 days 
post induction, at which point they began long term treatment of 35mg/kg NVP-BEZ235 twice-
daily plus 30mg/kg MEK162 once daily 1 hour after the first NVP-BEZ235 dose (combo R1). 
Mice were treated daily and monitored closely for signs of toxicity, until a survival end point. 
Similarly to Apcf/+ KrasLSL/+ mice, soon after the experiment began, it was apparent this 
combination was also toxic for Apcf/+ Ptenf/f KrasLSL/+ mice as 6/11 mice were culled due to 
dramatic weight loss (weight loss shown on figure 6.16 and survival of mice depicted on 
(Figure 6.17). Despite this, 5/11mice displayed some survival benefit compared to vehicle 
controls with one mouse surviving up to 217 days post induction. In spite of this, the median 
survival for the whole cohort was found to be 39 days post induction, and not significantly 
altered from a median survival of 40 days post induction for vehicle controls (n≥11, p value = 
0.118 for Long-Rank and p value = 0.478 for Wilcoxon test) (Figure 6.17).  
Given these toxicity issues, the further reduced combination strategy (35mg/kg NVP-BEZ235 
once daily plus 30mg/kg MEK162 once daily) which was found to be effective in Apcf/+ KrasLSL/+ 
mice, was subsequently used to evaluate the chronic effects of combination therapy in Apcf/+ 
Ptenf/f KrasLSL/+ mice. Additionally, as NVP-BEZ235 as a twice-daily treatment regimen 
significantly increased survival of Apcf/+ Ptenf/f KrasLSL/+ mice, a cohort of mice were also 
administered 35mg/kg NVP-BEZ235 once daily, as a control single agent treatment for the 
reduced combination therapy. Given that MEK162 had no effect on survival when 
administered as a twice-daily regimen, it was anticipated that a once-daily treatment regimen 
would also not have any significant effect on survival and so was an unnecessary control. 
Interestingly, Kaplan-Meier survival analysis revealed NVP-BEZ235 did not elicit any beneficial 
effect on survival of Apcf/+ Ptenf/f KrasLSL/+ mice when administered as a once-daily treatment 
regimen  (median survival: NVP-BEZ235 mice = 36 days vs vehicle mice = 40 days post 
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induction, n ≥ 12 per cohort, p value ≥ 0.05 for both Log-Rank and Wilcoxon test) (Figure 6.18), 
indicating that Apcf/+ Ptenf/f KrasLSL/+ mice are particularly sensitive to the dose of NVP-BEZ235. 
These finding support the dose-dependent effect of NVP-BEZ235 observed in Apcf/+ KrasLSL/+ 
mice however this effect was more dramatic in Apcf/+ Ptenf/f KrasLSL/+ mice.  The further 
reduced combination treatment (combo R2) here, was well tolerated (Figure 6.16) and 
significantly increased survival of Apcf/+ Ptenf/f KrasLSL/+ mice from a median of 40 days to 125 
days post induction (n ≥12 per cohort, p value ≤ 0.0001 for Log-Rank and Wilcoxon test) 
(Figure 6.18). As neither single agent controls had any significant beneficial effect on survival 
of Apcf/+ Ptenf/f KrasLSL/+ mice, the combination treatment here resulted in a synergistic 
increase in survival, indicating this as a well tolerated and beneficial therapeutic strategy.  
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Similarly to toxicity in Apcf /+ KrasLSL/+  mice (figure 5.16), administration of 35mg/kg NVP-
BEZ235 twice-daily plus 30mg/kg MEK162 once daily, led to notable fluctuations in body 
weight, n=9/12 mice were culled due 20% original weight loss. A further reduced combination 
regimen of 35mg/kg NVP-BEZ235 once daily plus 30mg/kg MEK162 once daily (1 hour later) – 
Combo R2, was subsequently evaluated and appeared to be better tolerated. Weights of wild 
type mice on twice daily combination is used to illustrate toxicity and single agent NVP-BEZ235 
twice daily which was well tolerated in Apcf/+ Ptenf/f KrasLSL/+ mice chosen as a positive 
comparison.  
 
 
 
 
 
Figure 6.16 Toxicity of combination treatment in Apcf/+ Ptenf/f KrasLSL/+ mice 
247 
 
 
 
Figure 6.17 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f KrasLSL/+ mice on combination 
treatment (combo R1) compared to single agent treatment and vehicle controls 
Apcf/+ Ptenf/f KrasLSL/+ mice were induced and aged to 22 days post induction, at which point 
mice received 35mg/kg NVP-BEZ235 twice-daily plus 30mg/kg MEK162 once-daily (1 hour 
later)- combo R1. This was found to have no significant benefit on median survival of mice due 
to toxicity, despite some mice appearing to benefit partially. Control dose of twice daily NVP-
BEZ235 and MEK162 is also illustrated here. (Median survival: combo 1 = 39 days vs veh = 40 
days, vs MEK162 = 36 days and NVP-BEZ235 = 104 days post induction, p values ≥ 0.05 for all  
Log-Rank and wilcoxon test  comparisons n ≥12 mice per cohort).  
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Figure 6.18 Kaplan-Meier survival analysis of Apcf/+ Ptenf/f KrasLSL/+ mice on further reduced 
combo 2 (Combo R2) dose compared to vehicle, MEK162 T-D and NVP-BEZ235 O-D controls 
Apcf/+ Ptenf/f KrasLSL/+ mice were induced and aged to 22 days post induction, at which point 
mice received 35mg/kg NVP-BEZ235 once-daily plus 30mg/kg MEK162 once-daily (1 hour 
later)- combo R2. Additionally, a reduced once-daily treatment of NVP-BEZ235 was conducted 
as a control for the reduced combination. Reduced combination (combo R2) was found to 
synergistically increase survival of mice from 40 days (vehicle controls) to 125 days post 
induction (p value ≤ 0.0001 for all Log-Rank and wilcoxon test comparisons n ≥13 mice per 
cohort). Interestingly, once-daily NVP-BEZ235 had no benefit on survival of Apcf/+ Ptenf/f 
KrasLSL/+ mice (median survival = 36 days post induction p value ≥ 0.05 for both Log-Rank and 
wilcoxon test comparisons n ≥13 mice per cohort) 
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6.2.8 Tumour burden analysis of Apcf/+ Ptenf/f KrasLSL/+ mice on various treatments 
Having identified that NVP-BEZ235 as a single agent and in combination with MEK162 is 
beneficial in extending longevity of Apcf/+ Ptenf/f KrasLSL/+ mice, the effect of these and control 
treatments on tumour burden was next evaluated.  For this, the total number of tumours 
present at death was scored from H&E stained sections of the small intestines, and tumours 
were also staged according to tumour severity (described previously in methods section 2.7.4). 
In chapters 4 and 5, analysis of tumour burden also involved analysis of total tumour area per 
mouse however, in Apcf/+ Ptenf/f KrasLSL/+ mice the edge of individual tumours was often not 
clearly visible, therefore it was difficult to accurately measure individual tumours 
macroscopically. The parameters of tumour burden were also evaluated in a cohort of mice 
culled at the treatment start point which in this tumour model was 22 days post induction.  
The number of tumours present in mice from each cohort was scored blind from 3 H&E 
stained small intestine sections to increase the probability of scoring all tumours present. 
These were averaged per section and further averaged per mouse for each cohort. As shown 
in Figure 6.19 A, the total number of tumours in vehicle treated mice was not significantly 
altered compared to the cohort of mice culled at 22 days post induction (the start cohort) 
(Median number of tumours: start = 29.5, vehicle = 44 p value = 0.217, n≥8, Mann Whitney U 
test). This indicates that treatment in these mice was not prophylaxis and mice bore 
statistically similar number of tumours at the start as they would have done at death. 
Interestingly, mice on NVP-BEZ235 T-D, MEK162 and combo R2 at death, had similar median 
number of tumours to both start and vehicle cohorts suggesting that these particular 
treatments resulted in tumour growth stasis, regardless of the effect on survival of mice 
(Median number of tumours: start = 29.5, vehicle = 44, NVP-BEZ235 T-D = 34.5 p value = 0.787 
for start and p value = 0.215 for vehicle comparison, MEK162 = 30.3 p value = 0.856 for start 
and p value = 0.0644 for vehicle comparison, combo R2 = 30.7 p value = 0.592 for start and p 
value = 0.0525 for vehicle comparison, n≥8, Mann Whitney U test) (Figure 6.19 A).  
Whilst treatment of  Apcf/+ Ptenf/f KrasLSL/+ mice with reduced dose NVP-BEZ235 (O-D) had no 
effect on survival of mice, analysis of tumour number following treatment indicated mice had 
significantly more tumours in comparison with the start cohort and the twice-daily NVP-
BEZ235 (T-D) treatment, with a trend towards increased tumours number in comparison with 
the vehicle treated cohorts (median number of tumours: start = 29.5, vehicle = 44, NVP-
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BEZ235 T-D = 34.5, NVP-BEZ235 O-D = 62.2; p value = 0.0228 for start cohort, p value = 0.133 
for vehicle cohort, p value = 0.0014 for NVP-BEZ235 T-D comparison n≥8, Mann Whitney U 
test) (Figure 6.19 A). These observations suggest an increase in tumour burden with NVP-
BEZ235 O-D treatment in Apcf/+ Ptenf/f KrasLSL/+ mice.  
Although combo R1 was found to be toxic for the majority of mice in the cohort, tumour 
numbers were found to be significantly reduced in comparison to the start and vehicle cohorts 
(median number of tumours: start = 29.5, vehicle = 44, combo R1 = 13.2; p value = 0.0456 for 
start and p value = 0.0011 for vehicle comparisons, n≥6, Mann Whitney U test) (Figure 6.19 A). 
These observations suggest that in the absence of toxicity, this treatment regimen may have 
proven beneficial for Apcf/+ Ptenf/f KrasLSL/+ mice.  
To address the effect of treatment on tumour severity in Apcf/+ Ptenf/f KrasLSL/+ mice, tumours 
on H&E stained sections of the small intestine were scored according to the criteria for grading 
described in section 2.7.4. The average number of each grade was calculated and is displayed 
as a proportion of the total number of tumours due to differences observed in the total 
number of tumours at death (Figure 6.19 A). Similarly to Apcf/+ KrasLSL/+ mice, the majority of 
tumours present in all Apcf/+ Ptenf/f KrasLSL/+ mice are the less invasive microadenomas and 
adenomas, and so therefore, treatments predominantly altered the proportions of these. 
Tumour severity scoring in vehicle treated mice indicated a trend for reduced microadenomas, 
but a significant increase in the proportion of adenomas in comparison to the start cohort 
(proportion of mAds: start = 86.5%, vehicle = 67% p value = 0.699; proportion of Ads: start = 
12%, vehicle = 31% p value = 0.0018, n≥8, Mann Whitney U test) (Figure 6.19 B). This 
observation highlights that although the number of lesions between the start and vehicle 
cohort are not significantly different, tumour growth is observed between the start of 
treatment and at death in vehicle treated mice.  
Assessment of tumours in treated cohorts revealed NVP-BEZ235 T-D treatment had no 
substantial effect on severity of lesions present in Apcf/+ Ptenf/f KrasLSL/+ mice, although mice 
had significantly reduced adenomas in comparison with vehicle treated mice (proportion of 
mAds: start = 86.5%, vehicle = 67%, NVP-BEZ235 T-D = 78% p value = 0.847 for start and p 
value = 0.603 for vehicle comparison; proportion of Ads: start = 12%, vehicle = 31%, NVP-
BEZ235 T-D = 19.5% p value = 0.132 for start and p value = 0.0114 for vehicle cohort; 
proportion of EIAs: start = 1.5%, vehicle = 2%, NVP-BEZ235 T-D = 2.3% p value = 0.4 for start 
and p value = 0.447 for vehicle cohort, n≥8, Mann Whitney U test) (Figure 6.19 B). 
Interestingly, the reduced NVP-BEZ235 treatment (once daily, O-D) significantly increased the 
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proportion of adenomas and EIAs present in Apcf/+ Ptenf/f KrasLSL/+ mice, indicating treatment 
augmented tumour progression, due to the lack of significant survival benefit obtained from 
this treatment (proportion of mAds: start = 86.5%, vehicle = 67%, NVP-BEZ235 O-D = 53% p 
value = 0.616 for start and p value = 0.751 for vehicle comparison; proportion of Ads: start = 
12%, vehicle = 31%, NVP-BEZ235 O-D = 32% p value = 0.003 for start and p value = 0.1571 for 
vehicle cohort; proportion of EIAs: start = 1.5%, vehicle = 2%, NVP-BEZ235 O-D = 14% p value = 
0.0004 for start and p value = 0.0001 for vehicle cohort, n≥8, Mann Whitney U test) (Figure 
6.19 B).  
Scoring of tumour severity in MEK162 treated Apcf/+ Ptenf/f KrasLSL/+ mice revealed significant 
differences in tumour severity in comparison to the start and vehicle cohorts. Here, although 
the proportion of microadenomas was not found to be significantly reduced, adenomas were 
increased in comparison to vehicle treated mice and EIAs were increased in comparison to 
both the start and vehicle cohorts, highlighting progression of tumourigenesis (proportion of 
mAds: start = 86.5%, vehicle = 67%, MEK162 = 69% p value = 0.294 for start and p value = 
0.1916 for vehicle comparison; proportion of Ads: start = 12%, vehicle = 31%, MEK162 = 24% p 
value = 0.119 for start and p value = 0.0051 for vehicle cohort; proportion of EIAs: start = 1.5%, 
vehicle = 2%, MEK162 = 6.8% p value = 0.0035 for start and p value = 0.0144 for vehicle cohort, 
n≥8, Mann Whitney U test) (Figure 6.19 B). These findings of tumour progression with MEK162 
treatment also suggest an exacerbated effect on tumourigenesis, similar to NVP-BEZ235 O-D 
treatment, as treatment had no benefit on survival of mice.  
The proportion of microadenomas and adenomas in mice following long term combo R1 were 
significantly reduced in comparison to vehicle treatment mice and also appeared to be 
proportionally more invasive. However, this later observation was not statistically significant 
perhaps because mice had significantly less tumours in total (proportion of mAds: start = 
86.5%, vehicle = 67%, combo R1 = 63.5% p value =0.0088 for start and p value = 0.0027 for 
vehicle comparison; proportion of Ads: start = 12%, vehicle = 31%, combo R1 = 29% p value = 
0.824 for start and p value = 0.194 for vehicle cohort; proportion of EIAs: start = 1.5%, vehicle 
= 2%, combo R1 = 6.61% p value = 0.824 for start and p value = 0.18 for vehicle cohort, n≥6, 
Mann Whitney U test) (Figure 6.19 B). 
Scoring of tumour severity in mice treated with combo R2 revealed significant indications of 
tumour progression. Here, mice presented with a significant reduction in the proportion of 
microadenomas and an increase in the proportion of adenomas in comparison to vehicle 
treated mice, and also a significant increase in the proportion of EIAs in comparison to both 
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start and vehicle treated mice (proportion of mAds: start = 86.5%, vehicle = 67%, combo R2 = 
49% p value =0.0574 for start and p value = 0.0289 for vehicle comparison; proportion of Ads: 
start = 12%, vehicle = 31%, combo R2 = 28% p value = 0.137 for start and p value = 0.127 for 
vehicle cohort; proportion of EIAs: start = 1.5%, vehicle = 2%, combo R2 = 22% p value = 
0.0021 for start and p value = 0.0036 for vehicle cohort, n≥8, Mann Whitney U test) (Figure 
6.19 B). The observation of significantly more invasive lesions are present at death in combo 
R2 treated mice, together with the increased lifespan of mice indicates increased tumour 
burden and may be indicative of resistant tumour growth.    
Interestingly, during the assessment of histological sections for scoring of tumour severity, 
distinct lesions which lacked the epithelial mucosal layer were notable. Closer analysis of these 
lesions revealed these to be superficial ulcers which had lost most or all of their epithelial cells, 
and were left with an inflamed basal layer (Figure 6.20). Further analysis of tumours revealed 
varied central areas of ulceration denoting potentially, the beginning stages of the ulceration 
process. The presence of these lesions was scored blind and interestingly, these were 
identified to only be present in cohorts exposed to NVP-BEZ235  (the % of mice which 
presented with ulcerated lesions: Start cohort = 0, vehicle = 0, NVP-BEZ235 T-D cohort = 50%, 
NVP-BEZ235 O-D cohort =33%, MEK162 cohort = 0, combo R1 cohort = 72%, combo R2 = 
63%)(Figure 6.20). Additionally, the presence of ulcerated lesions did not correlate to 
treatments which increased survival as NVP-BEZ235 O-D and combo R1 treatments had 
comparable numbers of mice with ulcerated lesions to their corresponding higher dose 
regimens. The reasons for the presence of these ulcerated lesions are currently unclear 
however it is hypothesised that due to loss of epithelial cells, a regenerative stromal response 
may have been activated to heal over the basal layer.  
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(A) Apc
f/+ 
Pten
f/f
 Kras
LSL/+
 mice on NVP-BEZ235 O-D had significantly increased tumours at death 
compared to the start cohort . Additionally, mice on combo R1 had significantly reduced tumours at 
death compared to start and vehicle cohorts.(B) Key: mAd – microadenoma, Ad – adenoma, EIA – early 
invasive adenocaricinoma, AIA – advanced invasive adenocarcinoma. Staging of tumours at death 
revealed a significant reduction in mAds and an increase in Ads with vehicle, NVP-BEZ235 T-D, MEK162 
and combo R2 treatments. An increase in EIAs in all cohorts except the vehicle and NVP-BEZ235 T-D 
cohort was observed in comparison with the start cohort.  Additionally, an increase in EIAs was 
observed in NVP-BEZ235 T-D and O-D, MEK162 and combo R2 cohorts compared to vehicle controls. 
Furthermore, a significant reduction in Ads  was observed with the NVP-BEZ235 T-D cohort in 
comparison to the vehicle treated cohort  (*p value ≤ 0.05, Mann Whitney U test).  
Figure 6.19 Tumour burden analysis of Apc
f/+ 
Pten
f/f 
Kras
LSL/+
mice on all long term treatments 
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 (A) Histological analysis of Apcf/+ Ptenf/f KrasLSL/+ small intestine sections revealed tumours with 
varying signs of ulceration. Scoring of the total number of mice which had ulcered lesions 
revealed approximately 50% of mice on NVP-BEZ235 T-D had tumours with ulceration whereas 
less mice (approximately 30%) of mice on NVP-BEZ235 O-D had ulcered lesions. Furthermore, 
70% of mice on combo R1 had lesions with signs of ulceration and similarly 62% of mice on 
combo R2 bore ulcerated lesions. (B) H&E images of the varying degree of ulceration. Some 
adenomas with small signs of ulceration were observed as in (i) as well as large areas of 
ulceration showing signs of inflammatory response and also with and without surrounding 
tumour tissue were observed (ii), (iii) and (iv).   
Figure 6.20 Ulceration of tumours in Apcf/+ Ptenf/f KrasLSL/+ mice on long term treatments 
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6.3 Discussion 
6.3.1 The effects of acute and chronic NVP-BEZ235 in Apcf/+ Ptenf/f KrasLSL/+ mice 
Mutations in the oncogene KRAS and those resulting in activation of PI3K signalling co-exist in 
approximately a third of all human CRC. In light of this, work described in this chapter 
investigated therapeutic targeting of the PI3K pathway with the dual PI3K/mTOR inhibitor 
NVP-BEZ235 and the MAPK pathway by inhibition of MEK1/2 through MEK162, as rational 
therapeutic strategies for this tumour sub-group. These investigations employed the use of 
the Apcf/+ Ptenf/f KrasLSL/+ mouse model where, heterozygous deletion of Apc and homozygous 
deletion of Pten together with activation of oncogenic Kras is driven by the VillinCreER 
transgene. This leads to development of invasive adenocarcinoma in the small intestine driven 
by activation of AKT and ERK, and a reduced lifespan of just 41 days post induction (Davies EJ, 
unpublished). For all experiments described in this chapter, 10 week old mice were induced by 
i.p injections of Tamoxifen and allowed to age either until the long term intervention start 
point of 22 days post induction, or until they presented with distinct symptoms of tumour 
burden (paling feet, bloating, rectal bleeding). At this point they received a single dose of 
treatment and were harvested at short time points for investigation of anti-tumour and 
pharmacodynamic effects.  
Acutely, NVP-BEZ235 led to inhibition of all PI3K and mTOR effectors assessed, including pAKT 
at Ser473 and Thr308, pS6RP as well as p4EBP1 (Figure 6.3). Additionally, a significant increase 
in histological apoptosis and cleaved caspase 3 scoring, together with no detectable effect on 
mitosis, indicated favourable pro-apoptotic effects following NVP-BEZ235 (Figure 6.1, 6.2). 
Given the role of PI3K signalling in controlling survival and apoptosis, the increase in levels of 
apoptosis may be attributable to the reduction of signalling, potentially through reduced 
phosphorylation of pro-apoptotic proteins including BAD and BIM (She et al., 2010). 
Interestingly, NVP-BEZ235 also led to a significant reduction in the levels of pERK a 
downstream effector of MAPK signalling (Figure 6.3). This was surprising given that recent 
findings suggest mTORC1 inhibition by rapamycin, upstream of pS6RP and p4EBP1, led to 
activation of MAPK signalling through pERK rather than inhibition (Carracedo et al., 2008b). 
This has formally been evidenced through expression of the rapamycin insensitive- 
constitutively active S6 Kinase and pharmacological inhibition of PI3K, both of which led to 
reduced MAPK activation upon rapamycin treatment (Carracedo et al., 2008a). Interestingly, a 
recent study investigating the non-receptor tyrosine kinase SYK has evidenced a role for this 
protein in regulating mTOR signalling in lymphoma. Furthermore, the effects of SYK have been 
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confirmed to be PI3K dependent and interestingly, inhibition of SYK led to downregulation of 
MEK and ERK signalling in some AML cell lines. Nevertheless, the functions of SYK are limited 
to hematopoietic cells and so identification of a similar protein in epithelial cells may be 
attributable to the observations here. The mechanism by which PI3K and mTOR inhibition in 
Apcf/+ Ptenf/f KrasLSL/+ tumours led to a reduction in MAPK signalling through pERK, is still 
unclear and requires further investigation, as this may identify a novel protein interaction 
which controls feedback loops affecting both signalling pathways. 
Despite the favourable anti-tumour and pharmacodynamic effects characterised at 4 hours, 
NVP-BEZ235 led to a significant increase in PI3K signalling, reduced histological apoptosis and 
increased proliferation at 24 hours (Figure 6.1, 6.2, 6.3). Surprisingly, cleaved caspase 3 was 
still found to be significantly increased at 24 hours contradicting previous apoptosis scoring, 
but possibly highlighting an on-going shift in the delicate balance between cell death and 
survival in response to treatment. The increase in PI3K signalling observed here, may be 
attributable to feedback loops activated to increase signalling, and may be characteristic of a 
re-balancing mechanism to restore the initially reduced PI3K signalling.  
Subsequently, a twice-daily administration regimen was selected for the long term treatment 
experiment to ensure inhibition of signalling. For this, mice were randomised to receive either 
0.5% Methyl cellulose (vehicle treatment) or 35mg/kg NVP-BEZ235 twice-daily by oral gavage, 
from 22 days post induction until a survival end point. Kaplan-Meier survival analysis revealed 
administration of NVP-BEZ235 increased survival from 40 days to 104 days post induction, 
more than doubling the lifespan of Apcf/+ Ptenf/f KrasLSL/+  mice (Figure 6.5). Analysis of tumour 
burden at death indicated that the NVP-BEZ235 treated cohort had comparable tumour 
numbers to the start cohort and vehicle treated mice, as well as a similar tumour severity 
profile, indicating tumour growth stasis with increased survival (Figure 6.19). Interestingly, 
reduced treatment of NVP-BEZ235 to a once-daily regimen as a control arm for combination 
treatment (with MEK162) had no beneficial effect on survival of mice (Figure 6.17). 
Additionally, tumour burden analysis in this cohort indicated that treatment augmented 
tumour progression as mice had significantly fewer benign lesions and more invasive 
adenocarcinomas characterised by sub-mucosal invasion (Figure 6.19). Although these 
observations corroborate findings from chapter 5 of dose-dependent effects of NVP-BEZ235, 
Apcf/+ Ptenf/f KrasLSL/+ mice were found to be more sensitive to the dose of NVP-BEZ235 than 
Apcf/+ KrasLSL/+ mice. I postulate that these later observations may be attributable to the 
increased PI3K/mTOR signalling observed at 24 hours following NVP-BEZ235, causing non-
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response to treatment and promoting progression of tumourigenesis. Studies by Kinross et al. 
corroborated the dose dependent effects of PI3K/mTOR pathway inhibitors as low dose PF-
04691502 (Pfizer) also mitigated the survival benefit shown by the higher dose in a Kras 
mutant and Pten deficient tumour setting (Kinross et al., 2011). Nevertheless, NVP-BEZ235 
treatment significantly increased longevity of Apcf/+ Ptenf/f KrasLSL/+ mice, highlighting this as an 
efficacious therapeutic strategy for this tumour sub-group.           
Interestingly, a range of ulcerated lesions were observed in response to PI3K/mTOR inhibition. 
Although these were not correlated to a survival response, these lesions represent effective 
killing of tumour cells from drug treatment. Additionally, no correlation was observed with 
presence of these lesions and increased drug treatment (Figure 6.20). Such lesions are thought 
to be precursors from which an epithelial layer could regenerate or alternatively, a superficial 
lesion would persist. Additionally, it is not known whether the immune cells present in the 
larger lesions were recruited during treatment to kill tumour cells or whether immune cells are 
present to aid the healing process. Nevertheless, the presence of these lesions shows effective 
and quick killing of tumour cells following treatment and the observation that these lesions 
are only present in the cohorts treated with NVP-BEZ235 (including combination cohorts) 
indicates this as the main treatment inducing these lesions.   
6.3.2 MEK inhibition induces favourable anti-tumour and pharmacodynamic effects 
however does not increase survival of Apcf/+ Ptenf/f KrasLSL/+ mice 
Given the concurrent activation of oncogenic Kras in this Pten deficient tumour setting, the 
effects of MEK inhibition were next evaluated in an acute exposure setting and in a long term 
therapeutic intervention setting. Previously, mutations activating PI3K signalling have proven 
to reduce sensitivity of Kras mutant tumours to MEK inhibition. This was evidenced in a 
number of tumour models including xenograft models of colorectal cancer (Wee et al., 2009) 
and a GEM model of lung cancer (Chen et al., 2012b). To further evaluate this in a CRC setting, 
I employed the MEK inhibitor MEK162 for use in our autochtonous mouse model of intestinal 
cancer mutant for Apc, Pten and Kras. Acutely, MEK162 led to prolonged inhibition of MAPK 
signalling through pERK (Figure 6.8). As described previously, this has implications for cancer 
cell survival due to the involvement of MAPK/RAS/ERK signalling in promoting cell survival and 
inhibition of apoptosis (Johnson and Lapadat, 2002), and may be attributable to the increase 
in cleaved caspase 3 staining observed 4 hours post exposure to MEK162 (Figure 6.7). 
Interestingly, at this 4 hour time point, substantial inhibition of PI3K signalling was also 
observed, as evidenced by significantly reduced levels of pAKT at Ser473 and Thr308, and 
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pS6RP as well as a trend towards reduced p4EBP1 levels (Figure 6.8). The cross-talk of 
signalling observed here may be due to interactions between MEK and TSC2 (Ma et al., 2007) 
which, together with TSC1, act to modulate mTORC1 signalling, directly upstream pS6RP and 
p4EBP1. Despite this, the reduction of pAKT at Ser473 mediated by mTORC2 and at Thr308 
mediated by PDK1 is not accounted for. Further investigations of these effects may uncover 
novel feedback mechanisms.  
Despite the surprising inhibition of PI3K signalling in Apcf/+ Ptenf/f KrasLSL/+ tumours 
immediately following MEK162, probing of pathway effectors in tumour samples 24 hours post 
MEK162 revealed an increase in PI3K/mTORC1 signalling evidenced through increased pS6RP 
and p4EBP1 (Figure 6.8). This could be attributable to the increase in cellular proliferation as 
identified through increased BrdU scoring in tumours, however the mechanism for this is yet 
to be defined (Figure 6.7). The apparent cross-talk between MAPK and PI3K pathways 
observed here are likely to result from negative feedback loops, however it remains to be 
established whether these are downstream of pERK through RSK mediated regulation of TSC2 
(Roux et al., 2007, O'Reilly et al., 2006), due to the promiscuous nature of Kras (Kodaki et al., 
1994) or downstream of mTOR which can lead to activation of PI3K signalling through 
regulation of receptor tyrosine kinases, including IGF-1 (O'Reilly et al., 2006).  
Nevertheless, MEK inhibition was further investigated in this tumour model in a long term 
therapeutic setting. Given the favourable immediate effects of MEK162, it was hypothesised 
that treatment may provide some benefit for Apcf/+ Ptenf/f KrasLSL/+ mice, however MEK162 
administered at 30mg/kg twice-daily had no effect on survival of mice (Figure 6.10). Kaplan 
Meier survival analysis showed mice to have a median survival of 36 days compared to 40 days 
post induction for vehicle treated mice. Tumour burden analysis of Apcf/+ Ptenf/f KrasLSL/+ mice 
at death revealed that mice on MEK162 had the same number of lesions at death in 
comparison to the start and vehicle treated cohorts however, mice had a higher proportion of 
invasive lesions, as characterised by invasion into the sub-mucosal layer (Figure 6.19). Similarly 
to the observations for the once-daily NVP-BEZ235 treatment, I hypothesise that the tumour 
progression observed with MEK162 treatment is perhaps due to increased PI3K signalling 
detected 24 hours after a single dose of MEK162.         
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6.3.3 Combination therapy synergistically increases survival of Apcf/+ Ptenf/f KrasLSL/+ mice 
Given the therapeutic efficacy of PI3K/mTOR inhibition but the lack of influence from chronic 
MEK inhibition, even though favourable effects on PI3K signalling were initially noted, the 
efficacy of combination therapy was next investigated in this tumour context. The rationale for 
combination therapy here stems from observation that mutations activating PI3K signalling 
tend to co-exist with Kras mutations and predict non-response to MEK inhibition (Balmanno et 
al., 2009, Chen et al., 2012b, Dry et al., 2010), as described previously (section 4.3.2). A 
number of studies have previously characterised the benefits of this in multiple in vivo tumour 
models. Kinross et al showed increased efficacy of dual PI3K/mTOR and MEK inhibition in the 
KrasG12D Pten deleted mouse model of ovarian cancer, Engelman et al evidenced the 
combination therapy in the KrasG12D and PIK3CA H1047R lung cancer model whilst Miller et al. 
showed efficacy in the TPO-KrasG12D Pten deleted thyroid tumour model (Kinross et al., 2011, 
Engelman et al., 2008, Miller et al., 2009).   
In this study, I first evaluated the short term anti-tumour and pharmacodynamic effects of the 
three differing combination strategies to identify whether compound mutant tumours were 
sensitive to the schedule of inhibitor administration similarly to Apcf/+ Ptenf/f tumours, or not 
so, similarly to Apcf/+ KrasLSL/+ tumours. Western blot analysis for effectors of MAPK and PI3K 
signalling revealed no stark differences between the three schedules, similar to Apcf/+ KrasLSL/+ 
tumours. Here, all three combination strategies led to a reduction in levels of pERK and pS6RP 
indicating inhibition of MAPK and PI3K/mTOR signalling (Figure 6.13). Additionally, combo 1 
led to moderate inhibition of pAKT308, combo 3 led to inhibition of pAKT473 and both combo 
2 and 3 led to inhibition of p4EBP1 (Figure 6.13).  Also similarly to Apcf/+ KrasLSL/+ tumours, the 
ability of NVP-BEZ235 to effectively reduce levels of pAKT was reduced in the combination 
treatment however, unlike Apcf/+ KrasLSL/+ tumours, these effects cannot be attributed to an 
additive effect (Figure 6.13). In this case, single agent NVP-BEZ235 led to complete inhibition 
of PI3K/mTOR signalling, and single agent MEK162 reduced MAPK signalling and also led to 
inhibition of PI3K signalling. Previous studies investigating combination therapy have reported 
complete loss of signalling at pAKT, pS6RP and pERK (Kinross et al., 2011) however, this may 
be due to differences in the agents used, doses or the regimen adopted for treatment. 
Nevertheless, all three combination strategies increased apoptosis, as detected through 
scoring of histological apoptosis and cleaved caspase 3 (Figure 6.11. 6.12). Therefore, to 
remain consistent between the three models assessed for combination therapy, combination 
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strategy 2 which involved administration of NVP-BEZ235 prior to MEK162, was employed for 
all further combinatorial experiments.  
Subsequently, combo 2 was investigated at a 24 hour time point post administration to further 
assess the anti-tumour or pharmacodynamic effects. Although a reduction in proliferation and 
increase in apoptosis was observed (Figure 6.14), PI3K signalling was found to be 
predominantly increased through pAKT at Ser473 and Thr308 as well as p4EBP1 (Figure 6.15). 
Despite this, levels of pERK were found to be reduced potentially indicating synergy as 
previously single agent MEK162 moderately reduced pERK and single agent NVP-BEZ235 had 
no effect on MAPK signalling 24 hours post exposure (Figure 6.8). 
Despite the moderately favourable pharmacodynamic effects, the selected combination 
strategy was next investigated in a therapeutic setting. As with Apcf/+ KrasLSL/+ mice, in the first 
instance combination therapy administered to Apcf/+ Ptenf/f KrasLSL/+ mice from 22 days post 
induction involved twice-daily NVP-BEZ235 plus once-daily MEK162, 1 hour after the initial 
NVP-BEZ235 dose (combo R1), as tolerability of this regimen in this tumour setting was not 
known. Shortly after the experiment began, toxic effects as illustrated by substantial weight 
loss was apparent in Apcf/+ Ptenf/f KrasLSL/+ mice and led to 6/11 mice being culled due to 
weight loss. Surprisingly, 5/11 mice showed some advantage as observed by Kaplan-Meier 
survival analysis on Figure 6.17. As discussed previously in section 5.3.3, the reasons as to why 
this combination strategy was tolerated in Apcf/+ Ptenf/f mice and not in Apcf/+ Ptenf/f KrasLSL/+ or 
Apcf/+ KrasLSL/+ mice in currently unclear. The observation that both Apcf/+ KrasLSL/+ and Apcf/+ 
Ptenf/f KrasLSL/+ models are driven by the VillinCreERT transgene and the Apcf/+ Ptenf/f model is 
driven by the AhCreERT suggests that the differences in tolerability may be due to the 
differences in experimental systems within these cohorts. When induced, the VillinCreERT 
transgene, leads to activation of genetic modifications in all intestinal cells. A recent study in 
the Clarke lab investigating the effects of Apcf/+ Ptenf/f KrasLSL/+ alterations on normal intestinal 
homeostasis found these mutations result in an increased number of cells per half villus and a 
significant reduction in the number of enteroendocrine and paneth cells in comparison to 
controls, similar to the effects of Apcf/+ KrasLSL/+ within the intestinal epithelium (Davies EJ, 
unpublished). The lack of these absorptive differentiated cells may be the cause of reduced 
nutrient intake in the intestines, which subsequently leads to weight loss and death of mice, 
when challenged by the combination therapy however, these observations need further 
investigation.  Despite this, no gross alterations in the histological architecture of the small or 
large intestines were observed, similar to the Apcf/+ KrasLSL/+ mice, indicating that either the 
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effect on normal intestinal homeostasis is minimal or that the toxic effects may be due to 
alternative factors as described previously (section 5.3.3).  
Due to the toxicity issues described above, the further reduced combination dose as with 
Apcf/+ KrasLSL/+ mice was next investigated. This involved once-daily administration of 35mg/kg 
NVP-BEZ235 plus 30mg/kg MEK162 once-daily, an hour following the NVP-BEZ235 dose 
(combo R2). Interestingly, this was found to be well tolerated in Apcf/+ Ptenf/f KrasLSL/+ mice, as 
shown in Figure 6.16, and led to a synergistic increase in survival from 40 days post induction 
to 125 days post induction, when administered from 22 days post induction (Figure 6.18). 
These effects were found to be synergistic as although single agent NVP-BEZ235 displayed 
efficacy when administered twice-daily, the control for the combination therapy which 
involved once-daily administration of NVP-BEZ235 had no beneficial effect on survival. The 
synergistic effects observed here are surprising given the lack of favourable 
pharmacodynamics from short term experiments but perhaps investigation of the 
combination at further short time points may provide some insight into the synergistic 
mechanisms. Surprisingly, tumour burden analysis revealed that although the number of 
lesions in Apcf/+ Ptenf/f KrasLSL/+ mice on combo R2 was unaltered in comparison to the start 
and vehicle cohorts, tumours were significantly more invasive, as characterised by submucosal 
invasion (Figure 6.19). These later findings suggest tumour progression and corroborate 
previous findings where increased PI3K signalling observed at short time points, led to tumour 
progression after chronic treatment. The exception here is that mice had increased median 
survival and therefore these observations may indicate resistant tumour growth. Together, the 
investigations in this chapter are the first to show synergistic effects of PI3K/mTOR and MEK 
inhibition in an autochtonous mouse model of intestinal cancer driven by concurrent loss of 
Pten and activation of Kras.       
6.4 Summary 
In summary, the work described in this chapter indicate combined targeting of PI3K/mTOR 
signalling through NVP-BEZ235 and MEK inhibition through MEK162 as a beneficial therapeutic 
strategy for Apcf/+ Ptenf/f KrasLSL/+ mice. Results also indicate dose-dependent effects of NVP-
BEZ235 however, Apcf/+ Ptenf/f KrasLSL/+ appeared more sensitive to the dose, possibly due to 
activation of negative feedback signalling activated by mutant Kras in this setting. Additionally, 
work described in this chapter corroborates previous findings that concurrent mutations in the 
PI3K signalling cascade predict non-response of the otherwise sensitive Kras mutant tumours, 
to MEK inhibition.  
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6.5 Further work 
6.5.1 Further investigation of feedback mechanisms in Apcf/+ Ptenf/f KrasLSL/+ tumours 
Analysis of the immediate pharmacodynamic effects following PI3K/mTOR or MEK inhibition in 
Apcf/+ Ptenf/f KrasLSL/+ tumours uncovered a number of puzzling effects on parallel signalling 
cascades. Firstly, although PI3K/mTOR inhibition led to complete reduction of pathway 
effectors, this also resulted in inhibition of MAPK signalling through pERK. Subsequently, 
PI3K/mTOR signalling was found to be increased at 24 hours following the initial reduction in 
signalling at 4 hours. Furthermore, acute MEK inhibition reduced PI3K and mTOR signalling 
components but increased expression of these at the 24 hour time point. The observations 
summarised above of collateral signalling effects may be associated with convergence of 
pathways at mTOR. Further probing of intracellular signalling components upstream mTOR 
including TSC2 and TSC1 as well as downstream of mTOR including S6K-IRS-1, may be 
insightful.        
6.5.2 Further evaluation of synergy between NVP-BEZ235 and MEK162 in Apcf/+ Ptenf/f 
KrasLSL/+ mice 
Investigation of the three combination strategies in Apcf/+ Ptenf/f KrasLSL/+ tumours revealed 
that no stark differences between the three strategies. Nevertheless, combination strategy 2 
was taken forward for further investigations. Here, although an increase in PI3K/mTOR 
signalling was observed at short time points, chronic dosing led to a synergistic increase in 
survival. Investigation at further time point for example at 1, 2, 3, 8 or 12 hours post exposure, 
may help dissect any potential synergistic effects which may have led to the observed effects. 
Furthermore, to formally identify the differences between the combination strategies, 
investigation of combination strategies 1 and 3 in the long term setting may also be insightful 
for evaluating synergy.  
6.5.3 Mechanisms of resistance to chronic PI3K and combination therapy 
Mutations activating oncogenic Kras and those leading to aberrant activation of PI3K signalling 
co-exist in a third of all human CRCs. The work described in this chapter highlights that 
perhaps a dual PI3K/mTOR inhibitor in combination with a MEK inhibitor could be beneficial 
for Kras mutant and PI3K activated tumours. Despite this, resistance to treatments is 
frequently observed and therefore characterisation of any mechanisms used by tumours to 
escape treatment may provide insightful information. For this, immunohistochemistry for 
effectors of both signalling pathways together with scoring of proliferation and apoptosis 
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could be used to determine whether tumours were still responding to treatment or not when 
harvested at death. Additionally, as described in 5.5.3, these could then be correlated to 
tumour severity to identify whether tumour progression is associated with non-response of 
resistance tumour growth.     
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7 Characterisation and delivery of anti-cancer ‘ProTide’ agents into a mouse 
model of colorectal cancer 
 
7.1 Introduction 
Whilst work described in chapters 3-6 evaluated a number of established small molecule 
inhibitors which specifically targeted pathways known to be deregulated in genetically 
engineered mouse models, this thesis also aimed to assess novel therapeutic compounds 
designed to improve the efficacy of existing compounds.  
The chemotherapeutic agent 5-fluorouracil (5-FU) remains the cornerstone of therapeutic 
intervention for CRC despite the promise of targeted therapy. 5-FU is an anti-metabolite drug 
(Rutman et al., 1954) which functions by inhibiting essential biosynthesis and by incorporating 
into molecules such as DNA or RNA and inhibiting their normal function. The cytotoxic effects 
of 5-FU are therefore attributed to misincorporation into DNA and RNA and also, its ability to 
inhibit the nucleotide synthetic enzyme thymidylate synthase (TS) (Longley et al., 2003). 
Despite the continued use of 5-FU based chemotherapy, response rates in the first-line setting 
for advanced CRCs are only 10-15% (Johnston and Kaye, 2001), highlighting an urgent need for 
new and effective therapeutic strategies.  
5-FU is a pyrimidine nucleoside derivative and belongs to the family of cytotoxic nucleoside 
analogues, which includes cladribine and fludarabine (used against low grade blood 
malignancies) as well as gemcitabine (used against pancreatic and bladder cancers), all of 
which require metabolic activation in their target cell to the bio-active tri-phosphate form 
(Galmarini et al., 2001)(Figure 7.1). This requirement can often limit their therapeutic potential 
due to a number of factors. These include poor metabolism to activate the mono-phosphate 
form, rapid deactivation of the bio-active molecule, reduced active transport which is required 
to allow entry into the cell in the initial stages, and most often, development of resistance, 
either through kinases, polymerases or transporters (Mehellou et al., 2009).  
In an effort to address these issues, particularly to improve the delivery of such agents, 
prodrug technologies which aim to deliver the bio-active nucleoside monophosphates into 
cells have been utilised, to improve the therapeutic potential of anti-cancer nucleosides. This 
approach involves using the mono-phosphate form of the nucleoside and masking the charge 
of the phosphate form by addition of phosphoramidate groups, in order to allow passive cell 
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membrane penetration. Subsequently upon entering the cell, the masking phosphoramidate 
groups are enzymatically cleaved to release the bio-active phosphorylated nucleoside 
molecule (Mehellou et al., 2009). This phosphoramidate method (also known as the ProTide 
method) developed by McGuigan et al. has successfully been applied to numerous antiviral 
nucleosides (Bourdin et al., 2013, Madela and McGuigan, 2012) and more recently has been 
applied to the anti-cancer agent gemcitabine to create NUC1031 which is currently undergoing 
phase 1/2 clinical trials in humans with pancreatic cancer (Saif et al., 2012, Jordheim et al., 
2013).  
The main aim of this study was to utilise the ProTide approach to allow passive entry of 
compounds which aim to target the cause of 5-FU resistance3. When metabolised, 5-FU is 
converted into fluorodeoxyuridine monophosphate (FdUMP), fluorodeoxyuridine triphosphate 
(FdUTP) and fluorouridine triphosphate (FUTP) (Figure 7.1), all of which disrupt RNA synthesis 
and the inhibitory actions of TS (Longley et al., 2003). The normal physiological function of TS 
is to catalyse the reduction of deoxyuridine monophosphate (dUMP) to deoxythymidine 
monophosphate (dTMP), providing a de novo source of thymidylate (Roberts et al., 2006). 
Subsequently, FdUMP forms a tertiary complex with the enzyme TS, and CH2THF (5,10-
methylenetrahydrofolate, a methyl donor) which blocks binding of dUMP, inhibiting dTMP 
synthesis (Santi et al., 1974, Sommer and Santi, 1974). Despite this, overexpression of TS is 
widely regarded as the major molecular mechanism of resistance to 5-FU in humans; high 
levels of TS prior to treatment have been shown to predict poor response (Johnston et al., 
1992, Priest et al., 1980) but also, increased RNA expression and protein expression through 
an auto-regulatory feedback mechanism, has been previously shown to mediate 5-FU 
resistance (Chu et al., 1993b, Chu et al., 1993a). Given these findings, we sought to exploit the 
ProTide approach to target TS overexpressing cancer cells with the anti-viral agent Brivudin 
(BDVU) commonly used against Herpes Simplex Virus (HSV) and Varicella Zoster Virus (VZV) 
(Figure 7.2).  
 
                                                          
3
 Some data presented in this chapter was collected and analysed together with Dr Trevor Hay 
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Figure 7.1 Schematic summarising metabolism of 5-FU 
5-FU is converted to three active metabolites: fluorodeoxyuridine monophosphate (FdUMP) 
through thymidine phosphorylase (TP) and thymidine kinase (TK), followed by subsequent 
phosphorylations to yield fluorodeoxyuridine triphosphate (FdUTP) and fluorouridine 
triphosphate (FUTP) through sequential phosphorylations. Dihydropyrimidine dehydrogenase 
(DPD) mediated conversion of 5-FU to dihydrofluorouracil (DHFU) is the rate limiting step of 5-
FU catabolism in normal and tumour cells. Up to 80% of administered 5-FU is broken down by 
DPD in the liver  
 
The metabolites of BVDU (BVdUMP) have been shown to act as an alternative competitive 
substrate for TS in vitro (Lackey et al., 2001). Additionally, previous work has shown BVdUMP 
is converted into cytotoxic products by intracellular TS without causing activation of the 
enzyme (Lackey et al., 2001). However, as the charge of BVdUMP prevents entry into the cell, 
the molecule was converted into a ProTide form, to allow better entry of the bio-active form 
of the compound. Recently, the phosphoramidate technology was applied to BVdUMP to yield 
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NB1011 (Thymectacin, New Biotics). Thymectacin has previously been shown to result in cell 
cytotoxicity and accumulation of BVdUMP in TS overexpressing and hence 5-FU resistant, 
human colorectal cancer cells (H630-R10) and breast carcinoma cells (MCF7TDX) in 
comparison with normal counterpart cell lines (Lackey et al., 2001). Despite this, McGuigan et 
al found thymectacin to be less potent than the parent agent (BVDU) in vitro due to poor 
intracellular delivery of the BVDU monophosphate (McGuigan et al., 2002). 
 
 
 
 
 
 
 
 
Figure 7.2 Schematic summarising the concept of using ProTide BVDU to target upregulated 
TS in 5-FU resistant cells.  
The 5-FU metabolite FdUMP inhibits the enzyme TS which leads to anti-cancer effects due to 
the role of TS in cellular proliferation and DNA synthesis. However, cells become resistant to 5-
FU simply by upregulating expression of TS. Therefore, the hypothesis was to utilise BVDU, 
which is not activated by the human enzyme TK, and using the ProTide technology to allow 
better entry of the BVDU metabolite BVdUMP into the cell. Subsequently, BVdUMP is 
converted into anti-cancer metabolites by the excess TS, and elicits anti-tumour effects.  
 
In light of these findings, a small family of analogues of thymectacin with modifications in the 
aryl, ester, aromatic and amino acid regions were prepared (by Dr Stephanie Rats and Dr Sahar 
Khandil, Professor Chris McGuigans research group, Cardiff University) and evaluated in this 
chapter. These were initially evaluated in vitro against MCF7 (breast cancer) and counterpart 
MCF7TDX (TS overexpressing) cell lines to determine half maximal inhibitory concentrations 
(IC50s) in comparison to the parent compound BVDU and thymectacin. Potent ProTide 
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compounds were then selected for further evaluation by a colony forming assay to establish 
their effects on proliferation. These compounds were also assessed in vivo in the AhCreER 
driven Apcf/+ Ptenf/f (Apcf/+ Ptenf/f) mouse model of invasive intestinal adenocarcinoma, in a 
short term dosing experiment to assess the anti-tumour effects of the selected compounds. 
Given the reduced efficacy of 5-FU in the advanced tumour setting, the Apcf/+ Ptenf/f tumour 
model was chosen to assess these novel agents due to the invasive disease phenotype but also 
the relatively short latency of tumour development. From these studies, two lead ProTide 
compounds were then selected for evaluation in a therapeutic setting. For this, the 
compounds were administered daily to a cohort of Apcf/+ Ptenf/f mice, from a chosen start 
point to a survival end point, to determine the effect of continuous treatment on survival. 
Furthermore, as the compounds evaluated are hypothesised to be more active in a 5-FU 
resistant and hence TS upregulated tumour setting, I next sought to develop mice bearing TS 
upregulated tumours, from continuous 5-FU treatment. Although 5-FU treatment in the clinic 
varies according to several factors, including age of patient and stage of disease, it is regularly 
administered as a bolus regimen which often involves a high dose for a short period of time - 
for example for 5 days, every 4 weeks. To mimic the clinical setting, a dose of 50mg/kg once 
weekly from 60 days post induction was initially selected. Three additional regimens of 5-FU 
treatment were also undertaken which involved administration of 50mg/kg once weekly from 
50 days post induction, 25mg/kg tri-weekly from 60 days post induction and 100mg/kg once 
weekly from 60 days post induction, to further investigate 5-FU treatment and subsequent 
resistance.  
7.2 Results 
7.2.1 Cell viability assay of thymectacin phosphoramidates in MCF7 and MCF7TDX cell 
lines 
To confirm upregulation of TS in MCF7TDX cells in comparison with parent MCF7 cells, cell 
extracts were prepared, subjected to RNA extraction and corresponding cDNA synthesis 
(methods section 2.9.4, 2.10). Levels of TS were quantified by qRTPCR and revealed a 
significant 90 fold increase in levels of TS (∆CT values: MCF7 cells = 16.05 ± 0.41, MCF7TDX 
cells = 9.56 ± 0.03, p value = 0.0404, n=3, One-tailed Mann Whitney U test) (Figure 7.3).  
Having confirmed increased levels of TS mRNA in MCF7TDX cells compared to MCF7 cells, the 
effects of various thymectacin ProTides on cellular viability was next evaluated using the cell 
titre blue assay 72 hours following treatment (described in methods section 2.9.5). As outlined 
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in Table 7.1, thymectacin showed improved activity in comparison with the parent compound 
BVDU in both MCF7 and MCF7TDX cells however, thymectacin failed to show increased 
potency in the TS upregulated MCF7TDX cells in comparison with controls (IC50 values: BVDU 
>250 µM in MCF7 and MCF7TDX cells, thymectacin = 101µM in MCF7 cells and 113.5 µM in 
MCF7TDX cells). These later findings are in contrast to those reported by Lackey et al whereby 
thymectacin was found to be 69 fold more active in MCF7TDX cells in comparison with MCF7 
cells (IC50 values: MCF7 = 207μM vs MCF7TDX = 3μM) (Lackey et al., 2001). Thymectacin 
ProTides assessed by the cell titre blue cell viability assay showed variable potency in 
comparison with thymectacin in MCF7 cells. Of the 15 ProTide compounds evaluated, 5 
showed poor activity in vitro with IC50 values of >250μM (CPF476, CPF481, CPF486, CPF489 
and CPF494) (Table 7.1), therefore showing less potency than thymectacin and similar potency 
to the BVDU in MCF7 cells. Although 3 of these compounds showed increased potency in 
MCF7TDX cells (IC50 values: CPF476 > 250µM in MCF7 cells vs 16.6µM in MCF7TDX cells; 
CPF481 > 250µM in MCF7 cells vs 137µM in MCF7TDX cells; and CPF486 > 250µM in MCF7 
cells vs 112.5 µM in MCF7TDX cells) (Table 7.1), more efficacious compounds were available. 
Additionally, compounds such as CPF474 and CPF485 were also eliminated from further 
evaluation due to only moderate in vitro activity (IC50 values: CPF474 = 61.6µM vs 8.8µM in 
MCF7TDX cells; CPF485 = 105µM vs 43.7µM). Compounds selected for further evaluation not 
only showed potency in MCF cells- IC50 values of <20μM, but also showed increased potency 
in MCF7TDX cells- IC50 values of <10μM. These include CPF472, CPF473, CPF552, CPF555 and 
CPF3172 (Table 7.1).  
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Quantitative-RTPCR analysis of TS in MCF7 and MCF7TDX cells revealed a significant 90 fold 
increase in TS expression in MCF7TDX cells (ΔCT MCF7 cells = 16.05 ± 0.41, MCF7TDX cells = 
9.56 ± 0.03, p value = 0.0404, Mann Whitney U test).  
 
 
 
 
 
 
 
 
 
Figure 7.3 Increased expression of TS in MCF7TDX cancer cells 
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IC50 values of various ProTide agents, BVDU and thymectacin assessed in MCF7 and MCF7TDX 
cells. Cells were exposed to agents for 72 hours and then assayed using the Cell titer blue 
reagent to assess cell viability. Values represent an average of 6 biological repeats.  
 
 
 
 
Table 7-1 IC50 values (µM) of ProTide compounds assessed by cell viability assay 
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7.2.2 Colony forming assay of selected thymectacin ProTides in MCF7 and MCF7TDX cell 
lines 
In order to evaluate the clonogenic potential of the selected ProTide compounds i.e the 
proportion of cells able to extensively replicate following drug treatment, a colony forming 
assay was performed using both MCF7 and MCF7TDX cell lines (as described in methods 
section 2.9.6). As observed in Figure 7.4, all five compounds selected (CPF473, CPF473, 
CPF552, CPF555 and CPF3172) were more effective than thymectacin in inhibiting colony 
formation in both MCF7 and MCF7TDX cell lines. Interestingly, CPF473, CPF555 and CPF3172 
displayed less potency than CPF472 and CPF552 (Figure 7.4). Here, all colonies were killed with 
25μM, in comparison to 100μM with CPF473, CPF555 and CPF3172. Nevertheless, CPF473, 
CPF555 and CPF3172 displayed increased potency in MCF7TDX cells as more colonies were 
killed with the 50μM concentration, albeit this varied between the compounds (Figure 7.4). 
Here, more colonies were killed with CPF3172 administrations in comparison with CPF473 and 
CPF555 in MCF7TDX cells, and so this compound was regarded as a favourable candidate for 
further evaluation. CPF555 was eliminated from further evaluation as was found to be the 
least potent compound in MCF7TDX cells with regards to colony forming ability.  
Although CPF472 and CPF552 displayed increased efficacy in inhibiting colony formation in 
comparison with thymectacin, CPF473, CPF555 and CPF3172, only CPF472 showed increased 
potency in the TS upregulated MCF7TDX cells and therefore progressed for further evaluation 
(Figure 7.4). All remaining four compounds and thymectacin were next evaluated in vivo to 
determine which, if any, resulted in favourable anti-tumour effects in intestinal tumours from 
short term exposure, as described in section 7.2.3. 
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Figure 7.4 Colony forming assay comparing cell growth in MCF7 and MCF7TDX cells 
A colony forming assay was conducted on 5 selected ProTide agents and thymectacin to 
evaluate clonogenic potential of agents in MCF7 and MCF7TDX cells. All compounds were 
shown to be more potent than thymectacin in both MCF7 and MCF7TDX cells. Interestingly, 
CFP472 and CFP3172 were shown to be more potent in TS overexpressing MCF7TDX cell lines 
in comparison with MCF7 cells  
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7.2.3 In vivo anti-tumour effects of thymectacin and selected ProTide agents 
The Apcf/+ Ptenf/f tumour model of invasive intestinal adenocarcinoma was utilised to 
determine the anti-tumour potential of selected ProTide agents and thymectacin in an 
invasive tumour setting. Here, 10 week old mice were induced and aged to 85 days post 
induction at which point mice were known to carry a tumour burden (it was previously 
established that tumours were present at 77 days post induction -chapter 4, median survival 
for  Apcf/+ Ptenf/f mice is 100 days post induction). A cohort of 4 mice (per treatment) were 
administered with 50mg/kg of thymectacin, CPF472, CPF473, CPF552, CPF3172 or vehicle once 
daily by oral gavage for 4 consecutive days. Mice were culled 6 hours following the final dose 
and dissected as described previously (section 2.4).  
Following exposure to selected ProTide compounds or vehicle, the anti-tumour effects on 
small intestinal tumours (SITs) were characterised by assessment of histological mitosis and 
apoptosis from H&E stained slides (Figure 7.5). Scoring of mitotic figures revealed a significant 
reduction in mitotic figures from CPF472 exposure only (vehicle = 0.48 ± 0.18, CPF472 = 0.28 ± 
0.21 p value = 0.05, n≥10 tumours, 4 mice, Mann Whitney U test) (Figure 7.5 A). Thymectacin, 
CPF473, CPF552 and CPF3172 had no significant effect on levels of mitosis (vehicle = 0.48 ± 
0.18; thymectacin = 0.84 ± 0.49, p value = 0.153; CPF473 = 0.32 ± 0.16, p value = 0.298; CPF 
552 = 0.89 ± 0.61, p value = 0.259; CPF3172 = 0.47 ± 0.17, p value =0.773, n≥10 tumours, 4 
mice, Mann Whitney U test) (Figure 7.5 A). Scoring of histological apoptosis revealed 
thymectacin led to a significant reduction in levels of apoptosis whereas CPF473 and CPF552 
had no effect on apoptosis (vehicle = 0.82 ± 0.24, thymectacin = 0.42 ± 0.14, p value = 0.032; 
CPF473 = 0.84 ± 0.34, p value = 0.81; CPF552 = 0.93 ± 0.48, p values = 0.668, n≥10 tumours, 4 
mice, Mann Whitney U test) (Figure 7.5 B). CPF472 led to a trend towards increased apoptosis 
and CPF3172 resulted in a significant increase in apoptosis (vehicle = 0.82 ± 0.24; CPF472 = 
1.26 ± 0.67, p value = 0.119, CPF3172 = 1.53 ± 0.7, p value = 0.0119; n≥10 tumours, 4 mice, 
Mann Whitney U test) (Figure 7.5 B), identifying these as perhaps more effective compounds 
in vivo. 
To further characterise the anti-tumour effects of the selected ProTide compounds in 
comparison with thymectacin in vivo, IHC for BrdU and cleaved caspase 3 was performed and 
subsequently scored (Figure 7.6). This revealed thymectacin exposure resulted in significantly 
reduced BrdU positive cells in comparison with vehicle controls (vehicle = 33.7 ± 2.06; 
thymectacin = 23.1 ± 3.78, p value = 0.0107, n≥4 tumours from at least 2 mice, Mann Whitney 
U test) (Figure 7.6 A), indicating a reduction in cells in the S phase of the cell cycle. No 
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significant effect was observed with CPF472, CPF473, CPF552 or CPF3172 exposure (vehicle = 
33.7 ± 2.06; CPF472 = 27.2 ± 7.78, p value = 0.391; CPF473 = 31.1 ± 4.15, p value = 0.471; 
CPF552 = 31.5 ± 7.14, p value = 0.55; CPF3172 = 38.5 ± 4.32, p value = 0.051, n≥10 tumours, 4 
mice, Mann Whitney U test) (Figure 7.6 A). Finally, scoring of cleaved caspase 3, to further 
characterise any pro-apoptotic effect from ProTide or thymectacin treatment in Apcf/+ Ptenf/f 
SITs, revealed that thymectacin exposure resulted in substantially reduced staining, 
corroborating histological apoptosis findings, whilst the ProTide agents had no significant 
effect on cleaved caspase 3 staining (vehicle = 5.7 ± 2.16; thymectacin = 0.65 ± 0.3, p value = 
0.0005; CPF472 = 7.07 ± 2.07, p value = 0.203; CPF473 = 5.21 ± 1.77, p value = 0.936; CPF552 = 
5.09 ± 2.23, p value = 0.531; CPF3172 = 7.03 ± 3.79, p value = 0.629, n≥10 tumours, 4 mice, 
Mann Whitney U test) (Figure 7.6 B) 
The anti-tumour effects characterised here, together with the results from the cell viability 
and colony forming assays performed on the selected ProTide compounds and thymectacin 
are summarised in table 7.2. These reveal CPF472 and CPF3172 were more effective 
compounds than CPF473 and CPF552 in comparison with thymectacin, and were therefore 
selected as lead compounds for further evaluation in a chronic treatment setting. As an 
additional control, thymectacin was also selected for chronic treatment to determine whether 
ProTide compounds were indeed more effective in a survival setting. CPF473 and CPF552 were 
eliminated from further characterisation as they failed to display any anti-proliferative or pro-
apoptotic effects in tumours.  
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Apcf/+ Ptenf/f mice were administered with 50mg/kg of selected ProTide agents CFP472, 
CFP473, CPF555 or CFP3172 or thymectacin for 4 consecutive days. Following exposure, 
assessment of histological mitosis revealed only CPF472 resulted in a significant reduction in 
levels of mitosis in tumours. Thymectacin and CFP552 resulted in a trend towards increased 
levels whereas CPF473 and CPF3172 had no effect on levels of mitosis. Scoring of histological 
apoptosis revealed thymectacin resulted in a significant reduction in levels whereas CPF3972 
significantly increased apoptosis in tumours following exposure. CFP472, CFP473 and CFP552 
had no effect on apoptosis in Apcf/+ Ptenf/f  tumours. (p value ≤ 0.05, n≥10 tumours, 4 mice, 
Mann Whitney U test). Error bars represent standard deviation.  
Figure 7.5 Assessment of anti-proliferative and pro-apoptotic effects in Apcf/+ Ptenf/f 
tumours following short term treatment of selected ProTides and thymectacin. 
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Scoring of BrdU (A) and cleaved caspase 3 (B) in Apcf/+ Ptenf/f mice  exposed to 50mg/kg of 
selected ProTide agents CFP472, CFP473, CPF555 or CFP3172 or thymectacin for 4 consecutive 
days . Thymectacin treatment resulted in a significant decrease in BrdU scoring indicating an 
anti-proliferative effect, however also resulted in a significant reduction in cleaved caspase 3 
scoring, signifying an anti-apoptotic effect. ProTides had no significant effect on BrdU scoring 
or cleaved caspase 3. p value ≤ 0.05, n≥4 tumours, at least 2 mice, Mann Whitney U test). 
Error bars represent standard deviation 
Figure 7.6 Further assessment of anti-proliferative and pro-apoptotic effects through 
BrdU and cleaved caspase 3 scoring in Apcf/+ Ptenf/f tumours following short term 
treatment of selected ProTides and thymectacin. 
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 Thymectacin CPF472 CPF473 CPF552 CPF3172 
Cell viability assay 
(IC50 in MCF7 
MCF7TDX cells, µM) 
101.3 113.5 4.33.4 6.12.7 14.45.3 3.72.6 
Colony forming 
assay (growth in 
MCF7 MCF7TDX 
cells, µM) 
No difference 
at 150µM 
Reduction 
from 
25µM15µM 
Reduction 
at 50µM 
No 
difference 
at 15µM 
Reduction 
at 50µM 
Histological mitosis 
 
     
Histological 
apoptosis 
 
     
BrdU scoring 
 
     
Cleaved caspase 3 
scoring 
     
Table 7-2 Summary of short term in vitro and in vivo anti-tumour effects of selected 
ProTides and thymectacin. Table shows the average IC50 values in MCF7 and MCF7TDX cells, 
differences observed in colony forming ability and short term in vivo effects of ProTides and 
thymectacin. Blue horizontal arrow indicates no difference, green arrow indicates anti-tumour 
effects and red arrow indicates pro-tumour effects.  
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7.2.4 Long term treatment of lead ProTide agents in the Apcf/+ Ptenf/f tumour model  
To investigate the therapeutic potential of the selected ProTide agents CPF472 and CPF3172, a 
long term treatment experiment was conducted (similar to those in Chapter 4) to determine 
their effect on survival, in comparison to vehicle and thymectacin treatment. For this, a cohort 
of 15 mice per cohort, were induced and aged to 77 days post induction at which point daily 
treatment commenced. Mice were randomly selected to receive either 75mg/kg of CPF472, 
CPF3172, thymectain or the equivalent vehicle volume once daily, until a survival end point 
(anaemia, bloating, ≥10% loss of body weight).  
Continuous treatment of CPF472, CPF3172 and thymectacin was found to be well tolerated in 
Apcf/+ Ptenf/f mice (according to body weight), however CPF472 and CPF3172 failed to 
significantly increase survival of mice (median survival of vehicle mice = 94, CPF472 = 107, p 
value = 0.61, CPF3172 = 112, p value = 0.203, n≥15, Log Rank method) (Figure 7.7). 
Surprisingly, daily thymectacin treatment significantly increased median survival of Apcf/+ 
Ptenf/f mice from 94 to 133 days post induction (p value = 0.029, n≥15, Log Rank method) 
(Figure 7.7).  
These findings were surprising, given the lack of efficacy in in vitro experiments from 
thymectacin exposure and in comparison, the potency of CPF472 and CPF3172 in these 
settings. Despite this, it was postulated that CPF472 and CPF3172 may be more effective in the 
5-FU resistant and hence TS upregulated setting. To model this, I next investigated the effects 
of chronic 5-FU treatment to determine whether this led to an increase in TS in Apcf/+ Ptenf/f 
tumours.  
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Figure 7.7 Kaplan Meier survival analysis of Apcf/+ Ptenf/f mice on long term CPF472, CPF3172 
or thymectacin treatment. 
Apcf/+ Ptenf/f mice were induced and aged to 77 days post induction, at which point mice were 
randomised to receive either vehicle control or 75mg/kg of CFP472, CFP3172 or thymectain 
once daily until a survival end point. Continuous ProTide treatment resulted in no significant 
benefit in median survival of Apcf/+ Ptenf/f mice (median survival of 107 and 112 days post 
induction for CPF472 and CFP3172, respectively, p value ≥ 0.05 for both, n ≥ 10 mice per 
cohort, Log Rank method) whereas daily thymectacin treatment significantly increased median 
survival of mice from 94 days to 133 days post induction (p value = 0.029, n ≥ 10 mice per 
cohort, Log Rank method) 
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7.2.5 Investigation of chronic 5-FU treatment 
Prior to 5-FU treatment, it was important to determine the basal levels of TS expression in 
tumours in comparison with normal small intestine tissue. For this, a cohort of 3 mice which 
presented with symptoms of tumour burden (paling feet, bloating, rectal bleeding) were 
culled, then normal small intestine and tumour tissue was dissected and snap frozen (as 
outlined methods section 2.4) for TS expression analysis. Following RNA and corresponding 
cDNA synthesis, qRTPCR analysis revealed a 2-fold increase in Apcf/+ Ptenf/f tumours, in 
comparison with small intestinal tissue (∆CT values: Small intestine normal (SIN) tissue = 9.48 ± 
0.127; small intestine tumour (SIT) = 8.32 ± 0.131, p value = 0.0404) (figure 7.8). This finding 
was not surprising, given the role of TS in DNA replication however, it was pertinent to 
determine this given that 5-FU has previously been shown to be ineffective in TS upregulated 
tumours. 
To determine the effects of 5-FU treatment in Apcf/+ Ptenf/f mice, a chronic dosing strategy was 
employed firstly, to investigate the effects of treatment on increasing longevity of mice and 
secondly, to establish whether tumours established resistance to 5-FU by increasing 
expression of TS.  Given that Apcf/+ Ptenf/f mice are often culled shortly after presenting with 
symptoms of disease, 5-FU treatment was commenced prior to the onset of disease symptoms 
to allow more time for tumours to develop resistance. The four strategies used for 5-FU 
treatment were as follows; 50mg/kg 5-FU weekly from 60 days post induction, 50mg/kg 5-FU 
weekly from 50 days post induction, 25mg/kg 5-FU tri-weekly from 57 days post induction and 
100mg/kg 5-FU weekly from 60 days post induction, all administered by i.p injection, until a 
survival end point. Treatment regimens were found to be well tolerated by mice, except for 
the 100mg/kg 5-FU strategy which resulted in weight loss 24 hours following the dose 
administration. Subsequent Kaplan Meier survival analysis revealed this regimen had no 
significant effect on increasing longevity of mice (median survivals: vehicle = 94 days, 
100mg/kg 5-FU = 98 days post induction, p value = 0.665, n≥6 per cohort, Log Rank method) 
(Figure 7.9). Interestingly, out of the three tolerated regimens, the only significant increase in 
median survival was observed with the 50mg/kg 5-FU regimen that commenced at 50 days 
post induction (median survivals: vehicle = 94 days, 50mg/kg 5-FU day 60 = 120 days, p value = 
0.09, 50mg/kg 5-FU day 50 = 131 days, p value = 0.006, 25mg/kg 5-FU tri-weekly = 120 days 
post induction p value = 0.349, n≥8, Log Rank method) (Figure 7.9). Given the differences 
observed increase in median survivals, tumours from mice in various cohorts were analysed 
for expression of TS.   
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To assess the expression of TS in SITs from Apcf/+ Ptenf/f mice exposed to 5-FU, individual 
tumours snap frozen at dissection were subjected to RNA extraction, cDNA synthesis and 
qRTPCR analysis. Analysis to evaluate the expression of TS was conducted in individual 
tumours (as described in methods section 2.10). It was hypothesised that tumours from mice 
culled following short exposure to 5-FU would show no alteration in levels of TS indicating no 
response to 5-FU, whilst those tumours from mice exposed to 5-FU for longer periods of time 
would present with increased levels of TS.  
In comparison with tumours from untreated mice, those exposed to only 1 weekly doses of 
50mg/kg 5-FU from days 60 post induction (culled at 61 days post induction) showed no 
significant difference in levels of TS, indicating 5-FU had no effect on TS expression levels here 
(Figure 7.10 A). Additionally, no obvious increase in expression of TS was observed in tumours 
from mice exposed to 11 or 14 weekly doses of 50mg/kg 5-FU from 60 days post induction, 
although three tumours (from two mice culled at 127 and 148 days post induction) trended 
towards an increase in TS expression (Figure 7.10 A, B). Interestingly, a high degree of 
variability was notable within tumours from the same mouse, which may be reflective of the 
proliferative nature of the tumours given the normal physiological function of TS in DNA 
replication. Interestingly, three out of six tumours analysed following exposure to 28 weekly 
doses of 50mg/kg 5-FU (culled at 246 days post induction) from 60 days post induction had 
reduced TS expression, perhaps indicating tumours were responding to 5-FU treatment but 
not resistant at this time (Figure 7.10 C).  
A similar trend to that described above of no significant alteration in TS expression was 
observed in mice exposed to 7 weekly doses of 50mg/kg 5-FU (culled at 101 days post 
induction) from 50 days post induction (Figure 7.11 A).  Finally, assessment of tumours from 
mice which survived the longest (culled at 303 days post induction following 36 weekly doses 
of 50mg/kg 5-FU) also failed to show an increased TS expression in the majority of tumours 
(Figure 7.10 B, C). Only one tumour from six showed a 2.5 fold increase in TS expression and 
may be indicative of differences in the proliferative nature of tumours and not of a single 
resistant tumour (Figure 7.10 C).  
In summary, the findings from these investigations suggest that Apcf/+ Ptenf/f mice showed 
little to no responsiveness to 5-FU treatment. This could be due to the severe tumour 
phenotype present in this model or alternatively the regimens chosen for 5-FU administration 
in these mice were not appropriate to observe a substantial beneficial effect. The later 
observation suggests further investigation of the metabolism of 5-FU is required to better 
283 
 
understand the effects of 5-FU. Nevertheless, the findings here are in concert with clinical 
evaluations of 5-FU, which report limited overall benefits in patients of only 10-15%. 
Furthermore, expression analysis of TS in long term 5-FU treated tumours which appeared to 
have some response to 5-FU, failed to reveal an increase in TS expression. This may be due to 
alternative mechanisms of resistance or tumours not being ‘truly resistant’. 
 
 
 
 
 
 
 
 
 
 
Figure 7.8 Increased expression of TS in Apcf/+ Ptenf/f small intestinal tumours (SITs) in 
comparison with normal small intestinal tissue (SIN). 
Quantitative-RTPCR analysis of TS in small intestinal normal (SIN) tissue from Apcf/+ Ptenf/f mice 
in comparison with small intestinal tumour (SIT) tissue revealed a significant two-fold increase 
in TS expression. (ΔCT SIN = 0.948 ± 0.127, SIN = 8.32 ± 0.131, p value = 0.0404, n= 3 mice, 
Mann Whitney U test)  
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Figure 7.9 Kaplan Meier survival analysis of Apcf/+ Ptenf/f mice on long term 5-FU treatment. 
Apcf/+ Ptenf/f mice were induced and aged prior to start of various 5-FU treatment regimens, as 
outlined above. Weekly 50mg/kg 5-FU treatment from day 60, tri-weekly 25mg/kg 5-FU from 
day 57 or weekly 100mg/kg 5-FU from day 60 post induction had no significant effect on 
median survival of Apcf/+ Ptenf/f mice. Only weekly administration of 50mg/kg 5-FU from day 50 
post induction significantly increased survival of Apcf/+ Ptenf/f mice from a median of 94 to 131 
days post induction. (50mg/kg 5-FU from 50 days post induction p value = 0.006, for all other 
treatments p ≥ 0.05, n ≥ 10 mice per cohort, Log Rank method) 
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Figure 7.10 quantitative-RTPCR analysis of individual untreated Apc
f/+
 Pten
f/f
 tumours in comparison 
with those exposed to 50mg/kg 5-FU treatment from day 60 post induction for varied periods of time. 
Expression analysis of TS in small intestinal tumours (SITs) from untreated Apcf/+ Ptenf/f mice in 
comparison with those exposed to 5-FU up to 148 days post induction showed no significant 
difference in TS expression. Interestingly, some tumours from one mouse exposed to 5-FU up to 
246 days post induction showed reduced levels of TS (ΔCT values of treated tumours were 
normalised to the averaged ΔCTs of untreated tumours to calculate ΔΔCT values). 
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Figure 7.11 quantitative-RTPCR analysis of individual untreated Apc
f/+
 Pten
f/f
 tumours in comparison 
with those exposed to 50mg/kg 5-FU treatment from day 50 post induction for varied periods of time 
Expression analysis of TS in small intestinal tumours (SITs) from untreated Apcf/+ Ptenf/f mice in 
comparison with  those exposed to 5-FU showed either up to 110 days or 303 days post induction 
showed  mostly unaltered TS expression. One tumour from a mouse exposed to 5-FU for up to 303 
days showed increased expression of TS of 2.5 fold. (ΔCT values of treated tumours were 
normalised to the averaged ΔCTs of untreated tumours to calculate ΔΔCT values) 
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7.3 Discussion 
7.3.1 In vitro and in vivo characterisation of ProTide compounds  
The ProTide approach has previously proved effective in increasing the therapeutic potential 
of a number of anti-viral agents and more recently anti-cancer nucleoside agents, such as 
gemcitabine. This approach involves the use of phosphoramidate groups to mask the charge 
on the mono-phosphate form of the nucleoside, eliminating the requirement of the initial 
rate-limiting step in the metabolism of the nucleoside agent, whilst also improving the 
intracellular delivery of the compound. Once into the cell, the additional phosphoramidate 
groups are enzymatically cleaved to release the pre-formed monophosphate nucleoside for 
further phosphorylations. Hence, a widespread library with different alterations in the amino 
acid, aromatic moiety, ester, or the Br constituent of BVDUMP was synthesised and initially 
evaluated in vitro.  
Initial in vitro characterisation of ProTide agents involved a cell titer blue cell viability assay, 
conducted 72 hours following ProTide exposure in both MCF7 and TS overexpressing 
MCF7TXD cells. Compounds were found to have varied cytotoxic effects from this assay in 
comparison with Thymectacin and also the parent compound BVDU (Table 7.1). The most 
active compounds from this assay were further evaluated in vitro using a colony forming assay, 
which also involved 72 hours of drug exposure, to examine the ability of ProTide agents to 
inhibit cell growth. From this, all compounds were found to have improved efficacy in 
comparison with Thymectacin, however only 3 compounds were found to be notably more 
effective in MCF7TDX cells in comparison with MCF7 cells – CPF472, CPF473 and CPF3172 
(Figure 7.4). Whilst CPF552 was not found to have increased potency in the MCF7TDX cells, the 
observation that colony growth was completely killed with the 25µM concentration (in both 
cell lines) indicated this to be a potent compound nevertheless (Figure 7.4). Finally, despite the 
improved efficacy of CPF555 in comparison with Thymectacin in the in vitro cell viability and 
colony forming assays, this compound was not further evaluated due to lack of potency in 
comparison with the remaining ProTide agents.  
Subsequently the four remaining ProTide agents were evaluated in an in vivo tumour setting. 
For these evaluations, the AhCreER driven Apcf/+ Ptenf/f tumour model was selected due to the 
invasive nature of the tumour phenotype present and the reduced latency for tumour 
development in comparison with Apcf/+  controls. Following induction, Apcf/+ Ptenf/f mice aged 
to 85 days post induction were administered consecutive doses of 50mg/kg thymectacin, 
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CPF472, CP7473, CPF552, CPF3172 or vehicle once daily for four days and culled 6 hours 
following the final dose. Tumours from mice exposed to the ProTide agents or thymectacin 
were evaluated for anti-tumour effects, in comparison with vehicle treated tumours (Figures 
7.5, 7.6). Whilst both CPF472 and CPF3172 induced favourable pro-apoptotic effects, CPF473 
and CPF552 induced no biological effect in Apcf/+ Ptenf/f tumours, indicating lack of in vivo 
efficacy (Figures 7.5, 7.6). This lack of in vivo efficacy may be due to a number of factors 
including in vivo metabolism of the agents as well as lipophilicity which vastly differs in in vitro 
and in vivo systems. From anti-proliferative investigations, only CPF472 reduced proliferation 
in Apcf/+ Ptenf/f tumours, showing further favourable in vivo efficacy. Whilst thymectacin 
treatment resulted in a reduction of cells in the S phase of the cell cycle, treatment also 
induced anti-apoptotic effects in tumours as detected by scoring of histological apoptosis and 
cleaved caspase 3 staining (Figures 7.5, 7.6). From the short term in vivo study, ProTides 
CPF472 and CPF3172 were chosen for further in vivo investigations, given their favourable 
anti-tumour effects from short term treatments. This would formally determine their efficacy 
in a long term therapeutic setting and ultimately determine whether continuous treatment 
can improve survival of Apcf/+ Ptenf/f mice.  
Despite the anti-tumour effects of CPF472 and CPF3172 in the short term in vivo experiment, 
both compounds failed to significantly increase survival of Apcf/+ Ptenf/f mice when 
administered at 75mg/kg daily. CPF472 treated Apcf/+ Ptenf/f   mice from 77 days post 
induction, had a median survival of 107 days whilst CPF3172 treatment increased survival of 
equivalent mice to 112 days post induction (vehicle cohort had a median survival of 94 days 
post induction) (Figure 7.7). Surprisingly, continuous thymectacin treatment significantly 
improved survival of mice to 133 days post induction indicating increased potency in 
comparison with CPF472 and CPF3172 (Figure 7.7). These findings were particularly surprising 
given the lack of efficacy of thymectacin in the in vitro cell viability and colony forming assays, 
as well as the short term in vivo experiment. However, these findings to some extent 
corroborate previous studies which reported efficacy of thymectacin in vivo. Lackey et al 
reported that whilst thymectacin failed to show efficacy in MCF7 cells in comparison with 
MCF7TDX cells (IC50 = 207µM in MCF7 vs IC50 = 3µM in MCF7TDX), continuous treatment 
significantly inhibited growth in both MCF7 and MC7TDX xenograft settings comparably 
(Lackey et al., 2001), further suggesting the in vivo efficacy of thymectacin is not reflected 
from in vitro studies. Whilst findings in this chapter corroborate the lack of efficacy of 
thymectacin in MCF7 cells but potency in the in vivo setting, this study did not find 
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thymectacin to be increasingly potent in MCF7TDX cells, but this perhaps could be attributed 
to differences in the in vitro experiments conducted.      
These findings suggest further characterisation and validation of CPF472 and CPF3172 is 
required with regards to in vivo stability, lipophilicity and metabolism. These further 
investigations are required to determine in vivo uptake of ProTide agents in tumour cells, 
enzymatic cleavage of the additional phosphoramidate groups and accumulation of BVDUMP 
in vivo to understand the lack of in vivo efficacy.     
 
7.3.2 Alternative mechanisms of resistance to 5-FU 
5-FU remains the most widely used chemotherapeutic agent for the treatment of CRC, despite 
the very modest response rates of only 10-15% as first line therapy in patients (Johnston and 
Kaye, 2001). Efforts to understand the mechanisms by which 5-FU causes cytotoxicity in cells 
and subsequently how tumours develop resistance to 5-FU are essential for predicting 
response and also for developing methods to overcome resistance. As described previously, 
when metabolised, 5-FU is converted into several metabolites including FdUMP, FdUTP as well 
as FUTP which disrupt RNA synthesis and inhibit the actions of TS (Figure 7.1) (Longley et al., 
2003). In particular, the 5-FU metabolite FdUMP binds to the nucleotide binding site of TS, 
forming a stable tertiary structure with the enzyme and CH2THF (a methyl donor) to block 
binding of the normal substrate dUMP, subsequently inhibiting dTMP synthesis. Furthermore, 
dUTP can be misincorporated into DNA causing false nucleotide incorporation, excision and 
repair, subsequently causing DNA strand breaks and cell death (Yoshioka et al., 1987, 
Mitrovski et al., 1994). In addition, misincorporation of the 5-FU metabolite FUTP into RNA can 
also disrupt normal RNA processing and function, and has previously been associated with loss 
of clonogenic potential in human colorectal cancer cell lines (Glazer and Lloyd, 1982).  
Given the role of TS in mediating the cytotoxic effects of 5-FU in cancer cells, it is not 
surprising that a number of studies have shown TS expression to be a key determinant of 
sensitivity and resistance to 5-FU. Clinical investigations have previously evaluated TS levels by 
immunohistochemistry as well as RT-PCR techniques to show improved response of 5-FU in 
patients with low tumoural TS expression (Johnston et al., 1995, Edler et al., 1997). 
Additionally, 5-FU treatment has been shown to increase TS expression in both cell lines and 
tumours, and is regarded as a mechanism of resistance, as increased TS expression would 
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result in increased TS protein levels which would facilitate enzymatic recovery (Chu et al., 
1993a, Longley et al., 2003).   
Studies in this chapter aimed to model TS overexpression through 5-FU exposure, in the Apcf/+ 
Ptenf/f tumour model to further investigate the therapeutic potential of novel BVDUMP 
ProTide agents previously evaluated in this chapter. To achieve 5-FU response and subsequent 
resistance, four differing dosing strategies were employed, to mimic the clinical setting. These 
involved once weekly 50mg/kg 5-FU either from day 60 or 50 post induction, 25mg/kg tri-
weekly from day 57 post induction and 100mg/kg once weekly from day 60 post induction, all 
of which were administered to a survival end point (Figure 7.9). Whilst the 100mg/kg 
treatment was found to induce mild toxicity effects, Kaplan Meier survival analysis revealed 
only the 50mg/kg once weekly from day 50 post induction had a significant effect on 
increasing median survival of Apcf/+ Ptenf/f mice in comparison with vehicle treatment (Figure 
7.9). Mice in this cohort appeared to respond to 5-FU treatment, however as mice are culled 
at a survival end point, it was thought that tumours may have become resistant to 5-FU 
treatment. Surprisingly the equivalent dose of 50mg/kg weekly but from day 60 and the 
25mg/kg tri-weekly regimen from day 57 failed to significantly increase survival of mice (Figure 
7.9). This may be attributable to the presence of fewer tumours or perhaps less invasive 
tumours at day 50 in comparison with day 57 or 60 post induction. To evaluate whether 
tumours from the responding cohort resulted in increased levels of TS, qRT-PCR analysis was 
used to assess levels of TS mRNA expression in individual tumours, in comparison with a 
cohort of untreated tumours (Figure 7.10, 7.11). Although qRT-PCR analysis did not show 
increased levels of TS with increased exposure to 5-FU, this did reveal variation between 
tumours from the same mouse, which may be attributable to differences in the basal levels of 
proliferation between less or more invasive lesions. Alternatively, these findings suggest that 
in Apcf/+ Ptenf/f mice, TS overexpression may not be the primary mechanism of resistance to 5-
FU (Figure 7.10, 7.11).  
Whilst TS overexpression is often regarded as the primary mechanism of resistance to 5-FU, a 
number of other biological factors have also been implicated in determining response and 
resistance to 5-FU, and may be attributable to the non-response or resistance following 5-FU 
treatment in Apcf/+ Ptenf/f tumours. The enzyme thymidine phosphorylase (TP) which can 
reversibly convert 5-FU to FUDR, which can subsequently be converted to the active 
metabolite FdUMP is also implicated in non-response and resistance to 5-FU although the 
current literature is contradictory (Longley et al., 2003). TP overexpression in cell culture and 
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xenografts has previously shown sensitivity to 5-FU however mRNA expression analysis of 
colorectal tumours with high levels of TP were shown to be less likely to respond to 5-FU 
(Evrard et al., 1999, Metzger et al., 1998). These contrasting findings however, may be 
attributable to the observation that TP is also an angiogenic endothelial cell growth factor 
which has been associated with more invasive disease, less likely to respond to chemotherapy 
(Takebayashi et al., 1996). 
Additionally, the rate-limiting enzyme of 5-FU catabolism dihydropyrimidine dehydrogenase 
(DPD) which converts 5-FU to dihydrofluorouracil (DHFU) is also implicated in non-response to 
5-FU (Diasio and Johnson, 1999, Johnson et al., 1999). DPD is abundantly expressed in the liver 
where it leads to more than 80% of 5-FU catabolism. Therefore patients deficient in DPD show 
toxicity to 5-FU due to decreased drug catabolism (Johnson et al., 1999). Despite this, in vitro 
studies and expression analyses of patient samples have also shown DPD overexpression 
confers resistance to 5-FU (Takebe et al., 2001, Salonga et al., 2000), perhaps reflecting higher 
DPD mediated degradation of 5-FU in tumours.           
As well as TP and DPD expression, mutations in several genes have also been associated with 
poor response to 5-FU including microsatellite instability inducing genes such as MLH1, MSH2 
and MSH6 (Claij and te Riele, 1999), as well as loss of the tumour suppressor protein p53, 
which mediates DNA integrity and response to DNA damage (Bunz et al., 1999). Disruption of 
both alleles of the p53 gene or the pro-apoptotic gene BAX can result in cells resistant to 
apoptosis induced by 5-FU (Bunz et al., 1999, Zhang et al., 2000). This has also been validated 
in clinical studies through p53 overexpression as a surrogate marker of p53 mutations (Ahnen 
et al., 1998).  
7.4 Summary 
This study evaluated novel compounds synthesised using the phosphoramidate prodrug 
approach applied to the anti-viral agent BVDU. These nucleoside ProTide derivatives 
demonstrated increased biological activity in comparison to the parent compound BVDU as 
well as thymectacin, a BVDU prodrug, currently under pre-clinical evaluation. Despite 
improved in vitro and short term in vivo activity of selected ProTide agents in comparison with 
thymectacin, the selected lead ProTide agents were found to be less efficacious than 
thymectacin in increasing survival of tumour bearing Apcf/+ Ptenf/f mice. Despite this, it was 
hypothesised these agents would be more active in a TS overexpressing tumour setting, a key 
enzyme implicated in resistance to 5-FU given that the metabolite of BVDU is a substrate for 
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TS. However, continuous 5-FU treatment did not result in increased expression of TS, 
suggesting an alternative mechanism of resistance may be attributable to 5-FU resistance in 
the Apcf/+ Ptenf/f mouse model. Therefore the hypothesis that these ProTide agents would be 
more active in the TS upregulated tumour setting remains to be tested in vivo.  
7.5 Further work 
7.5.1 Further in vivo investigations of ProTides agents 
Whilst the short term in vivo characterisation of selected ProTide agents presented in this 
chapter showed that the two lead ProTide agents induced favourable biological activity in 
tumours, these effects were not correlated to long term activity of the compounds. Therefore, 
it would be useful to conduct a short term dose escalation study, whereby accumulation of 
BVDU metabolites are detected in the tumours and correlated to biological activity. Such 
experiments may help determine how well the compounds are getting into the tumours and 
also how well they are metabolised to release the bioactive phosphate nucleoside. 
Additionally, these experiments may help determine the most effective dose to use for long 
term therapeutic studies, as in the study presented here, although a high dose administered, it 
was not determined whether a higher dose could be used instead. Moreover, such 
experiments may help determine whether any solubility or lipophilicity issues are preventing 
effective delivery of compounds into the tumours. To conduct these experiments, mass 
spectrometry may be required to detect accumulation of BVDUMP in tumours.  
7.5.2 Modulation of 5-FU in the Apcf/+ Ptenf/f tumour model 
As mentioned previously, 5-FU treatment was only efficacious in Apcf/+ Ptenf/f mice when 
administered at 50mg/kg from day 50 post induction, in comparison to the alternative 
treatment regimens. However, it is not known whether this is the optimal treatment regimen 
for 5-FU in mice. Additionally, target validation studies were not conducted to determine 
whether 5-FU treatment resulted in reduced TS expression. Conducting such experiments may 
identify a better treatment regimen for 5-FU in mice which may result in an improved 
response. For this, it would be useful to administer a single dose of 5-FU, at varying 
concentrations, and investigate the effects on tumour TS expression from day 1 to 7, as 
treatment was most commonly administered weekly. This may yield informative findings 
regarding the modulation of 5-FU in the Apcf/+ Ptenf/f tumour model.    
Furthermore, alternative mechanisms of resistance to 5-FU treatment have been described 
and include increased expression of the enzyme TP or depletion of DPD, both of which are 
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involved in the catabolism of 5-FU. Also, mutations in a number of genes including p53, BAX 
and microsatellite instability inducing genes are commonly associated with resistance. 
Investigation these would be useful to further explore resistance in Apcf/+ Ptenf/f tumours 
following 5-FU treatment.  
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8 General Discussion 
 
8.1 The use of genetically engineered mouse models for pre-clinical studies 
As the third most commonly diagnosed malignancy, colorectal cancer (CRC) leads to more 
than 16,000 deaths annually (Cancer Research, UK). The high mortality rate associated with 
CRC is often attributed to patients presenting with late stage disease in the clinic, and also the 
lack of correlative early symptoms to diagnose the disease. The current treatment strategies 
for CRC predominantly rely on the use of combinations of cytotoxic agents, which include 5-
fluorouracil (5-FU), irinotecan and oxaliplatin in either the FOLFOX or FOLFIRI regimen (FOLinic 
acid, Fluoroural and OXaliplatin or FOLinic acid, Fluorouracil and IRInotecan, respectively, 
Cancer Research, UK), with the addition of anti-epidermal growth factor receptor (EFGR) 
targeted agents such as cetuximab and panitumumab more recently. Despite this, CRC is the 
second most common cause of death by cancer, indicating mortality rates remain high. 
Subsequently, the need for more effective treatment strategies is urgent.  
Recently, efforts to identify further mutations involved in CRC by sequencing have increased 
with the availability of new technologies. Such systematic characterisation of somatic 
mutations within cancer genomes not only increase our understanding of the disease, but also 
help to identify novel therapeutic targets. Despite this, the fact that only 1 in 10 novel 
compounds successful at phase I evaluations is eventually approved by regulators, highlights 
major flaws in the pre-clinical development process (Johnston and Kaye, 2001). This high 
attrition rate is often attributed to poor pre-clinical strategies such as the use of xenografted 
human tumours in immune-compromised mice, which fail to accurately predict the in vivo 
efficacy of novel agents. Furthermore, these fail to recapitulate a number of processes 
involved in human cancer such as the sporadic nature of tumour formation, the tumour 
microenvironment, as well as angiogenesis. A number of notable failures in the clinic from 
promising xenograft studies highlight this issue. For example, thiazolidinediones (TZDs) which 
are antagonists of PPAR-γ (perixome proliferator-activated receptor γ) showed impressive 
anti-tumour activity in cultured and xenografted colon cancer cell lines (Sarraf et al., 1998). 
However, in the clinic, these were a clear failure for patients with CRC, and led to rapid 
progression of disease (Kulke et al., 2002). Similarly, novel anti-angiogenesis agents such as 
endostatin and angiostatin, showed potent anti-cancer effects in xenografts and human 
cancer cell lines (Boehm et al., 1997, O'Reilly et al., 1996, Holmgren et al., 1995), however 
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have yet to demonstrate any single-agent activity against CRC (Twombly, 2002, Thomas et al., 
2003). Furthermore, farnesyltransferase inhibitors (FTIs) expected to inhibit RAS function 
showed activity in xenograft studies, however were less active in human cancers (Kohl et al., 
1994, Omer et al., 2000, Berndt et al., 2011). Studies of these in genetically engineered mouse 
models (GEMMs) showed that anti-tumour activity of FTIs was not RAS dependent. As well as 
the lack of predictive power of xenograft studies for clinical trials, these provide limited 
information regarding the genetic or epigenetic mutations present in tumours which could 
help predict the response of a particular tumour to novel agents (such as Kras or Pten/PIK3CA 
gene mutation status in anti-EGFR trials).     
GEMMs which develop tumours within the tissue of interest with an intact immune system 
may better recapitulate the human disease and furthermore, may better predict the efficacy 
of novel agents in vivo. Evidence for this was clearly provided by Olive et al. assessing the 
efficacy of the chemotherapeutic agent gemcitabine in models of pancreatic cancer. This study 
found that whilst gemcitabine showed activity in xenografts, the limited activity of this in 
GEMMs was due to the presence of tumour associated stromal tissue and that depletion of 
this with a Hedgehog pathway inhibitor, led to better delivery and efficacy of gemcitabine in 
vivo (Olive et al., 2009).  
Given the discussions presented here, the overall aim of this thesis was to investigate novel 
therapeutic strategies for CRC using autochthonous mouse models. Recent studies within the 
Clarke lab have generated mouse models of invasive intestinal adenocarcinomas mutant for 
the tumour suppressor proteins Apc and Pten as well as the oncogene Kras, using two 
intestinal specific transgenes, namely the AhCreER and VillinCreER transgenes (Marsh et al., 
2008, Davies et al., in press). One aspect of work outlined in this thesis was to utilise these 
models to investigate therapeutic agents which target relevant pathways primarily driving 
tumourigenesis in these models, namely the PI3K and MAPK signalling pathways.        
   
8.1.1 PI3K/mTOR inhibitor treatment in increasing lifespan of GEMMs 
The rationale behind the use of a PI3K/mTOR inhibitor in Apcf/+ Ptenf/f mice stemmed from the 
observation that tumour progression in these mice coincides with increased levels of pAKT as 
reported by Marsh et al., and as confirmed in chapter 3 (Marsh et al., 2008). Furthermore, the 
PI3K pathway was found to be elevated in Apcf/+ KrasLSL/+ colon tumours (chapter 3), not 
surprising given that oncogenic Kras also impinges on the PI3K pathway (Kodaki et al., 1994). 
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Moreover, presence of all three genetic mutations driven by the VillinCreER transgene 
resulted in increased tumour number, progression and substantially reduced lifespan of mice 
(Davies et al., in press). All three tumour models present as useful pre-clinical models given the 
well-defined survival profiles, and genetic differences which could help distinguish between 
responding and non-responding tumours. 
As hypothesised, long term PI3K and mTOR inhibition using NVP-BEZ235 significantly increased 
lifespan of all three tumour models (summarised in table 8.1, chapters 4-6), highlighting the 
importance of PI3K/mTOR signalling in tumours and suggesting this as a beneficial therapeutic 
strategy for Pten deleted and Kras activated colorectal cancers. Whilst the dependence of 
these tumour models on PI3K signalling could be attributed to the genetic alterations present, 
i.e. Pten deletion and oncogenic Kras activation, targeting of the PI3K/mTOR signalling 
pathway has long been associated with increased longevity. mTOR which is a serine/threonine 
protein kinase of the PI3K pathway, is a master regulator of cellular growth and metabolism, 
and modulation of mTOR complex 1 (mTORC1) coincides with increased longevity (Stanfel et 
al., 2009). Whilst mTORC1 is activated by insulin and growth factor signalling through the PI3K 
and AKT pathway, it can also be activated by environmental nutrients (such as amino acids), 
and repressed by AMPK, a key sensor of cellular energy (Johnson et al., 2013). Subsequently, 
mTORC1 can increase protein synthesis through pS6 kinases and 4EBP1, as well as promote 
lipid biosynthesis, activate autophagy, regulate glucose metabolism and mitochondrial 
function, all of which are known to contribute to increasing longevity (Johnson et al., 2013). 
Given the extensive beneficial effects of mTORC1 inhibition, the increase in longevity observed 
in Apcf/+ Ptenf/f, Apcf/+ KrasLSL/+and Apcf/+ Ptenf/f KrasLSL/+mice following NVP-BEZ235 treatment 
(chapters 4-6) may to some extent be attributable to the effects of mTORC1 inhibition as 
opposed to the presence of genetic mutations which render tumours sensitive to PI3K 
pathway inhibition. Furthermore, given that NVP-BEZ235 treatment also increased survival of 
Apcf/+ mice (summarised in table 8.1, chapter 3), tumours from which do not show activation 
of PI3K signalling, it could be suggested that the benefits of NVP-BEZ235 are to some extent 
not associated with the presence of PI3K pathway genetic alterations. Also of interest is the 
association of mTOC1 inhibition with rejuvenation of stem cell function in a number of tissues. 
Yilmaz et al showed that rapamycin mediated mTORC1 inhibition, protected against loss of 
intestinal stem cell function during aging by protecting the stem cell niche (Yilmaz et al., 2012), 
perhaps implicating an alternative mechanism for NVP-BEZ235 induced longevity. 
Nevertheless, NVP-BEZ235 treatment in Apcf/+ Ptenf/f, Apcf/+ KrasLSL/+and Apcf/+ Ptenf/f 
KrasLSL/+mice more than doubled survival of mice whereas treatment in Apcf/+ mice only 
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increased survival by 100 days (vehicle = 270 days vs NVP-BEZ235 = 371 days post induction) 
(chapters 4-6), suggesting increased benefits in the stratified Pten deficient and Kras mutant 
genetic tumour settings. 
These findings have direct relevance to the clinic highlighting the potential benefits of 
PI3K/mTOR inhibitors for increasing longevity of PI3K and KRAS mutant, as well as wild-type 
tumours. It may be useful to assess the effects of PI3K inhibition and mTORC1 inhibition 
independently using specific inhibitors (Pan-PI3K inhibitors vs rapamycin which preferentially 
inhibits mTORC1) to assess the independent effects on survival of Pten deficient, Kras 
activated and wild-type tumour bearing mice.  
 
8.1.2 Pten deletion as a marker of non-response to MEK inhibitor treatment 
Prior to MEK inhibitor treatment experiments, the levels of MAPK pathway activation was 
assessed through immunoblotting for pERK, a key MAPK pathway effector, in colon and small 
intestinal tumours from Apcf/+, Apcf/+ KrasLSL/+, Apcf/+ Ptenf/f and Apcf/+ Ptenf/f KrasLSL/+mice 
(chapter 3). Whilst these experiments confirmed activation of MAPK signalling in Apcf/+ 
KrasLSL/+ colon and small intestinal tumours in comparison with Apcf/+ controls, surprisingly, 
levels of pERK were also found to be increased in Apcf/+ Ptenf/f and not in Apcf/+ Ptenf/f KrasLSL/+ 
small intestinal tumours. Whilst the reasons for increased MAPK signalling in Apcf/+ Ptenf/f 
tumours are not fully understood, the lack of MAPK signalling in Apcf/+ Ptenf/f KrasLSL/+ tumours 
may be attributable to increased tumour burden within a substantially reduced lifespan. 
Despite the differences in pathway activation, long term MEK inhibition was investigated in all 
four models. Subsequently, MEK inhibition through MEK162 was found to significantly 
increase survival of Apcf/+ and Apcf/+ KrasLSL/+ mice (summarised in table 8.1, chapter 3, 5) and 
deletion of Pten emerged as a marker of non-response to MEK inhibitor treatment, 
independently (in the Apcf/+ Ptenf/f mice) but also in the context of Kras mutant tumours (in the 
Apcf/+ Ptenf/f KrasLSL/+mice) (chapter 4, 6). These findings are in accordance with previous 
studies and provide evidence for the notion that Kras mutational status alone is not sufficient 
as a prognostic marker for response to MEK inhibition (Chen et al., 2012b). Moreover, 
mutations activating the PI3K pathway such as Pten deletion could also be used to predict 
non-response of Kras wild-type tumours to MEK inhibition given the increased survival benefit 
observed in Apcf/+ mice (summarised in table 8.1, chapter 3-4).   
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8.1.3 Combinatorial therapy in Kras mutant and Pten deficient tumour settings 
Despite the attractiveness of combination therapy, there is currently little data in the 
literature to advice on the most appropriate dosing schedule for the combination of PI3K and 
MEK inhibitors. This is crucial, as whilst agents may be effective as single agents, antagonism 
between two agents when combined, especially given cross-talk between the two pathways 
may be evident. Furthermore, due to overlapping sensitivities, the combination may result in 
no net clinical gain when administered jointly (Dancey and Chen, 2006). To address some of 
these issues, three varied combination strategies which differed in the order of agent 
administered was investigated. Here, MEK162 was administered 1 hour prior to (combo 1), 
post (combo 2) or at the same time (combo 3) as NVP-BEZ235 to determine whether 
scheduling is key to achieve concomitant pathway inhibition. Interestingly, sensitivity to the 
scheduling was primarily detected in Apcf/+ Ptenf/f tumours whereby MEK162 administered 
prior to or at the same time as NVP-BEZ235 diminished sensitivity of Pten deficient tumours to 
complete PI3K and mTOR inhibition (chapter 4). Given that the most favourable anti-tumour 
effects, in terms of increased apoptosis and reduced proliferation, were also observed by this 
strategy, it was surprising that long term administration provided no additional benefits to 
single agent NVP-BEZ235 (summarised in table 8.1, chapter 4). These findings suggest that 
MAPK signalling is not required for tumour maintenance in Apcf/+ Ptenf/f mice, despite the 
increase in signalling observed through pERK in chapter 3.  
 In direct contrast to the Apcf/+ Ptenf/f setting, Apcf/+KrasLSL/+ and Apcf/+ Ptenf/f KrasLSL/+ tumours 
in response to the combination strategies displayed less efficacy and less variation in inhibition 
of both pathways (chapter 5, 6). Nevertheless, the observation that chronic administration of 
the combination increased median survival additively in Apcf/+KrasLSL/+ mice and synergistically 
in Apcf/+ Ptenf/f KrasLSL/+ mice indicates that whilst some antagonism may be suggested by the 
short term combination studies, the two pathways are essential in tumour maintenance 
(chapter 5, 6). These data suggest that combination therapy in Kras mutant settings could 
provide substantial benefits in the clinical setting. To formally determine whether scheduling 
of the PI3K/mTOR inhibitor NVP-BEZ235, and MEK inhibitor MEK162 is crucial in Apcf/+KrasLSL/+ 
and Apcf/+ Ptenf/f KrasLSL/+ mice, long term treatment experiments with the combo 1 and combo 
3 strategies could be conducted. These findings may also be crucial for translation into the 
clinic.  
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Treatment Parameters 
assessed 
Genotype 
  Apcf/+ Apcf/+ Ptenf/f Apcf/+ KrasLSL/+ Apcf/+ Ptenf/f 
KrasLSL/+ 
MEK162 Survival 270401 DPI No effect 153287 DPI No effect 
Tumour 
number 
No effect No effect Reduction in SIT 
and colon polyps 
No effect 
Tumour area No effect No effect Smaller lesions in 
SI only, no effect 
on colon tumours 
N/A 
Tumour 
progression 
No effect No effect No effect More invasive SI 
lesions 
NVP-BEZ235 Survival 270370 DPI 99266 DPI 153343 DPI 41104 DPI 
Tumour 
number 
No effect Less tumours No effect No effect 
Tumour area No effect Increased 
tumour area  
Smaller lesions in 
SI only, no effect 
on colon tumours 
N/A 
Tumour 
progression 
No effect in 
colon, less 
invasive 
lesions in SI 
More invasive SI 
lesions 
Less invasive 
lesions in SI, no 
effect in colon 
More invasive SI 
lesions 
Combination Survival N/A 99270 DPI 153 389 DPI 41125 DPI 
Tumour 
number 
N/A Less tumours in 
SI 
Less colon 
tumours, no 
difference in SI 
No effect 
Tumour area N/A Increased area No difference in 
colon, smaller SI 
lesions 
N/A 
Tumour 
progression 
N/A Fewer benign 
and more 
invasive SI 
lesions 
No effect in 
colon, less 
invasive lesions in 
SI 
More invasive SI 
lesions 
Table 8.1 Summary of outcomes from long term treatments with NVP-BEZ235 and MEK162 
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8.1.4 The MRC FOCUS 4 trial 
The findings reported in this thesis regarding the efficacy of PI3K and MEK inhibitors have 
major clinical implications. In terms of predictions, the studies here suggest dual PI3K and 
mTOR targeting could be useful for Pten deficient and hence PI3K activated tumours, whilst 
combined targeting of PI3K/mTOR and MAPK signaling could be clinically beneficial for Kras 
mutant as well as compound Pten deficient and Kras mutant tumours. These predictions are 
particularly pertinent given the start of the MRC FOCUS-4 trial in January 2013. This trial aims 
to conduct a molecularly stratified phase II trial for metastatic CRC using similar parameters 
addressed in this thesis. As outlined in the schematic below (figure 8.1), this trial aims to 
determine the molecular sub-group of tumours following a course of standard chemotherapy, 
and subsequently treat with molecularly targeted agents until a primary end point of 
progression free survival (PFS). Additionally, this trial aims to conduct regular biopsies to 
address target validation as well as to investigate changes in pathology or mechanisms of 
resistance following novel agent treatments. For B-RAF mutant tumours which lead to 
activation of MAPK signalling downstream of KRAS, this trial aims to assess combinatorial anti-
B-raf and anti-EGFR targeted agents whereas for KRAS mutant tumours, this trial aims to use 
an AKT inhibitor in combination with a MEK inhibitor. Additionally, for PIK3CA mutant tumours 
resulting in activation of the PI3K pathway, this trial aims to use a dual PI3K and mTOR 
inhibitor.  In the event of no mutations in B-RAF, KRAS or PIK3CA, patients will be administered 
an anti-EGFR targeted agent (Maughan, 2012).  
Interestingly, whilst B-RAF and KRAS mutations are known to be mutually exclusive, a third of 
human CRCs are known to accumulate KRAS and PI3K pathway activating mutations. The 
FOCUS-4 trial does not currently outline the course of proposed targeted therapy for these 
patients, but findings from this thesis indicate beneficial effects of combined MEK and 
PI3K/mTOR inhibitor treatment (chapter 6). Additionally, findings from this thesis indicate 
equipotent effects of independent PI3K/mTOR and MEK inhibition in the Kras mutant tumour 
setting (chapter 5). Currently, the FOCUS 4 trial does not include control arms for the 
proposed combination therapy (AKT inhibitor plus MEK inhibitor treatment) which patients 
with KRAS mutant tumours will be stratified to receive. If included, this would provide 
insightful information regarding the predictive nature of the GEMMs used in this study, and 
could clearly indicate the potential benefits of combination therapy. Furthermore, findings 
from this study suggest importance of scheduling, particularly as agents target closely 
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associated signalling pathways, an aspect which is not currently addressed by the FOCUS 4 
trial.   
Finally, given the direct relevance of findings from this thesis to the FOCUS-4 trial, it would be 
useful to investigate mechanisms of resistance to such molecularly targeted agents in our 
genetically defined mouse models, to provide further information to the clinic.  
 
 
 
 
 
 
 
 
 
 
 
Figure 8.1 Outline of the MRC-FOCUS 4 phase II clinical trial 
Following a diagnostic biopsy, patients with metastatic CRC will be recruited to the FOCUS 4 
trial. During an initial treatment of first line chemotherapy for up to 16 weeks, tumours will be 
analysed for genetic alterations in the following genes: B-RAF, KRAS or PIK3CA. The stable or 
responding patients will subsequently be stratified upon genetic alterations detected within 
tumours, to receive either a combination of B-RAF and EGFR inhibitor treatment, AKT and MEK 
inhibitor treatment or a dual PI3K/mTOR inhibitor treatment for relevant disease. In the event 
of no genetic mutations in any of the three genes evaluated, patients will receive anti-EGFR 
targeted therapy. Patients will receive therapy to a primary end point of progression free 
survival (PFS). It is anticipated that these molecularly targeted agents will improve PFS in 
patients.    
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8.1.5 The drug discovery and development process applied to 5-FU 
Another novel aspect of work outlined in this thesis involved applying the drug discovery and 
development process to overcome 5-fluorouracil (5-FU) resistance. Whilst targeted therapy 
holds great promise for the treatment of CRC, 5-FU remains the cornerstone of treatment for 
CRC as 5-FU based chemotherapy continually improves overall and progression-free survival of 
patients with resected disease. Despite this, in the advanced stage setting, response rates to 5-
FU are modest, at only 10-15% (Johnston and Kaye, 2001). This highlights an urgent need in 
the clinic to improve prospects for patients.  
The current drug discovery and development process is an inefficient process as reflected by 
the high attrition rate of potential anti-cancer agents. As outlined by Sharpless and DePinho, 
the root of the problem with regards to drug discovery and development relates to a number 
of needs: firstly, a robust rate-limiting cancer target; secondly, identification of effective and 
tolerated lead compounds for the target; thirdly, a clear genetic or cellular context in which 
the target is required for maintenance of a fully established tumour; and finally, identification 
of biomarkers for drug efficacy which are translatable into early phase clinical trials (Sharpless 
and Depinho, 2006).  
Non-response and resistance of patients to 5-FU coincides with elevation of the target enzyme 
thymidylate synthase (TS) albeit this varies greatly between patients (Li et al., 2001). 
Nevertheless, TS presents as a rational therapeutic target given its central role on thymidine 
synthesis and cellular proliferation. The rationale behind the use of the anti-viral agent 
Brivudin (BVDU) as a parent compound to target increased expression of TS stemmed from the 
observation that TS was capable of using the metabolite of BVDU- BVDUMP, as a substrate 
and converting this to thiethyl-deoxyuridylate derivatives (these then have anti-tumour 
properties) (Barr et al., 1983). The charged nature of BVDUMP however prevents passive entry 
of the compounds into the cell. Therefore, the phosphoramidate technology was used to mask 
the charged nature of BVDUMP using temporary ester, aryl, amino acid or aromatic moieties 
to facilitate intracellular delivery of BVDUMP. In light of these observations, a small family of 
analogues of thymectacin (a phosphoramidate derivative of BVDUMP, currently under clinical 
evaluation) were prepared and evaluated in vitro in an effort to identify lead compounds 
which displayed efficacy in the MCF7 cancer cells but also showed increased efficacy in the TS 
overexpressing MCF7TDX cells (chapter 7). Whilst the lead compounds following in vitro 
evaluations showed increased potency in comparison with thymectacin and the parent BVDU 
compound, these showed varied biological effects in an in vivo setting (chapter 7). 
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Furthermore, due to the lack of a robust biomarker of sensitivity, it was not ascertained 
whether effective intracellular delivery of BVDUMP was indeed achieved or whether the 
additional temporary moieties were appropriately cleaved to release the active nucleoside 
molecule in vivo. Knowledge of this would provide useful information for further optimization 
of the ProTide agents and to improve the efficacy of the lead compounds in the in vivo setting. 
One major caveat of the research presented here was the lack of a 5-FU induced TS 
upregulated tumour model to evaluate efficacy of the lead ProTide agents. Nevertheless, the 
relevance of the AhCreER Apcf/+ Ptenf/f mouse model of invasive adenocarcinoma remains 
strong. As mentioned previously, the response rates of 5-FU in an advanced human tumour 
setting remain low. This was directly modelled in the AhCreER Apcf/+ Ptenf/f mouse model, 
where efficacy of 5-FU treatment, even in a prophylactic setting, fell short of the efficacy 
observed from the PI3K/mTOR inhibitor NVP-BEZ235 treatment. Interestingly, in this invasive 
model of adenocarcinoma, thymectacin treatment resulted in a similar increase in median 
survival in comparison with 5-FU treatment (median survival thymectacin= 133 days, 5-FU = 
131 days, vehicle =94 days post induction) indicating equally beneficial effects.  
Nevertheless, the studies presented in this thesis highlight the relevance of genetically 
engineered mouse models in generating clinically relevant hypotheses which following further 
clinical evaluation, may improve outcomes for patients with CRC.   
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